The sixth report of the Joint National Committee on pretreatment of high blood pressure

Archives of Internal Medicine 157, 2413-2446

DOI: 10.1001/archinte.157.21.2413

Citation Report

#	Article	lF	CITATIONS
1	Evolution of the Joint National Committee Reports, 1988-1997. Archives of Internal Medicine, 1997, 157, 2401.	4.3	8
2	JNC Guidelines. JAMA - Journal of the American Medical Association, 1997, 278, 1778.	3.8	14
3	JNC VI: timing is everything. Lancet, The, 1997, 350, 1413-1414.	6.3	17
4	Personal viewpoint: new developments in the therapy of diabetic hypertensive disease. The ABCD study adds to strong evidence favoring the prime use of ACE inhibitors. Appropriate Blood Pressure Control in Diabetes., 1998, 12, 233-238.		2
5	Nifedipine after acute myocardial infarction-sola dosis facit venenum: only the dose determines the harm., 1998, 12, 149-150.		0
6	Principles of combination therapy for hypertension: what we learn from the HOT and other studiesa personal point of view., 1998, 12, 425-429.		4
7	Psychological changes accompanying and mediating stress-management training for essential hypertension. Applied Psychophysiology Biofeedback, 1998, 23, 159-178.	1.0	10
8	Relationship between joint national committeeâ€VI classification of hypertension and ambulatory blood pressure in patients with hypertension diagnosed by casual blood pressure. Clinical Cardiology, 1998, 21, 801-806.	0.7	9
9	A Review of the New Angiotensin II-Receptor Antagonist Irbesartan. Cardiovascular Drug Reviews, 1998, 16, 169-194.	4.4	20
10	Decreased excretion of nitrate and nitrite in essential hypertensives with renal vasoconstriction. Kidney International, 1998, 54, S10-S13.	2.6	5
11	Continuing Education Forum. Diagnostic Evaluation for Hypertension. Journal of the American Academy of Nurse Practitioners, 1998, 10, 269-280.	1.4	0
12	The International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment (INSIGHT) trial. American Journal of Cardiology, 1998, 82, 23-28.	0.7	28
13	Calcium antagonists and the diabetic patient: a response to recent controversies. American Journal of Cardiology, 1998, 82, 40-41.	0.7	43
14	Risk factors for cardiovascular and cerebrovascular diseases and dementia in the elderly. Current Problems in Cardiology, 1998, 23, 1-62.	1.1	13
15	JNC VI: what's new and why?. ACC Current Journal Review, 1998, 7, 31-34.	0.1	0
16	Effects of clonidine on power spectral analysis of heart rate variability in mild essential hypertension. Journal of the Autonomic Nervous System, 1998, 74, 152-159.	1.9	17
17	Trends in prescribing calcium-channel blockers. Lancet, The, 1998, 352, 1708.	6.3	2
18	JNC VI guidelines. Lancet, The, 1998, 351, 288.	6.3	1

#	Article	IF	CITATIONS
19	Angiotensin II, VEGF, and diabetic retinopathy. Lancet, The, 1998, 351, 837.	6.3	1
20	Hypertension Optimal Treatment (HOT) trial. Lancet, The, 1998, 352, 571.	6.3	3
21	Reducing mortality and increasing awareness. Lancet, The, 1998, 352, S20.	6.3	1
22	An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Clinical Therapeutics, 1998, 20, 398-409.	1.1	97
23	Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine ER in the treatment of hypertension. Clinical Therapeutics, 1998, 20, 527-538.	1.1	4
24	Continuation of initial antihypertensive medication after 1 year of therapy. Clinical Therapeutics, 1998, 20, 671-681.	1.1	288
25	$\hat{l}^2$ -blockers were not as efficacious as diuretics when used as first-line therapy in elderly patients with uncomplicated hypertension. Evidence-based Cardiovascular Medicine, 1998, 2, 102.	0.0	0
26	The use of calcium antagonists and ACE inhibitors increased between 1992 and 1995. Evidence-based Cardiovascular Medicine, 1998, 2, 54.	0.0	O
27	Results of Therapy With Carvedilol, a \$beta;-Blocker Vasodilator With Antioxidant Properties, in Hypertensive Patients. American Journal of Hypertension, 1998, 11, 15S-22S.	1.0	45
28	Comparative Efficacy of Two Angiotensin II Receptor Antagonists, Irbesartan and Losartan, in Mild-to-Moderate Hypertension. American Journal of Hypertension, 1998, 11, 445-453.	1.0	150
29	Dose-Related Antihypertensive Effects of Irbesartan in Patients With Mild-to-Moderate Hypertension. American Journal of Hypertension, 1998, 11, 462-470.	1.0	104
30	Fixed low-dose perindopril-indapamide combination in hypertensive patients with chronic renal failure. American Journal of Hypertension, 1998, 11, 1087-1092.	1.0	11
31	Pharmacologic treatment of hypertension in the Department of Veterans Affairs during 1995 and 19961. American Journal of Hypertension, 1998, 11, 1271-1278.	1.0	13
32	Postprandial hypotension: evaluation by ambulatory blood pressure monitoringâ <sup>*</sup> †. American Journal of Hypertension, 1998, 11, 1358-1363.	1.0	39
33	The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. American Journal of Hypertension, 1998, 11, 1433-1441.	1.0	18
34	The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older menâ~†. American Journal of Hypertension, 1998, 11, 1405-1412.	1.0	100
35	The role of combination antihypertensive therapy and the progression of renal disease hypertensionLooking toward the next millennium. American Journal of Hypertension, 1998, 11, 158S-162S.	1.0	21
36	The clinical significance of systolic hypertension. American Journal of Hypertension, 1998, 11, 182S-185S.	1.0	19

#	Article	IF	Citations
37	NEPHROPATHY AND HYPERTENSION IN DIABETES. Medical Clinics of North America, 1998, 82, 877-907.	1.1	31
38	Death Rates from Coronary Disease — Progress and a Puzzling Paradox. New England Journal of Medicine, 1998, 339, 915-917.	13.9	61
39	Comparative Tolerability Profile of Hypertensive Crisis Treatments. Drug Safety, 1998, 19, 99-122.	1.4	61
40	Moexipril. Drugs, 1998, 55, 845-860.	4.9	18
41	Management of the Hypertensive Patient Who Smokes. Drugs, 1998, 56, 177-187.	4.9	9
42	Drug Treatment of Hypertension Complicating Diabetes Mellitus. Drugs, 1998, 56, 189-202.	4.9	26
43	Candesartan Cilexetil. Drugs, 1998, 56, 847-869.	4.9	122
44	Trandolapril. Drugs, 1998, 56, 871-893.	4.9	15
45	Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary Hypertension. Clinical Drug Investigation, 1998, 15, 217-227.	1.1	23
46	Efficacy and Tolerability of Valsartan in Combination with Hydrochlorothiazide in Essential Hypertension. Clinical Drug Investigation, 1998, 16, 203-210.	1.1	26
47	Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients. Clinical Drug Investigation, 1998, 16, 229-240.	1.1	8
48	Force of European and other Societies on Coronary Prevention1European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.1.2Published simultaneously in the European Heart Journal 1998:19:1434–1503 and the Journal	0.4	760
49	of Hypertension (Summary only) 1998. Atherosclerosis, 1998, 140, 199-270. Urapidil. Drugs, 1998, 56, 929-955.	4.9	52
52	Guidelines for the Prevention of Coronary Heart Disease. Disease Management and Health Outcomes, 1998, 4, 217-224.	0.3	0
53	Hypertension as a Candidate for Disease Management Initiatives. Disease Management and Health Outcomes, 1998, 3, 215-227.	0.3	2
55	The cost of treating hypertension can we keep it under control without compromising the level of care?. American Journal of Hypertension, 1998, 11, 120S-127S.	1.0	16
56	The Rationale for Differing National Recommendations for the Treatment of Hypertension. American Journal of Hypertension, 1998, 11, 79S-88S.	1.0	32
57	Executive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Archives of Internal Medicine, 1998, 158, 1855.	4.3	807

#	Article	IF	CITATIONS
58	The Role of Combination Therapy in the Treatment of Hypertension. American Journal of Hypertension, 1998, 11, 73S-78S.	1.0	48
59	Sodium Reduction and Weight Loss in the Treatment of Hypertension in Older Persons. JAMA - Journal of the American Medical Association, 1998, 279, 839.	3.8	1,048
60	Setting the TONE for Ending the Hypertension Epidemic. JAMA - Journal of the American Medical Association, 1998, 279, 878.	3.8	17
61	Calcium-Channel Blockers for Hypertension — Uncertainty Continues. New England Journal of Medicine, 1998, 338, 679-681.	13.9	85
62	When Should Heart Disease Prevention Begin?. New England Journal of Medicine, 1998, 338, 1690-1692.	13.9	29
63	Conflict of Interest in the Debate over Calcium-Channel Antagonists. New England Journal of Medicine, 1998, 338, 1696-1698.	13.9	4
64	Prevention and Treatment of Hypertension Study (PATHS): Effects of an Alcohol Treatment Program on Blood Pressure. Archives of Internal Medicine, 1998, 158, 1197.	4.3	120
65	Self-recorded Blood Pressures. Archives of Internal Medicine, 1998, 158, 425.	4.3	2
66	Are $\hat{I}^2$ -Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?. JAMA - Journal of the American Medical Association, 1998, 279, 1903.	3.8	488
67	Current Recommendations for Initial Therapy in Hypertension: Are They Still Valid? Introduction. American Journal of Hypertension, 1998, 11, 69S-72S.	1.0	4
68	Number needed to treat: solid science or a path to pernicious rationing?. American Journal of Hypertension, 1998, 11, 128S-134S.	1.0	13
69	Updating recommendations for prevention of coronary heart disease. Journal of Hypertension, 1998, 16, 1401-1402.	0.3	0
70	Prevalence, Clinical Correlates, and Treatment of Hypertension in Elderly Nursing Home Residents. Archives of Internal Medicine, 1998, 158, 2377.	4.3	61
71	Impact of Major Cardiovascular Disease Risk Factors, Particularly in Combination, on 22-Year Mortality in Women and Men. Archives of Internal Medicine, 1998, 158, 2007.	4.3	142
72	Comparison of the Efficacy of Dihydropyridine Calcium Channel Blockers in African American Patients With Hypertension. Archives of Internal Medicine, 1998, 158, 2029.	4.3	27
73	Nephroprotective effect of antihypertensive drugs in essential hypertension. Journal of Hypertension, 1998, 16, 555-567.	0.3	22
74	Adverse prognostic value of a blunted circadian rhythm of heart rate in essential hypertension. Journal of Hypertension, 1998, 16, 1335-1343.	0.3	78
75	Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide. Journal of Hypertension, 1998, 16, 1677-1684.	0.3	56

#	Article	IF	CITATIONS
76	Calcium supplementation in patients with essential hypertension. Journal of Hypertension, 1998, 16, 1693-1699.	0.3	26
77	Effect of an α-Adrenergic Blocker, and ACE Inhibitor and Hydrochlorothiazide on Blood Pressure and on Renal Function in Type 2 Diabetic Patients with Hypertension and Albuminuria. Nephron, 1998, 80, 175-182.	0.9	36
78	A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients. Journal of Hypertension, 1998, 16, 1049-1054.	0.3	23
79	Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. Journal of Hypertension, 1998, 16, 1325-1333.	0.3	285
80	Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. Journal of Hypertension, 1998, 16, 2039-2043.	0.3	48
81	Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement. Journal of Hypertension, 1998, 16, 971-975.	0.3	648
82	Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997. Journal of Hypertension, 1998, 16, 1379-1387.	0.3	72
83	Treatment of Hypertension on the Basis of Home Measurements. Japanese Circulation Journal, 1998, 62, 858-859.	1.0	1
84	An Inverse Relationship between Serum Vitamin C and Blood Pressure in a Japanese Community Journal of Nutritional Science and Vitaminology, 1998, 44, 853-867.	0.2	17
85	Recent advances: General medicine. BMJ: British Medical Journal, 1998, 317, 792-795.	2.4	0
86	Screening for diabetes: what are we really doing?. BMJ: British Medical Journal, 1998, 317, 1644-1646.	2.4	24
87	Target Blood Pressure in the Treatment of Essential Hypertension. Kidney and Blood Pressure Research, 1998, 21, 271-273.	0.9	0
88	Update in Nephrology. Annals of Internal Medicine, 1998, 129, 636.	2.0	1
89	New Guidelines for Prevention, Detection, Evaluation, and Treatment of Hypertension. Chest, 1998, 113, 263-265.	0.4	23
90	The 6th Joint National Committee Report (JNC-6): New Guidelines for Hypertension Therapy from the USA Keio Journal of Medicine, 1998, 47, 99-105.	0.5	22
91	INFLUENCE OF REGULAR SWIMMING ON PROFILE OF MOOD STATES IN OBESE SUBJECTS WITH ESSENTIAL HYPERTENSION. Japanese Journal of Physical Fitness and Sports Medicine, 1999, 48, 447-452.	0.0	3
92	Antihypertensive Effect of Sardine Peptide and Valyl-Tyrosine in Spontaneously Hypertensive Rats Nihon EiyŕShokuryŕGakkai Shi = Nippon EiyŕShokuryŕGakkaishi = Journal of Japanese Society of Nutrition and Food Science, 1999, 52, 271-277.	0.2	21
93	Update in General Internal Medicine. Annals of Internal Medicine, 1999, 131, 199.	2.0	6

#	Article	IF	CITATIONS
94	Urinary Glycosaminoglycans and Their Relationship to Microalbuminuria in Arterial Hypertension. Nephron, 1999, 81, 444-445.	0.9	0
95	Abated cardiovascular responses to chronic oral lisinopril treatment in conscious elderly rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 276, R1408-R1415.	0.9	3
96	British guidelines on managing hypertension. BMJ: British Medical Journal, 1999, 319, 589-590.	2.4	15
97	Diuretics and $\hat{I}^2$ -Blockers Do Not Have Adverse Effects at 1 Year on Plasma Lipid and Lipoprotein Profiles in Men With Hypertension. Archives of Internal Medicine, 1999, 159, 551.	4.3	88
98	Blood Pressure Biofeedback Treatment, Organ Damage and Sympathetic Activity in Mild Hypertension. Psychotherapy and Psychosomatics, 1999, 68, 341-347.	4.0	14
100	Reliability of patients measuring blood pressure at home: prospective observational study. BMJ: British Medical Journal, 1999, 319, 1172-1172.	2.4	53
101	Blood pressure control in type 2 diabetesâ€"what does the United Kingdom prospective diabetes study (UKPDS) tell us?. Nephrology Dialysis Transplantation, 1999, 14, 2562-2564.	0.4	12
102	Managing Hypertension in the Southeastern United States: Applying the Guidelines from the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). American Journal of the Medical Sciences, 1999, 318, 357-364.	0.4	7
103	Evaluating Hypertension Control in a Managed Care Setting. Archives of Internal Medicine, 1999, 159, 2673.	4.3	96
104	Is it wise to combine an ACE inhibitor and an angiotensin receptor antagonist?. Nephrology Dialysis Transplantation, 1999, 14, 2855-2856.	0.4	6
105	Cross-classification of JNC VI Blood Pressure Stages and Risk Groups in the Framingham Heart Study. Archives of Internal Medicine, 1999, 159, 2206.	4.3	53
106	Left Ventricular Hypertrophy in Hypertension. New England Journal of Medicine, 1999, 340, 1279-1280.	13.9	32
107	Inadequate Management of Blood Pressure in a Hypertensive Population. New England Journal of Medicine, 1999, 340, 1593-1595.	13.9	2
108	Effect of Chronic Treatment with Lacidipine or Lisinopril on Intracellular Partitioning of Glucose Metabolism in Type 2 Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1544-1550.	1.8	13
109	Relationship Between Low Cardiorespiratory Fitness and Mortality in Normal-Weight, Overweight, and Obese Men. JAMA - Journal of the American Medical Association, 1999, 282, 1547.	3.8	914
110	Prescribing for Seniors. JAMA - Journal of the American Medical Association, 1999, 282, 113.	3.8	99
111	Emerging Noninvasive Biochemical Measures to Predict Cardiovascular Risk. Archives of Internal Medicine, 1999, 159, 237.	4.3	56
112	Dietary Sodium Intake and Subsequent Risk of Cardiovascular Disease in Overweight Adults. JAMA - Journal of the American Medical Association, 1999, 282, 2027.	3.8	416

#	Article	IF	CITATIONS
113	Low Risk-Factor Profile and Long-term Cardiovascular and Noncardiovascular Mortality and Life Expectancy. JAMA - Journal of the American Medical Association, 1999, 282, 2012.	3.8	606
114	The Use of Sublingual Nifedipine. Archives of Internal Medicine, 1999, 159, 2259-60.	4.3	11
115	National Recommendations for the Pharmacological Treatment of Hypertension. Archives of Internal Medicine, 1999, 159, 1403.	4.3	12
116	Improving Treatment Effectiveness in Hypertension. Archives of Internal Medicine, 1999, 159, 2517.	4.3	16
117	The Role of Diastolic Blood Pressure When Treating Isolated Systolic Hypertension. Archives of Internal Medicine, 1999, 159, 2004.	4.3	296
118	Conquering Cardiovascular Disease. JAMA - Journal of the American Medical Association, 1999, 282, 2068.	3.8	13
119	Renoprotective effects of antihypertensive drugs. American Journal of Hypertension, 1999, 12, 19S-32S.	1.0	19
120	Predicting Cardiovascular Risk Using Conventional vs Ambulatory Blood Pressure in Older Patients With Systolic Hypertension. JAMA - Journal of the American Medical Association, 1999, 282, 539.	3.8	1,369
121	Type 2 Diabetes Mellitus. Archives of Internal Medicine, 1999, 159, 1033.	4.3	58
122	Which Blood Pressure Measurement Is More Important in the Elderly?. Archives of Internal Medicine, 1999, 159, 1165.	4.3	9
123	Trends in the Prevalence of Hypertension, Antihypertensive Therapy, and Left Ventricular Hypertrophy from 1950 to 1989. New England Journal of Medicine, 1999, 340, 1221-1227.	13.9	245
124	Antihypertensives. Archives of Internal Medicine, 1999, 159, 535.	4.3	10
125	Chronic Disease Management. Archives of Internal Medicine, 1999, 159, 2739.	4.3	47
126	Public Health in the Twentieth Century: Advances and Challenges. Annual Review of Public Health, 1999, 20, xiii-xxx.	7.6	39
127	Diabetic Nephropathy. Diabetes Technology and Therapeutics, 1999, 1, 489-496.	2.4	7
128	Prevalence and management of hypertension in Type $1$ diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Diabetic Medicine, 1999, 16, 41-48.	1.2	58
129	AMLODIPINE, A LONG-ACTING CALCIUM CHANNEL BLOCKER, ATTENUATES MORNING BLOOD PRESSURE RISE IN HYPERTENSIVE PATIENTS. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 500-504.	0.9	17
130	Pharmacology of Antihypertensive Drugs. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 1999, 28, 649-659.	0.2	3

#	ARTICLE	IF	Citations
131	Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. Journal of Human Hypertension, 1999, 13, 569-592.	1.0	548
132	Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia, 1999, 42, 263-285.	2.9	253
133	Second manifestations of ARTerial disease (SMART) study: rationale and design. European Journal of Epidemiology, 1999, 15, 773-781.	2.5	326
134	Beta-blockers for the treatment of hypertension in patients with diabetes: exploring the contraindication myth., 1999, 13, 435-439.		32
135	Mortality in the Jerusalem 70-year-olds longitudinal study: does nifedipine have a role?. Geriatric Nephrology and Urology, 1999, 9, 5-10.	0.4	4
136	The hypertensive elderly male with prostatism. Geriatric Nephrology and Urology, 1999, 9, 57-60.	0.4	1
137	The importance of randomized clinical trials and evidenceâ€based medicine: A clinician's perspective. Clinical Cardiology, 1999, 22, 6-12.	0.7	21
138	Nonpharmacologic therapies that reduce blood pressure: A fresh perspective. Clinical Cardiology, 1999, 22, 1-5.	0.7	42
139	Dietary approaches to stop hypertension (DASH) in clinical practice: A primary care experience. Clinical Cardiology, 1999, 22, 16-22.	0.7	38
140	Hypertension in multicultural and minority populations: Linkin communication to compliance. Current Hypertension Reports, 1999, 1, 482-488.	1.5	105
141	Risk factors for nephropathy in type 2 diabetes mellitus. Comprehensive Therapy, 1999, 25, 366-369.	0.2	8
142	Home blood pressure teletransmission for better diagnosis and treatment. Current Hypertension Reports, 1999, 1, 489-494.	1.5	38
143	Unmet needs in hypertension: Challenges and opportunities. Current Hypertension Reports, 1999, 1, 495-501.	1.5	3
144	Compliance and hypertension. Current Hypertension Reports, 1999, 1, 502-506.	1.5	28
145	Controversies surrounding the treatment of the hypertensive patient with diabetes. Current Hypertension Reports, 1999, 1, 512-520.	1.5	9
146	Hypertensive cardiovascular disease in African Americans. Current Hypertension Reports, $1999, 1, 521-528$ .	1.5	28
147	Obesity, hypertension, and sympathetic nervous system activity. Current Hypertension Reports, 1999, 1, 119-126.	1.5	62
148	Obesity, hypertension, and vascular disease. Current Hypertension Reports, 1999, 1, 140-144.	1.5	8

#	ARTICLE	IF	CITATIONS
149	Current Trials. Current Hypertension Reports, 1999, 1, 201-203.	1.5	0
150	Isolated systolic hypertension, pulse pressure, and arterial stiffness as risk factors for cardiovascular disease. Current Hypertension Reports, 1999, 1, 204-211.	1.5	46
151	The renin-angiotensin system antagonism in the treatment of hypertension. Current Hypertension Reports, $1999,1,275-277.$	1.5	1
152	Old antihypertensive agents-diuretics and $\hat{l}^2$ -Blockers: Do we know how and in whom they lower blood pressure?. Current Hypertension Reports, 1999, 1, 296-304.	1.5	10
153	Reflections on the sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Current Hypertension Reports, 1999, 1, 342-345.	1.5	10
154	Three recently published trials in hypertension. Current Hypertension Reports, 1999, 1, 377-378.	1.5	0
155	Hypertension: Goal systolic and diastolic blood pressure. Current Hypertension Reports, 1999, 1, 411-413.	1.5	0
156	Calcium-channel blockers and the progression of renal disease. Current Hypertension Reports, 1999, 1, 436-445.	1.5	16
157	Hypertensive crises. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 1-9.	0.4	0
158	Renal artery stenosis. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 55-62.	0.4	4
159	Summary of the dietary approaches to stop hypertension (dash) randomized clinical trial. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 295-298.	0.4	5
160	Left ventricular hypertrophy. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 219-230.	0.4	5
161	Comparison of Two Home Blood Pressure Monitors with a Mercury Sphygmomanometer in an Ambulatory Population. Pharmacotherapy, 1999, 19, 333-339.	1.2	5
162	Dietary salt reduction in hypertension—What is the evidence and why is it still controversial?. Progress in Cardiovascular Diseases, 1999, 42, 23-38.	1.6	33
163	Obesity and hypertension. Progress in Cardiovascular Diseases, 1999, 42, 39-58.	1.6	114
164	Ambulatory blood pressure monitoring and echocardiographyâ€"Noninvasive techniques for evaluation of the hypertensive patient. Progress in Cardiovascular Diseases, 1999, 41, 397-440.	1.6	14
165	Special considerations in the therapy of diabetic hypertension. Progress in Cardiovascular Diseases, 1999, 41, 461-470.	1.6	14
166	Effects of candesartan cilexetil in patients with severe systemic hypertension. American Journal of Cardiology, 1999, 84, 289-293.	0.7	35

#	Article	IF	Citations
167	Impact of hypertension and antihypertensive treatment on organ damage. American Journal of Cardiology, 1999, 84, 18-24.	0.7	107
168	Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. American Journal of Cardiology, 1999, 84, 7-12.	0.7	13
169	Guidelines for assessing outcomes of antihypertensive treatment. American Journal of Cardiology, 1999, 84, 2-4.	0.7	9
170	Long-term benefits of angiotensin II blockade: is the consensus changing?. American Journal of Cardiology, 1999, 84, 16-21.	0.7	54
171	Do pharmacologic differences among antihypertensive agents point to clinical benefits?. American Journal of Cardiology, 1999, 84, 22-27.	0.7	1
172	Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. American Journal of Cardiology, 1999, 84, 28-34.	0.7	99
173	Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. American Journal of Cardiology, 1999, 84, 35-41.	0.7	13
174	Counseling for women with preeclampsia or eclampsia. Seminars in Perinatology, 1999, 23, 91-98.	1.1	9
175	Current status of calcium channel blockers in patients with cardiovascular disease. Current Problems in Cardiology, 1999, 24, 229-340.	1.1	13
176	STRATEGIES FOR THE PREOPERATIVE EVALUATION OF THE HYPERTENSIVE PATIENT. Anesthesiology Clinics, 1999, 17, 529-548.	1.4	2
177	The diabetic patient as paradigm for selective antihypertensive therapy. Clinical Cornerstone, 1999, 2, 1-12.	1.0	10
178	Update on Hypertension Management. Geriatric Nursing, 1999, 20, 218-219.	0.9	5
179	Evaluation of Patients with Hypertension. Disease Management and Health Outcomes, 1999, 5, 263-271.	0.3	0
180	Efficacy and Safety of an Oral Fixed Low-Dose Perindopril 2 mg/Indapamide 0.625 mg Combination: A Randomized, Double-Blind, Placebo-Controlled Study in Elderly Patients with Mild to Moderate Hypertension. Clinical and Experimental Hypertension, 1999, 21, 1097-1110.	0.5	26
181	Galenic Development and Pharmacokinetic Profile of Indapamide Sustained Release 1.5mg. Clinical Pharmacokinetics, 1999, 37, 13-19.	1.6	8
182	Clinical Implications of Indapamide Sustained Release 1.5mg in Hypertension. Clinical Pharmacokinetics, 1999, 37, 21-32.	1.6	9
183	Concluding Remarks. Clinical Pharmacokinetics, 1999, 37, 33-38.	1.6	4
184	Aerobic Exercise and Resting Blood Pressure in Women: A Meta-Analytic Review of Controlled Clinical Trials. Journal of Women's Health and Gender-Based Medicine, 1999, 8, 787-803.	1.7	29

#	Article	IF	CITATIONS
185	Guidelines for Treatment of Hypertension in Latin America: The Brazilian Experience. Clinical and Experimental Hypertension, 1999, 21, 683-692.	0.5	3
186	Women's health, chronic disease, and disease management: new words and old music?. Women's Health Issues, 1999, 9, 2-17.	0.9	16
187	Quality measurement issues in heart disease in women. Women's Health Issues, 1999, 9, 241-249.	0.9	0
188	JNC-VI, hypertension, and you. Home Care Provider, 1999, 4, 142-143.	0.1	0
189	Treatment of hypertension in patients with comorbidities Results from the study of hypertensive prescribing practices (SHyPP). American Journal of Hypertension, 1999, 12, 333-340.	1.0	21
190	Management of the hypertensive patient with coronary artery disease. American Journal of Hypertension, 1999, 12, 56S-62S.	1.0	4
191	Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate. American Journal of Hypertension, 1999, 12, 806-814.	1.0	65
192	Detection, treatment, and control of adult hypertension in Northwest Indiana. American Journal of Hypertension, 1999, 12, 830-834.	1.0	7
193	Comparison of two strategies for intensifying antihypertensive treatment Low-dose combination (enalapril + felodipine ER) versus increased dose of monotherapy (enalapril). American Journal of Hypertension, 1999, 12, 691-696.	1.0	7
194	Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. American Journal of Hypertension, 1999, 12, 797-805.	1.0	119
195	Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. American Journal of Hypertension, 1999, 12, 925-928.	1.0	17
196	Angiotensin converting enzyme gene polymorphism and activity in Turkish patients with essential hypertension. American Journal of Hypertension, 1999, 12, 1038-1043.	1.0	24
197	Comparisons of the effects of different long-acting delivery systems on the pharmacokinetics and pharmacodynamics of diltiazem. American Journal of Hypertension, 1999, 12, 1030-1037.	1.0	10
198	Will better-tolerated antihypertensive agents improve blood pressure control? JNC VI revisited. American Journal of Hypertension, 1999, 12, 225-230.	1.0	15
199	Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin ii receptor antagonists in the treatment of hypertension. American Journal of Hypertension, 1999, 12, 189-194.	1.0	64
200	Overview of JNC VI: new directions in the management of hypertension and cardiovascular risk. American Journal of Hypertension, 1999, 12, 65-72.	1.0	28
201	Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. American Journal of Hypertension, 1999, 12, 73-79.	1.0	34
202	Combinations in the treatment of hypertension: ACE inhibitors and calcium antagonists. American Journal of Hypertension, 1999, 12, 86-90.	1.0	37

#	Article	IF	Citations
203	Benefits of combination angiotensin- converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. American Journal of Hypertension, 1999, 12, 80-85.	1.0	31
204	Barriers to hypertension care and control in young urban black men. American Journal of Hypertension, 1999, 12, 951-958.	1.0	87
205	The effect of weight loss intervention on antihypertensive medication requirements in the hypertension optimal treatment (HOT) study. American Journal of Hypertension, 1999, 12, 1175-1180.	1.0	75
206	Canadian hypertension society guidelines for ambulatory blood pressure monitoring. American Journal of Hypertension, 1999, 12, 1149-1157.	1.0	59
207	Treating multiple-risk hypertensive populations. American Journal of Hypertension, 1999, 12, 121-129.	1.0	7
208	Optimal blood pressure: how low should we go?. American Journal of Hypertension, 1999, 12, 113-120.	1.0	11
209	Current antihypertensive treatment: can we do better?. American Journal of Hypertension, 1999, 12, 131-138.	1.0	8
210	Hypertension control: multifactorial contributions. American Journal of Hypertension, 1999, 12, S164-S169.	1.0	13
211	Effect of chronic moxonidine therapy on peripheral sympathetic activity in essential hypertension. American Journal of Hypertension, 1999, 12, 28.	1.0	9
212	Electrocardiographic left ventricular hypertrophy by five criteria among civil servants in Benin City, Nigeria: prevalence and correlates. International Journal of Cardiology, 1999, 70, 1-14.	0.8	16
213	Causes of death and associated factors among patients with non-insulin-dependent diabetes mellitus in Taipei, Taiwan. Diabetes Research and Clinical Practice, 1999, 43, 101-109.	1.1	16
214	High prevalence of impaired fasting glucose and type 2 diabetes mellitus in Penghu Islets, Taiwan: evidence of a rapidly emerging epidemic?. Diabetes Research and Clinical Practice, 1999, 44, 59-69.	1.1	23
215	Trandolapril and human diabetic neuropathy. Lancet, The, 1999, 353, 926.	6.3	5
216	Trandolapril and human diabetic neuropathy. Lancet, The, 1999, 353, 927.	6.3	0
217	Which drug for treatment of hypertension?. Lancet, The, 1999, 353, 604-605.	6.3	31
218	A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the hypertension and BPH intervention trial (HABIT). Clinical Therapeutics, 1999, 21, 1732-1748.	1.1	44
219	Hypertension in the elderly with coexisting benign prostatic hyperplasia. Urology, 1999, 53, 7-13.	0.5	16
220	Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Urology, 1999, 54, 81-85.	0.5	16

#	Article	IF	CITATIONS
221	The Molecular Basis of Hypertension. Annual Review of Biochemistry, 1999, 68, 127-155.	5.0	69
222	EVALUATION AND TREATMENT OF HYPERTENSION. Rheumatic Disease Clinics of North America, 1999, 25, 521-537.	0.8	3
223	ASSESSMENT OF THE AGING MAN. Medical Clinics of North America, 1999, 83, 1131-1149.	1.1	4
227	NUTRITION SCREENING AND ASSESSMENT. Medical Clinics of North America, 1999, 83, 1525-1546.	1.1	27
228	Nebivolol in the Management of Essential Hypertension. Drugs, 1999, 57, 633-651.	4.9	96
229	Renal Protection and Antihypertensive Drugs. Drugs, 1999, 57, 665-693.	4.9	46
230	Epidemiology of Risk Factors for Hypertension. Drugs, 1999, 57, 695-712.	4.9	46
231	Perindopril 2mg/Indapamide 0.625mg. Drugs, 1999, 58, 297-302.	4.9	6
232	How to Use Calcium Antagonists in Hypertension. Drugs, 1999, 58, 579-587.	4.9	14
233	Assessment of Heart Rate Variability after Calcium Antagonist and ??-Blocker Therapy in Patients with Essential Hypertension. Clinical Drug Investigation, 1999, 17, 111-118.	1.1	5
234	Calcium-Antagonist Drugs. New England Journal of Medicine, 1999, 341, 1447-1457.	13.9	393
235	Guidelines — a missed opportunity. Atherosclerosis, 1999, 143, S7-S12.	0.4	5
236	Treatment of Perioperative Hypertension in the Ambulatory Plastic Surgery Patientâ <sup>†</sup> t, â <sup>†</sup> tâ <sup>†</sup> t. Aesthetic Surgery Journal, 1999, 19, 257-259.	0.9	3
237	Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. American Heart Journal, 1999, 138, S238-S245.	1.2	14
238	Diabetes and hypertension: blood pressure control and consequences. American Journal of Hypertension, 1999, 12, S170-S178.	1.0	29
239	Rationale for Time-Qualified Reference Standards for 24-Hour Blood Pressure Values and Their Circadian Rhythms in Japanese Normotensive Adults. Japanese Circulation Journal, 1999, 63, 744-751.	1.0	5
240	Management of Hypertension in Renal Disease. Mineral and Electrolyte Metabolism, 1999, 25, 80-83.	1.1	1
241	Taste and health. 4. 7. Table salt and health. Its involvement with hypertension Kagaku To Seibutsu, 1999, 37, 196-201.	0.0	O

#	Article	IF	CITATIONS
242	Prevalence and Correlates of Elevated Serum Creatinine Levels. Archives of Internal Medicine, 1999, 159, 1785.	4.3	171
243	Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. Journal of Hypertension, 1999, 17, 1033-1039.	0.3	61
244	No linkage of the lipoprotein lipase locus to hypertension in Caucasians. Journal of Hypertension, 1999, 17, 39-43.	0.3	16
245	Blood pressure control in a hypertension hospital clinic. Journal of Hypertension, 1999, 17, 835-841.	0.3	27
246	Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial. Journal of Hypertension, 1999, 17, 1917-1923.	0.3	14
247	Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. Journal of Hypertension, 1999, 17, 1023-1032.	0.3	7
248	Influence of a rapid change of left ventricular dimensions on the echocardiographic measurement of left ventricular mass by the Penn convention. Journal of Hypertension, 1999, 17, 1323-1328.	0.3	6
249	Detection of non-dipper hypertensives in clinical practice: does it really matter?. Nephrology Dialysis Transplantation, 1999, 14, 2969-2970.	0.4	5
250	Ambulatory blood pressure predicts end-organ damage only in subjects with reproducible recordings. Journal of Hypertension, 1999, 17, 465-473.	0.3	38
251	Effect of the calcium channel blocker nitrendipine in normotensive and spontaneously hypertensive, diabetic rats on kidney morphology and urinary albumin excretion. Journal of Hypertension, 1999, 17, 973-981.	0.3	9
252	Value of blood pressure self-monitoring as a predictor of progression of diabetic nephropathy. Journal of Hypertension, 1999, 17, 597-601.	0.3	59
253	Evidence-based medicine and hypertension. Journal of Hypertension, 1999, 17, 1511-1516.	0.3	41
254	Undertreatment of hypertension in community-dwelling older adults. Journal of Hypertension, 1999, 17, 1633-1640.	0.3	28
255	Guidelines for arterial hypertension. Journal of Hypertension, 1999, 17, 735-736.	0.3	10
256	A prospective study of hypertension and the incidence of kidney stones in men. Journal of Hypertension, 1999, 17, 1017-1022.	0.3	82
257	The impact of different echocardiographic diagnostic criteria on the prevalence of left ventricular hypertrophy in essential hypertension. Journal of Hypertension, 1999, 17, 1471-1480.	0.3	65
258	Influence of treated blood pressure on progression of silent cerebral infarction. Journal of Hypertension, 1999, 17, 679-684.	0.3	18
259	Reliability and limitations of echocardiographic measurement of left ventricular mass for risk stratification and follow-up in single patients. Journal of Hypertension, 1999, 17, 1955-1963.	0.3	69

#	Article	IF	CITATIONS
260	Impact of Hypertension Guideline Implementation on Blood Pressure Control and Drug Use in Primary Care Clinics. The Joint Commission Journal on Quality Improvement, 1999, 25, 68-77.	1.5	28
261	Reliability of Self-reported Blood Pressure Measurements. Archives of Internal Medicine, 1999, 159, 2689.	4.3	96
263	Depressor Effect by Exercise Training Is Associated with Amelioration of Hyperinsulinemia and Sympathetic Overactivity Internal Medicine, 2000, 39, 1013-1019.	0.3	36
264	Improving Hypertension Control: A Team Approach in a Primary Care Setting. The Joint Commission Journal on Quality Improvement, 2000, 26, 623-632.	1.5	20
265	Implications of a Health Lifestyle and Medication Analysis for Improving Hypertension Control. Archives of Internal Medicine, 2000, 160, 481.	4.3	94
266	Placebo-Associated Blood Pressure Response and Adverse Effects in the Treatment of Hypertension. Archives of Internal Medicine, 2000, 160, 1449.	4.3	78
267	Hypertension in Older Adults. Advances in Chronic Kidney Disease, 2000, 7, 22-31.	2.2	1
268	Cost-effectiveness of the Lower Treatment Goal (of JNC VI) for Diabetic Hypertensive Patients. Archives of Internal Medicine, 2000, 160, 1277.	4.3	56
269	Cardiac Arrhythmias and Left Ventricular Hypertrophy in Dipper and Nondipper Patients With Essential Hypertension. Japanese Circulation Journal, 2000, 64, 499-504.	1.0	41
271	Exercise and hypertension. Coronary Artery Disease, 2000, 11, 99-102.	0.3	59
272	Risk factors for coronary artery disease in old persons in an academic hospital-based geriatrics practice. Coronary Artery Disease, 2000, 11, 437-439.	0.3	8
273	Hypertension in end-stage renal disease patients. Current Opinion in Nephrology and Hypertension, 2000, 9, 279-283.	1.0	5
274	Determination of ambulatory blood pressure control in treated patients with controlled office blood pressures. Blood Pressure Monitoring, 2000, 5, 263-269.	0.4	9
275	Rising Levels of Cardiovascular Mortality in Mississippi, 1979-1995. American Journal of the Medical Sciences, 2000, 319, 131-137.	0.4	6
276	The Association of Left Ventricular Mass with Cardiovascular Risk Factors in African American Women. American Journal of the Medical Sciences, 2000, 320, 13-17.	0.4	2
277	Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. Journal of Hypertension, 2000, 18, 327-334.	0.3	67
278	Physiological and pathophysiological role of magnesium in the cardiovascular system. Journal of Hypertension, 2000, 18, 1177-1191.	0.3	140
279	Patterns of hypertension management in Italy. Journal of Hypertension, 2000, 18, 1691-1699.	0.3	86

#	Article	IF	Citations
280	Therapeutic studies and arterial stiffness in hypertension. Journal of Hypertension, 2000, 18, 1527-1535.	0.3	179
281	Platelet $\hat{l}\pm 2$ -adrenoceptor alterations in patients with essential hypertension are normalized after treatment with doxazosin but not propranolol. Journal of Hypertension, 2000, 18, 217-221.	0.3	11
282	Fixed low-dose combination therapy in hypertension - a dose response study of perindopril and indapamide. Journal of Hypertension, 2000, 18, 317-325.	0.3	44
283	Headache in patients with mild to moderate hypertension is generally not associated with simultaneous blood pressure elevation. Journal of Hypertension, 2000, 18, 437-444.	0.3	41
284	Multiple risk factor clustering of hypertension in a screened cohort. Journal of Hypertension, 2000, 18, 1379-1385.	0.3	34
285	Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg. Journal of Hypertension, 2000, 18, 1465-1475.	0.3	162
286	Systolic hypertension in older patients: are calcium channel antagonists safe?. Coronary Artery Disease, 2000, 11, 621-623.	0.3	1
287	Ambulatory blood pressure of adults in Novosibirsk, Russia: interim report on a population study. Blood Pressure Monitoring, 2000, 5, 291-296.	0.4	31
288	Comparison of nurse- and physician-determined clinic blood pressure levels in patients referred to a hypertension clinic. Journal of Hypertension, 2000, 18, 391-398.	0.3	74
289	Incidence and correlates of hypertension in the Atherosclerosis Risk in Communities (ARIC) study and the Monitoring Trends and Determinants of Cardiovascular Disease (POL-MONICA) project. Journal of Hypertension, 2000, 18, 999-1006.	0.3	35
290	Comparison of wrist blood pressure measurement with conventional sphygmomanometry at a cardiology outpatient clinic. Journal of Hypertension, 2000, 18, 1013-1018.	0.3	22
291	Determinants for the development of hypertension in adolescents. A 6-year follow-up. Journal of Hypertension, 2000, 18, 1557-1561.	0.3	25
292	A new approach to assessing antihypertensive therapy. Journal of Hypertension, 2000, 18, 1683-1690.	0.3	41
293	How well is hypertension controlled in Europe?. Journal of Hypertension, 2000, 18, 1348-1349.	0.3	34
294	Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients. European Heart Journal, 2000, 21, 2-7.	1.0	10
295	Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population. Journal of Hypertension, 2000, 18, 847-854.	0.3	209
296	Lack of association of the angiotensinogen-6 polymorphism with blood pressure levels in the comprehensive NHLBI Family Blood Pressure Program. Journal of Hypertension, 2000, 18, 867-876.	0.3	45
297	Use of an age-adjusted Doppler E/A ratio in patients with moderate to severe hypertension. Journal of Hypertension, 2000, 18, 1477-1481.	0.3	2

#	Article	IF	CITATIONS
298	Fibromuscular dysplasia. Current Opinion in Rheumatology, 2000, 12, 41-47.	2.0	138
299	Blood pressure levels and obesity trends in hypertensive and normotensive Finnish population from 1982 to 1997. Journal of Hypertension, 2000, 18, 255-262.	0.3	51
300	Guidelines for the use of self-blood pressure monitoring. Journal of Hypertension, 2000, 18, 493-508.	0.3	200
301	Women's health. Journal of General Internal Medicine, 2000, 15, 600-602.	1.3	14
303	The challenge of obesity-related chronic diseases. Journal of General Internal Medicine, 2000, 15, 828-829.	1.3	27
304	Failure of evidence-based medicine in the treatment of hypertension in older patients. Journal of General Internal Medicine, 2000, 15, 702-709.	1.3	30
305	A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension. British Journal of Clinical Pharmacology, 2000, 50, 215-220.	1.1	186
306	Implications of recent hypertension trials for the generalist physician: whom do we treat, and how?., 2000, 1, 22.		O
307	Cardiovascular disease prevention practices by U.S. physicians for patients with diabetes. Journal of General Internal Medicine, 2000, 15, 220-228.	1.3	55
308	The Role of Nutrition Therapy in the Management of Diabetes Mellitus. Nutrition in Clinical Care: an Official Publication of Tufts University, 2000, 3, 334-348.	0.2	0
309	Obesity and cardiovascular disease. Journal of Diabetes and Its Complications, 2000, 14, 154-174.	1.2	123
310	Hypertension, hormones, and aging. Translational Research, 2000, 135, 379-386.	2.4	25
311	Retrospective Evaluation of the Conversion of Amlodipine to Alternative Calcium Channel Blockers. Pharmacotherapy, 2000, 20, 1072-1078.	1.2	6
312	Effect of Pharmacist Intervention and Initiation of Home Blood Pressure Monitoring in Patients with Uncontrolled Hypertension. Pharmacotherapy, 2000, 20, 1384-1389.	1.2	143
313	The Role of Pharmacists in the Detection, Management, and Control of Hypertension: A National Call To Action. Pharmacotherapy, 2000, 20, 119-122.	1.2	26
314	Pharmacologic, Pharmacokinetic, and Therapeutic Differences Among Angiotensin II Receptor Antagonists. Pharmacotherapy, 2000, 20, 130-139.	1.2	55
315	Prognosis of congestive heart failure after prior myocardial infarction in older men and women with abnormal versus normal left ventricular ejection fraction. American Journal of Cardiology, 2000, 85, 1382-1384.	0.7	44
316	Usefulness of providing physicians the results of risk factor assessments and treatment recommendations at discharge after coronary artery bypass grafting. American Journal of Cardiology, 2000, 86, 455-457.	0.7	6

#	Article	IF	CITATIONS
317	Certain cardiac risk factors predict risk factor interventions and influence communication between physicians and patients. American Journal of Cardiology, 2000, 86, 783-785.	0.7	1
318	Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. Journal of Thrombosis and Thrombolysis, 2000, 10, 169-180.	1.0	44
319	Beneficial effect of verapamil added to chronic ACE inhibitor treatment on renal function in hypertensive elderly patients. International Urology and Nephrology, 2000, 32, 165-169.	0.6	12
320	Cardiovascular mortality in non-insulin-dependent diabetes mellitus. A controlled study among 683 diabetics and 683 age- and sex-matched normal subjects. European Journal of Epidemiology, 2000, 16, 677-684.	2.5	33
321	Which antihypertensive drug classes have been shown to be beneficial? What are their benefits? A critique of hypertension treatment trials., 2000, 14, 357-366.		6
322	Diuretic downsides-but in low doses they still seem among the best authenticated antihypertensives. , 2000, 14, 407-409.		5
323	Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. , 2000, 14, 295-301.		38
324	Sex differences in the medication choice for hypertension in general practice. A study with written case simulations. International Journal of Clinical Pharmacy, 2000, 22, 140-146.	1.4	5
325	Cardiovascular Disease in Elders: Is It Inevitable?. Journal of Adult Development, 2000, 7, 101-111.	0.8	5
326	Are we treating health or physical appearance when we prescribe drugs for obesity?. Clinical Pharmacology and Therapeutics, 2000, 67, 193-195.	2.3	5
327	The role of diet in the prevention and treatment of hypertension. Current Atherosclerosis Reports, 2000, 2, 521-528.	2.0	32
328	Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure. Current Atherosclerosis Reports, 2000, 2, 281-283.	2.0	0
329	Diet and pharmacologic therapy of obesity to modify atherosclerosis. Current Atherosclerosis Reports, 2000, 2, 314-320.	2.0	11
330	Joint national committee VI: Individualized versus indiscriminate therapy for hypertension. Current Hypertension Reports, 2000, 2, 243-246.	1.5	3
331	The influence of national guidelines on antihypertensive prescribing patterns. Current Hypertension Reports, 2000, 2, 247-252.	1.5	9
332	Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?. Current Hypertension Reports, 2000, 2, 253-259.	1.5	30
333	Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy. Current Hypertension Reports, 2000, 2, 260-270.	1.5	0
334	Antihypertensive drug therapy in the third millennium: Are there benefits beyond blood pressure?. Current Hypertension Reports, 2000, 2, 291-294.	1.5	1

#	Article	IF	Citations
335	Treatment of hypertension in diabetes mellitus. Current Hypertension Reports, 2000, 2, 335-342.	1.5	8
336	The need to lower systolic blood pressure. Current Hypertension Reports, 2000, 2, 433-440.	1.5	4
337	How aggressively should blood pressure be treated in renal transplant recipients?. Current Hypertension Reports, 2000, 2, 473-477.	1.5	2
338	The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure. Current Hypertension Reports, 2000, 2, 378-383.	1.5	12
339	Vasopeptidase inhibition: A new direction in cardiovascular treatment. Current Hypertension Reports, 2000, 2, 384-391.	1.5	9
340	Angiotensin converting enzyme inhibitors: Are they preferred first-line therapy?. Current Hypertension Reports, 2000, 2, 392-397.	1.5	0
341	Evidence-based treatment of hypertension. Current Hypertension Reports, 2000, 2, 398-398.	1.5	3
342	Treatment of white coat hypertension. Current Hypertension Reports, 2000, 2, 412-417.	1.5	24
343	Hypertension-induced organ damage in african americans: Transforming growth factor- $\hat{l}^21$ excess as a mechanism for increased prevalence. Current Hypertension Reports, 2000, 2, 184-191.	1.5	28
344	Postmenopausal hypertension. Current Hypertension Reports, 2000, 2, 202-207.	1.5	34
345	Preventing renal disease progression: Is it the drug or the blood pressure reduction, or both?. Current Hypertension Reports, 2000, 2, 497-499.	1.5	3
346	Observational studies of antihypertensive medication use and compliance: Is drug choice a factor in treatment adherence?. Current Hypertension Reports, 2000, 2, 515-524.	1.5	60
347	Recent advances in the management of hypertension in the elderly. Current Hypertension Reports, 2000, 2, 543-550.	1.5	1
348	Hypertension in patients presenting with stroke. Current Hypertension Reports, 2000, 2, 551-557.	1.5	4
349	Ambulatory blood pressure monitoring. Current Hypertension Reports, 2000, 2, 558-564.	1.5	23
350	Unstable angina. Current Treatment Options in Cardiovascular Medicine, 2000, 2, 37-53.	0.4	0
351	Atherosclerotic complications after renal transplantation. Transplant International, 2000, 13, S14-S19.	0.8	8
352	Plasma Aldosterone Concentrations Are Not Related to the Degree of Angiotensin-Converting Enzyme Inhibition in Essential Hypertensive Patients Hypertension Research, 2000, 23, 25-31.	1.5	30

#	Article	IF	CITATIONS
353	Relationship between Home Blood Pressure Measurement and Medication Compliance and Name Recognition of Antihypertensive Drugs Hypertension Research, 2000, 23, 21-24.	1.5	59
354	The Influence of the Peripheral Reflection Wave on Left Ventricular Hypertrophy in Patients with Essential Hypertension Hypertension Research, 2000, 23, 451-458.	1.5	42
356	The Rapidity of Drug Dose Escalation Influences Blood Pressure Response and Adverse Effects Burden in Patients With Hypertension. Archives of Internal Medicine, 2000, 160, 1842.	4.3	30
357	Regional Variations in the Incidence of End-Stage Renal Failure in Japan. JAMA - Journal of the American Medical Association, 2000, 284, 2622.	3.8	77
358	Antihypertensive Therapy: Beta-Blockers and Diureticsâ€"Why Do Physicians Not Always Follow Guidelines?. Baylor University Medical Center Proceedings, 2000, 13, 128-134.	0.2	10
359	Participation in School Sports Clubs and Related Effects on Cardiovascular Risk Factors in Young Males Hypertension Research, 2000, 23, 227-232.	1.5	27
360	Hypertension in the Elderly. Archives of Internal Medicine, 2000, 160, 283.	4.3	32
361	Can We Restore the Endothelial Dysfunction in Patients with Essential Hypertension with Calcium Channel Blockers?. Sunhwan'gi, 2000, 30, 1010.	0.3	2
362	Therapeutic Strategies of Coronary Artery Disease in Diabetic Patients. Sunhwan'gi, 2000, 30, 1184.	0.3	0
363	Physician Practice Variation in Assignment of Return Interval. Archives of Internal Medicine, 2000, 160, 205.	4.3	31
364	Response of blood pressure to maximum exercise in hypertensive patients under different therapeutic programs. Arquivos Brasileiros De Cardiologia, 2000, 75, 285-288.	0.3	1
365	Is There Any Difference between Intermediate-Acting and Long-Acting Calcium Antagonists in Diurnal Blood Pressure and Autonomic Nervous Activity in Hypertensive Coronary Artery Disease Patients?. Hypertension Research, 2000, 23, 7-14.	1.5	23
366	Comparison of the Effect of Blood Pressure on the Development of Stroke, Acute Myocardial Infarction, and End-Stage Renal Disease Hypertension Research, 2000, 23, 143-149.	1.5	37
367	Reducing premature death and renal failure in Australian Aboriginals. Medical Journal of Australia, 2000, 172, 473-479.	0.8	77
368	Eating Habits and Intensity of Medication in Elderly Hypertensive Outpatients Hypertension Research, 2000, 23, 195-200.	1.5	6
369	Effect of Combination Therapy of Angiotensin-Converting Enzyme Inhibitor plus Calcium Channel Blocker on Urinary Albumin Excretion in Hypertensive Microalubuminuric Patients with Type II Diabetes Hypertension Research, 2000, 23, 219-226.	1.5	30
370	THE EFFECTS OF MONOTHERAPY OR COMBINED THERAPY WITH AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR FOLLOWING INITIAL TREATMENT WITH CALCIUM CHANNEL BLOCKERS ON RESIDUAL CARDIOVASCULAR ABNORMALITIES. Clinical and Experimental Hypertension, 2000, 22, 493-506.	0.5	1
371	Review: low-dose thiazides are the most effective first-line drugs for hypertension. Evidence-Based Medicine, 2000, 5, 10-10.	0.6	0

#	Article	IF	CITATIONS
372	The Effect of Home Monitoring and Telemanagement on Blood Pressure Control Among African Americans. Telemedicine and E-Health, 2000, 6, 15-23.	1.3	45
373	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ: British Medical Journal, 2000, 321, 412-419.	2.4	1,737
374	Home Blood Pressure Monitoring. Archives of Internal Medicine, 2000, 160, 1251.	4.3	110
375	Unmet Health Needs of Uninsured Adults in the United States. JAMA - Journal of the American Medical Association, 2000, 284, 2061.	3.8	614
376	Blood pressure and long-term coronary heart disease mortality in the Seven Countries Study: implications for clinical practice and public health. European Heart Journal, 2000, 21, 1639-1642.	1.0	18
377	Do Depression Symptoms Predict Early Hypertension Incidence in Young Adults in the CARDIA Study?. Archives of Internal Medicine, 2000, 160, 1495.	4.3	326
378	C-reactive protein, inflammation and atherosclerosis: do we really understand it yet?. European Heart Journal, 2000, 21, 958-960.	1.0	18
379	Hypertension and Diabetes. Archives of Internal Medicine, 2000, 160, 1585.	4.3	45
380	Efficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension. Archives of Internal Medicine, 2000, 160, 2185.	4.3	229
381	Dietary Nutrients and Blood Pressure in Urban Minority Adolescents at Risk for Hypertension. JAMA Pediatrics, 2000, 154, 918.	3.6	45
382	Blood Pressure and the Risk of Cardiovascular Disease. New England Journal of Medicine, 2000, 342, 50-52.	13.9	73
383	Coronary Heart Disease in Patients with Diabetes. New England Journal of Medicine, 2000, 342, 1040-1042.	13.9	204
384	Regional and Racial Differences in Response to Antihypertensive Medication Use in a Randomized Controlled Trial of Men With Hypertension in the United States. Archives of Internal Medicine, 2000, 160, 825.	4.3	138
385	Self-reported Hypertension Treatment Practices Among Primary Care Physicians. Archives of Internal Medicine, 2000, 160, 2281.	4.3	323
386	High Blood Pressure and Diabetes Mellitus. Archives of Internal Medicine, 2000, 160, 2447.	4.3	112
387	Pulse Pressure Not Mean Pressure Determines Cardiovascular Risk in Older Hypertensive Patients. Archives of Internal Medicine, 2000, 160, 1085.	4.3	502
388	HDA-an Internet-enabled system for healthcare management. , 0, , .		0
389	Determinants of Peripheral Arterial Disease in the Elderly. Archives of Internal Medicine, 2000, 160, 2934.	4.3	233

#	Article	IF	CITATIONS
390	A Randomized Trial of Improved Weight Loss With a Prepared Meal Plan in Overweight and Obese Patients. Archives of Internal Medicine, 2000, 160, 2150.	4.3	164
391	Is Leptin Associated with Hypertensive Retinopathy? <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 683-687.	1.8	22
392	Role of Adipose Tissue for Cardiovascular-Renal Regulation in Health and Disease. Hormone and Metabolic Research, 2000, 32, 485-499.	0.7	91
393	The Growing Role of Calcium Antagonists in Treating Hypertension in the Elderly. The American Journal of Geriatric Cardiology, 2000, 9, 42-48.	0.7	3
394	Treatment of Hypertension in the Institutionalized Elderly. The American Journal of Geriatric Cardiology, 2000, 9, 34-41.	0.7	0
395	The Role of Echocardiography in Hypertensive Heart Disease in the Elderly. The American Journal of Geriatric Cardiology, 2000, 9, 330-341.	0.7	0
396	Lipid Management and Control of Other Coronary Risk Factors in the Postmenopausal Woman. Journal of Women's Health and Gender-Based Medicine, 2000, 9, 235-243.	1.7	2
397	The Evidence for Lifestyle Modification in Lowering Blood Pressure in the Elderly. The American Journal of Geriatric Cardiology, 2000, 9, 27-33.	0.7	6
398	National Guidelines, Clinical Trials, and Quality of Evidence. Archives of Internal Medicine, 2000, 160, 2577.	4.3	9
399	Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine. Archives of Internal Medicine, 2000, 160, 685-93.	4.3	679
400	Cardiovascular Effects of Occupational Exposure to Carbon Disulphide. Occupational Medicine, 2000, 50, 43-47.	0.8	14
401	Diastolic blood pressure and weight gain predicted future risk of hypertension. Evidence-based Nursing, 2000, 3, 26-26.	0.1	0
402	Exercise and Weight Loss Reduce Blood Pressure in Men and Women With Mild Hypertension. Archives of Internal Medicine, 2000, 160, 1947.	4.3	232
403	Doxazosin was associated with more stroke and cardiovascular disease events than chlorthalidone in high risk hypertension. Evidence-Based Medicine, 2000, 5, 172-172.	0.6	0
404	A genetic model defines the importance of the atrial natriuretic peptide receptor (guanylyl cyclase-A) in the regulation of kidney function. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4369-4373.	3.3	40
405	Primary Hyperaldosteronism in Essential Hypertensives: Prevalence, Biochemical Profile, and Molecular Biology $<$ sup $>$ 1 $<$ /sup $>$ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1863-1867.	1.8	381
406	Angiotensin II Receptor Blockers. Archives of Internal Medicine, 2000, 160, 1905.	4.3	53
407	Optimizing Treatment of Hypertension in Patients With Diabetes. JAMA - Journal of the American Medical Association, 2000, 283, 3177.	3.8	61

#	Article	IF	CITATIONS
408	New Guidelines for Potassium Replacement in Clinical Practice. Archives of Internal Medicine, 2000, 160, 2429.	4.3	252
409	Evidence-Based Reduction of Heart Failure Events With the Involvement of Pharmacists. Archives of Internal Medicine, 2000, 160, 1698-1698.	4.3	2
410	Olive Oil and Reduced Need for Antihypertensive Medications. Archives of Internal Medicine, 2000, 160, 837.	4.3	238
411	Diuretics vs $\hat{l}$ ±-Blockers for Treatment of Hypertension. JAMA - Journal of the American Medical Association, 2000, 283, 2013.	3.8	35
412	Hyperinsulinemia, Hyperglycemia, and Impaired Hemostasis. JAMA - Journal of the American Medical Association, 2000, 283, 221.	3.8	469
413	Relation between Psychosocial Risk Factors and Incident Erectile Dysfunction: Prospective Results from the Massachusetts Male Aging Study. American Journal of Epidemiology, 2000, 152, 533-541.	1.6	118
414	AHA Prevention V: Broadening the Concept of Primary Prevention. Preventive Cardiology, 2000, 3, 42-44.	1.1	0
415	Risk Factors for Ischemic Stroke in Older Persons in an Academic Hospital Based Geriatrics Practice. Preventive Cardiology, 2000, 3, 118-120.	1.1	2
416	Prevalence of Coronary Artery Disease, Ischemic Stroke, and Symptomatic Peripheral Arterial Disease and of Associated Risk Factors in Older Men and Women With and Without Diabetes Mellitus. Preventive Cardiology, 2000, 3, 160-163.	1.1	11
417	The Gap Between Knowledge and Practice in the Treatment and Prevention of Cardiovascular Disease. Preventive Cardiology, 2000, 3, 167-171.	1.1	9
418	Management of patients with hypertension and diabetes mellitus: advances in the evidence for intensive treatment. American Journal of Medicine, 2000, 108, 238-245.	0.6	31
419	What does STOP-2 tell us about management of hypertension?. Lancet, The, 2000, 355, 653.	6.3	1
420	HOPE and extension of the indications for ACE inhibitors?. Lancet, The, 2000, 355, 246-247.	6.3	18
421	Measures and meaning of blood pressure. Lancet, The, 2000, 355, 159.	6.3	9
422	Efficacy of valsartan in patients aged ≥65 years with systolic hypertension. Clinical Therapeutics, 2000, 22, 961-969.	1.1	32
423	Treatment of hypertension in patients ≥65 years of age: experience with amlodipine. Clinical Therapeutics, 2000, 22, 1473-1482.	1.1	6
424	A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged ≥65 years with mild to moderate hypertension. Clinical Therapeutics, 2000, 22, 1213-1224.	1.1	41
425	Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Research and Clinical Practice, 2000, 49, 187-194.	1.1	73

#	Article	IF	CITATIONS
427	Assessment and nursing management of hypertension in the perioperative period. Journal of Perianesthesia Nursing, 2000, 15, 163-168.	0.3	2
428	Obesity, independent of insulin resistance, is a major determinant of blood pressure in normoglycemic Hong Kong Chinese. Metabolism: Clinical and Experimental, 2000, 49, 1523-1528.	1.5	41
429	Influence of proteinuria on long-term outcome among patients with diabetes: The evidence continues to accumulate. American Heart Journal, 2000, 139, 934-935.	1.2	4
430	Prevalence, Treatment, Control, and Awareness of High Blood Pressure and the Risk of Stroke in Northwest England. Preventive Medicine, 2000, 30, 288-294.	1.6	8
431	Efficacy of rilmenidine, a selective I1 imidazoline receptor binding agent in diabetic hypertensive patients. American Journal of Hypertension, 2000, 13, S123-S126.	1.0	3
432	Trends in hypertension prevalence and management in Southwestern France, 1985–1996. Journal of Clinical Epidemiology, 2000, 53, 1230-1235.	2.4	20
433	Autonomic imbalance, hypertension, and cardiovascular risk. American Journal of Hypertension, 2000, 13, S112-S122.	1.0	191
434	Treating high-risk hypertensive patients. American Journal of Hypertension, 2000, 13, S68-S73.	1.0	5
435	Worldwide trends and shortcomings in the treatment of hypertension. American Journal of Hypertension, 2000, 13, S57-S61.	1.0	13
436	Comparisons in a competitive worldWhen is one drug superior to another?. American Journal of Hypertension, 2000, 13, 457-459.	1.0	3
437	New clinical trials of angiotensin blockade in cardiovascular disease: foreword. American Journal of Hypertension, 2000, 13, S55-S56.	1.0	0
438	Evidence in favor of moderate dietary sodium reduction. American Journal of Hypertension, 2000, 13, 8-13.	1.0	11
439	Risk stratification in hypertension: new insights from the Framingham study*1. American Journal of Hypertension, 2000, 13, S3-S10.	1.0	430
440	Can risk factor modification prevent nephropathy in type 2 diabetes mellitus?. American Journal of Kidney Diseases, 2000, 36, 1054-1056.	2.1	2
441	Impact of angiotensin II on the kidney: Does an angiotensin II receptor blocker make sense?. American Journal of Kidney Diseases, 2000, 36, S18-S23.	2.1	18
442	Treating high-risk diabetic hypertensive patients with comorbid conditions. American Journal of Kidney Diseases, 2000, 36, \$10-\$17.	2.1	17
443	NHLBI Family Blood Pressure Program. Annals of Epidemiology, 2000, 10, 389-400.	0.9	160
444	Stress Management Intervention for Primary Prevention of Hypertension Detailed Results from Phase I of Trials of Hypertension Prevention (TOHP-I). Annals of Epidemiology, 2000, 10, 45-58.	0.9	26

#	Article	IF	CITATIONS
445	Medicare and drug coverage: a women's health issue. Women's Health Issues, 2000, 10, 47-53.	0.9	10
446	Genetic variations of the apolipoprotein E gene determine the plasma triglyceride levels after heart transplantation. Journal of Heart and Lung Transplantation, 2000, 19, 765-770.	0.3	5
447	Nutrition in the prevention of disease. American Journal of Preventive Medicine, 2000, 18, 351-353.	1.6	2
448	Management of mild chronic hypertension during pregnancy: a review*1. Obstetrics and Gynecology, 2000, 96, 849-860.	1.2	135
449	Efficacy of celiprolol in the treatment of hypertension in the elderly: An open-label study. Current Therapeutic Research, 2000, 61, 49-60.	0.5	0
450	Drug surveillance study of amlodipine in patients with hypertension not controlled with drug therapy: NORCON study. Current Therapeutic Research, 2000, 61, 863-870.	0.5	4
451	Open-label, uncontrolled, clinical trial of barnidipine hydrochloride in Korean patients with renal parenchymal hypertension. Current Therapeutic Research, 2000, 61, 927-937.	0.5	4
452	EFFICACY AND SAFETY OF A FIXED LOW-DOSE PERINDOPRIL/INDAPAMIDE COMBINATION IN ESSENTIAL HYPERTENSION. A RANDOMISED CONTROLLED STUDY. Clinical and Experimental Hypertension, 2000, 22, 23-32.	0.5	18
453	USE OF ANTIHYPERTENSIVE DRUGS IN THE ITALIAN HOSPITALS. Pharmacological Research, 2000, 41, 249-253.	3.1	10
454	Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus. New England Journal of Medicine, 2000, 342, 905-912.	13.9	1,063
456	La insuficiencia cardÃaca congestiva en atención primaria (I) Semergen, 2000, 26, 5-13.	0.2	5
457	Strength Training in the Elderly. Sports Medicine, 2000, 30, 249-268.	3.1	253
458	Epoetin Alfa Drug Use Evaluation Using A Software System. Disease Management and Health Outcomes, 2000, 8, 287-295.	0.3	1
459	Achieving Patient Buy-In and Long Term Compliance with Antihypertensive Treatment. Disease Management and Health Outcomes, 2000, 7, 13-20.	0.3	3
460	Losartan. Drugs and Aging, 2000, 16, 227-250.	1.3	39
461	Pathoaetiology, Epidemiology and Diagnosis of Hypertension. Drugs, 2000, 59, 1-12.	4.9	37
462	Diuretics as a Basis of Antihypertensive Therapy. Drugs, 2000, 59, 21-25.	4.9	17
463	Clinical Positioning of Indapamide Sustained Release 1.5mg in Management Protocols for Hypertension. Drugs, 2000, 59, 27-38.	4.9	17

#	Article	IF	CITATIONS
464	Valsartan: a novel angiotensin Type 1 receptor antagonist. Expert Opinion on Pharmacotherapy, 2000, 1, 337-350.	0.9	32
465	Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ: British Medical Journal, 2000, 321, 1440-1444.	2.4	908
466	Hypertension in the Aging Patient: New Imperatives, New Options. The American Journal of Geriatric Cardiology, 2000, 9, 12-15.	0.7	8
467	Safety of Drugs Commonly Used to Treat Hypertension, Dyslipidemia, and Type 2 Diabetes (The Metabolic) Tj ETC	Qq <u>1</u> .4 0.7	84314 rgBT
468	Ambulatory blood pressure in women: Family history of hypertension and personality. Psychology, Health and Medicine, 2000, 5, 227-240.	1.3	13
469	Improvements in Chronic Diseases With a Comprehensive Natural Medicine Approach: A Review and Case Series. Behavioral Medicine, 2000, 26, 34-46.	1.0	26
470	Prospective Study of the Association between Sleep-Disordered Breathing and Hypertension. New England Journal of Medicine, 2000, 342, 1378-1384.	13.9	4,294
476	DRUG THERAPY OF HEART FAILURE CAUSED BY SYSTOLIC DYSFUNCTION IN THE ELDERLY. Clinics in Geriatric Medicine, 2000, 16, 513-534.	1.0	2
477	Difficult-to-Control Hypertension: In Response. Mayo Clinic Proceedings, 2000, 75, 655-656.	1.4	0
478	$\hat{A}_{\hat{i}}$ Se utilizan adecuadamente los f $\tilde{A}_{\hat{i}}$ rmacos antihipertensivos?. Hipertension Y Riesgo Vascular, 2000, 17, 302-306.	0.3	1
482	Hipertensi $\tilde{A}^3$ n arterial refractaria. Hipertension Y Riesgo Vascular, 2000, 17, 114-123.	0.3	4
490	EVALUATION OF THE OBESE PATIENT. Medical Clinics of North America, 2000, 84, 387-399.	1.1	26
491	The best way to manage hypertension after renal transplantation., 2000, 10, 3-6.		7
495	Seguridad y efectividad de amlodipino en pacientes hipertensos no controlados farmacol $\tilde{A}^3$ gicamente en el $\tilde{A}_1$ mbito de Atenci $\tilde{A}^3$ n Primaria. Hipertension Y Riesgo Vascular, 2000, 17, 296-301.	0.3	2
496	Hipertensi $\tilde{A}^3$ n arterial y astenia marcada. Semergen, 2000, 26, 414-415.	0.2	0
497	Hipertensión arterial y menopausia reciente: estudio comparativo de dos fármacos hipotensores. Hipertension Y Riesgo Vascular, 2000, 17, 42-46.	0.3	0
503	Nifedipine, a calcium antagonist, was just as effective as co-amilozide, a diuretic, in preventing stroke, MI, heart failure or cardiovascular death in hypertensive patients. Evidence-based Cardiovascular Medicine, 2000, 4, 101-103.	0.0	0
504	Felodipine/Metoprolol. Drugs, 2000, 59, 141-157.	4.9	29

#	Article	IF	CITATIONS
505	Irbesartan. Drugs, 2000, 59, 1187-1206.	4.9	39
506	Eprosartan. Drugs, 2000, 60, 177-201.	4.9	26
507	Management of Type 2 Diabetes Mellitus and Cardiovascular Risk. Drugs, 2000, 60, 975-983.	4.9	41
508	Lercanidipine. Drugs, 2000, 60, 1123-1140.	4.9	86
509	A Comparative Evaluation of Amlodipine and Hydrochlorothiazide as Monotherapy in the Treatment of Isolated Systolic Hypertension in the Elderly. Clinical Drug Investigation, 2000, 19, 317-326.	1.1	10
510	Efficacy and Safety of Quinapril 40mg Once Daily as Monotherapy for Patients with Poorly Controlled Hypertension. Clinical Drug Investigation, 2000, 20, 81-88.	1.1	3
511	Patterns and Costs for Hypertension Treatment in the United States. Clinical Drug Investigation, 2000, 20, 181-195.	1.1	15
512	Influence of leisure time physical activity and television watching on atherosclerosis risk factors in the NHLBI Family Heart Study. Atherosclerosis, 2000, 153, 433-443.	0.4	162
513	Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. New England Journal of Medicine, 2001, 344, 3-10.	13.9	4,625
514	Treating Hypertension in Women of Child-Bearing Age and during Pregnancy. Drug Safety, 2001, 24, 457-474.	1.4	50
515	Metabolic Profile of Indapamide Sustained-Release in Patients with Hypertension. Drug Safety, 2001, 24, 1155-1165.	1.4	52
516	Drug Interactions with Irbesartan. Clinical Pharmacokinetics, 2001, 40, 605-614.	1.6	32
517	Perindopril. Drugs, 2001, 61, 867-896.	4.9	60
518	Monotherapy versus Combination Therapy as First Line Treatment of Uncomplicated Arterial Hypertension. Drugs, 2001, 61, 943-954.	4.9	46
519	Perindopril/Indapamide 2/0.625 mg/day. Drugs, 2001, 61, 1211-1229.	4.9	13
520	Telmisartan. Drugs, 2001, 61, 1501-1529.	4.9	176
521	Manidipine. Drugs, 2001, 61, 1777-1799.	4.9	30
523	Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease. Annals of Internal Medicine, 2001, 135, 73.	2.0	927

#	Article	IF	Citations
524	Medical Treatment of Peripheral Arterial Disease and Claudication. New England Journal of Medicine, 2001, 344, 1608-1621.	13.9	1,018
525	Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease. New England Journal of Medicine, 2001, 345, 1291-1297.	13.9	1,729
527	MANAGEMENT OF TYPE 2 DIABETES. Obstetrics and Gynecology Clinics of North America, 2001, 28, 401-420.	0.7	1
529	Hipertensión arterial (II). Aspectos médicos y sanitarios. ClÃnica E Investigación En Arteriosclerosis, 2001, 13, 125-129.	0.4	O
530	Algunas consideraciones sobre el Consenso de la Sociedad Española de Diabetes y de la Sociedad Española de Medicina Familiar y Comunitaria sobre los criterios y pautas de terapia combinada en la diabetes tipo 2. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2001, 48, 220-221.	0.8	O
533	Decisiones y actitudes terapéuticas en los pacientes con hipertensión clÃnica aislada. Revista Clinica Espanola, 2001, 201, 174-178.	0.2	7
534	Nifedipina en las crisis hipertensivas: ¿hasta cuándo?. Hipertension Y Riesgo Vascular, 2001, 18, 248-249.	0.3	0
535	Benefits of Treating Hypertension in the Elderly. Drugs and Aging, 2001, 18, 631-638.	1.3	5
536	Exercise Prescription for the Elderly. Sports Medicine, 2001, 31, 809-818.	3.1	197
537	Treatment Expectations in Hypertension. Disease Management and Health Outcomes, 2001, 9, 631-640.	0.3	1
538	CLINICAL STUDY. Hypertension and the Risk of Acute Myocardial Infarction in Argentina. Preventive Cardiology, 2001, 4, 57-64.	1.1	9
539	Aerobic Exercise and Resting Blood Pressure: A Meta-Analytic Review of Randomized, Controlled Trials. Preventive Cardiology, 2001, 4, 73-80.	1.1	155
540	Emergence of Obesity and Cardiovascular Risk for Coronary Artery Disease: The Bogalusa Heart Study. Preventive Cardiology, 2001, 4, 116-121.	1.1	52
541	A Comparison of NCEP and Absolute Risk Stratification Methods for Lipid-Lowering Therapy in Middle-Aged Adults: The ARIC Study. Preventive Cardiology, 2001, 4, 148-157.	1.1	2
542	Alcohol Consumption and Hypertension. Journal of Clinical Hypertension, 2001, 3, 166-170.	1.0	43
543	The ? Blockers: Are They as Protective in Hypertension as in other Cardiovascular Conditions?. Journal of Clinical Hypertension, 2001, 3, 236-243.	1.0	8
544	Treatment of Hypertension to Prevent Stroke: Translating Evidence into Clinical Practice. Journal of Clinical Hypertension, 2001, 3, 153-164.	1.0	8
545	Emergency Room Management of Hypertensive Urgencies and Emergencies. Journal of Clinical Hypertension, 2001, 3, 158-164.	1.0	47

#	Article	IF	CITATIONS
546	The Role of Home Blood Pressure Monitoring in Hypertension Control. Journal of Clinical Hypertension, 2001, 3, 171-173.	1.0	4
547	Behavioral Treatment of Hypertension. Journal of Clinical Hypertension, 2001, 3, 115-117.	1.0	0
548	The Challenge of Controlling Systolic Blood Pressure: Data from the National Health and Nutrition Examination Survey (NHANES III), 1988?1994. Journal of Clinical Hypertension, 2001, 3, 211-216.	1.0	39
549	Diuretics Revisited?Again. Journal of Clinical Hypertension, 2001, 3, 136-138.	1.0	7
550	Beyond the Usual Strategies for Blood Pressure Reduction: Therapeutic Considerations and Combination Therapies. Journal of Clinical Hypertension, 2001, 3, 346-353.	1.0	13
551	Health Care Improvement and Cost Reduction Opportunities in Hypertensive Medicaid Beneficiaries. Journal of Clinical Hypertension, 2001, 3, 279-318.	1.0	2
552	Caffeine and Stress: Implications for Risk, Assessment, and Management of Hypertension. Journal of Clinical Hypertension, 2001, 3, 354-382.	1.0	28
553	Combination Calcium Channel Blocker Therapy in the Treatment of Hypertension. Journal of Clinical Hypertension, 2001, 3, 322-327.	1.0	17
554	Advances in Antihypertensive Combination Therapy: Benefits of Low-Dose Thiazide Diuretics in Conjunction With Omapatrilat, a Vasopeptidase Inhibitor. Journal of Clinical Hypertension, 2001, 3, 307-312.	1.0	4
555	Diastolic Dysfunction in Arterial Hypertension. Journal of Clinical Hypertension, 2001, 3, 22-27.	1.0	31
556	Management of High-Risk Hypertensive Patients with Diabetes: Potential Role of Angiotensin II Receptor Antagonists. Journal of Clinical Hypertension, 2001, 3, 225-235.	1.0	3
557	Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension. Journal of Clinical Hypertension, 2001, 3, 283-318.	1.0	233
558	Low-Dose Combination Therapy: Why Include a Diuretic?. Journal of Clinical Hypertension, 2001, 3, 273-275.	1.0	1
559	Choosing Initial Antihypertensive Drug Therapy for the Uncomplicated Hypertensive Patient. Journal of Clinical Hypertension, 2001, 3, 37-44.	1.0	5
560	Ambulatory Blood Pressure Monitoring: How Important Is It in Estimating Risk or Guiding Therapy?. Journal of Clinical Hypertension, 2001, 3, 11-13.	1.0	3
561	Up-Regulation of Endothelial Nitric Oxide Synthase through β2-Adrenergic Receptor—The Role of a β-Blocker with NO-Releasing Action. Biochemical and Biophysical Research Communications, 2001, 280, 589-594.	1.0	28
562	The Effect of Common Polymorphisms of the $\hat{I}^2$ 2-Adrenergic Receptor on Agonist-Mediated Vascular Desensitization. New England Journal of Medicine, 2001, 345, 1030-1035.	13.9	344
563	Current utilization trends for $\hat{l}^2$ -blockers in cardiovascular disease. American Journal of Medicine, 2001, 110, 2-6.	0.6	18

#	Article	IF	CITATIONS
564	Pitfalls in assessing the quality of care for patients with cardiovascular disease. American Journal of Medicine, 2001, 111, 297-303.	0.6	18
565	The effect of biofeedback in hypertension. Applied Nursing Research, 2001, 14, 29-35.	1.0	45
566	The chiropractic profession, dietary calcium, and the diseases associated with calcium-deficient diets. Journal of Manipulative and Physiological Therapeutics, 2001, 24, 305-307.	0.4	0
567	Reducing the personal risk of perceived disease: The chiropractic patients' self-care endeavor. Journal of Manipulative and Physiological Therapeutics, 2001, 24, 378-384.	0.4	2
568	Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clinical Therapeutics, 2001, 23, 108-123.	1.1	36
569	Delphi panel study of current hypertension treatment patterns. Clinical Therapeutics, 2001, 23, 160-167.	1.1	7
570	Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clinical Therapeutics, 2001, 23, 833-850.	1.1	119
571	Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clinical Therapeutics, 2001, 23, 1193-1208.	1.1	61
572	Assessment of the association between blood pressure control and health care resource use. Clinical Therapeutics, 2001, 23, 1773-1782.	1.1	11
573	Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clinical Therapeutics, 2001, 23, 1999-2010.	1.1	172
574	A STUDY OF HYPERINSULINAEMIA AND DYSLIPIDAEMIA IN HYPERTENSIVE PATIENTS OF ARMED FORCES. Medical Journal Armed Forces India, 2001, 57, 312-316.	0.3	0
575	A plea for harmonising guidelines. International Journal of Cardiology, 2001, 79, 129-132.	0.8	1
576	Prevalence of type 2 diabetes mellitus in Taiwan: ethnic variation and risk factors. Diabetes Research and Clinical Practice, 2001, 51, 59-66.	1.1	24
577	Early alterations of blood pressure in normotensive and normoalbuminuric Type 1 diabetic patients. Diabetes Research and Clinical Practice, 2001, 53, 85-90.	1.1	23
578	Angiotensin-converting enzyme gene polymorphism and microvascular complications in Turkish type 2 diabetic patients. Diabetes Research and Clinical Practice, 2001, 54, 95-104.	1.1	34
579	Angiotensin-converting enzyme inhibitors. Advances in Protein Chemistry, 2001, 56, 13-75.	4.4	48
580	A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. American Journal of Hypertension, 2001, 14, 14-19.	1.0	49
581	Device-guided breathing exercises reduce blood pressure: ambulatory and home measurements. American Journal of Hypertension, 2001, 14, 74-76.	1.0	83

#	ARTICLE	IF	CITATIONS
582	A systematic review of predictors of maintenance of normotension after withdrawal of antihypertensive drugs. American Journal of Hypertension, 2001, 14, 98-105.	1.0	33
583	Combination therapy as the initial drug treatment for hypertension: when is it appropriate?. American Journal of Hypertension, 2001, 14, 293-295.	1.0	5
584	Rapid adjustment of antihypertensive drugs produces a durable improvement in blood pressure. American Journal of Hypertension, 2001, 14, 345-350.	1.0	15
585	Weight reduction and pharmacologic treatment in obese hypertensives. American Journal of Hypertension, 2001, 14, 530-538.	1.0	79
586	Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass. American Journal of Hypertension, 2001, 14, 357-363.	1.0	41
587	Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. American Journal of Hypertension, 2001, 14, 84-86.	1.0	61
588	Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. American Journal of Hypertension, 2001, 14, 567-572.	1.0	51
589	The measurement of arterial properties in hypertension. American Journal of Hypertension, 2001, 14, 183-185.	1.0	11
590	Low-dose combination therapy: an important first-line treatment in the management of hypertension. American Journal of Hypertension, 2001, 14, 286-292.	1.0	54
591	Rationalizing the treatment of hypertension. American Journal of Hypertension, 2001, 14, S3-S7.	1.0	7
592	Antihypertensive Therapy in Diabetic Hypertensive Patients. American Journal of Hypertension, 2001, 14, S12-S16.	1.0	27
593	Low-dose combination therapy: The rationalization for an ace inhibitor and a calcium channel blocker in higher risk patients. American Journal of Hypertension, 2001, 14, S8-S11.	1.0	14
594	Ambulatory blood pressure of adults in Novosibirsk, Russia: interim report on a population study. American Journal of Hypertension, 2001, 14, A37.	1.0	6
595	The use of antihypertensive therapy: The reply. American Journal of Hypertension, 2001, 14, 600-601.	1.0	0
596	Diabetic nephropathy in African Americans. American Journal of Hypertension, 2001, 14, S132-S138.	1.0	8
597	Fibrosis and ischemia: the real risks in hypertensive heart disease. American Journal of Hypertension, 2001, 14, S194-S199.	1.0	68
598	Are low intakes of calcium and potassium important causes of cardiovascular disease?. American Journal of Hypertension, 2001, 14, S206-S212.	1.0	48
599	Management of hypertensive patients with multiple cardiovascular risk factors. American Journal of Hypertension, 2001, 14, S221-S224.	1.0	4

#	Article	IF	CITATIONS
600	Clinical overview of hypertension and emerging treatment considerations. American Journal of Hypertension, 2001, 14, S226-S230.	1.0	3
601	Issues in hypertension: drug tolerability and special populations. American Journal of Hypertension, 2001, 14, S231-S236.	1.0	46
602	Pharmacology and clinical efficacy of angiotensin receptor blockers. American Journal of Hypertension, 2001, 14, S242-S247.	1.0	18
603	Impact of smoking cessation on ambulatory blood pressure and heart rate in postmenopausal women. American Journal of Hypertension, 2001, 14, 942-949.	1.0	34
604	Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. American Journal of Hypertension, 2001, 14, 963-968.	1.0	81
605	Herbs and alternative therapies in the hypertension clinic. American Journal of Hypertension, 2001, 14, 971-975.	1.0	81
606	Pharmacology of cardiovascular chronotherapeutic agents. American Journal of Hypertension, 2001, 14, S296-S301.	1.0	26
607	Vasodilatory edema: a common side effect of antihypertensive therapy. American Journal of Hypertension, 2001, 14, 978-979.	1.0	71
608	Changes in the pharmacologic treatment of hypertension in the department of veterans affairs 1997倓1999: decreased use of calcium antagonists and increased use of β-blockers and thiazide diuretics. American Journal of Hypertension, 2001, 14, 957-962.	1.0	15
609	Is resistant hypertension really resistant?. American Journal of Hypertension, 2001, 14, 1263-1269.	1.0	151
610	Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study. American Journal of Hypertension, 2001, 14, 1226-1230.	1.0	69
611	Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. American Journal of Hypertension, 2001, 14, 1219-1225.	1.0	20
612	Management of hypertensive crises: the scientific basis for treatment decisions. American Journal of Hypertension, 2001, 14, 1154-1167.	1.0	105
613	Antihypertensive medications in pregnant women with chronic hypertension. Primary Care Update for Ob/Gyns, 2001, 8, 175-177.	0.1	0
614	Blood pressure response to combination therapy with ramipril or captopril plus hydrochlorothiazide: a randomized, active-controlled, crossover study. Current Therapeutic Research, 2001, 62, 16-25.	0.5	0
615	A review of irbesartan in antihypertensive therapy: comparison with other antihypertensive agents. Current Therapeutic Research, 2001, 62, 505-523.	0.5	17
616	Comparison of the antihypertensive effect of imidapril and enalapril in the treatment of mild to moderate essential hypertension: a randomized, double-blind, parallel-group study. Current Therapeutic Research, 2001, 62, 437-450.	0.5	3
617	Effect of controlled-release nifedipine on left ventricular hypertrophy in Japanese patients with hypertension: An open-label, uncontrolled study. Current Therapeutic Research, 2001, 62, 773-782.	0.5	2

#	Article	IF	CITATIONS
618	Optimal medical management of patients with chronic ischemic heart disease. Disease-a-Month, 2001, 47, 150-196.	0.4	0
619	Endothelial Dysfunction, Nitric Oxide and Platelet Activation in Hypertensive and Diabetic Type II Patients. Thrombosis Research, 2001, 102, 107-114.	0.8	72
620	Walking and resting blood pressure in adults: A Meta-analysis. Preventive Medicine, 2001, 33, 120-127.	1.6	99
621	ABCs of secondary prevention of CHD: easier said than done. Lancet, The, 2001, 357, 972-973.	6.3	36
622	Blood-pressure lowering for the secondary prevention of stroke. Lancet, The, 2001, 358, 1026-1027.	6.3	49
623	Riesgo cardiovascular asociado a la insuficiencia renal. Hipertension Y Riesgo Vascular, 2001, 18, 285-290.	0.3	1
625	Hipertensi $\tilde{A}^3$ n y tratamiento antihipertensivo como factores de riesgo de diabetes mellitus tipo 2. Cl $\tilde{A}$ nica E Investigaci $\tilde{A}^3$ n En Arteriosclerosis, 2001, 13, 44-45.	0.4	0
626	$\hat{A}_{z}$ C $\hat{A}^{3}$ mo diagnosticar la hipertensi $\hat{A}^{3}$ n secundaria?. FMC Formacion Medica Continuada En Atencion Primaria, 2001, 8, 447-457.	0.0	1
627	Riesgo cardiovascular absoluto en hipertensos y su evoluci $\tilde{A}^3$ n con el tratamiento antihipertensivo. Hipertension Y Riesgo Vascular, 2001, 18, 72-77.	0.3	2
628	Automedida de la presi $ ilde{A}^3$ n arterial: estado actual de la cuesti $ ilde{A}^3$ n. Semergen, 2001, 27, 70-79.	0.2	10
630	El documento Colesterol 2000: ¿útil para el enfermo renal?. Revista Espanola De Cardiologia, 2001, 54, 807.	0.6	1
631	¿Comparado con qué es seguro y efectivo el tratamiento combinado con Verapamilo y Trandolapril?. Revista Espanola De Geriatria Y Gerontologia, 2001, 36, 302-303.	0.2	0
632	EvaluaciÃ <sup>3</sup> n de la eficacia de la combinaciÃ <sup>3</sup> n de verapamilo y trandolapril en ancianos hipertensos institucionalizados, insuficientemente controlados con monoterapia. Revista Espanola De Geriatria Y Gerontologia, 2001, 36, 15-20.	0.2	3
636	Hipertensión arterial (I). Aspectos fisiopatológicos. ClÃnica E Investigación En Arteriosclerosis, 2001, 13, 80-84.	0.4	2
637	Hipertensión arterial (III). Aspectos diagnósticos y terapéuticos. ClÃnica E Investigación En Arteriosclerosis, 2001, 13, 167-171.	0.4	0
640	Efectos sobre la presión arterial de la restricción dietética del sodio y dieta del Dietary Approaches to Stop Hypertension (DASH) Study. ClÃnica E Investigación En Arteriosclerosis, 2001, 13, 282-283.	0.4	0
641	Detecci $\tilde{A}^3$ n del fen $\tilde{A}^3$ meno de bata blanca en atenci $\tilde{A}^3$ n primaria. Semergen, 2001, 27, 51-53.	0.2	0
642	Impacto de la hipertensión en las cardiopatÃas en España. Estudio CARDIOTENS 1999. Revista Espanola De Cardiologia, 2001, 54, 139-149.	0.6	82

#	Article	IF	CITATIONS
643	Diabetes and Hypertension. Blood Pressure, 2001, 10, 311-321.	0.7	37
647	Complicaciones de la diabetes mellitus. Diagnóstico y tratamiento. Semergen, 2001, 27, 132-145.	0.2	6
648	HipertensiÃ <sup>3</sup> n arterial en el paciente dislipémico. ClÃnica E InvestigaciÃ <sup>3</sup> n En Arteriosclerosis, 2001, 13, 179-194.	0.4	4
650	Simultaneous aortic replacement and renal artery revascularization: The influence of preoperative renal function on early risk and late outcome. Journal of Vascular Surgery, 2001, 34, 1041-1049.	0.6	19
651	Incidencia de alteraciones electrocardiogr $ ilde{A}_i$ ficas en la hipertensi $ ilde{A}^3$ n arterial. Estudio MINACOR. Hipertension Y Riesgo Vascular, 2001, 18, 213-217.	0.3	0
652	The current status of antihypertensive treatments: into the new millennium. Expert Opinion on Pharmacotherapy, 2001, 2, 731-737.	0.9	2
653	Challenges for the Prevention of Primary and Secondary Stroke. The importance of lowering blood pressure and total cardiovascular risk. Blood Pressure, 2001, 10, 344-351.	0.7	28
654	Pharmacoeconomics of Hypertension Management. Pharmacoeconomics, 2001, 19, 337-347.	1.7	32
655	What is the Optimal Blood Pressure in Patients with Diabetes Mellitus?. American Journal of Cardiovascular Drugs, 2001, 1, 173-177.	1.0	3
656	Characteristics of Patients with Uncontrolled Hypertension in the United States. New England Journal of Medicine, 2001, 345, 479-486.	13.9	728
657	AMBULATORY BLOOD PRESSURE MONITORING AND CLINICAL CHARACTERISTICS OF THE TRUE AND WHITE-COAT RESISTANT HYPERTENSION. Clinical and Experimental Hypertension, 2001, 23, 203-211.	0.5	39
658	SALT-SENSITIVITY AND OTHER PREDICTORS OF STRESS-RELATED CARDIOVASCULAR REACTIVITY IN HEALTHY YOUNG MALES. Clinical and Experimental Hypertension, 2001, 23, 213-225.	0.5	17
659	Calcium Antagonists in Hypertension. Blood Pressure, 2001, 10, 387-397.	0.7	2
660	Insulin action and secretion in healthy Hispanic-Mexican first-degree relatives of subjects with Type 2 diabetes. Journal of Endocrinological Investigation, 2001, 24, 580-586.	1.8	16
661	Correlates of knowledge of one's blood pressure and cholesterol levels among older members of a managed care plan. Aging Clinical and Experimental Research, 2001, 13, 95-104.	1.4	7
662	Guidelines for the Management of Hypertension for General Practitioners Hypertension Research, 2001, 24, 613-634.	1.5	116
663	Selection of Antihypertensive Therapy for Patients With Hypertensive Renal Disease. JAMA - Journal of the American Medical Association, 2001, 285, 2774.	3.8	6
664	Therapeutic benefits of increasing natriuretic peptide levels. Cardiovascular Research, 2001, 51, 510-520.	1.8	17

#	Article	IF	CITATIONS
665	Determination of Optimal Blood Pressure for Patients with IgA Nephropathy Based on Renal Histology Hypertension Research, 2001, 24, 89-92.	1.5	9
666	Differences in Mechanisms between Weight Loss-Sensitive and -Resistant Blood Pressure Reduction in Obese Subjects Hypertension Research, 2001, 24, 371-376.	1.5	28
667	Management of Diabetic Nephropathy. Journal of the Royal Society of Medicine, 2001, 94, 210-217.	1.1	21
668	Characteristics associated with the dropout of hypertensive patients followed up in an outpatient referral clinic. Arquivos Brasileiros De Cardiologia, 2001, 76, 352-354.	0.3	28
669	Nutrition, Diet, and Hypertension., 2001,, 303-324.		9
670	Trandolaprilat, an Angiotensin-Converting Enzyme Inhibitor, Is Not Excreted in Bile via and ATP-Dependent Active Transporter(cMOAT) Hypertension Research, 2001, 24, 235-240.	1.5	5
671	Relative Wall Thickness Is an Independent Predictor of Left Ventricular Systolic and Diastolic Dysfunctions in Essential Hypertension Hypertension Research, 2001, 24, 493-499.	1.5	48
672	Typical and Atypical Symptoms of Myocardial Infarction Among African-Americans, Whites, and Koreans. Critical Care Nursing Clinics of North America, 2001, 13, 531-539.	0.4	13
673	Tolerability and Safety of a Calcium Channel Blocker in Comparison with a Diuretic in the Treatment of Elderly Patients with Hypertension: Secondary Analysis of the NICS-EH Hypertension Research, 2001, 24, 475-480.	1.5	20
674	Should Angiotensin-Converting Enzyme Inhibitors Be Added To The Water Supply Of Patients With Diabetes?. Endocrine Practice, 2001, 7, 59-63.	1.1	2
675	Comparison of the Effects of an ACE Inhibitor and .ALPHABETA. Blocker on the Progression of Renal Failure with Left Ventricular Hypertrophy: Preliminary Report Hypertension Research, 2001, 24, 153-158.	1.5	17
676	Exercise and hypertension. Current Opinion in Cardiology, 2001, 16, 356-359.	0.8	44
677	Usefulness of home blood pressure measurements in assessing the effect of treatment in a single-blind placebo-controlled open trial. Journal of Hypertension, 2001, 19, 179-185.	0.3	88
678	Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. Journal of Hypertension, 2001, 19, 829-842.	0.3	83
679	Association of body mass index with blood pressure in 80-year-old subjects. Journal of Hypertension, 2001, 19, 2165-2169.	0.3	28
680	Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy?. Current Opinion in Nephrology and Hypertension, 2001, 10, 617-624.	1.0	37
681	Ambulatory and conventional pulse pressures and mean pressures as determinants of the Sokolow-Lyon ECG voltage index in older patients with systolic hypertension. Blood Pressure Monitoring, 2001, 6, 197-202.	0.4	4
682	Effects of Kidney-Pancreas Transplantation on Atherosclerotic Risk Factors and Endothelial Function in Patients With Uremia and Type 1 Diabetes. Diabetes, 2001, 50, 496-501.	0.3	105

#	Article	IF	CITATIONS
683	Is coronary risk an accurate surrogate for cardiovascular risk for treatment decisions in mild hypertension? A population validation. Journal of Hypertension, 2001, 19, 691-696.	0.3	11
684	Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension, 2001, 19, 819-825.	0.3	56
685	Independent predictors of isolated clinic (white-coat') hypertension. Journal of Hypertension, 2001, 19, 1015-1020.	0.3	92
686	Relation between clinical and therapeutic variables and quality of life in hypertension. Journal of Hypertension, 2001, 19, 1913-1919.	0.3	49
687	Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure?. Current Opinion in Nephrology and Hypertension, 2001, 10, 643-648.	1.0	10
688	Risk and benefit of treatment of isolated systolic hypertension in the elderly: evidence from the Systolic Hypertension in Europe Trial. Current Opinion in Cardiology, 2001, 16, 342-348.	0.8	18
689	Association of high resting end tidal CO2 with carotid artery thickness in women, but not men. Journal of Hypertension, 2001, 19, 459-463.	0.3	8
690	Hypertension in South African adults: results from the Demographic and Health Survey, 1998. Journal of Hypertension, 2001, 19, 1717-1725.	0.3	145
691	High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. Journal of Hypertension, 2001, 19, 2063-2070.	0.3	242
692	Metabolic Effects and Safety Profile of Nebivolol. Journal of Cardiovascular Pharmacology, 2001, 38, S33-S35.	0.8	20
693	Polymorphism insertion/deletion of the ACE gene and ambulatory blood pressure circadian variability in essential hypertension. Blood Pressure Monitoring, 2001, 6, 27-32.	0.4	18
694	Cardiovascular Risk Factors in Young Adult Survivors of Childhood Acute Lymphoblastic Leukemia. The American Journal of Pediatric Hematology/oncology, 2001, 23, 424-430.	1.3	161
695	Cardiovascular risk stratification in hypertensive patients: Impact of echocardiography and carotid ultrasonography. Journal of Hypertension, 2001, 19, 375-380.	0.3	28
696	Exercise training causes skeletal muscle venular growth and alters hemodynamic responses in spontaneously hypertensive rats. Journal of Hypertension, 2001, 19, 931-940.	0.3	37
697	Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. Journal of Hypertension, 2001, 19, 1343-1348.	0.3	84
698	Hypertension trials: 1990 to 2000. Current Opinion in Nephrology and Hypertension, 2001, 10, 501-505.	1.0	12
699	Cardiovascular disease in diabetes: prevention and intervention. Current Opinion in Endocrinology, Diabetes and Obesity, 2001, 8, 101-110.	0.6	3
700	Prevalence of blood pressure cuff sizes in a referral practice of 430 consecutive adult hypertensives. Blood Pressure Monitoring, 2001, 6, 17-20.	0.4	37

#	Article	IF	Citations
701	Predictive values of automated blood pressure measurement: what can we learn from the Japanese population $\hat{a} \in \text{``the Ohasama study. Blood Pressure Monitoring, 2001, 6, 335-339.}$	0.4	40
702	Task Force II: Blood pressure measurement and cardiovacular outcome. Blood Pressure Monitoring, 2001, 6, 355-370.	0.4	170
703	Cardiovascular risk factors in normotensive and hypertensive Egyptians. Journal of Hypertension, 2001, 19, 1933-1940.	0.3	28
704	Self-measurement of blood pressure: accuracy, patient preparation for readings, technique and equipment. Blood Pressure Monitoring, 2001, 6, 133-138.	0.4	30
705	The importance of 24-h blood pressure control. Blood Pressure Monitoring, 2001, 6, 9-16.	0.4	29
706	Nitrendipine and Enalapril Combination Therapy in Mild to Moderate Hypertension: Assessment of Dose-Response Relationship by a Clinical Trial of Factorial Design. Journal of Cardiovascular Pharmacology, 2001, 38, 840-849.	0.8	22
707	Diabetes and All-Cause and Coronary Heart Disease Mortality Among US Male Physicians. Archives of Internal Medicine, 2001, 161, 242.	4.3	182
708	EVIDENCE-BASED TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE 2 DIABETES. Acta Clinica Belgica, 2001, 56, 96-102.	0.5	0
709	Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance?. Journal of Hypertension, 2001, 19, 149-155.	0.3	79
710	Management of Hypertension in Older People. Journal of Pharmacy Practice and Research, 2001, 31, 212-219.	0.2	0
711	A Practical Approach to Achieving Recommended Blood Pressure Goals in Diabetic Patients. Archives of Internal Medicine, 2001, 161, 2661.	4.3	82
712	Daily regimen and compliance with treatment. BMJ: British Medical Journal, 2001, 323, 647-647.	2.4	94
713	A Comparison of Selected Antihypertensives and the Use of Conventional vs Ambulatory Blood Pressure in the Detection and Treatment of Hypertension. Cardiology, 2001, 96, 3-9.	0.6	6
714	Evaluation of the Method for Nifedipine Administration for a Rapid Onset of Clinical Effect: A Clinical Study in Normal Volunteers Yakugaku Zasshi, 2001, 121, 355-364.	0.0	11
715	Blood Pressure Variability in Binswanger's Disease and Isolated Lacunar Infarction. Cerebrovascular Diseases, 2001, 11, 230-234.	0.8	6
716	Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clinical Science, 2001, 100, 591.	1.8	12
717	Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clinical Science, 2001, 100, 591-599.	1.8	48
718	Guidelines for the Management of Patients with Chronic Stable Angina: Treatment. Annals of Internal Medicine, 2001, 135, 616.	2.0	55

#	Article	IF	CITATIONS
719	Long-term Blood Pressure Variability and Cerebrovascular Changes on CT in a Community-based Elderly Population Journal of Epidemiology, 2001, 11, 190-198.	1.1	6
720	An Association between an Antibody against Chlamydia pneumoniae and Common Carotid Atherosclerosis Internal Medicine, 2001, 40, 208-213.	0.3	13
721	Clinical Determination of Dry Body Weight. Hemodialysis International, 2001, 5, 42-50.	0.4	21
722	Maternally Inherited Diabetes and Deafness: A Multicenter Study. Annals of Internal Medicine, 2001, 134, 721.	2.0	251
723	Long-Term Weight Loss and Changes in Blood Pressure: Results of the Trials of Hypertension Prevention, Phase II. Annals of Internal Medicine, 2001, 134, 1.	2.0	763
724	Cocaine-Related Vasculitis Causing Upper-Limb Peripheral Vascular Disease. Annals of Internal Medicine, 2001, 135, 142.	2.0	4
725	Quality Indicators for Appropriate Medication Use in Vulnerable Elders. Annals of Internal Medicine, 2001, 135, 703.	2.0	125
726	Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Guidelines Based on Current Evidence. Annals of Internal Medicine, 2001, 135, 1079.	2.0	58
727	Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension. Annals of Internal Medicine, 2001, 135, 1074.	2.0	43
728	Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. Journal of Hypertension, 2001, 19, 921-930.	0.3	267
729	Appropriate or inappropriate left ventricular mass in the presence or absence of prognostically adverse left ventricular hypertrophy. Journal of Hypertension, 2001, 19, 1113-1119.	0.3	58
730	Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. , 2001, 11, 474-490.		7
731	Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. Journal of Hypertension, 2001, 19, 335-341.	0.3	236
732	Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension, 2001, 19, 1139-1147.	0.3	234
733	CD-ROMs for blood pressure measurement. Blood Pressure Monitoring, 2001, 6, 195-196.	0.4	2
734	A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. Journal of Hypertension, 2001, 19, 343-350.	0.3	41
735	Changes in blood pressure among students attending Glasgow University between 1948 and 1968: analyses of cross sectional surveys Commentary: Changing population blood pressure levels. BMJ: British Medical Journal, 2001, 322, 885-889.	2.4	42
736	Dairy Food Consumption, Blood Pressure and Stroke. Journal of Nutrition, 2001, 131, 1875-1878.	1.3	89

#	Article	IF	Citations
737	Gene Expression Profiles of CLC Chloride Channels in Animal Models with Different Cardiovascular Diseases. Cellular Physiology and Biochemistry, 2001, 11, 321-330.	1.1	6
738	Effects of Crossing Legs on Blood Pressure Measurement. Clinical Nursing Research, 2001, 10, 202-213.	0.7	13
739	Seniors and Systolic Hypertension. Chest, 2001, 119, 323-327.	0.4	1
740	Epidemiologic Review of the Calcium Channel Blocker Drugs. Archives of Internal Medicine, 2001, 161, 1145.	4.3	56
741	Utility of prognostic stratification in adults with community-acquired bacterial meningitis. Comprehensive Therapy, 2001, 27, 72-77.	0.2	5
742	Controlling high blood pressure: A simple and effective approach. Comprehensive Therapy, 2001, 27, 209-212.	0.2	1
743	Innovative approaches to comprehensive cardiovascular disease risk reduction in clinical and community-based settings. Current Atherosclerosis Reports, 2001, 3, 498-506.	2.0	29
744	Treatment of coexisting diabetes and hypertension. Current Cardiology Reports, 2001, 3, 498-503.	1.3	3
745	Combating diabetic nephropathy with drug therapy. Current Diabetes Reports, 2001, 1, 148-156.	1.7	12
746	Treatment of hypertension in diabetic patients with nephropathy. Current Diabetes Reports, 2001, 1, 251-260.	1.7	6
747	Quality of life with nonpharmacologic treatment of hypertension. Current Hypertension Reports, 2001, 3, 466-472.	1.5	2
748	Actual practice in hypertension: Implications for persistence with and effectiveness of therapy.  Current Hypertension Reports, 2001, 3, 481-487.	1.5	11
749	The metabolic syndrome and related cardiovascular risk. Current Hypertension Reports, 2001, 3, 100-106.	1.5	22
750	Problems in the control of systolic blood pressure. Current Hypertension Reports, 2001, 3, 173-174.	1.5	0
751	Resistant hypertension and the birmingham hypertension square. Current Hypertension Reports, 2001, 3, 203-208.	1.5	5
752	Are sleep-related breathing disorders important contributing factors to the production of essential hypertension?. Current Hypertension Reports, 2001, 3, 209-215.	1.5	82
753	Using out of office blood pressure monitoring in the management of hypertension. Current Hypertension Reports, 2001, 3, 400-405.	1.5	13
<b>7</b> 54	Use of gene markers to guide antihypertensive therapy. Current Hypertension Reports, 2001, 3, 410-415.	1.5	6

#	Article	IF	CITATIONS
755	The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue?. Current Hypertension Reports, 2001, 3, 419-421.	1.5	1
756	Systolic hypertension and cardiovascular risk reduction: A clinical review. Current Hypertension Reports, 2001, 3, S11-S15.	1.5	4
757	Psychologic factors as precursors to hypertension. Current Hypertension Reports, 2001, 3, 25-32.	1.5	46
758	Statins and blood pressure regulation. Current Hypertension Reports, 2001, 3, 281-288.	1.5	49
759	Lessons learned from prematurely terminated clinical trials. Current Hypertension Reports, 2001, 3, 360-366.	1.5	2
760	The cardiovascular actions of omapatrilat in spontaneously hypertensive rats. Current Hypertension Reports, 2001, 3, S1-S5.	1.5	3
761	Intermittent claudication. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 167-180.	0.4	6
762	Renal artery stenosis. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 187-194.	0.4	3
763	Hypertension. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 333-345.	0.4	1
764	Population-based screening with the Coronary Heart Disease Risk Factor Calculator $\hat{A}^{\text{@}}$ . Advances in Therapy, 2001, 18, 21-32.	1.3	7
765	New insights into the effects on blood pressure of diets low in salt and high in fruits and vegetables and low-fat dairy products. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 71-74.	1.5	24
766	Diuretics: again the first step in the treatment of most patients with hypertension. , 2001, 2, 244.		5
767	Comments on ALLHAT and doxazosin. , 2001, 2, 254.		9
768	How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 298.	1.5	12
769	Ocular signs of systemic hypertension: A review. Ophthalmic and Physiological Optics, 2001, 21, 430-440.	1.0	14
770	Teaching about cost-effective use of medical resources. Journal of General Internal Medicine, 2001, 16, 419-421.	1.3	4
771	Cost-effectiveness of using angiotensin-converting enzyme inhibitors to slow nephropathy in normotensive patients with diabetes type II and microalbuminuria. Nephrology, 2001, 6, 71-77.	0.7	7
772	A critique of hypertension treatment trials and of their evaluation. Journal of Evaluation in Clinical Practice, 2001, 7, 149-164.	0.9	8

#	ARTICLE	IF	CITATIONS
773	Iron status and the risk of coronary heart disease: an example of the use of nutritional epidemiology in chronic disease research. Journal of Nutritional Biochemistry, 2001, 12, 170-182.	1.9	19
774	Maternal component in the familial aggregation of hypertension. Clinical Genetics, 2001, 60, 13-21.	1.0	40
775	Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clinical Cardiology, 2001, 24, 66-72.	0.7	46
776	Angiotensin receptor blockers: Evidence for preserving target organs. Clinical Cardiology, 2001, 24, 183-190.	0.7	36
777	Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia. International Urology and Nephrology, 2001, 33, 407-412.	0.6	20
778	Hypertension in the elderly. International Urology and Nephrology, 2001, 33, 563-569.	0.6	9
779	Dietary electrolytes and hypertension in the elderly. International Urology and Nephrology, 2001, 33, 575-582.	0.6	15
780	Hypertension and combinations of cardiovascular risk factors. An epidemiologic case-control study in an adult population in Guadeloupe (FWI). European Journal of Epidemiology, 2001, 17, 1089-1095.	2.5	14
781	A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension. International Urology and Nephrology, 2001, 32, 519-523.	0.6	3
782	Clinical pharmacology-physiology conference. A chrono-therapeutic approach to the treatment of hypertension. International Urology and Nephrology, 2001, 33, 265-268.	0.6	0
783	Patient-perceived problems, compliance, and the outcome of hypertension treatment. International Journal of Clinical Pharmacy, 2001, 23, 60-64.	1.4	22
784	Commentary on treatment of hypertension in the elderly. , 2001, 15, 281-282.		4
785	Gender differences in the self-regulation of hypertension. Journal of Behavioral Medicine, 2001, 24, 469-487.	1.1	36
786	The pharmaceutical care of patients with hypertension: an examination of service models in primary care in the US. International Journal of Clinical Pharmacy, 2001, 23, 189-194.	1.4	9
787	Prescribing for Seniors: It's a Balancing Act. Journal of the American Academy of Nurse Practitioners, 2001, 13, 108-112.	1.4	2
788	Aggressive Secondary Prevention: A Perspective from the Coronary Interventional Setting. Journal of Interventional Cardiology, 2001, 14, 559-562.	0.5	0
789	Sex, drugs, and hypertension: a methodological approach for studying a sensitive subject. International Journal of Impotence Research, 2001, 13, 31-40.	1.0	23
790	Influence of different echocardiographic criteria for detection of left ventricular hypertrophy on cardiovascular risk stratification in recently diagnosed essential hypertensives. Journal of Human Hypertension, 2001, 15, 619-625.	1.0	7

#	Article	IF	CITATIONS
791	Patients $\hat{a} \in \mathbb{T}^{M}$ perceived problems with hypertension and attitudes towards medical treatment. Journal of Human Hypertension, 2001, 15, 755-761.	1.0	33
792	Perceptions and behaviour of hypertensive patients: a divine intervention or a case for Hippocrates?. Journal of Human Hypertension, 2001, 15, 751-754.	1.0	3
793	Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. Journal of Human Hypertension, 2001, 15, 849-856.	1.0	47
794	Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study. Journal of Human Hypertension, 2001, 15, 841-848.	1.0	29
795	Prognosis of congestive heart failure after prior myocardial infarction in older persons with atrial fibrillation versus sinus rhythm. American Journal of Cardiology, 2001, 87, 224-225.	0.7	63
796	Risk factors for new coronary events in older Hispanic men and women. American Journal of Cardiology, 2001, 88, 901-903.	0.7	0
798	Antihypertensive drugs during pregnancy. Seminars in Perinatology, 2001, 25, 159-164.	1.1	25
799	Optimal medical management of patients with chronic ischemic heart disease. Current Problems in Cardiology, 2001, 26, 195-238.	1.1	0
800	Trandolapril restores circadian blood pressure variation in normoalbuminuric normotensive Type 1 disabetic patients. Journal of Diabetes and Its Complications, 2001, 15, 75-79.	1.2	12
801	Impaired glucose tolerance is a more advanced stage of alteration in the glucose metabolism than impaired fasting glucose. Journal of Diabetes and Its Complications, 2001, 15, 34-37.	1.2	17
802	Cardiovascular disease and the renal transplant recipient. American Journal of Kidney Diseases, 2001, 38, S36-S43.	2.1	49
803	Prematurely Terminated Clinical Trials and Their Application to Cardiovascular Medicine. Congestive Heart Failure, 2001, 7, 265-271.	2.0	4
804	Diet and hypertension in the Asia-Pacific region: a brief review. Asia Pacific Journal of Clinical Nutrition, 2001, 10, 97-102.	0.3	2
805	Discontinuation of Antihypertensive Drugs Due to Adverse Events: A Systematic Review and Meta-analysis. Pharmacotherapy, 2001, 21, 940-953.	1.2	71
806	Management of Coronary Heart Disease Risk Factors and Progression with Calcium Channel Blockers. Pharmacotherapy, 2001, 21, 195S-208S.	1.2	3
807	Impact of the Cost of Prescription Drugs on Clinical Outcomes in Indigent Patients with Heart Disease. Pharmacotherapy, 2001, 21, 1455-1463.	1.2	53
808	Evaluation of Electrocardiographic and Hemodynamic Effects of Caffeine with Acute Dosing in Healthy Volunteers. Pharmacotherapy, 2001, 21, 437-442.	1.2	58
809	Patient-Reported Adherence to Guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Pharmacotherapy, 2001, 21, 828-841.	1.2	41

#	Article	IF	Citations
810	Association Between Blood Pressure Level and the Risk of Myocardial Infarction, Stroke, and Total Mortality. Archives of Internal Medicine, 2001, 161, 1183.	4.3	362
811	Prevalence of High Blood Pressure and Elevated Serum Creatinine Level in the United States. Archives of Internal Medicine, 2001, 161, 1207.	4.3	493
812	White-Coat Hypertensionâ€"To Treat or Not to Treat. Archives of Internal Medicine, 2001, 161, 2655.	4.3	8
813	Individualized Stress Management for Primary Hypertension. Archives of Internal Medicine, 2001, 161, 1071.	4.3	81
814	Evaluation of the Insulin Resistance Syndrome in 5- to 10-Year-Old Overweight/Obese African-American Children. Diabetes Care, 2001, 24, 1359-1364.	4.3	189
815	Incidence and Predictive Factors of Cerebrovascular Events in 8,846 Elderly Treated Hypertensive Patients during a 3-Year Follow-Up: The PRESAGE Study. European Neurology, 2001, 45, 89-96.	0.6	4
816	A New Approach for Measuring Quality of Care for Women With Hypertension. Archives of Internal Medicine, 2001, 161, 1329.	4.3	55
817	What Is Goal Blood Pressure for the Treatment of Hypertension?. Archives of Internal Medicine, 2001, 161, 1480.	4.3	17
818	Sodium Sensitivity Related to Albuminuria Appearing Before Hypertension in Type 2 Diabetic Patients. Diabetes Care, 2001, 24, 111-116.	4.3	55
819	Risk Factors in Established Coronary Heart Disease: Evaluation of a Secondary Prevention Programme. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 73-79.	3.1	7
820	Epidemiological Findings Imply That Goals for Drug Treatment of Hypertension Need to Be Revised. Circulation, 2001, 103, 1188-1190.	1.6	45
821	Should New Drugs Be Used Without Outcome Data?. Archives of Internal Medicine, 2001, 161, 511.	4.3	4
822	Antihypertensive Drug Therapies and the Risk of Ischemic Stroke. Archives of Internal Medicine, 2001, 161, 37.	4.3	62
823	Factors affecting the difference between screening and home blood pressure measurements: The Ohasama Study. Journal of Hypertension, 2001, 19, 13-19.	0.3	41
824	Increasing daily walking lowers blood pressure in postmenopausal women. Medicine and Science in Sports and Exercise, 2001, 33, 1825-1831.	0.2	210
825	Antihypertensive pharmacogenetics: getting the right drug into the right patient. Journal of Hypertension, 2001, 19, 1-11.	0.3	78
826	Drug treatment of isolated systolic hypertension. Nephrology Dialysis Transplantation, 2001, 16, 1095-1097.	0.4	11
827	Imaging techniques for non-invasive assessment of coronary heart disease in hypertension: value of an integrated approach. Journal of Hypertension, 2001, 19, 679-682.	0.3	5

#	Article	IF	CITATIONS
828	Efficacy of Different Drug Classes Used to Initiate Antihypertensive Treatment in Black Subjects. Archives of Internal Medicine, 2001, 161, 965.	4.3	84
829	RR interval variation, the QT interval index and risk of primary cardiac arrest among patients without clinically recognized heart disease. European Heart Journal, 2001, 22, 165-173.	1.0	40
830	Patients, families and populations at high risk for coronary heart disease. European Heart Journal, 2001, 22, 1682-1690.	1.0	8
831	The Treatment of Coronary Heart Disease: An Update. Current Medical Research and Opinion, 2001, 17, 18-26.	0.9	28
832	Exercise characteristics and the blood pressure response to dynamic physical training. Medicine and Science in Sports and Exercise, 2001, 33, S484-S492.	0.2	379
833	Controversy on optimal blood pressure on haemodialysis: lower is not always better. Nephrology Dialysis Transplantation, 2001, 16, 475-478.	0.4	22
834	Blood pressure measurement is changing!. British Heart Journal, 2001, 85, 3-5.	2.2	6
835	Angiotensin II Subtype 1 Receptor Blockers and Renal Function. Archives of Internal Medicine, 2001, 161, 1492.	4.3	53
836	Talking Effect and "White Coat―Effect in Hypertensive Patients: Physical Effort or Emotional Content?. Behavioral Medicine, 2001, 26, 149-157.	1.0	17
837	Women and Cardiovascular Disease: Addressing Disparities through Prevention Research and a National Comprehensive State-Based Program. Journal of Women's Health and Gender-Based Medicine, 2001, 10, 717-724.	1.7	10
838	Control of Hypertension â€" An Important National Priority. New England Journal of Medicine, 2001, 345, 534-535.	13.9	79
839	Treatment of Hypertension in Type 2 Diabetes. Journal of Women's Health and Gender-Based Medicine, 2001, 10, 897-905.	1.7	2
840	Prevalence of Left Ventricular Hypertrophy and Carotid Thickening in a Large Selected Hypertensive Population: Impact of Different Echocardiographic and Ultrasonographic Diagnostic Criteria. Blood Pressure, 2001, 10, 142-149.	0.7	46
841	Lipid and Blood Pressure Treatment Goals for Type 1 Diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care, 2001, 24, 1053-1059.	4.3	165
842	Fenoldopam â€" A Selective Peripheral Dopamine-Receptor Agonist for the Treatment of Severe Hypertension. New England Journal of Medicine, 2001, 345, 1548-1557.	13.9	255
843	Reduced Cardiovascular Morbidity and Mortality in Hypertensive Diabetic Patients on First-Line Therapy With an ACE Inhibitor Compared With a Diuretic/Â-Blocker-Based Treatment Regimen: A subanalysis of the Captopril Prevention Project. Diabetes Care, 2001, 24, 2091-2096.	4.3	230
844	Orthostatic Hypertension in Patients With Type 2 Diabetes. Diabetes Care, 2001, 24, 1783-1786.	4.3	73
845	Risk Factors for Coronary Disease: the Time for a Paradigm Shift?. Clinical Chemistry and Laboratory Medicine, 2001, 39, 907-19.	1.4	10

#	Article	IF	CITATIONS
846	Dose Discrepancies Between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events. Archives of Internal Medicine, 2001, 161, 957.	4.3	57
847	High-Normal Serum Creatinine Concentration Is a Predictor of Cardiovascular Risk in Essential Hypertension. Archives of Internal Medicine, 2001, 161, 886.	4.3	149
848	Similarities and Differences between the United States and Europe in the Development of Fixed Combination Products for the Treatment of Hypertension. Drug Information Journal, 2001, 35, 599-605.	0.5	0
849	Renin-Angiotensin System Gene Polymorphisms, Blood Pressure, Dyslipidemia, and Diabetes in Hong Kong Chinese: A significant association of the ACE insertion/deletion polymorphism with type 2 diabetes. Diabetes Care, 2001, 24, 356-361.	4.3	96
850	Effects of Diet and Sodium Intake on Blood Pressure: Subgroup Analysis of the DASH-Sodium Trial. Annals of Internal Medicine, 2001, 135, 1019.	2.0	475
851	Relationship of Blood Pressure to 25-Year Mortality Due to Coronary Heart Disease, Cardiovascular Diseases, and All Causes in Young Adult Men. Archives of Internal Medicine, 2001, 161, 1501.	4.3	258
852	Is It Time for a New Approach to the Initial Treatment of Hypertension?. Archives of Internal Medicine, 2001, 161, 1140.	4.3	12
853	Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care. JAMA - Journal of the American Medical Association, 2001, 286, 1317.	3.8	2,332
854	Effects of Reduced Sodium Intake on Hypertension Control in Older Individuals. Archives of Internal Medicine, 2001, 161, 685.	4.3	234
855	Is "Isolated Home" Hypertension as Opposed to "Isolated Office" Hypertension a Sign of Greater Cardiovascular Risk?. Archives of Internal Medicine, 2001, 161, 2205.	4.3	109
856	AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update. Circulation, 2001, 104, 1577-1579.	1.6	564
857	Adverse Drug Effects, Compliance, and Initial Doses of Antihypertensive Drugs Recommended by the Joint National Committee vs the Physicians' Desk Reference. Archives of Internal Medicine, 2001, 161, 880.	4.3	58
858	Elevated Midlife Blood Pressure Increases Stroke Risk in Elderly Persons. Archives of Internal Medicine, 2001, 161, 2343.	4.3	75
859	Behavior of Ambulatory Blood Pressure Surrounding Episodes of Headache in Mildly Hypertensive Patients. Archives of Internal Medicine, 2001, 161, 252.	4.3	41
860	Fasting Plasma Homocysteine Levels in the Insulin Resistance Syndrome: The Framingham Offspring Study. Diabetes Care, 2001, 24, 1403-1410.	4.3	288
861	Relation Between Soluble Adhesion Molecules and Insulin Sensitivity in Type 2 Diabetic Individuals: Role of adipose tissue. Diabetes Care, 2001, 24, 1961-1966.	4.3	49
862	Meta-analysis of Hypertension Trials in Diabetic Patients: Response to Parving and Rossing. Diabetes Care, 2001, 24, 178-180.	4.3	0
863	Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BMJ: British Medical Journal, 2001, 323, 142-146.	2.4	99

#	Article	IF	CITATIONS
864	Longâ€term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrology Dialysis Transplantation, 2001, 16, 2207-2213.	0.4	151
865	Angiotensin II receptor blockers for the treatment of hypertension. Expert Opinion on Pharmacotherapy, 2001, 2, 1795-1804.	0.9	23
866	The role of endothelin receptor antagonists in cardiovascular pharmacotherapy. Expert Opinion on Emerging Drugs, 2001, 6, 3-11.	1.1	7
867	Effects of Physical Activity Counseling in Primary Care: The Activity Counseling Trial: A Randomized Controlled Trial. JAMA - Journal of the American Medical Association, 2001, 286, 677-687.	3.8	335
868	Beating High Blood Pressure with Low-Sodium DASH. New England Journal of Medicine, 2001, 344, 53-55.	13.9	28
869	High-Normal Blood Pressure â€" More "High―Than "Normal― New England Journal of Medicine, 2001, 345, 1337-1340.	13.9	33
870	Blood pressure reduction as part of the multifactorial approach to treatment of cardiovascular disease. European Heart Journal Supplements, 2001, 3, B32-B36.	0.0	0
871	Principal results from the international nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT)*1. European Heart Journal Supplements, 2001, 3, B20-B26.	0.0	4
872	Depression and Risk of Heart Failure Among Older Persons With Isolated Systolic Hypertension. Archives of Internal Medicine, 2001, 161, 1725.	4.3	176
873	Controversies in the Treatment of Hypercholesterolemia in the Elderly: Who Should Be Treated and How?. The American Journal of Geriatric Cardiology, 2001, 10, 152-158.	0.7	2
874	Renal Participation in Cardiovascular Risk in Essential Hypertension. Blood Pressure, 2001, 10, 322-326.	0.7	3
875	EXAMINATION OF ANGIOTENSIN II TYPE 1 AND TYPE 2 RECEPTOR EXPRESSION IN HUMAN KIDNEYS BY IMMUNOHISTOCHEMISTRY. Clinical and Experimental Hypertension, 2001, 23, 257-266.	0.5	28
876	Reawakening of Interest in Aldosterone and Aldosterone Antagonists: Implications for Treatment of Cardiovascular Disease. The American Journal of Geriatric Cardiology, 2001, 10, 166-169.	0.7	0
877	Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2001, 10, 111-113.	0.7	O
878	Treating Hypertension in the Elderly. The American Journal of Geriatric Cardiology, 2001, 10, 355-365.	0.7	4
879	Treatment of the Elderly Postâ€Myocardial Infarction Patient. The American Journal of Geriatric Cardiology, 2001, 10, 316-323.	0.7	4
880	Treatment of Hypertension in the Elderly. The American Journal of Geriatric Cardiology, 2002, 11, 11-22.	0.7	14
881	Common Drug Pathways and Interactions. Diabetes Spectrum, 2002, 15, 249-255.	0.4	10

#	Article	IF	CITATIONS
882	Results of Antihypertensive Treatment Trials in the Elderly. The American Journal of Geriatric Cardiology, 2002, 11, 41-48.	0.7	10
883	Epidemiology of Hypertension in the Elderly. The American Journal of Geriatric Cardiology, 2002, 11, 23-28.	0.7	59
884	Risk Stratification and Prevention in Chronic Coronary Artery Disease: Use of a Novel Prognostic and Computer-Based Clinical Decision Support System in a Large Primary Managed-Care Group Practice. Disease Management: DM, 2002, 5, 197-213.	1.0	2
885	High Blood Pressure in the Geriatric Population: Treatment Considerations. The American Journal of Geriatric Cardiology, 2002, 11, 223-232.	0.7	25
886	Pharmacologic Therapy for the Older Patient With Cardiovascular Disease: New Information and Continued Challenges. The American Journal of Geriatric Cardiology, 2002, 11, 215-256.	0.7	0
887	Medically Supervised Water-Only Fasting in the Treatment of Borderline Hypertension. Journal of Alternative and Complementary Medicine, 2002, 8, 643-650.	2.1	39
888	The Role of Losartan in Cost-effective Hypertension Control. Current Medical Research and Opinion, 2002, 18, 139-145.	0.9	7
889	Hypertension, Insulin, and Proinsulin in Participants With Impaired Glucose Tolerance. Hypertension, 2002, 40, 679-686.	1.3	45
890	Relation between blood pressure after an acute coronary event and subsequent cardiovascular risk. British Heart Journal, 2002, 88, 555-558.	2.2	2
892	Blood pressure control in stroke patients. Neurology, 2002, 59, 23-25.	1.5	29
893	RELATIONSHIP BETWEEN PERSONALITY AND SELF-MEASURED BLOOD PRESSURE VALUE AT HOME: THE OHASAMA STUDY. Clinical and Experimental Hypertension, 2002, 24, 115-123.	0.5	16
894	Worry Regarding Major Diseases Among Older African-American, Native-American, and Caucasian Women. Women and Health, 2002, 36, 83-99.	0.4	25
895	Initial Cost of Care Results in Medically Supervised Water-Only Fasting for Treating High Blood Pressure and Diabetes. Journal of Alternative and Complementary Medicine, 2002, 8, 696-697.	2.1	15
896	THE TOLERANCE-HYPERBARIC TEST: A CHRONOBIOLOGIC APPROACH FOR IMPROVED DIAGNOSIS OF HYPERTENSION. Chronobiology International, 2002, 19, 1183-1211.	0.9	51
897	Coronary Risk Versus Cardiovascular Risk for Treatment Decisions in Mild Hypertension. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 275-280.	3.1	1
898	Prevalence and Trends in Obesity Among US Adults, 1999-2000. JAMA - Journal of the American Medical Association, 2002, 288, 1723.	3.8	5,349
899	Superior Physicians and the Treatment of Hypertension. Archives of Internal Medicine, 2002, 162, 387.	4.3	10
900	The Prevalence of Hypertension and Utilization of Antihypertensive Therapy in a District Diabetes Population. Diabetes Care, 2002, 25, 2107-2108.	4.3	17

#	Article	IF	CITATIONS
901	Residual Lifetime Risk for Developing Hypertension in Middle-aged Women and Men. JAMA - Journal of the American Medical Association, 2002, 287, 1003-10.	3.8	1,125
902	A Primary Care Home for Americans. JAMA - Journal of the American Medical Association, 2002, 288, 889.	3.8	237
903	Cellular Basis of Diabetic Nephropathy: 1. Study Design and Renal Structural-Functional Relationships in Patients With Long-Standing Type 1 Diabetes. Diabetes, 2002, 51, 506-513.	0.3	188
904	Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by $\hat{l}^2$ -adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. Journal of Human Hypertension, 2002, 16, 13-19.	1.0	107
905	The epidemiology of hypertension in South America. Journal of Human Hypertension, 2002, 16, S3-S6.	1.0	11
906	Hypertension control and medication increase in primary care. Journal of Human Hypertension, 2002, 16, 313-318.	1.0	28
907	Long-term persistence with antihypertensive drugs in new patients. Journal of Human Hypertension, 2002, 16, 439-444.	1.0	120
908	Properly defining white coat hypertension. European Heart Journal, 2002, 23, 106-109.	1.0	79
909	Definition of new targets in cardiovascular prevention from young into old age. European Heart Journal, 2002, 23, 507-509.	1.0	0
910	Concomitant Impairment of Growth Hormone Secretion and Peripheral Sensitivity in Obese Patients with Obstructive Sleep Apnea Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5052-5057.	1.8	61
911	Rates of progression to hypertension among non-hypertensive subjects: implications for blood pressure screening. European Heart Journal, 2002, 23, 1067-1070.	1.0	18
912	Recommendations for the screening and management of patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2002, 17, 19-28.	0.4	69
913	Cardiovascular Disease Mortality in Hispanics and Non-Hispanic Whites. American Journal of Epidemiology, 2002, 156, 919-928.	1.6	66
914	Do diabetes and hypertension interact to accelerate vascular ageing?. Journal of Hypertension, 2002, 20, 1693-1696.	0.3	16
915	Evolving concepts and a new approach for management of hyperlipidemia. European Heart Journal Supplements, 2002, 4, J1-J3.	0.0	5
916	Ambulatory blood pressure monitoring in clinical practice. Journal of Hypertension, 2002, 20, 1925-1927.	0.3	18
917	Enhancing risk stratification in hypertensive subjects: how far should we go in routine screening for target organ damage?. Journal of Hypertension, 2002, 20, 1255-1257.	0.3	13
918	Trough-to-Peak Ratio, Smoothness Index, and Circadian Blood Pressure Profile After Treatment With Once-Daily Fixed Combination of Losartan 100 and Hydrochlorothiazide 25 in Essential Hypertension. Journal of Cardiovascular Pharmacology, 2002, 39, 824-833.	0.8	18

#	Article	IF	CITATIONS
919	Dexmedetomidine-Induced Sedation in Volunteers Decreases Regional and Global Cerebral Blood Flow. Anesthesia and Analgesia, 2002, 95, 1052-1059.	1.1	159
920	Pharmacokinetics of Irbesartan Are Not Altered in Special Populations. Journal of Cardiovascular Pharmacology, 2002, 40, 112-122.	0.8	22
921	Improving Cardiovascular Health in Postmenopausal Women by Addressing Medication Adherence Issues. Journal of the American Pharmacists Association, 2002, 42, 63-73.	0.6	16
922	Physician-Related Barriers to the Effective Management of Uncontrolled Hypertension. Archives of Internal Medicine, 2002, 162, 413.	4.3	423
923	Hypertension in black people: pathophysiology and therapeutic aspects. Journal of Human Hypertension, 2002, 16, S11-S12.	1.0	18
924	Isolated systolic hypertension: a new challenge in medicine. Journal of Human Hypertension, 2002, 16, S44-S47.	1.0	5
925	Successful Blood Pressure Control in the African American Study of Kidney Disease and Hypertension. Archives of Internal Medicine, 2002, 162, 1636.	4.3	122
926	Recruitment and coaching of healthy elderly subjects for invasive cardiovascular research with right-sided catheterisation. European Journal of Cardiovascular Nursing, 2002, 1, 289-298.	0.4	3
927	Angiotensin-Receptor Blockers, Type 2 Diabetes, and Renoprotection. New England Journal of Medicine, 2002, 346, 705-707.	13.9	18
928	Large therapeutic studies in elderly patients with hypertension. Journal of Human Hypertension, 2002, 16, S38-S43.	1.0	6
929	Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. Journal of Human Hypertension, 2002, 16, 399-404.	1.0	60
930	Elevated Dehydroepiandrosterone Sulfate Levels as the Reproductive Phenotype in the Brothers of Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2134-2138.	1.8	134
931	Systolic vs diastolic blood pressure: community burden and impact on blood pressure staging. Journal of Human Hypertension, 2002, 16, 163-167.	1.0	33
932	A high level of awareness but a poor control of hypertension among elderly Greeks. The Nemea primary care study. Journal of Human Hypertension, 2002, 16, 285-287.	1.0	11
933	Microalbuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive subjects. Journal of Human Hypertension, 2002, 16, 249-254.	1.0	31
934	Prevalence of hypertension in the adult population of Belgium: report of a worksite study, Attention Hypertension. Journal of Human Hypertension, 2002, 16, 47-52.	1.0	38
935	Factors Associated With Hypertension Control in the General Population of the United States. Archives of Internal Medicine, 2002, 162, 1051.	4.3	206
936	Incident Open-Angle Glaucoma and Blood Pressure. JAMA Ophthalmology, 2002, 120, 954.	2.6	220

#	Article	IF	CITATIONS
937	Risk factors for coronary heart disease: implications of gender. Cardiovascular Research, 2002, 53, 538-549.	1.8	227
938	Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. Journal of Human Hypertension, 2002, 16, 5-11.	1.0	114
939	Smoking trends in hypertensive and normotensive Finns during 1982–1997. Journal of Human Hypertension, 2002, 16, 299-303.	1.0	8
940	Relation of urinary urea to blood pressure: interaction with urinary sodium. Journal of Human Hypertension, 2002, 16, 205-212.	1.0	26
941	New strategies for blood pressure control. Journal of Human Hypertension, 2002, 16, S124-S127.	1.0	2
942	Systolic vs diastolic blood pressure and the burden of hypertension. Journal of Human Hypertension, 2002, 16, 147-150.	1.0	49
943	Distribution of blood pressure and prevalence of hypertension in Tehran adult population: Tehran Lipid and Glucose Study (TLGS), 1999–2000. Journal of Human Hypertension, 2002, 16, 305-312.	1.0	80
944	Bruce Psaty and the risks of calcium channel blockers. Quality and Safety in Health Care, 2002, 11, 294-296.	2.5	5
945	Long-term Efficacy and Tolerability of Telmisartan as Monotherapy and in Combination with Other Antihypertensive Medications. Blood Pressure, 2002, 11, 302-309.	0.7	21
946	Ambulatory blood pressure and brain atrophy in the healthy elderly. Neurology, 2002, 59, 713-719.	1.5	70
947	Results from the TIP (Tritace in Proteinuria) Intensified Monitoring Project. Kidney and Blood Pressure Research, 2002, 25, 80-86.	0.9	1
948	The Prevention of Dementia With Antihypertensive Treatment <subtitle>New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study</subtitle> . Archives of Internal Medicine, 2002, 162, 2046.	4.3	784
949	BENEFICIAL EFFECT ON BLOOD PRESSURE AND LIPID PROFILE BY PROGRAMMED EXERCISE TRAINING IN TAIWANESE PATIENTS WITH MILD HYPERTENSION. Clinical and Experimental Hypertension, 2002, 24, 315-324.	0.5	36
950	The Usefulness of Ophthalmoscopy in Risk Evaluation of Hypertensive Patients. Blood Pressure, 2002, 11, 263-269.	0.7	11
952	Reduction of Left Ventricular Hypertrophy After Exercise and Weight Loss in Overweight Patients With Mild Hypertension. Archives of Internal Medicine, 2002, 162, 1333.	4.3	82
953	Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease < SUBTITLE > Results From the AASK Trial < / SUBTITLE > . JAMA - Journal of the American Medical Association, 2002, 288, 2421.	3.8	1,792
954	Preoperative Evaluation of the Patient With Hypertension. JAMA - Journal of the American Medical Association, 2002, 287, 2043.	3.8	64
955	Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA - Journal of the American Medical Association, 2002, 288, 2981-2997.	3.8	5,319

#	Article	IF	Citations
956	Promoting Healthy Lifestyles: Alternative Models' Effects (PHLAME). Health Education Research, 2002, 17, 586-596.	1.0	29
957	The Dietary Approaches to Stop Hypertension diet lowered systolic blood pressure in stage 1 isolated systolic hypertension. Evidence-Based Medicine, 2002, 7, 41-41.	0.6	0
958	Antihypertensive Efficacy and Tolerability of Lercanidipine in Daily Clinical Practice. The ELYPSE Study. Blood Pressure, 2002, 11, 95-100.	0.7	54
959	Primary Prevention of Hypertension < SUBTITLE > Clinical and Public Health Advisory From the National High Blood Pressure Education Program < /SUBTITLE > . JAMA - Journal of the American Medical Association, 2002, 288, 1882.	3.8	1,212
960	Guidelines for the Reporting of Renal Artery Revascularization in Clinical Trials. Circulation, 2002, 106, 1572-1585.	1.6	222
961	Relation of Drinking Alcohol to Atherosclerotic Risk in Type 2 Diabetes. Diabetes Care, 2002, 25, 1223-1228.	4.3	46
962	Losartan reduced strokes and new onset diabetes more than atenolol in essential hypertension. Evidence-Based Medicine, 2002, 7, 174-174.	0.6	0
963	Control of Cardiovascular Risk Factors in Patients With Diabetes and Hypertension at Urban Academic Medical Centers. Diabetes Care, 2002, 25, 718-723.	4.3	211
964	Metabolic Syndrome and Development of Diabetes Mellitus: Application and Validation of Recently Suggested Definitions of the Metabolic Syndrome in a Prospective Cohort Study. American Journal of Epidemiology, 2002, 156, 1070-1077.	1.6	756
965	Exercise Training and the Cardiovascular Consequences of Type 2 Diabetes and Hypertension. JAMA - Journal of the American Medical Association, 2002, 288, 1622.	3.8	223
966	Dairy Consumption, Obesity, and the Insulin Resistance Syndrome in Young Adults. JAMA - Journal of the American Medical Association, 2002, 287, 2081.	3.8	919
967	Association Between Pulse Pressure and Mortality in Patients Undergoing Maintenance Hemodialysis. JAMA - Journal of the American Medical Association, 2002, 287, 1548.	3.8	350
968	The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men. JAMA - Journal of the American Medical Association, 2002, 288, 2709.	3.8	4,071
969	Hypertension Control and Kidney Disease. JAMA - Journal of the American Medical Association, 2002, 288, 2466.	3.8	2
970	Critical Pathways. Critical Pathways in Cardiology, 2002, 1, 184-193.	0.2	0
971	Hypertension prevalence, control and survivorship in an Afro-Caribbean population. Journal of Hypertension, 2002, 20, 2363-2369.	0.3	28
972	Cardiovascular Disease Among Women Residing in Rural America: Epidemiology, Explanations, and Challenges. American Journal of Public Health, 2002, 92, 548-551.	1.5	45
973	Smoking as a modifier of the systolic blood pressure-induced risk of cardiovascular events and mortality: a population-based prospective study of middle-aged men. Journal of Hypertension, 2002, 20, 1759-1764.	0.3	32

#	ARTICLE	IF	CITATIONS
974	Exercise-induced changes in insulin action are associated with ACE gene polymorphisms in older adults. Physiological Genomics, 2002, 11, 73-80.	1.0	26
975	Future developments in ambulatory blood pressure monitoring and self-blood pressure monitoring in clinical practice. Blood Pressure Monitoring, 2002, 7, 21-25.	0.4	35
976	Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care, 2002, 25, 213-229.	4.3	201
978	Progression of Renal Failure Delayed by Use of Losartan in a Case of IgA Nephropathy Internal Medicine, 2002, 41, 1167-1170.	0.3	1
979	Left Ventricular Hypertrophy was Infrequent in Patients Starting Dialysis after Undergoing a Strict Blood Pressure Control in the Pre-dialytic Period Internal Medicine, 2002, 41, 925-930.	0.3	4
980	Alcohol Consumption and Risk for Congestive Heart Failure in the Framingham Heart Study. Annals of Internal Medicine, 2002, 136, 181.	2.0	204
981	Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. International Journal of Obesity, 2002, 26, 469-474.	1.6	62
982	Tests of Glycemia for the Diagnosis of Type 2 Diabetes Mellitus. Annals of Internal Medicine, 2002, 137, 263.	2.0	169
983	Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists. Journal of Human Hypertension, 2002, 16, S17-S23.	1.0	14
984	Risk factor modification in intermittent claudication: effect on life expectancy and walking capacity. European Heart Journal Supplements, 2002, 4, B50-B54.	0.0	6
985	Left ventricular hypertrophy screening using a hand-held ultrasound device. European Heart Journal, 2002, 23, 1516-1521.	1.0	56
986	Effects of Age on the Relationship between Drinking and Atherosclerotic Risk Factors. Gerontology, 2002, 48, 151-156.	1.4	30
987	Salt-sensitivity, hypertension and cardiovascular ageing: broadening our view without missing the point. Journal of Hypertension, 2002, 20, 561-563.	0.3	4
988	Self blood pressure monitoring at home by wrist devices: a reliable approach?. Journal of Hypertension, 2002, 20, 573-578.	0.3	37
989	Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. Journal of Hypertension, 2002, 20, 1519-1525.	0.3	47
990	Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods. Journal of Hypertension, 2002, 20, 2173-2182.	0.3	19
991	Long-term renal consequences of hypertension for normal and diseased kidneys. Current Opinion in Nephrology and Hypertension, 2002, 11, 73-80.	1.0	96
992	Effect of recorded home blood pressure measurements on the staging of hypertensive patients. Blood Pressure Monitoring, 2002, 7, 157-161.	0.4	18

#	Article	IF	CITATIONS
993	Proteinuria in renal artery occlusion is related to active renin concentration and contralateral kidney size. Journal of Hypertension, 2002, 20, 139-144.	0.3	15
994	The risk of hypertension in men: direct and indirect effects of chronic smoking. Journal of Hypertension, 2002, 20, 187-193.	0.3	91
995	The ABCD of anti-hypertensive therapy?. Journal of Hypertension, 2002, 20, 615-616.	0.3	3
996	Relationship between physical activity and blood pressure in dipper and non-dipper hypertensive patients. Journal of Hypertension, 2002, 20, 1097-1104.	0.3	119
997	Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach Journal of Hypertension, 2002, 20, 1315-1321.	0.3	61
998	Gender influence on the dose-ranging of a low-dose perindopril–indapamide combination in hypertension: effect on systolic and pulse pressure. Journal of Hypertension, 2002, 20, 1653-1661.	0.3	22
999	Alpha-adducin Gly460Trp polymorphism is associated with low renin hypertension in younger subjects in the Ohasama study. Journal of Hypertension, 2002, 20, 1779-1784.	0.3	53
1000	Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects: The Suita Study. Journal of Hypertension, 2002, 20, 2017-2021.	0.3	37
1001	Lercanidipine in Type II Diabetic Patients With Mild to Moderate Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2002, 40, 133-139.	0.8	23
1002	Spontaneous baroreflex sensitivity: toward an ideal index of cardiovascular risk in hypertension?. Journal of Hypertension, 2002, 20, 935-944.	0.3	76
1003	Too much of a good thing? A critique of overemphasis on the use of ambulatory blood pressure monitoring in clinical practice. Journal of Hypertension, 2002, 20, 1917-1923.	0.3	37
1004	Lowering blood pressure for cardiovascular risk reduction: moving the goalposts or spreading the net?. Journal of Hypertension, 2002, 20, 1945-1948.	0.3	3
1005	Pulse wave velocity and the second derivative of the finger photoplethysmogram in treated hypertensive patients. Journal of Hypertension, 2002, 20, 2415-2422.	0.3	102
1006	Sleep apnoea and hypertension. Current Opinion in Nephrology and Hypertension, 2002, 11, 201-214.	1.0	20
1007	Interactions between hypercholesterolemia and hypertension: implications for therapy. Current Opinion in Nephrology and Hypertension, 2002, 11, 489-496.	1.0	52
1008	Recent developments in the treatment of obesity-related hypertension. Current Opinion in Nephrology and Hypertension, 2002, 11, 497-502.	1.0	11
1009	Rationale and design of HOMED-BP Study: Hypertension Objective treatment based on Measurement by Electrical Devices of Blood Pressure Study. Blood Pressure Monitoring, 2002, 7, 77-82.	0.4	54
1010	Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. Journal of Hypertension, 2002, 20, 1297-1302.	0.3	99

#	Article	IF	CITATIONS
1011	Prevalence, awareness, treatment and control of hypertension in a Canarian population. Relationship with glucose tolerance categories. The GuÃa Study. Journal of Hypertension, 2002, 20, 1965-1971.	0.3	16
1012	Treatment of Hypertension with Alternative Therapies (THAT) Study: a randomized clinical trial. Journal of Hypertension, 2002, 20, 2063-2068.	0.3	30
1013	Cardiovascular risk evaluation. Journal of Hypertension, 2002, 20, 2127-2130.	0.3	12
1014	Characteristics of conventional blood pressure in studies on the predictive power of ambulatory blood pressure. Blood Pressure Monitoring, 2002, 7, 33-36.	0.4	9
1015	Role of blood pressure monitoring in non-pharmacological management of hypertension. Blood Pressure Monitoring, 2002, 7, 51-54.	0.4	10
1016	Inter-arm differences in blood pressure: when are they clinically significant?. Journal of Hypertension, 2002, 20, 1089-1095.	0.3	147
1017	Migraine is more frequent in individuals with optimal and normal blood pressure: a population-based study. Journal of Hypertension, 2002, 20, 1303-1306.	0.3	78
1018	Carotid and femoral intima–media thickness in relation to three candidate genes in a Caucasian population. Journal of Hypertension, 2002, 20, 1551-1561.	0.3	58
1019	Comparison of conventional and automated blood pressure measurements: interim analysis of the THOP trial. Blood Pressure Monitoring, 2002, 7, 61-62.	0.4	18
1020	Regional variation in end-stage renal disease. Current Opinion in Nephrology and Hypertension, 2002, 11, 343-346.	1.0	17
1021	Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study. Blood Pressure Monitoring, 2002, 7, 111-116.	0.4	49
1022	Frequency of spontaneous fist clenching during routine blood pressure measurements and its effect on measurement accuracy. Blood Pressure Monitoring, 2002, 7, 145-147.	0.4	4
1023	Limitations of current validation protocols for home blood pressure monitors for individual patients. Blood Pressure Monitoring, 2002, 7, 313-318.	0.4	80
1024	Making Diabetes Management Routine. American Journal of Nursing, 2002, 102, 26-32.	0.2	4
1025	Prevention of hypertension. Current Opinion in Cardiology, 2002, 17, 531-536.	0.8	61
1026	Losartan titration versus diuretic combination in type 2 diabetic patients. Journal of Hypertension, 2002, 20, 715-719.	0.3	11
1027	Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. Journal of Hypertension, 2002, 20, 1307-1314.	0.3	153
1028	Systolic and diastolic blood pressure control in antihypertensive drug trials. Journal of Hypertension, 2002, 20, 1461-1464.	0.3	233

#	Article	IF	Citations
1029	Quality of hypertension treatment and risk of stroke in the general population. Journal of Hypertension, 2002, 20, 1949-1950.	0.3	3
1030	Hypertension magnitude and management in the elderly population of Spain. Journal of Hypertension, 2002, 20, 2157-2164.	0.3	217
1031	Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. Journal of Hypertension, 2002, 20, 323-331.	0.3	146
1032	Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic $\hat{l}^21$ -selective receptor blockade. Journal of Hypertension, 2002, 20, 421-428.	0.3	51
1033	Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. Journal of Hypertension, 2002, 20, 771-777.	0.3	95
1034	Blood pressure control and the implementation of guidelines in clinical practice: can we fill the gap?. Journal of Hypertension, 2002, 20, 1251-1253.	0.3	41
1035	Antihypertensive treatment in patients with type-2 diabetes mellitus. Journal of Hypertension, 2002, 20, 2099-2110.	0.3	121
1036	Non-pharmacological treatment of hypertension in primary health care. Journal of Hypertension, 2002, 20, 2505-2512.	0.3	62
1037	Treating Hypertension in Patients with Diabetes. Nurse Practitioner, 2002, 27, 11-15.	0.2	1
1038	Blood pressure should be measured in both arms on the first consultation. Journal of Hypertension, 2002, 20, 1045-1046.	0.3	17
1039	SELF-MEASURED SYSTOLIC BLOOD PRESSURE IN THE MORNING IS A STRONG INDICATOR OF DECLINE OF RENAL FUNCTION IN HYPERTENSIVE PATIENTS WITH NON-DIABETIC CHRONIC RENAL INSUFFICIENCY. Clinical and Experimental Hypertension, 2002, 24, 249-260.	0.5	47
1040	Severity of Hypertension Affects Improved Resistance Artery Endothelial Function by Angiotensin-Converting Enzyme Inhibition. Journal of Cardiovascular Pharmacology, 2002, 39, 668-676.	0.8	16
1041	Mechanical factors predicting cardiovascular risk and drug treatment of hypertension. Journal of Hypertension, 2002, 20, 349-352.	0.3	3
1042	Hostility explains some of the discrepancy between daytime ambulatory and clinic blood pressure Health Psychology, 2002, 21, 202-206.	1.3	17
1043	Biobehavioral approaches to the treatment of essential hypertension Journal of Consulting and Clinical Psychology, 2002, 70, 569-589.	1.6	42
1044	Finapres arterial pulse wave analysis with Modelflow $\hat{A}^{\otimes}$ is not a reliable non-invasive method for assessment of cardiac output. Clinical Science, 2002, 103, 143-149.	1.8	66
1045	Finapres arterial pulse wave analysis with Modelflow is not a reliable non-invasive method for assessment of cardiac output. Clinical Science, 2002, 103, 143.	1.8	16
1046	Prognostic Value of Systolic and Diastolic Blood Pressure in Treated Hypertensive Men. Archives of Internal Medicine, 2002, 162, 577.	4.3	147

#	Article	IF	CITATIONS
1047	Time Trends in High Blood Pressure Control and the Use of Antihypertensive Medications in Older Adults. Archives of Internal Medicine, 2002, 162, 2325.	4.3	127
1048	Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic Dysfunction. JAMA - Journal of the American Medical Association, 2002, 288, 1252.	3.8	423
1049	Meta-analysis on the Therapeutic State of Hypertensive Population in Japan: Focusing on the Impact of New Diagnostic Criteria of Japanese Guideline for the Management of Hypertension 2000 Journal of Epidemiology, 2002, 12, 112-119.	1.1	4
1050	Difference between Consciousness of Intervention for Improving Lifestyle by Public Health Nurses and Recipients of a Company Health Check Journal of Epidemiology, 2002, 12, 287-294.	1.1	1
1051	Large Scale Cohort Study of the Relationship Between Serum Cholesterol Concentration and Coronary Events With Low-Dose Simvastatin Therapy in Japanese Patients With Hypercholesterolemia. Primary Prevention Cohort Study of the Japan Lipid Intervention Trial (J-LIT) Circulation Journal, 2002, 66, 1087-1095.	0.7	243
1052	Cardioselective $\hat{I}^2$ -Blockers in Patients with Reactive Airway Disease. Annals of Internal Medicine, 2002, 137, 715.	2.0	211
1053	Utility of Captopril Renal Scans for Detecting Renal Artery Stenosis. Archives of Internal Medicine, 2002, 162, 1981.	4.3	46
1054	Glucose Tolerance and Cardiovascular Risk in Young Adult African Americans. American Journal of the Medical Sciences, 2002, 323, 231-237.	0.4	7
1055	Supplementation of Plant Sterols and Minerals Benefits Obese Zucker Rats Fed an Atherogenic Diet. Journal of Nutrition, 2002, 132, 231-237.	1.3	28
1056	Systolic vs Diastolic Blood Pressure Control in the Hypertensive Patients of the PAMELA Population. Archives of Internal Medicine, 2002, 162, 582.	4.3	97
1057	Meeting the Therapeutic Challenge of the Patient With Osteoarthritis. Journal of the American Pharmacists Association, 2002, 42, 74-82.	0.6	12
1058	NHBPEP: Working to Reduce Death and Disability From High Blood Pressure. Journal of the American Pharmacists Association, 2002, 42, 886-888.	0.6	0
1059	Blood pressure response after two-step exercise as a powerful predictor of hypertension: the Osaka Health Survey. Journal of Hypertension, 2002, 20, 1507-1512.	0.3	40
1060	Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. Journal of Hypertension, 2002, 20, 2301-2307.	0.3	65
1061	Metabolic Effects of Combined Antihypertensive Treatment in Patients With Essential Hypertension. Journal of Cardiovascular Pharmacology, 2002, 40, 916-921.	0.8	8
1062	Evaluation of the Tensioday ambulatory blood pressure monitor according to the protocols of the British Hypertension Society and the Association for the Advancement of Medical Instrumentation. Blood Pressure Monitoring, 2002, 7, 191-197.	0.4	31
1063	Identification of mechanically induced genes in human monocytic cells by DNA microarrays. Journal of Hypertension, 2002, 20, 685-691.	0.3	51
1064	ESH Scientific Newsletter. Blood Pressure, 2002, 11, 253-254.	0.7	5

#	ARTICLE	IF	CITATIONS
1065	Should we treat high-normal blood pressure?. Journal of Hypertension, 2002, 20, 2057-2062.	0.3	8
1066	Autonomic dysfunction associates with prolongation of QT intervals and blunted night BP in obese women with visceral obesity. Journal of Endocrinological Investigation, 2002, 25, RC32-RC35.	1.8	24
1067	Results of a Heart Disease Risk-Factor Screening Among Traditional College Students. Journal of American College Health, 2002, 50, 291-296.	0.8	45
1068	Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications. Diabetes Care, 2002, 25, 148-198.	4.3	745
1069	Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. European Heart Journal, 2002, 23, 528-535.	1.0	113
1070	Renal Dysfunction Complicating the Treatment of Hypertension. New England Journal of Medicine, 2002, 347, 1256-1261.	13.9	286
1071	Cardiovascular disease in neurofibromatosis 1: Report of the NF1 Cardiovascular Task Force. Genetics in Medicine, 2002, 4, 105-111.	1.1	330
1072	The Treatment of Hypertension in Adult Patients With Diabetes. Diabetes Care, 2002, 25, 134-147.	4.3	280
1073	Attempts at Changing Dietary and Exercise Habits to Reduce Risk of Cardiovascular Disease: Who's Doing What in the Community? Preventive Cardiology, 2002, 5, 102-108.	1.1	23
1074	Hypertension in the Elderly: A Review of the Importance of Systolic Blood Pressure Elevation. Journal of Clinical Hypertension, 2002, 4, 108-119.	1.0	25
1075	Physician Practice Patterns in the Treatment of Isolated Systolic Hypertension in a Primary Care Setting. Journal of Clinical Hypertension, 2002, 4, 93-100.	1.0	10
1076	The Effect of a Losartan-Based Treatment Regimen on Isolated Systolic Hypertension. Journal of Clinical Hypertension, 2002, 4, 101-107.	1.0	72
1077	Factors Influencing the Systolic Blood Pressure Response to Drug Therapy. Journal of Clinical Hypertension, 2002, 4, 35-40.	1.0	20
1078	Use of Lipid‣owering Drugs and Blood Pressure Control in Patients With Arterial Hypertension. Journal of Clinical Hypertension, 2002, 4, 277-285.	1.0	35
1079	Therapeutic Considerations in the Treatment of Obesity Hypertension. Journal of Clinical Hypertension, 2002, 4, 189-196.	1.0	7
1080	Why Do Treated Hypertensives Suffer Strokes? An Internist's Perspective. Journal of Clinical Hypertension, 2002, 4, 338-344.	1.0	10
1081	Refractory or Resistant Hypertension. Journal of Clinical Hypertension, 2002, 4, 61-61.	1.0	0
1082	Blood Pressure Changes in the Leg on Standing. Journal of Clinical Hypertension, 2002, 4, 350-354.	1.0	30

#	Article	IF	CITATIONS
1083	The Diagnosis of Hypertension. Journal of Clinical Hypertension, 2002, 4, 166-180.	1.0	1
1084	Reproducibility of Blood Pressure Response to Hydrochlorothiazide. Journal of Clinical Hypertension, 2002, 4, 408-412.	1.0	7
1085	Essential Hypertension of Caribbean Hispanics: Sodium, Renin, and Response to Therapy. Journal of Clinical Hypertension, 2002, 4, 266-273.	1.0	20
1086	How Relevant and Frequent Is the Presence of Mild Renal Insufficiency in Essential Hypertension?. Journal of Clinical Hypertension, 2002, 4, 332-336.	1.0	39
1087	Antihypertensive Efficacy of Olmesartan Medoxomil, a New Angiotensin II Receptor Antagonist, as Assessed by Ambulatory Blood Pressure Measurements. Journal of Clinical Hypertension, 2002, 4, 325-331.	1.0	42
1088	Premature Termination of Clinical Trials-Lessons Learned. Journal of Clinical Hypertension, 2002, 4, 219-225.	1.0	4
1089	A "Touch―of High Blood Pressure. Journal of Clinical Hypertension, 2002, 4, 10-12.	1.0	0
1090	The Association Between Hypertension and Other Cardiovascular Risk Factors in Young Adult African Americans. Journal of Clinical Hypertension, 2002, 4, 17-22.	1.0	16
1091	Effectiveness of the Electronic Medical Record in Improving the Management of Hypertension. Journal of Clinical Hypertension, 2002, 4, 415-419.	1.0	23
1092	Should $\hat{l}^2$ Blockers Be Used in the Treatment of Hypertension in the Elderly?. Journal of Clinical Hypertension, 2002, 4, 286-294.	1.0	7
1093	Clinical Impact of Renin-Angiotensin System Blockade: Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Antagonists. Journal of Clinical Hypertension, 2002, 4, 11-31.	1.0	5
1094	Will We Ever Wipe Out Stroke?. Journal of Clinical Hypertension, 2002, 4, 337-344.	1.0	0
1095	Alcohol's (other) Dark Side. Journal of Clinical Hypertension, 2002, 4, 362-362.	1.0	0
1096	Sleep Apnea and Hypertension. Journal of Clinical Hypertension, 2002, 4, 437-440.	1.0	3
1097	Update on the Management of Hypertension: Do Recent Clinical Trial Results Indicate a Change in National Recommendations for Therapy?. Journal of Clinical Hypertension, 2002, 4, 20-31.	1.0	8
1098	Nondiabetic Kidney Disease. New England Journal of Medicine, 2002, 347, 1505-1511.	13.9	121
1099	Diuretic Therapy, the α-Adducin Gene Variant, and the Risk of Myocardial Infarction or Stroke in Persons With Treated Hypertension. JAMA - Journal of the American Medical Association, 2002, 287, 1680.	3.8	189
1100	African American Women and Men at High and Low Risk for Hypertension: A Signal Detection Analysis of NHANES III, 1988–1994. Preventive Medicine, 2002, 35, 303-312.	1.6	37

#	Article	IF	CITATIONS
1101	Task Force #3â€"getting results: who, where, and how?. Journal of the American College of Cardiology, 2002, 40, 615-630.	1.2	15
1102	Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. Fertility and Sterility, 2002, 78, 51-57.	0.5	26
1103	Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis, 2002, 165, 191-199.	0.4	100
1104	Initial Management of Glycemia in Type 2 Diabetes Mellitus. New England Journal of Medicine, 2002, 347, 1342-1349.	13.9	309
1105	Systolic blood pressure is a better predictor of cardio-vascular disease risk than diastolic blood pressure in hypertensive men. Evidence-based Cardiovascular Medicine, 2002, 6, 162-163.	0.0	0
1106	Low-income African Americans' views about hypertension differ from medical understanding. Evidence-Based Healthcare and Public Health, 2002, 6, 173.	0.0	0
1107	Clinical Pharmacokinetics and Selective Pharmacodynamics of New Angiotensin Converting Enzyme Inhibitors. Clinical Pharmacokinetics, 2002, 41, 207-224.	1.6	97
1108	??-Adrenergic Blockers in Systemic Hypertension. Clinical Pharmacokinetics, 2002, 41, 505-516.	1.6	63
1109	Quinapril. Drugs, 2002, 62, 339-385.	4.9	15
1110	Rationale for Fixed-Dose Combinations in the Treatment of Hypertension. Drugs, 2002, 62, 443-462.	4.9	263
1111	Candesartan Cilexetil plus Hydrochlorothiazide Combination. Drugs, 2002, 62, 787-816.	4.9	42
1112	Candesartan Cilexetil. Drugs, 2002, 62, 1253-1287.	4.9	62
1114	Valsartan/Hydrochlorothiazide. Drugs, 2002, 62, 1983-2005.	4.9	64
1115	The Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in the Management of Diabetic Complications. Drugs, 2002, 62, 2007-2012.	4.9	13
1116	Fixed Combination Trandolapril/Verapamil Sustained-Release. Drugs, 2002, 62, 2541-2569.	4.9	11
1117	Low-Dose Combination Therapy with Perindopril and Indapamide Compared with Irbesartan. Clinical Drug Investigation, 2002, 22, 553-560.	1.1	15
1118	Impact of a Low-Dose Combination of Isradipine SRO and Spirapril on Left Ventricular Mass and Left Ventricular Performance in Patients with Hypertension and Left Ventricular Hypertrophy. Clinical Drug Investigation, 2002, 22, 667-675.	1.1	1
1119	Metoprolol Succinate SR plus Hydrochlorothiazide (Beloc-Zok?? Comp) in Patients with Essential Hypertension in General Practice. Clinical Drug Investigation, 2002, 22, 719-729.	1.1	3

#	Article	IF	CITATIONS
1120	Modeling the circadian variability of ambulatorily monitored blood pressure by multiple-component analysis. Chronobiology International, 2002, 19, 461-481.	0.9	106
1121	Long-Term Trends in the Incidence of and Survival with Heart Failure. New England Journal of Medicine, 2002, 347, 1397-1402.	13.9	1,877
1122	Improving Primary Care for Patients With Chronic Illness. JAMA - Journal of the American Medical Association, 2002, 288, 1775.	3.8	2,349
1123	Smooth Blood Pressure Control Obtained with Extended-Release Felodipine in Elderly Patients with Hypertension. Drugs and Aging, 2002, 19, 541-551.	1.3	8
1124	Issues in the Perioperative Management of the Elderly Patient with Cardiovascular Disease. Drugs and Aging, 2002, 19, 429-451.	1.3	44
1125	Periodontal Assessment of Patients Undergoing Angioplasty for Treatment of Coronary Artery Disease. Journal of Periodontology, 2002, 73, 631-636.	1.7	20
1126	Antagonistas de los receptores de la angiotensina II. Una revisión farmacoterapéutica. Hipertension Y Riesgo Vascular, 2002, 19, 129-138.	0.3	1
1127	Documento de consenso 2002 sobre pautas e detección, prevención y tratamiento e la nefropatÃa diabética en España. Semergen, 2002, 28, 631-638.	0.2	8
1129	Pautas de detección, prevención y tratamiento de la nefropatÃa diabética en españa. Hipertension Y Riesgo Vascular, 2002, 19, 412-420.	0.3	1
1131	Prevalencia de la hipertensión arterial sistólica aislada en una población mayor de 60 años. Hipertension Y Riesgo Vascular, 2002, 19, 384-389.	0.3	2
1132	Antihipertensivos clásicos o modernos en el tratamiento de la hipertensión arterial: ¿debe seguir existiendo controversia en su elección?. Semergen, 2002, 28, 560-572.	0.2	1
1133	COMPARISON OF THE EFFECTS OF AMLODIPINE AND LOSARTAN ON 24-HOUR AMBULATORY BLOOD PRESSURE IN HYPERTENSIVE PATIENTS. Clinical and Experimental Hypertension, 2002, 24, 41-50.	0.5	14
1134	Nebivolol vs Amlodipine as First-line Treatment of Essential Arterial Hypertension in the Elderly. Blood Pressure, 2002, 11, 182-188.	0.7	42
1135	ESH Scientific Newsletter. Blood Pressure, 2002, 11, 63-64.	0.7	0
1136	Comparison of amlodipine and enalapril in the treatment of isolated systolic hypertension in the elderly: an open-label, randomized, parallel-group study. Current Therapeutic Research, 2002, 63, 153-164.	0.5	2
1137	Irbesartan monotherapy in systemic hypertension: An open-label, uncontrolled trial. Current Therapeutic Research, 2002, 63, 176-185.	0.5	1
1138	Chronic hypertension in pregnancy. Obstetrics and Gynecology, 2002, 100, 369-377.	1.2	246
1139	A Review of Olmesartan Medoxomil Monotherapy: Antihypertensive Efficacy Similar to That of Other Angiotensin II Receptor Blocker/Hydrochlorothiazide Combinations?. Congestive Heart Failure, 2002, 8, 313-320.	2.0	13

#	Article	IF	CITATIONS
1140	Amlodipine and chlorthalidone are equally effective for stage I isolated systolic hypertension. Evidence-based Cardiovascular Medicine, 2002, 6, 114-115.	0.0	0
1141	Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: The Framingham Heart Study. American Heart Journal, 2002, 144, 733-739.	1.2	62
1142	Simple, shared guidelines raise the quality of antihypertensive treatment in routine care. American Heart Journal, 2002, 144, 726-732.	1.2	11
1143	Age-Related Changes in Risk Factor Effects on the Incidence of Coronary Heart Disease. Annals of Epidemiology, 2002, 12, 173-181.	0.9	75
1144	Use of medications and polypharmacy are increasing among the elderly. Journal of Clinical Epidemiology, 2002, 55, 809-817.	2.4	374
1145	Are there meaningful differences in blood pressure control with current antihypertensive agents?. American Journal of Hypertension, 2002, 15, S14-S21.	1.0	11
1146	Relationship between obesity decrease and regression of hypertensive left ventricular hypertrophy. American Journal of Hypertension, 2002, 15, A198.	1.0	0
1147	Insights from Laragh's review course: the role of the renin-angiotensin system in blood pressure regulation. American Journal of Hypertension, 2002, 15, 653-654.	1.0	6
1148	Risk stratification of older patients. American Journal of Hypertension, 2002, 15, S77-S81.	1.0	5
1149	Recent landmark clinical trials: how do they modify the therapeutic paradigm?. American Journal of Hypertension, 2002, 15, S82-S84.	1.0	9
1150	Relationships between new risk factors and circadian blood pressure variation in untreated subjects with essential hypertension. American Journal of Hypertension, 2002, 15, 600-604.	1.0	34
1151	Transforming growth factor- $\hat{l}^21$ levels in hypertensive patients: association with body mass index and leptin1. American Journal of Hypertension, 2002, 15, 759-765.	1.0	46
1152	Ambulatory pulse pressure aspredictor of outcome in older patients with systolic hypertension. American Journal of Hypertension, 2002, 15, 835-843.	1.0	93
1153	Hypertension guidelines: criteria that might make them more clinically useful. American Journal of Hypertension, 2002, 15, 917-923.	1.0	36
1154	Arterial hypertension and mortality in the elderly. American Journal of Hypertension, 2002, 15, 958-966.	1.0	19
1155	Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. American Journal of Hypertension, 2002, 15, 1042-1049.	1.0	83
1156	Differential effects of antihypertensive drug therapy on arterial compliance. American Journal of Hypertension, 2002, 15, 1096-1100.	1.0	35
1157	Left ventricular mass change during treatment and outcome in patients with essential hypertension. American Journal of Hypertension, 2002, 15, 1021-1028.	1.0	101

#	Article	IF	Citations
1158	Angiotensin II type 1 receptor polymorphisms in the cardiovascular health study: relation to blood pressure, ethnicity, and cardiovascular events. American Journal of Hypertension, 2002, 15, 1050-1056.	1.0	56
1159	Treatment of type 2 diabetic nephropathy by blockade of the renin–angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists. Current Opinion in Pharmacology, 2002, 2, 182-188.	1.7	4
1160	Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Research and Clinical Practice, 2002, 55, 113-121.	1.1	50
1161	A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. Clinical Therapeutics, 2002, 24, 930-941.	1.1	3
1162	Changing patterns of initial drug therapy for the treatment of hypertension in a medicaid population, 1997–2000. Clinical Therapeutics, 2002, 24, 1451-1462.	1.1	8
1163	Treatment of hypertension with an angiotensin Il—receptor antagonist compared with an angiotensin-converting enzyme inhibitor: A review of clinical studies of telmisartan and enalapril. Clinical Therapeutics, 2002, 24, 1484-1501.	1.1	41
1164	Pharmacologic management of diabetic nephropathy. Clinical Therapeutics, 2002, 24, 1741-1756.	1.1	25
1165	Validation of the short form of the Spanish hypertension quality of life questionnaire (MINICHAL). Clinical Therapeutics, 2002, 24, 2137-2154.	1.1	37
1166	A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: The MAPAVEL study. Clinical Therapeutics, 2002, 24, 126-138.	1,1	36
1167	Health-related quality of life in patients treated for hypertension: A review of the literature from 1990 to 2000. Clinical Therapeutics, 2002, 24, 142-169.	1.1	18
1168	Assessment of antihypertensive drug use in primary care in Ravenna, Italy, based on data collected in the PANDORA Project. Clinical Therapeutics, 2002, 24, 249-259.	1.1	7
1169	A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension. Clinical Therapeutics, 2002, 24, 786-797.	1.1	8
1172	Role of Ambulatory Blood Pressure Measurement in Diagnosis and Control of Hypertension. Medical Journal Armed Forces India, 2002, 58, 307-309.	0.3	0
1173	Hypertension in the elderly: evidence-based management. International Congress Series, 2002, 1237, 75-85.	0.2	1
1174	Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis, 2002, 161, 403-408.	0.4	64
1177	Estudio de actitud, comportamiento y satisfacción de los médicos de APS con el tratamiento antihipertensivo actual. Hipertension Y Riesgo Vascular, 2002, 19, 338-344.	0.3	1
1178	Bloqueadores betaadrenérgicos: análisis comparativo. FMC Formacion Medica Continuada En Atencion Primaria, 2002, 9, 605-612.	0.0	0
1179	Respuesta a un "análisis―crÃŧico sobre la atención farmacéutica. Semergen, 2002, 28, 51-54.	0.2	3

#	Article	IF	CITATIONS
1180	Tratamiento de las crisis hipertensivas. FMC Formacion Medica Continuada En Atencion Primaria, 2002, 9, 355-365.	0.0	2
1184	Higher prevalence of obstructive airway disease in patients with thoracic or abdominal aortic aneurysm. Journal of Vascular Surgery, 2002, 36, 35-40.	0.6	23
1188	Hipertensi?n arterial. EMC - Tratado De Medicina, 2002, 6, 1-9.	0.0	2
1190	Menopausia e hipertensión arterial. Hipertension Y Riesgo Vascular, 2002, 19, 351-358.	0.3	1
1192	Use of Antihypertensive Drug Therapy in Older Persons in an Academic Nursing Home. Journal of the American Medical Directors Association, 2002, 3, 243-245.	1.2	9
1198	Cambios en la presión arterial y la frecuencia cardÃaca inducidos por la práctica y cese de ejercicio fÃsico moderado en jóvenes normotensos. ClÃnica E Investigación En Arteriosclerosis, 2002, 14, 9-16.	0.4	0
1200	Evaluaci $\tilde{A}^3$ n econ $\tilde{A}^3$ mica retrospectiva con costes espa $\tilde{A}\pm$ oles de un estudio comparativo de amlodipino y enalapril en el tratamiento de la hipertensi $\tilde{A}^3$ n ligera a moderada. Hipertension Y Riesgo Vascular, 2002, 19, 271-278.	0.3	1
1201	Clinical pharmacology of antihypertensive drugs. Cardiology Clinics, 2002, 20, 265-280.	0.9	9
1202	Hipertensi $\tilde{A}^3$ n arterial y enfermedad vascular perif $\tilde{A}$ ©rica de origen ateroscler $\tilde{A}^3$ tico. Hipertension Y Riesgo Vascular, 2002, 19, 17-27.	0.3	1
1203	Hypertension detection and control: population and policy implications. Cardiology Clinics, 2002, 20, 187-194.	0.9	4
1205	Effective strategies for blood pressure control. Cardiology Clinics, 2002, 20, 321-333.	0.9	12
1206	Tratamiento de la hipertensi $\tilde{A}^3$ n arterial con antagonistas de los receptores de la angiotensina II. Hipertension Y Riesgo Vascular, 2002, 19, 257-261.	0.3	0
1209	Estatinas en el tratamiento de la hipertensi $\tilde{A}^3$ n arterial. Hipertension Y Riesgo Vascular, 2002, 19, 400-405.	0.3	3
1210	Detecci $\tilde{A}^3$ n precoz de la hipertensi $\tilde{A}^3$ n arterial: $\hat{A}_z$ hay un lugar para las oficinas de farmacia?. Hipertension Y Riesgo Vascular, 2002, 19, 297-298.	0.3	0
1211	Evolución del control de la hipertensión arterial en España. Resultados del estudio Controlpres 2001. Hipertension Y Riesgo Vascular, 2002, 19, 390-399.	0.3	89
1212	El problema del control de la hipertensión en España. Hipertension Y Riesgo Vascular, 2002, 19, 377-381.	0.3	5
1213	Hipertensión arterial en el paciente dislipidémico. Hipertension Y Riesgo Vascular, 2002, 19, 222-237.	0.3	3
1217	Preventive health care for older patients. Primary Care - Clinics in Office Practice, 2002, 29, 599-614.	0.7	3

#	Article	IF	CITATIONS
1218	A Randomized Trial of an Intervention to Improve Self-Care Behaviors of African-American Women With Type 2 Diabetes: Impact on physical activity. Diabetes Care, 2002, 25, 1576-1583.	4.3	228
1219	Dysmetabolic Syndrome: Multiple Risk Factors for Premature Adult Disease in an Adolescent Girl. Pediatrics, 2002, 110, e14-e14.	1.0	22
1220	Blood Pressure Control Assessed by Home, Ambulatory and Conventional Blood Pressure Measurements in the Japanese General Population: the Ohasama Study. Hypertension Research, 2002, 25, 57-63.	1.5	74
1221	Questionnaire Survey on the Japanese Guidelines for Treatment of Hypertension in the Elderly: 1999 Revised Version. Hypertension Research, 2002, 25, 69-75.	1.5	10
1222	Antihypertensive Effects of Aerobic Exercise in Middle-Aged Normotensive Men with Exaggerated Blood Pressure Response to Exercise Hypertension Research, 2002, 25, 507-514.	1.5	22
1223	Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 821-826.	0.2	15
1224	Selection of the Dose of Angiotensin Converting Enzyme Inhibitor for Patients with Diabetic Nephropathy Depends on the Presence or Absence of Left Ventricular Hypertorphy Hypertension Research, 2002, 25, 865-873.	1.5	11
1225	Effects of Hormone Replacement Therapy on Left Ventricular Hypertrophy and Growth-Promoting Factors in Hypertensive Postmenopausal Women. Hypertension Research, 2002, 25, 153-159.	1.5	34
1226	Epworth's sleepiness scale in outpatients with different values of arterial blood pressure. Arquivos Brasileiros De Cardiologia, 2002, 78, 17-24.	0.3	11
1227	Comparison between young males and females with acute myocardial infarction. Arquivos Brasileiros De Cardiologia, 2002, 79, 518-525.	0.3	18
1228	Systolic blood pressure. BMJ: British Medical Journal, 2002, 325, 917-918.	2.4	39
1229	Increase in Pulse Pressure Relates to Diabetes Mellitus and Low HDL Cholesterol, but Not to Hyperlipidemia in Hypertensive Patients Aged 50 Years or Older Hypertension Research, 2002, 25, 335-341.	1.5	21
1230	Relationship between Home Blood Pressure and Longitudinal Changes in Target Organ Damage in Treated Hypertensive Patients. Hypertension Research, 2002, 25, 167-173.	1.5	80
1231	Irbesartan in Primary Hypertension in Thai Patients: A Multicentre, Non-Comparative Study. Cardiology, 2002, 2, 228-234.	0.3	1
1232	Effective diabetes care: a need for realistic targets. BMJ: British Medical Journal, 2002, 324, 1577-1580.	2.4	84
1233	Hepatocyte Growth Factor and 24-Hour Ambulatory Blood Pressure Monitoring Hypertension Research, 2002, 25, 655-660.	1.5	10
1234	Relationship between Changes in Serum Leptin Levels and Blood Pressure after Weight Loss Hypertension Research, 2002, 25, 881-886.	1.5	49
1235	Pharmacogenetics and cardiovascular disease: Impact on drug response and applications to disease management. American Journal of Health-System Pharmacy, 2002, 59, 1241-1252.	0.5	28

#	Article	IF	CITATIONS
1236	Maintenance of Low-Density Lipoprotein Goal with Step-Down Pravastatin Therapy. Pharmacotherapy, 2002, 22, 21-26.	1.2	9
1237	A Review of Vasopeptidase Inhibitors: A New Modality in the Treatment of Hypertension and Chronic Heart Failure. Pharmacotherapy, 2002, 22, 27-42.	1.2	44
1238	Improving Blood Pressure Control in a Pharmacist-Managed Hypertension Clinic. Pharmacotherapy, 2002, 22, 1533-1540.	1.2	157
1239	Compliance with National Guidelines in Patients with Diabetes in a Family Practice Clinic. Pharmacotherapy, 2002, 22, 1541-1546.	1.2	6
1240	National Pharmacy Cardiovascular Council Treatment Guidelines for the Management of Type 2 Diabetes Mellitus: Toward Better Patient Outcomes and New Roles for Pharmacists. Pharmacotherapy, 2002, 22, 436-444.	1.2	28
1241	Noninvasive 24-Hour Ambulatory Blood Pressure Monitoring: Overview of Technology and Clinical Applications. Pharmacotherapy, 2002, 22, 597-612.	1.2	25
1242	The Use of Combination Drug Therapy in the Treatment of Hypertension. Progress in Cardiovascular Nursing, 2002, 17, 81-95.	0.5	17
1243	Controlling Hypertension to Reduce the Risk of Stroke. Progress in Cardiovascular Nursing, 2002, 17, 186-191.	0.5	3
1244	Associations of Community-based Health Education Programs with Food Habits and Cardiovascular Disease Risk Factors Among Native Americans with Diabetes. Journal of the American Dietetic Association, 2002, 102, 1132-1135.	1.3	12
1245	Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade. American Journal of Cardiology, 2002, 90, 662-663.	0.7	25
1246	Comparison of usefulness of systolic, diastolic, and mean blood pressure and pulse pressure as predictors of cardiovascular death in patients $\hat{a}\%$ 460 years of age (The Dubbo Study). American Journal of Cardiology, 2002, 90, 1398-1401.	0.7	19
1247	Implementing practice guidelines for depression: Applying a new framework to an old problem. General Hospital Psychiatry, 2002, 24, 35-42.	1.2	87
1248	Alcoholic Cardiomyopathy: Is It Dose-Dependent?. Congestive Heart Failure, 2002, 8, 303-312.	2.0	26
1249	Nutritional Factors in the Control of Blood Pressure and Hypertension. Nutrition in Clinical Care: an Official Publication of Tufts University, 2002, 5, 9-19.	0.2	55
1250	Importance of blood pressure control in patients with diabetes mellitus. Journal of Diabetes and Its Complications, 2002, 16, 87-91.	1.2	1
1251	Diabetes and macrovascular disease. Journal of Diabetes and Its Complications, 2002, 16, 235-245.	1.2	103
1252	Treatment of hypertension from volume to vasoconstriction: The ACE up your sleeve. Seminars in Vascular Surgery, 2002, 15, 225-236.	1.1	0
1253	Interrelations among smoking habits, casual blood pressure and intraocular pressure in middle and old-aged Japanese residents. Environmental Health and Preventive Medicine, 2002, 7, 162-168.	1.4	3

#	Article	IF	Citations
1254	Treated hypertensives with good medication compliance are still in a state of uncontrolled blood pressure in the Japanese elderly. Environmental Health and Preventive Medicine, 2002, 7, 193-198.	1.4	0
1255	Isolated systolic hypertension in the elderly. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 87-93.	0.4	5
1256	Proteinuria: An underappreciated risk factor in cardiovascular disease. Current Cardiology Reports, 2002, 4, 458-462.	1.3	23
1257	Systolic versus diastolic blood pressure versus pulse pressure. Current Cardiology Reports, 2002, 4, 463-467.	1.3	20
1258	Vasodilatory edema: A common side effect of antihypertensive therapy. Current Cardiology Reports, 2002, 4, 479-482.	1.3	116
1259	Microalbuminuria in diabetes: Focus on cardiovascular and renal risk reduction. Current Diabetes Reports, 2002, 2, 258-262.	1.7	9
1260	The choice of antihypertensive drugs in patients with diabetes: Angiotensin II and beyond. Current Diabetes Reports, 2002, 2, 423-430.	1.7	0
1261	Blood pressure control—Effects on diabetic nephropathy progression: How low does blood pressure have to be?. Current Diabetes Reports, 2002, 2, 530-538.	1.7	5
1262	Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Current Hypertension Reports, 2002, 4, 185-190.	1.5	17
1263	Resistant hypertension. Current Hypertension Reports, 2002, 4, 221-228.	1.5	49
1264	Cost of treating hypertension in the elderly. Current Hypertension Reports, 2002, 4, 420-423.	1.5	5
1265	Compliance and persistence with newer antihypertensive agents. Current Hypertension Reports, 2002, 4, 424-433.	1.5	41
1266	Obesity-related hypertension: Role of the sympathetic nervous system, insulin, and leptin. Current Hypertension Reports, 2002, 4, 112-118.	1.5	38
1267	Genetic targeting of the renin-angiotensin system for long-term control of hypertension. Current Hypertension Reports, 2002, 4, 25-31.	1.5	7
1268	Optimizing blood pressure control in the obese patient. Current Hypertension Reports, 2002, 4, 358-362.	1.5	5
1269	Putting LIFE into hypertension. Current Hypertension Reports, 2002, 4, 275-277.	1.5	1
1270	Is fixed combination therapy appropriate for initial hypertension treatment?. Current Hypertension Reports, 2002, 4, 278-285.	1.5	47
1271	Are angiotensin converting enzyme inhibitors and angiotensin receptor blockers becoming the treatment of choice in African-Americans?. Current Hypertension Reports, 2002, 4, 286-289.	1.5	12

#	Article	IF	Citations
1272	Fixed low-dose combination therapy for hypertension. Current Hypertension Reports, 2002, 4, 298-306.	1.5	7
1273	Contemporary treatment of heart failure: Is there adequate evidence to support a unique strategy for African-Americans? con position. Current Hypertension Reports, 2002, 4, 311-318.	1.5	9
1274	Renal protection by antihypertensive therapy. Current Hypertension Reports, 2002, 4, 324-328.	1.5	5
1275	Low sodium diet after DASH: Has the situation changed?. Current Hypertension Reports, 2002, 4, 329-332.	1.5	8
1276	Body position and blood pressure measurement in patients with diabetes mellitus. Journal of Internal Medicine, 2002, 251, 393-399.	2.7	32
1277	Development of hypertension over 6 years in a birth cohort of young middle-aged men: the Cardiovascular Risk Factor Study in southern Sweden (CRISS). Journal of Internal Medicine, 2002, 252, 21-26.	2.7	11
1278	Randomized, comparative, double-blind study of amlodipine vs. nicardipine as a treatment of isolated systolic hypertension in the elderly. Fundamental and Clinical Pharmacology, 2002, 16, 537-544.	1.0	6
1279	Angiotensin blockade in type 2 diabetic renal disease. Kidney International, 2002, 62, S61-S63.	2.6	2
1280	Comparing Cost-Effectiveness Analyses of Anti-Hypertensive Drug Therapy for Decision Making: Mission Impossible? Value in Health, 2002, 5, 359-371.	0.1	10
1281	Interventions to Promote Physical Activity Among African American Women. Public Health Nursing, 2002, 19, 321-335.	0.7	131
1282	Noncompliance with antihypertensive medications. Journal of General Internal Medicine, 2002, 17, 504-511.	1.3	314
1283	Screening for diabetes in an outpatient clinic population. Journal of General Internal Medicine, 2002, 17, 23-28.	1.3	38
1284	Management of patients with hypertensive urgencies and emergencies. Journal of General Internal Medicine, 2002, 17, 937-945.	1.3	135
1285	Diabetes Mellitus in a Subgroup of Older Mexicans: Prevalence, Association with Cardiovascular Risk Factors, Functional and Cognitive Impairment, and Mortality. Journal of the American Geriatrics Society, 2002, 50, 111-116.	1.3	54
1286	Use of Angiotensin onverting Enzyme Inhibitors in Patients with Heart Failure and Renal Insufficiency: How Concerned Should We Be by the Rise in Serum Creatinine?. Journal of the American Geriatrics Society, 2002, 50, 1297-1300.	1.3	73
1287	The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. British Journal of Clinical Pharmacology, 2002, 54, 212-220.	1.1	71
1288	A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy. Current Controlled Trials in Cardiovascular Medicine, 2002, 3, 7.	1.5	17
1289	Relationship between insulin resistance and accumulation of coronary risk factors. Diabetes, Obesity and Metabolism, 2002, 4, 388-393.	2.2	40

#	ARTICLE	IF	CITATIONS
1290	Partnership caring: a theory of high blood pressure control in Iranian hypertensives. International Journal of Nursing Practice, 2002, 8, 324-329.	0.8	27
1291	Obesity, weight change and risks for hypertension, diabetes and hypercholesterolemia in Japanese men. European Journal of Clinical Nutrition, 2002, 56, 601-607.	1.3	125
1292	Exacerbation of insulin resistance and postprandial triglyceride response in newly diagnosed hypertensive patients with hypertriglyceridaemia. Journal of Human Hypertension, 2002, 16, 487-493.	1.0	14
1293	The problem of uncontrolled hypertension. Journal of Human Hypertension, 2002, 16, S3-S8.	1.0	34
1294	AT1-receptor blockers: differences that matter. Journal of Human Hypertension, 2002, 16, S9-S16.	1.0	42
1295	Potential for antihypertensive treatment with an AT1-receptor blocker to reduce dementia in the elderly. Journal of Human Hypertension, 2002, 16, S71-S75.	1.0	14
1296	A population-based European cohort study of persistence in newly diagnosed hypertensive patients. Journal of Human Hypertension, 2002, 16, 569-575.	1.0	99
1297	Cardiac autonomic tone during trandolapril-irbesartan low-dose combined therapy in hypertension: a pilot project. Journal of Human Hypertension, 2002, 16, 597-604.	1.0	8
1298	Diuretic induced hyponatraemia in elderly hypertensive women. Journal of Human Hypertension, 2002, 16, 631-635.	1.0	125
1299	Relationship between transforming growth factor $\hat{l}^21$ and progression of hypertensive renal disease. Journal of Human Hypertension, 2002, 16, 641-645.	1.0	19
1300	Compliance to hypertension guidelines in clinical practice: a multicentre pilot study in Italy. Journal of Human Hypertension, 2002, 16, 699-703.	1.0	42
1301	Hypertension and the eye: changing perspectives. Journal of Human Hypertension, 2002, 16, 667-675.	1.0	77
1302	Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension. Journal of Human Hypertension, 2002, 16, 789-793.	1.0	60
1303	Persistence of the antihypertensive efficacy of amlodipine and nifedipine GITS after two †missed doses': a randomised, double-blind comparative trial in Asian patients. Journal of Human Hypertension, 2002, 16, 805-813.	1.0	11
1304	Renal and cardiovascular considerations for the nonpharmacological and pharmacological therapies of obesity-hypertension. Journal of Human Hypertension, 2002, 16, 819-827.	1.0	19
1305	Drugs targeting the renin–angiotensin–aldosterone system. Nature Reviews Drug Discovery, 2002, 1, 621-636.	21.5	385
1306	Alcohol Intake and Future Incidence of Hypertension in a General Japanese Population: The Hisayama Study. Alcoholism: Clinical and Experimental Research, 2002, 26, 1010-1016.	1.4	68
1307	Reducing global risk for cardiovascular disease: Using lifestyle changes and pharmacotherapy. Clinical Cardiology, 2002, 25, 205-212.	0.7	23

#	Article	IF	CITATIONS
1308	HLA associations with HBV carriage and proteinuria. Pediatric Nephrology, 2002, 17, 724-729.	0.9	5
1309	Trends in hypertension management in Type I diabetes across Europe, 1989/1990 ? 1997/1999. Diabetologia, 2002, 45, 1362-1371.	2.9	33
1310	Fosinopril improves left ventricular diastolic function in young mildly hypertensive patients without hypertrophy. Cardiovascular Drugs and Therapy, 2002, 16, 141-147.	1.3	5
1311	Antihypertensive medication and quality of lifesilent treatment of a silent killer?. Cardiovascular Drugs and Therapy, 2002, 16, 353-364.	1.3	35
1312	Beta-blockers and diabetes: the bad guys come good. Cardiovascular Drugs and Therapy, 2002, 16, 457-470.	1.3	25
1313	Clinical profile of eprosartan. Cardiovascular Drugs and Therapy, 2002, 16, 543-549.	1.3	6
1314	Cardiovascular therapy in patients with renal insufficiency. Cardiovascular Drugs and Therapy, 2002, 16, 497-501.	1.3	0
1315	Epidemiology of essential hypertension: The role of genetic polymorphism. European Journal of Epidemiology, 2002, 18, 211-219.	2.5	5
1316	Urine Dipstick as a Screening Test for Serum Creatinine Elevation in Emergency Department Patients with Severe Hypertension. Academic Emergency Medicine, 2002, 9, 27-34.	0.8	5
1317	The relationship between physicians and the pharmaceutical industry: ethical problems with the every-day conflict of interest. HEC Forum, 2003, 15, 155-170.	0.6	10
1318	The role of brain natriuretic peptide in population screening. Heart Failure Reviews, 2003, 8, 349-354.	1.7	4
1319	Systolic, diastolic, and pulse pressures as coronary risk factors in a population with low cholesterol levels: A prospective 10-year evaluation. Clinical Cardiology, 2003, 26, 91-97.	0.7	15
1320	Angiotensin II blockade: A therapeutic strategy with wide applications. Clinical Cardiology, 2003, 26, 500-502.	0.7	4
1321	Getting to goal in complex patients. Clinical Cardiology, 2003, 26, 3-6.	0.7	1
1322	Evolution of calcium antagonists: Past, present, and future. Clinical Cardiology, 2003, 26, 12-16.	0.7	24
1323	Emerging data on calcium-channel blockers: The COHORT study. Clinical Cardiology, 2003, 26, 17-20.	0.7	22
1324	"What goes up must immediately come down!". Pediatric Nephrology, 2003, 18, 1-2.	0.9	18
1326	Target blood pressure for patients with type 2 diabetes is difficult to achieve in the setting of a busy diabetes clinic. Irish Journal of Medical Science, 2003, 172, 168-170.	0.8	4

#	Article	IF	CITATIONS
1327	Management of diabetes with coronary artery disease. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 75-88.	0.4	2
1328	The importance of systolic blood pressure control and cardiovascular disease prevention. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 271-277.	0.4	5
1329	Prevention of cardiovascular disease in women. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 287-298.	0.4	0
1330	Clinical trials report. Current Atherosclerosis Reports, 2003, 5, 339-340.	2.0	1
1331	Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?. Current Atherosclerosis Reports, 2003, 5, 38-43.	2.0	9
1332	Uncontrolled hypertension as a risk for coronary artery disease: Patient characteristics and the role of physician intervention. Current Atherosclerosis Reports, 2003, 5, 131-138.	2.0	13
1333	Trials in isolated systolic hypertension: An update. Current Cardiology Reports, 2003, 5, 427-434.	1.3	1
1334	Epidemiology of the insulin resistance syndrome. Current Diabetes Reports, 2003, 3, 73-79.	1.7	64
1335	Are low target blood pressure goals justified in persons with diabetes mellitus?. Current Hypertension Reports, 2003, 5, 231-238.	1.5	3
1336	Management of diabetic and hypertensive cardiovascular disease. Current Hypertension Reports, 2003, 5, 309-315.	1.5	3
1337	Trials in isolated systolic hypertension: An update. Current Hypertension Reports, 2003, 5, 329-336.	1.5	8
1338	Use of calcium antagonists in renal patients: Therapeutic benefit or medical malpractice?. Current Hypertension Reports, 2003, 5, 430-436.	1.5	1
1339	Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?. Current Neurology and Neuroscience Reports, 2003, 3, 21-26.	2.0	8
1341	Incidence, prevalence and coronary heart disease risk level in known Type 2 diabetes: a sentinel practice network study in the Basque Country, Spain. Diabetologia, 2003, 46, 899-909.	2.9	53
1342	Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. European Journal of Clinical Pharmacology, 2003, 59, 271-275.	0.8	26
1343	PASSCLAIM - Diet-related cardiovascular disease. European Journal of Nutrition, 2003, 42, 1-1.	1.8	48
1344	Austrian Moderate Altitude Study (AMAS 2000) – fluid shifts, erythropoiesis, and angiogenesis in patients with metabolic syndrome at moderate altitude (â‱1700Âm). European Journal of Applied Physiology, 2003, 88, 497-505.	1.2	26
1345	Dietary protein and hypertension:. Nutrition, 2003, 19, 385-386.	1.1	7

#	Article	IF	CITATIONS
1346	Anaesthesia and hypertension. Current Anaesthesia and Critical Care, 2003, 14, 100-107.	0.3	1
1347	Metabolic syndrome: what is it and how should I treat it?. ACC Current Journal Review, 2003, 12, 37-40.	0.1	3
1349	Aldosterone Receptor Antagonists: Focus on Eplerenone. Progress in Cardiovascular Nursing, 2003, 18, 54-59.	0.5	2
1350	Treating patients with peripheral arterial disease and claudication. Journal of Vascular Nursing, 2003, 21, 5-16.	0.2	14
1351	Hypertension in the Parsi community of Bombay: a study on prevalence, awareness and compliance to treatment. BMC Public Health, $2003$ , $3$ , $1$ .	1.2	103
1352	Overweight and obesity in relation to cardiovascular disease risk factors among medical students in Crete, Greece. BMC Public Health, 2003, 3, 3.	1.2	121
1353	Comparison of Changes in Blood Pressure Measurements and Antihypertensive Therapy in Older, Hypertensive, Ambulatory Care Patients Prescribed Celecoxib or Rofecoxib. Pharmacotherapy, 2003, 23, 1416-1423.	1.2	16
1354	Physician-Pharmacist Comanagement of Hypertension: A Randomized, Comparative Trial. Pharmacotherapy, 2003, 23, 209-216.	1.2	171
1355	Impact of Hospitalization on Blood Pressure Control in Italy: Results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). Pharmacotherapy, 2003, 23, 240-247.	1.2	10
1356	Losartan and E3174 Pharmacokinetics in Cytochrome P4502C9*1/*1,*1/*2, and*1/*3Individuals. Pharmacotherapy, 2003, 23, 720-725.	1.2	33
1357	Calcium Channel Blockers as the Treatment of Choice for Hypertension in Renal Transplant Recipients: Fact or Fiction. Pharmacotherapy, 2003, 23, 788-801.	1.2	30
1358	Angiotensin-Converting Enzyme Inhibitors and Type 2 Diabetic Nephropathy: A Meta-Analysis. Pharmacotherapy, 2003, 23, 909-915.	1.2	25
1359	Assessment of Factors Influencing Blood Pressure Control in a Managed Care Population. Pharmacotherapy, 2003, 23, 1060-1070.	1.2	13
1360	Acute Decompensated Heart Failure: A Contemporary Approach to Pharmacotherapeutic Management. Pharmacotherapy, 2003, 23, 997-1020.	1.2	32
1361	Prediction of mortality in patients with right bundle branch block referred for pharmacologic stress echocardiography. American Journal of Cardiology, 2003, 92, 1429-1433.	0.7	8
1362	Toward national comparable nurse practitioner data: proposed data elements, rationale, and methods. Journal of Biomedical Informatics, 2003, 36, 342-350.	2.5	8
1363	Comparative prognostic value of systolic, diastolic, and pulse pressure. American Journal of Cardiology, 2003, 91, 433-435.	0.7	10
1364	Edward David Frohlich, MD: a conversation with the editor**This series of interviews is underwritten by an unrestricted grant from Bristol-Myers Squibb American Journal of Cardiology, 2003, 92, 565-581.	0.7	0

#	Article	IF	CITATIONS
1365	Synthesis, $\hat{l}^2$ -adrenergic blocking activity and $\hat{l}^2$ -receptor binding affinities of 1-substituted-3-(2-isopropyl-5-methyl-phenoxy)-propan-2-ol oxalates. Il Farmaco, 2003, 58, 557-562.	0.9	8
1366	Pathogenesis and clinical physiology of hypertension. Current Problems in Cardiology, 2003, 28, 137-155.	1.1	5
1367	Atherosclerosis imaging for risk assessment and primary prevention of cardiovascular disease. Progress in Cardiovascular Diseases, 2003, 46, 115-121.	1.6	8
1368	Heart Failure in the Elderly. Congestive Heart Failure, 2003, 9, 311-323.	2.0	19
1369	Treatment of Heart Failure in Older Persons Congestive Heart Failure, 2003, 9, 142-147.	2.0	23
1370	$\hat{l}^21$ -adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clinical Pharmacology and Therapeutics, 2003, 74, 44-52.	2.3	269
1371	The role of lipid profile in determining the risk of ischemic stroke in the elderly: a case–control study. Archives of Gerontology and Geriatrics, 2003, 37, 51-62.	1.4	21
1372	Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Archives of Gerontology and Geriatrics, 2003, 37, 203-212.	1.4	39
1373	Better nutrient data improves public health: evidence and examples from the Dietary Approaches to Stop Hypertension (DASH) Trial. Journal of Food Composition and Analysis, 2003, 16, 313-321.	1.9	3
1374	Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 779-785.	0.9	16
1375	How Well Have Practices Followed Guidelines in Prescribing Antihypertensive Drugs: The Role of Health Insurance. Value in Health, 2003, 6, 18-28.	0.1	23
1376	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Traditional Cardiac Risk Factors in Individuals with Chronic Kidney Disease. Seminars in Dialysis, 2003, 16, 118-127.	0.7	85
1377	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Management of Heart Failure and Coronary Artery Disease in Patients with Chronic Kidney Disease. Seminars in Dialysis, 2003, 16, 165-172.	0.7	10
1379	Vascular disease risk factor management $4\hat{a} \in f$ years after carotid endarterectomy: are opportunities missed? ANZ Journal of Surgery, 2003, 73, 225-231.	0.3	3
1380	Characterizing blood pressure control in individuals with Type 2 diabetes: the relationship between clinic and self-monitored blood pressure. Diabetic Medicine, 2003, 20, 752-757.	1.2	13
1381	Blood pressure response to conventional and low-dose enalapril in chronic renal failure. British Journal of Clinical Pharmacology, 2003, 55, 139-146.	1.1	14
1382	The Association Between Time Since Last Meal and Blood Pressure in Older Adults: The Cardiovascular Health Study. Journal of the American Geriatrics Society, 2003, 51, 824-828.	1.3	19
1383	Misperceptions about Î <sup>2</sup> -blockers and diuretics. Journal of General Internal Medicine, 2003, 18, 977-983.	1.3	48

#	Article	IF	Citations
1384	Framingham-based tools to calculate the global risk of coronary heart disease. Journal of General Internal Medicine, 2003, 18, 1039-1052.	1.3	149
1385	Relation between body weight and health-related quality of life among the elderly in Spain. International Journal of Obesity, 2003, 27, 701-709.	1.6	101
1386	Silent ischemia is more prevalent among hypertensive patients with microalbuminuria and salt sensitivity. Journal of Human Hypertension, 2003, 17, 13-20.	1.0	17
1387	Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. Journal of Human Hypertension, 2003, 17, 37-44.	1.0	48
1388	Blood pressure measurement in an ambulatory setting: concordance between physician and patient self-measurement. Journal of Human Hypertension, 2003, 17, 45-50.	1.0	23
1389	Change in cardiovascular risk profile by echocardiography in medium-risk elderly hypertensives. Journal of Human Hypertension, 2003, 17, 101-106.	1.0	9
1390	Better blood pressure control: how to combine drugs. Journal of Human Hypertension, 2003, 17, 81-86.	1.0	135
1391	Normal blood pressure values as perceived by normotensive and hypertensive subjects. Journal of Human Hypertension, 2003, 17, 87-91.	1.0	25
1392	Assessment of cardiovascular reactivity by fractal and recurrence quantification analysis of heart rate and pulse transit time. Journal of Human Hypertension, 2003, 17, 111-118.	1.0	31
1393	The determinants of left ventricular hypertrophy defined by Sokolow–Lyon criteria in untreated hypertensive patients. Journal of Human Hypertension, 2003, 17, 159-164.	1.0	29
1394	Sagittal abdominal diameter is associated with insulin sensitivity in Chinese hypertensive patients and their siblings. Journal of Human Hypertension, 2003, 17, 193-198.	1.0	21
1395	Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. Journal of Human Hypertension, 2003, 17, 207-212.	1.0	41
1396	Renin-angiotensin-aldosterone system and G-protein beta-3 subunit gene polymorphisms in salt-sensitive essential hypertension. Journal of Human Hypertension, 2003, 17, 187-191.	1.0	42
1397	Is systolic blood pressure sufficient for classification of blood pressure and determination of hypertension based on JNC-VI in an Iranian adult population? Tehran lipid and glucose study (TLGS). Journal of Human Hypertension, 2003, 17, 287-291.	1.0	10
1398	Evaluation of hypertension control in Greek primary care units. The VANK study. Journal of Human Hypertension, 2003, 17, 297-298.	1.0	6
1399	How well are hypertension and albuminuria treated in type II diabetic patients?. Journal of Human Hypertension, 2003, 17, 413-418.	1.0	15
1400	Accurate measurement of arterial pressure. Journal of Human Hypertension, 2003, 17, 445-447.	1.0	9
1401	Why not prescribe the best drugs for hypertension now?. Journal of Human Hypertension, 2003, 17, 505-511.	1.0	7

#	Article	IF	CITATIONS
1402	Accuracy of telemedical home blood pressure measurement in the diagnosis of hypertension. Journal of Human Hypertension, 2003, 17, 549-554.	1.0	37
1403	Awareness of hypertension guidelines in primary care: results of a regionwide survey in Italy. Journal of Human Hypertension, 2003, 17, 541-547.	1.0	30
1404	Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertensionâ€"a randomised ABPM study. Journal of Human Hypertension, 2003, 17, 569-575.	1.0	23
1405	Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese — Nippon data 80. Journal of Human Hypertension, 2003, 17, 851-857.	1.0	150
1406	Aggressive blood pressure control in general practice (ABC-GP) study: can the new targets be reached?. Journal of Human Hypertension, 2003, 17, 767-773.	1.0	15
1408	Renal Ischemia as a Predictor of Cardiovascular Morbidity. Journal of Vascular and Interventional Radiology, 2003, 14, P159-P164.	0.2	0
1411	Preventing cardiovascular disease in diabetes and glucose intolerance: evidence and implications for care. Primary Care - Clinics in Office Practice, 2003, 30, 569-592.	0.7	17
1412	Factores de riesgo e ictus en pacientes de diferentes edades. Revista Clinica Espanola, 2003, 203, 189-192.	0.2	8
1413	Protección del riesgo vascular del paciente diabético hipertenso. Hipertension Y Riesgo Vascular, 2003, 20, 127-135.	0.3	0
1419	Hipertensión arterial de bata blanca o clÃnica aislada. Hipertension Y Riesgo Vascular, 2003, 20, 305-314.	0.3	1
1420	DÃa de análisis en Granada de la hipertensión arterial. Estudio DAGA. Hipertension Y Riesgo Vascular, 2003, 20, 195-199.	0.3	0
1424	The New Hypertension Guidelines From JNC 7: Is the Devil in the Details?. Mayo Clinic Proceedings, 2003, 78, 1078-1081.	1.4	5
1425	Estudio comparativo de efectividad y tolerabilidad de quinapril 40 mg frente a la combinaci $\tilde{A}^3$ n de quinapril 20 mg e hidroclorotiazida 12,5 mg en el tratamiento de la hipertensi $\tilde{A}^3$ n arterial ligera-moderada. Hipertension Y Riesgo Vascular, 2003, 20, 246-251.	0.3	1
1426	Malignant Hypertension as a Presenting Symptom of Takayasu Arteritis. Mayo Clinic Proceedings, 2003, 78, 231-236.	1.4	10
1428	Use of Antihypertensive Drug Therapy in Older Persons in an Academic Nursing Home. Journal of the American Medical Directors Association, 2003, 4, S20-S22.	1.2	10
1429	Manejo clÃnico de la hipertensión en el anciano. Revista Clinica Espanola, 2003, 203, 80-82.	0.2	0
1431	Criterios de derivación de pacientes hipertensos a una Unidad de Hipertensión Arterial. Hipertension Y Riesgo Vascular, 2003, 20, 354-360.	0.3	2
1433	Diabetes mellitus en el anciano. Medicine, 2003, 8, 5834-5840.	0.0	0

#	Article	IF	CITATIONS
1434	Hypertension art $\tilde{A}$ © rielle maligne Malignant hypertension. Reanimation: Journal De La Societe De Reanimation De Langue Française, 2003, 12, 297-305.	0.1	4
1435	Resultados de la primera encuesta sobre patrones de uso e interés por las nuevas tecnologÃas de los pacientes atendidos en Unidades de Hipertensión Arterial en España. Hipertension Y Riesgo Vascular, 2003, 20, 50-55.	0.3	4
1436	Efecto del tratamiento antihipertensivo con irbesartán sobre el riesgo cardiovascular absoluto. Revista Clinica Espanola, 2003, 203, 183-188.	0.2	2
1439	Evaluación económica del cambio de tratamiento de doxazosina estándar a doxazosina de liberación modificada en pacientes con hipertensión leve a moderada en condiciones habituales de cuidado médico. Hipertension Y Riesgo Vascular, 2003, 20, 200-211.	0.3	0
1441	A Practical Approach to Hypertension in the 21st Century. Journal of Vascular and Interventional Radiology, 2003, 14, 961-975.	0.2	5
1442	Diuréticos: clasificación y farmacologÃa clÃnica. Efectos secundarios. Indicaciones prácticas para su empleo clÃnico. Medicine, 2003, 8, 5998-6008.	0.0	0
1443	Actualización (2003) de las GuÃas de Práctica ClÃnica de la Sociedad Española de CardiologÃa en hipertensión arterial. Revista Espanola De Cardiologia, 2003, 56, 487-497.	0.6	37
1447	Nifedipino oral o sublingual: utilidad y efectividad a largo plazo de la educación médica para disminuir su uso en la hipertensiÁ³n. Revista Clinica Espanola, 2003, 203, 10-14.	0.2	2
1449	Utilización de antihipertensivos en Atención Primaria. Hipertension Y Riesgo Vascular, 2003, 20, 96-104.	0.3	5
1451	Prevalencia, grado de detección, tratamiento y control de la hipertensión arterial en población general. Estudio Hortega. Hipertension Y Riesgo Vascular, 2003, 20, 148-154.	0.3	4
1453	Heart Failure. New England Journal of Medicine, 2003, 348, 2007-2018.	13.9	1,692
1454	High prevalence of Chlamydia pneumoniae antibodies in white-coat hypertensives. Atherosclerosis, 2003, 167, 231-235.	0.4	8
1455	Hypertension, angiotensin II, aldosterone, and race**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology, Journal of the American College of Cardiology, 2003, 41, 1156-1158.	1.2	8
1456	Pharmacological Treatment of Patients with Peripheral Arterial Disease. Drugs, 2003, 63, 637-647.	4.9	10
1457	Current Treatment of Patients with Hypertension. Drugs, 2003, 63, 1435-1444.	4.9	7
1458	Lacidipine. Drugs, 2003, 63, 2327-2356.	4.9	51
1459	Managing Hypertension with Combination Diuretics and Methyldopa in Nigerian Blacks at????the???Primary Care Level. Clinical Drug Investigation, 2003, 23, 583-590.	1.1	3
1460	Effectiveness and Safety of Amlodipine in Newly Diagnosed Hypertensive Patients and in Previously Diagnosed Hypertensive Patients not Controlled with their Usual Treatment (NOTA Study). Clinical Drug Investigation, 2003, 23, 761-770.	1.1	4

#	Article	IF	CITATIONS
1461	Insulin resistance is independently related to age in Mexican women. Journal of Endocrinological Investigation, 2003, 26, 42-48.	1.8	13
1462	The Beneficial Effects of Tai Chi Chuan on Blood Pressure and Lipid Profile and Anxiety Status in a Randomized Controlled Trial. Journal of Alternative and Complementary Medicine, 2003, 9, 747-754.	2.1	213
1463	Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2003, 4, 1417-1430.	0.9	22
1464	Clinical review: the management of hypertensive crises. Critical Care, 2003, 7, 374.	2.5	154
1465	Progression of Coronary Artery Calcification in Type 1 Diabetes: The importance of glycemic control. Diabetes Care, 2003, 26, 2923-2928.	4.3	134
1466	Examining therapeutic goals: population versus individual-based approaches. American Journal of Hypertension, 2003, 16, 26-30.	1.0	5
1467	Impact of renin-angiotensin-aldosterone system gene variants on the severity of hypertension in patients with newly diagnosed hypertension. American Journal of Hypertension, 2003, 16, 1006-1010.	1.0	27
1468	Tolerability and treatment compliance with angiotensin II receptor antagonists. American Journal of Hypertension, 2003, 16, 1066-1073.	1.0	49
1469	Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. American Journal of Hypertension, 2003, 16, 1036-1042.	1.0	30
1470	Antihypertensive medication class and pulse pressure in the elderly: analysis based on the third National Health and Nutrition Examination Survey. American Journal of Medicine, 2003, 115, 536-542.	0.6	18
1471	Hypertension and nephropathy. American Journal of Medicine, 2003, 115, 49-54.	0.6	20
1472	Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure. American Heart Journal, 2003, 146, 736-740.	1.2	34
1473	Prognostic implications of intraventricular conduction defects in patients undergoing stress echocardiography for suspected coronary artery disease. American Journal of Medicine, 2003, 115, 12-18.	0.6	41
1474	Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. American Journal of Hypertension, 2003, 16, 434-438.	1.0	210
1475	Current Recommendations for Prevention of Cardiovascular Disease in Patients With Diabetes Mellitus. Preventive Cardiology, 2003, 6, 34-37.	1.1	0
1476	Hormone Replacement Therapy and Primary Prevention: Alas, Again?. Preventive Cardiology, 2003, 6, 61-62.	1.1	4
1477	Screening for Diabetes in General Practice. Preventive Cardiology, 2003, 6, 78-84.	1.1	16
1478	Psychologic Treatment for Hypertension Can Be Efficacious. Preventive Cardiology, 2003, 6, 48-53.	1.1	6

#	Article	IF	CITATIONS
1479	Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed-Dose Combination Approaches. Journal of Clinical Hypertension, 2003, 5, 202-209.	1.0	82
1480	Improving Patient Compliance: A Major Goal in the Management of Hypertension. Journal of Clinical Hypertension, 2003, 5, 127-132.	1.0	73
1481	The Differences Between ACE Inhibitor-Treated and Calcium Channel Blocker-Treated Hypertensive Patients. Journal of Clinical Hypertension, 2003, 5, 337-344.	1.0	2
1482	Drugs That Interrupt the Renin-Angiotensin System Should Be Among the Preferred Initial Drugs to Treat Hypertension. Journal of Clinical Hypertension, 2003, 5, 137-144.	1.0	8
1483	Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials. Journal of Clinical Hypertension, 2003, 5, 66-75.	1.0	26
1484	How Pharmacists Can Assist Physicians With Controlling Blood Pressure. Journal of Clinical Hypertension, 2003, 5, 31-37.	1.0	55
1485	Treatment of Hypertension in African Americans and Latinos: The Effect of JNC VI on Urban Prescribing Practices. Journal of Clinical Hypertension, 2003, 5, 107-112.	1.0	13
1486	Meta-Analysis, Meta-Regression, and Meta-Physics. Journal of Clinical Hypertension, 2003, 5, 64-75.	1.0	0
1487	Evaluation of Angiotensin II Receptor Blockers for 24-Hour Blood Pressure Control: Meta-Analysis of a Clinical Database. Journal of Clinical Hypertension, 2003, 5, 58-63.	1.0	63
1488	Meeting the Challenge to Improve the Treatment of Hypertension in Blacks. Journal of Clinical Hypertension, 2003, 5, 393-401.	1.0	17
1489	Physician-Nurse Team Approaches to Improve Blood Pressure Control. Journal of Clinical Hypertension, 2003, 5, 386-392.	1.0	5
1490	Drug-Induced Hypertension. Journal of Clinical Hypertension, 2003, 5, 83-85.	1.0	4
1491	Prospective Surveillance of Hypertension in Firefighters. Journal of Clinical Hypertension, 2003, 5, 315-320.	1.0	30
1492	Results of the ALLHAT Trial: Is the Debate About Initial Antihypertensive Drug Therapy Over?. Journal of Clinical Hypertension, 2003, 5, 5-8.	1.0	31
1493	Cardiovascular Disease: a Continuing Threat to Homeland Defense. Journal of Clinical Hypertension, 2003, 5, 350-351.	1.0	7
1494	Can I Stop Taking This Blood Pressure Medicine?. Journal of Clinical Hypertension, 2003, 5, 234-234.	1.0	0
1495	The Economic Impact of Hypertension. Journal of Clinical Hypertension, 2003, 5, 3-13.	1.0	86
1496	The Hypertension Management Program: Identifying Opportunities for Improvement. Journal of Clinical Hypertension, 2003, 5, 33-40.	1.0	3

#	Article	IF	CITATIONS
1497	The JNC 7: Stepped Care Is Alive and Well. Journal of Clinical Hypertension, 2003, 5, 187-195.	1.0	4
1498	The JNC 7 Report: Challenges and Dilemmas in Writing Guidelines. Journal of Clinical Hypertension, 2003, 5, 282-286.	1.0	0
1499	Rationale for Combination Therapy in the Management of Hypertension. Journal of Clinical Hypertension, 2003, $5$ , $17-25$ .	1.0	12
1500	Rationale for Combination Therapy as Initial Treatment for Hypertension. Journal of Clinical Hypertension, 2003, 5, 4-11.	1.0	16
1501	The First Hypertension Trial Comparing the Effects of Two Fixedâ€Dose Combination Therapy Regimens on Cardiovascular Events: Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH). Journal of Clinical Hypertension, 2003, 5, 29-35.	1.0	30
1502	The Effect of Intensified Diet Counseling on the Diet of Hypertensive Subjects in Primary Health Care: A 2-Year Open Randomized Controlled Trial of Lifestyle Intervention against Hypertension in Eastern Finland. Preventive Medicine, 2003, 36, 8-16.	1.6	33
1503	Effects of low-dose combination therapy with an angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study. Current Therapeutic Research, 2003, 64, 715-724.	0.5	4
1504	The Effects of Amlodipine Compared to Losartan in Patients With Mild to Moderately Severe Hypertension. Journal of Clinical Hypertension, 2003, 5, 17-30.	1.0	32
1505	Randomized controlled trial of the effects of nurse case manager and community health worker interventions on risk factors for diabetes-related complications in urban African Americans. Preventive Medicine, 2003, 37, 23-32.	1.6	190
1506	Effectiveness and equity of serum cholesterol and blood pressure testing: a population-based study in Spain. Preventive Medicine, 2003, 37, 82-91.	1.6	14
1507	Role of magnesium in the pathogenesis of hypertension. Molecular Aspects of Medicine, 2003, 24, 107-136.	2.7	174
1508	Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochemical and Biophysical Research Communications, 2003, 308, 698-705.	1.0	470
1509	Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception, 2003, 67, 19-24.	0.8	49
1510	Effects of Verapamil Slow Release Plus Trandolapril Combination Therapy on Essential Hypertension. Current Therapeutic Research, 2003, 64, 10-20.	0.5	1
1511	Efficacy and Tolerability of Nilvadipine in Combination with an Angiotensin II Receptor Antagonist in Patients with Essential Hypertension: A Multicenter, Open-Label, Uncontrolled Study. Current Therapeutic Research, 2003, 64, 151-166.	0.5	1
1512	Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial. Current Therapeutic Research, 2003, 64, 422-433.	0.5	5
1513	Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: a multicenter, randomized, double-blind, placebo-controlled, crossover study. Current Therapeutic Research, 2003, 64, 434-446.	0.5	11
1514	Comparison of candesartan and felodipine alone and combined in the treatment of hypertension: a single-center, double-blind, randomized, crossover trial. Current Therapeutic Research, 2003, 64, 380-388.	0.5	1

#	Article	IF	CITATIONS
1515	The hypertriglyceridemic waist phenotype among women. Atherosclerosis, 2003, 171, 123-130.	0.4	124
1516	Impaired fasting glucose and risk of diabetes in Taiwan: follow-up over 3 years. Diabetes Research and Clinical Practice, 2003, 60, 177-182.	1.1	42
1517	Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clinical Therapeutics, 2003, 25, 1872-1887.	1.1	13
1518	Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clinical Therapeutics, 2003, 25, B4-B31.	1.1	54
1519	Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: A two-year, randomized, placebo-controlled study. Clinical Therapeutics, 2003, 25, 2797-2808.	1,1	181
1520	Estrogen effect on heart rate variability in hypertensive postmenopausal women. Maturitas, 2003, 44, 39-48.	1.0	83
1521	Diabetic nephropathyâ€"the diabetologist's dream is currently a nightmare. International Congress Series, 2003, 1253, 183-188.	0.2	0
1522	Risk factors for cardiovascular disease in a Brazilian population-based cohort study. International Journal of Cardiology, 2003, 90, 205-211.	0.8	25
1523	High-amplitude QRS complex in the electrocardiograms of normotensive people and risk of subsequent hypertension. International Journal of Cardiology, 2003, 91, 37-42.	0.8	0
1524	Estimation of fruit and vegetable intake using a two-item dietary questionnaire: a potential tool for primary health care workers. Nutrition, Metabolism and Cardiovascular Diseases, 2003, 13, 12-19.	1.1	76
1525	Premier: a clinical trial of comprehensive lifestyle modification for blood pressure control: rationale, design and baseline characteristics. Annals of Epidemiology, 2003, 13, 462-471.	0.9	117
1526	Effects of blood pressure on neuropsychological functioning in Alzheimer's disease. Archives of Clinical Neuropsychology, 2003, 18, 19-32.	0.3	5
1527	Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke. Journal of Clinical Epidemiology, 2003, 56, 479-486.	2.4	65
1528	Development and evaluation of a medication adherence self-efficacy scale in hypertensive African-American patients. Journal of Clinical Epidemiology, 2003, 56, 520-529.	2.4	174
1529	Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit?. Journal of Clinical Epidemiology, 2003, 56, 977-982.	2.4	19
1530	Short-term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the second Australian National Blood Pressure Study (ANBP2). American Journal of Hypertension, 2003, 16, 39-45.	1.0	22
1531	Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. American Journal of Hypertension, 2003, 16, 116-122.	1.0	47
1532	Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. American Journal of Hypertension, 2003, 16, 11-20.	1.0	127

#	Article	IF	CITATIONS
1533	When can the practicing physician suspect white coat hypertension? Statement from the Working Group on Blood Pressure Monitoring of the European Society of Hypertension. American Journal of Hypertension, 2003, 16, 87-91.	1.0	64
1534	Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension. American Journal of Hypertension, 2003, 16, 51-58.	1.0	44
1535	Systolic blood pressure is the main etiology for poorly controlled hypertension. American Journal of Hypertension, 2003, 16, 140-143.	1.0	15
1536	A genome-wide affected sibpair linkage analysis of hypertension: the HyperGEN network. American Journal of Hypertension, 2003, 16, 148-150.	1.0	65
1537	Genome-wide linkage analyses for hypertension genes in two ethnically and geographically diverse populations. American Journal of Hypertension, 2003, 16, 154-157.	1.0	50
1538	Effectiveness of furosemide in uncontrolled hypertension in the elderly: role of renin profiling. American Journal of Hypertension, 2003, 16, 187-193.	1.0	24
1539	Ethnic differences in the hemodynamic mechanisms of ambulatory blood pressure regulation. American Journal of Hypertension, 2003, 16, 270-273.	1.0	13
1540	Is fasting blood glucose a reliable parameter for screening for diabetes in hypertension?. American Journal of Hypertension, 2003, 16, 297-301.	1.0	13
1541	The DASH diet enhances the blood pressure response to losartan in hypertensive patients. American Journal of Hypertension, 2003, 16, 337-342.	1.0	65
1542	Academic detailing to improve antihypertensive prescribing patterns. American Journal of Hypertension, 2003, 16, 508-511.	1.0	46
1543	Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. American Journal of Hypertension, 2003, 16, A70.	1.0	0
1544	Defining the antihypertensiveproperties of the angiotensinreceptor blocker telmisartanby a practice-based clinical trial. American Journal of Hypertension, 2003, 16, 460-466.	1.0	18
1545	Prevalence of left ventricular hypertrophy in patients with mild hypertension in primary care: impact of echocardiography on cardiovascular risk stratification. American Journal of Hypertension, 2003, 16, 556-563.	1.0	51
1546	How much exercise is required to reduce blood pressure in essential hypertensives: a dose–response study. American Journal of Hypertension, 2003, 16, 629-633.	1.0	113
1547	VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. American Journal of Hypertension, 2003, 16, 544-548.	1.0	97
1548	A 5-year follow-up of ambulatory blood pressure in healthy older adults. American Journal of Hypertension, 2003, 16, 640-645.	1.0	13
1549	Improved cardiovascular risk stratification by a simple ECG index in hypertension. American Journal of Hypertension, 2003, 16, 646-652.	1.0	59
1550	Comparative efficacy and safety ofnisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. American Journal of Hypertension, 2003, 16, 739-745.	1.0	13

#	Article	IF	CITATIONS
1551	Neurogenic essential hypertension revisited: the case for increased clinical and research attention. American Journal of Hypertension, 2003, 16, 881-888.	1.0	41
1552	Blood pressure and cognitive functioning among independent elderly. American Journal of Hypertension, 2003, 16, 818-826.	1.0	41
1553	Effects of endothelial nitric oxide synthase, $\hat{l}_{\pm}$ -adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. American Journal of Hypertension, 2003, 16, 834-839.	1.0	78
1554	β-blockers in hypertensionâ€"the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. American Journal of Hypertension, 2003, 16, 870-873.	1.0	61
1555	Blood pressure control in the hypertension clinic. American Journal of Hypertension, 2003, 16, 878-880.	1.0	19
1556	Carotid sinus stimulation responses are related with arterial elastic properties in hypertensive subjects. American Journal of Hypertension, 2003, 16, 914-918.	1.0	1
1557	Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes and Metabolism, 2003, 29, 65-71.	1.4	34
1558	Acute-phase proteins among patients with type 1 diabetes. Diabetes and Metabolism, 2003, 29, 405-411.	1.4	54
1559	L'automesure de la pression artérielle chez le diabétique. Diabetes and Metabolism, 2003, 29, 440-444.	1.4	6
1561	Clinical evaluation of the obese patient. Primary Care - Clinics in Office Practice, 2003, 30, 341-356.	0.7	5
1562	Tratamiento de la hipertensión arterial. Medicina ClÃnica, 2003, 120, 108-116.	0.3	1
1563	Evaluación del impacto del refuerzo educativo en la efectividad y tolerabilidad del tratamiento antihipertensivo con nifedipino OROS: Estudio EDUCA. Hipertension Y Riesgo Vascular, 2003, 20, 105-115.	0.3	0
1566	Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis. Annals of Internal Medicine, 2003, 139, 244.	2.0	945
1567	Unique Structureâ^'Activity Relationship for 4-Isoxazolyl-1,4-dihydropyridines. Journal of Medicinal Chemistry, 2003, 46, 87-96.	2.9	62
1568	The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure < SUBTITLE > The JNC 7 Report < /SUBTITLE > . JAMA - Journal of the American Medical Association, 2003, 289, 2560.	3.8	18,097
1573	Initial Treatment of Hypertension. New England Journal of Medicine, 2003, 348, 610-617.	13.9	102
1574	Exercise in Hypertension. Sports Medicine, 2003, 33, 585-598.	3.1	89
1575	Cardiovascular Drug Therapy in the Elderly: Theoretical and Practical Considerations. Drugs and Aging, 2003, 20, 445-463.	1.3	23

#	Article	IF	CITATIONS
1576	Systolic Blood Pressure Elevation. Drugs and Aging, 2003, 20, 287-288.	1.3	0
1577	Prevalence and Implications of Uncontrolled Systolic Hypertension. Drugs and Aging, 2003, 20, 277-286.	1.3	49
1578	Prevalence and Characteristics of the Metabolic Syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes, 2003, 52, 2160-2167.	0.3	394
1579	Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts. European Heart Journal, 2003, 24, 937-945.	1.0	301
1580	Drug Targets in the Voltage-Gated Calcium Channel Family: Why Some Are and Some Are Not. Assay and Drug Development Technologies, 2003, 1, 719-733.	0.6	39
1581	The HEDIS® Performance NAVIGATOR for Controlling High Blood Pressure: A Resource to Assist Health Plans Improve Patient Adherence. Disease Management: DM, 2003, 6, 43-51.	1.0	3
1582	The ALLHAT Study. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 3-6.	1.0	0
1583	Financial and Health Costs of Uncontrolled Blood Pressure in the United Kingdom. Pharmacoeconomics, 2003, 21, 33-41.	1.7	30
1584	The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy. Pharmacoeconomics, 2003, 21, 573-585.	1.7	15
1585	Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS). Current Medical Research and Opinion, 2003, 19, 205-217.	0.9	8
1587	A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2003, 290, 2805.	3.8	1,107
1588	A Controlled Trial of Web-Based Diabetes Disease Management: The MGH Diabetes Primary Care Improvement Project. Diabetes Care, 2003, 26, 750-757.	4.3	179
1589	Clustering of Cardiovascular Risk Factors and Risk of Development of Hypertension in Japanese Male Office Workers. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 213-220.	3.1	8
1590	Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics, 2003, 4, 53-65.	0.6	44
1591	Control of Hypertension in Diabetes. Diabetes Care, 2003, 26, 534-535.	4.3	4
1592	Psychosocial Factors and Risk of Hypertension. JAMA - Journal of the American Medical Association, 2003, 290, 2138.	3.8	310
1593	Obstructive Sleep Apnea. JAMA - Journal of the American Medical Association, 2003, 290, 1906.	3.8	1,020
1594	Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line Agents. JAMA - Journal of the American Medical Association, 2003, 289, 2534.	3.8	869

#	Article	IF	CITATIONS
1595	Estimated Number of Adults With Prediabetes in the U.S. in 2000: Opportunities for prevention. Diabetes Care, 2003, 26, 645-649.	4.3	172
1596	Aviation safety: a model for health care?. Quality and Safety in Health Care, 2003, 12, 162-163.	2.5	11
1597	Quality of Care for Patients Diagnosed With Diabetes at Screening. Diabetes Care, 2003, 26, 367-371.	4.3	11
1598	Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care, 2003, 26, S33-S50.	4.3	613
1599	Treatment of Uncomplicated Hypertension: Are ACE Inhibitors and Calcium Channel Blockers as Effective as Diuretics and Â-Blockers?. Journal of the American Board of Family Medicine, 2003, 16, 156-a-164.	0.8	6
1600	Patient Self-Referral for Radiologic Screening Tests: Clinical and Ethical Concerns. Journal of the American Board of Family Medicine, 2003, 16, 494-501.	0.8	27
1601	Design and Statistical Aspects of the African American Study of Kidney Disease and Hypertension (AASK). Journal of the American Society of Nephrology: JASN, 2003, 14, S154-S165.	3.0	86
1602	Associations of Diabetes Mellitus and Ethnicity with Mortality in a Multiethnic Asian Population: Data from the 1992 Singapore National Health Survey. American Journal of Epidemiology, 2003, 158, 543-552.	1.6	52
1603	Impact of Incident Diabetes and Incident Nonfatal Cardiovascular Disease on 18-Year Mortality: The Multiple Risk Factor Intervention Trial experience. Diabetes Care, 2003, 26, 848-854.	4.3	131
1604	Emerging Risk Factors for Atherosclerotic Vascular Disease. JAMA - Journal of the American Medical Association, 2003, 290, 932.	3.8	446
1605	Ethnicity and renal disease: questions and challenges. Clinical Medicine, 2003, 3, 578-582.	0.8	9
1606	Regular exercise, hormone replacement therapy and the age-related decline in carotid arterial compliance in healthy women. Cardiovascular Research, 2003, 57, 861-868.	1.8	172
1607	Results of ALLHAT. Archives of Internal Medicine, 2003, 163, 1269.	4.3	15
1608	Management of High Blood Pressure in African Americans <subtitle>Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks</subtitle> . Archives of Internal Medicine, 2003, 163, 525.	4.3	393
1609	Improving Risk of Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2003, 289, 2270.	3.8	13
1610	Stopping Medical Research to Save Money. JAMA - Journal of the American Medical Association, 2003, 289, 2128-31.	3.8	90
1611	Measuring Blood Pressure Accurately. JAMA - Journal of the American Medical Association, 2003, 289, 1027.	3.8	214
1612	Accurate Measurement of Blood PressureAccurate Measurement of Blood Pressure. JAMA - Journal of the American Medical Association, 2003, 289, 2792.	3.8	5

#	Article	IF	CITATIONS
1613	Lifestyle Modifications to Prevent Hypertension. JAMA - Journal of the American Medical Association, 2003, 289, 843.	3.8	1
1614	Lifestyle Modification and Blood Pressure Control. JAMA - Journal of the American Medical Association, 2003, 289, 2131-2.	3.8	27
1615	Effects of Blood Pressure Level on Progression of Diabetic Nephropathy <subtitle>Results From the RENAAL Study</subtitle> . Archives of Internal Medicine, 2003, 163, 1555.	4.3	399
1616	No Surprises in Blood Pressure Awareness Study Findings. Archives of Internal Medicine, 2003, 163, 654.	4.3	7
1617	Genome-wide linkage reveals a locus for human essential (primary) hypertension on chromosome 12p. Human Molecular Genetics, 2003, 12, 1273-1277.	1.4	49
1618	Treatment of Hypertension in Older Patients: An Updated Look at the Role of Calcium Antagonists. The American Journal of Geriatric Cardiology, 2003, 12, 319-327.	0.7	11
1619	Interventions to Improve Chronic Illness Care: Evaluating Their Effectiveness. Disease Management: DM, 2003, 6, 63-71.	1.0	144
1620	Strength Training and Hemodynamic Responses to Exercise. The American Journal of Geriatric Cardiology, 2003, 12, 97-106.	0.7	38
1621	ALLHAT and ANBP2: What Have We Learned From Recent Mega†rials?. The American Journal of Geriatric Cardiology, 2003, 12, 267-271.	0.7	4
1622	Renal participation in cardiovascular risk inessential hypertension. Expert Review of Cardiovascular Therapy, 2003, 1, 309-315.	0.6	2
1623	Lifestyle Modification to Improve Blood Pressure Control in Individuals With Diabetes: Is physician advice effective?. Diabetes Care, 2003, 26, 602-607.	4.3	45
1624	Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care, 2003, 26, 2433-2441.	4.3	387
1625	Low Glomerular Filtration Rate in Normoalbuminuric Type 1 Diabetic Patients: An Indicator of More Advanced Glomerular Lesions. Diabetes, 2003, 52, 1036-1040.	0.3	273
1626	Effects of Hypertension on Attention, Memory, and Executive Function in Older Adults Health Psychology, 2003, 22, 587-591.	1.3	97
1627	The Human Peroxisome Proliferator-Activated Receptor Â2 (PPARÂ2) Pro12Ala Polymorphism Is Associated With Decreased Risk of Diabetic Nephropathy in Patients With Type 2 Diabetes. Diabetes, 2003, 52, 3010-3013.	0.3	76
1629	Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA - Journal of the American Medical Association, 2003, 289, 2073.	3.8	646
1630	Sources of Variability in Blood Pressure Measurement using the Dinamap PRO 100 Automated Oscillometric Device. American Journal of Epidemiology, 2003, 158, 1218-1226.	1.6	35
1631	Effectiveness of Report Cards Based on Chart Audits of Residents' Adherence to Practice Guidelines on Practice Performance: A Randomized Controlled Trial. Teaching and Learning in Medicine, 2003, 15, 25-30.	1.3	22

#	Article	IF	CITATIONS
1632	Patients with Essential Hypertension Present Higher Levels of sEâ€Selectin and sVCAMâ€1 Than Normotensive Volunteers. Clinical and Experimental Hypertension, 2003, 25, 517-523.	0.5	23
1633	Awareness, treatment, and control of vascular risk factors in African Americans with stroke. Neurology, 2003, 60, 64-68.	1.5	43
1634	Ability of Exercise Testing to Predict Cardiovascular and All-Cause Death in Asymptomatic Women. JAMA - Journal of the American Medical Association, 2003, 290, 1600-7.	3.8	472
1635	Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. Nephrology Dialysis Transplantation, 2003, 18, 241-245.	0.4	27
1636	Validity of a Modified CHAMPS Physical Activity Questionnaire among African-Americans. Medicine and Science in Sports and Exercise, 2003, 35, 1537-1545.	0.2	98
1637	What defines an adolescent as having hypertension?. Journal of Hypertension, 2003, 21, 13-14.	0.3	3
1638	Difficult blood pressure control: watch out for non-compliance!. Nephrology Dialysis Transplantation, 2003, 18, 1969-1973.	0.4	14
1639	Primary care in the United States: Innovations in primary care in the United States * Commentary: What can primary care in the United States learn from the United Kingdom?. BMJ: British Medical Journal, 2003, 326, 796-799.	2.4	53
1640	The ALLHAT trial. Journal of Hypertension, 2003, 21, 229-232.	0.3	16
1641	Effects of Exercise and Weight Loss on Cardiac Risk Factors Associated With Syndrome X. Archives of Internal Medicine, 2003, 163, 1889.	4.3	115
1642	Secondary harmonic imaging overestimates left ventricular mass compared to fundamental echocardiography. European Journal of Echocardiography, 2003, 4, 178-181.	2.3	15
1643	Predictors of variation in office visit interval assignment. International Journal for Quality in Health Care, 2003, 15, 399-405.	0.9	19
1644	Treating Hypertension â€" What Are We to Believe?. New England Journal of Medicine, 2003, 348, 639-641.	13.9	59
1645	Biochemical Endothelial Markers and Cardiovascular Remodeling in Refractory Arterial Hypertension. Clinical and Experimental Hypertension, 2003, 25, 25-33.	0.5	10
1646	Drug Intolerance Due to Nonspecific Adverse Effects Related to Psychiatric Morbidity in Hypertensive Patients. Archives of Internal Medicine, 2003, 163, 592.	4.3	43
1647	Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. Cardiovascular Research, 2003, 57, 277-283.	1.8	31
1648	Outcome beyond blood pressure control?. European Heart Journal, 2003, 24, 504-514.	1.0	40
1649	Angiotensin receptor blockers and the cardiovascular continuum: what future is indicated by recent successes?. European Heart Journal Supplements, 2003, 5, C1-C4.	0.0	4

#	Article	IF	CITATIONS
1651	Use of Beta Blockers in the Patient With Diabetes. , 2003, 13, 116-123.		17
1652	Pharmacotherapy of Diabetes Mellitus: Implications for the Prevention and Treatment of Cardiovascular Disease. Heart Disease (Hagerstown, Md), 2003, 5, 18-33.	1.3	7
1653	How well are we managing and monitoring high blood pressure?. Current Opinion in Nephrology and Hypertension, 2003, 12, 299-304.	1.0	10
1654	Hormone replacement therapy causes a decrease in hepatocyte growth factor in hypertensive women. Journal of Hypertension, 2003, 21, 1151-1156.	0.3	5
1655	Is it time to measure microalbuminuria in hypertension?. Journal of Hypertension, 2003, 21, 1213-1220.	0.3	43
1656	Pharmacogenomics of hypertension. Current Opinion in Nephrology and Hypertension, 2003, 12, 61-70.	1.0	26
1657	Stroke and Ischemic Heart Disease Mortality Trends in Brazil from 1979 to 1996. Neuroepidemiology, 2003, 22, 179-183.	1.1	36
1658	Doxazosin as Combination Therapy for Patients with Stage 1 and Stage 2 Hypertension. Journal of Cardiovascular Pharmacology, 2003, 41, 866-869.	0.8	28
1659	Cardiovascular Disease in Type 2 Diabetes Mellitus. Archives of Internal Medicine, 2003, 163, 33.	4.3	132
1660	Influence of body and arm position on blood pressure readings. Journal of Hypertension, 2003, 21, 237-241.	0.3	63
1661	Therapeutic effects of evening administration of guanabenz and clonidine on morning hypertension. Journal of Hypertension, 2003, 21, 805-811.	0.3	42
1662	Do the ethanol metabolizing enzymes modify the relationship between alcohol consumption and blood pressure?. Journal of Hypertension, 2003, 21, 1097-1105.	0.3	39
1663	Self-measured versus ambulatory blood pressure in the diagnosis of hypertension. Journal of Hypertension, 2003, 21, 717-722.	0.3	109
1664	Comparative Effects of Irbesartan Versus Amlodipine on Left Ventricular Mass Index in Hypertensive Patients with Left Ventricular Hypertrophy. Journal of Cardiovascular Pharmacology, 2003, 42, 622-628.	0.8	37
1665	A Response to the Points by Manton and Williamson. Medical Care, 2003, 41, 28-31.	1.1	2
1666	Health-related quality of life of subjects with known and unknown hypertension. Journal of Hypertension, 2003, 21, 1283-1289.	0.3	148
1667	Hypertension in adolescents: a review of diagnosis and management. Current Opinion in Pediatrics, 2003, 15, 370-378.	1.0	18
1668	Blood pressure distribution in a Hungarian adolescent population. Journal of Hypertension, 2003, 21, 41-47.	0.3	35

#	Article	IF	CITATIONS
1669	What is normal blood pressure?. Current Opinion in Nephrology and Hypertension, 2003, 12, 285-292.	1.0	21
1670	Determinants of white-coat syndrome assessed by ambulatory blood pressure or self-measured home blood pressure. Blood Pressure Monitoring, 2003, 8, 37-40.	0.4	66
1671	Treatment of diabetic nephropathy with angiotensin II blockers. Nephrology Dialysis Transplantation, 2003, $18,21v-23$ .	0.4	28
1672	All hats off to ALLHAT. Journal of Hypertension, 2003, 21, 225-228.	0.3	12
1673	Combination of lisinopril and nifedipine GITS Increases Blood Pressure Control Compared with Single Drugs in Essential Hypertensive Patients. Journal of Cardiovascular Pharmacology, 2003, 41, 579-585.	0.8	13
1674	A Comprehensive Cardiac Rehabilitation Program in Post-CABG Patients. Critical Pathways in Cardiology, 2003, 2, 20-33.	0.2	0
1675	Removing confounders from the relationship between mortality risk and systolic blood pressure at low and moderately increased systolic blood pressure. Journal of Hypertension, 2003, 21, 49-56.	0.3	32
1676	Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension. Journal of Hypertension, 2003, 21, 125-135.	0.3	15
1677	Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample. Journal of Hypertension, 2003, 21, 1089-1095.	0.3	14
1678	Studies of aging, hypertension and cognitive functioning: With contributions from the Maine-Syracuse study. Advances in Cell Aging and Gerontology, 2003, 15, 89-131.	0.1	3
1679	The insulin resistance syndrome and coronary artery disease. Coronary Artery Disease, 2003, 14, 335-348.	0.3	50
1680	Hypertension in the Athlete. Current Sports Medicine Reports, 2003, 2, 79-83.	0.5	4
1681	Exercise Prescription for the Treatment of Medical Conditions. Current Sports Medicine Reports, 2003, 2, 159-165.	0.5	5
1682	Treatment of hypertension in renal transplant recipients. Current Opinion in Urology, 2003, 13, 91-98.	0.9	12
1683	Undiagnosed Hypertension and Hypercholesterolemia Among Uninsured and Insured Adults in the Third National Health and Nutrition Examination Survey. American Journal of Public Health, 2003, 93, 2051-2054.	1.5	93
1684	Risk Factors and Secondary Prevention in Women with Heart Disease: The Heart and Estrogen/progestin Replacement Study. Annals of Internal Medicine, 2003, 138, 81.	2.0	86
1685	Extent of Cardiovascular Risk Reduction Associated With Treatment of Isolated Systolic Hypertension. Archives of Internal Medicine, 2003, 163, 2728.	4.3	33
1686	Hypertension Control. Archives of Internal Medicine, 2003, 163, 2705.	4.3	104

#	Article	IF	CITATIONS
1687	Multiple Risk Factor Clustering and Risk of Hypertension in Japanese Male Office Workers. Industrial Health, 2003, 41, 327-331.	0.4	10
1688	Genetics of hypertension. Genetics in Medicine, 2003, 5, 413-429.	1.1	51
1689	Genetic evaluation for coronary artery disease. Genetics in Medicine, 2003, 5, 269-285.	1.1	59
1690	Cerebrovascular Disease and Stroke. , 2003, , 1123-1137.		1
1691	Hypertension and the Brain: Vulnerability of the Prefrontal Regions and Executive Functions Behavioral Neuroscience, 2003, 117, 1169-1180.	0.6	267
1692	Sex Differences in Risk for Coronary Heart Disease Mortality Associated With Diabetes and Established Coronary Heart Disease. Archives of Internal Medicine, 2003, 163, 1735.	4.3	151
1693	Mitochondrial 5178A/C Genotype is Associated With Acute Myocardial Infarction Circulation Journal, 2003, 67, 16-20.	0.7	55
1694	Exercise and Resting Blood Pressure in Children and Adolescents: A Meta-Analysis. Pediatric Exercise Science, 2003, 15, 83-97.	0.5	14
1695	Usefulness of a Hypertension Education Program. Southern Medical Journal, 2003, 96, 1133-1137.	0.3	15
1696	Effect of a Telephone Medication Renewal Service on Blood Pressure Control. Journal of the American Pharmacists Association: JAPhA, 2003, 43, 561-565.	0.7	2
1697	Blood Pressure and Lipid Lowering in the Prevention of Stroke: A Note to Neurologists. Cerebrovascular Diseases, 2003, 16, 33-38.	0.8	4
1698	Role of Organizational Factors in Poor Blood Pressure Control in Patients With Type 2 Diabetes <subtitle>The QuED Study Groupâ€"Quality of Care and Outcomes in Type 2 Diabetes</subtitle> . Archives of Internal Medicine, 2003, 163, 473.	4.3	51
1699	Validity of the JNC VI Recommendations for the Management of Hypertension in a General Population of Japanese Elderly. Archives of Internal Medicine, 2003, 163, 361.	4.3	103
1700	Trends in Blood pressure Control in Hypertensive Patients with Diabetes Mellitus in Japan. Hypertension Research, 2003, 26, 717-722.	1.5	12
1701	Drug Company Sponsorship of Clinical Conferences. AMA Journal of Ethics, 2003, 5, 185.	0.4	1
1702	Effects of Benidipine and Candesartan on Kidney and Vascular Function in Hypertensive Dahl Rats. Hypertension Research, 2003, 26, 569-576.	1.5	25
1703	Jananese Society of Hypertension (JSH) Guidelines for Self-Monitoring of Blood Pressure at Home. Hypertension Research, 2003, 26, 771-782.	1.5	295
1704	ART-VENA: Retinal Vaseular Caliber Measurement. Lecture Notes in Computer Science, 2003, , 598-605.	1.0	2

#	Article	IF	CITATIONS
1705	Blood Pressure-Lowering Effects of Biofeedback Treatment in Hypertension: A Meta-Analysis of Randomized Controlled Trials Hypertension Research, 2003, 26, 37-46.	1.5	65
1706	Relations of Blood Pressure to Angiotensinogen Gene T174M Polymorphism and Alcohol Intake. Journal of Physiological Anthropology and Applied Human Science, 2003, 22, 187-194.	0.4	7
1707	Factors Relating to Inadequate Control of Blood Pressure in Hypertensive Outpatients Hypertension Research, 2003, 26, 219-224.	1.5	22
1708	Continuity of Care and Recognition of Diabetes, Hypertension, and Hypercholesterolemia. Archives of Internal Medicine, 2003, 163, 1357.	4.3	55
1710	Clinical Trials: Evidence and Unanswered Questions – Hypertension. Cerebrovascular Diseases, 2003, 16, 18-24.	0.8	3
1711	Hypertensive diabetic patients: guidelines for conduct and their difficulties. Arquivos Brasileiros De Cardiologia, 2003, 81, 143-147.	0.3	4
1712	Prevalence of systemic hypertension in students aged 7 to 14 years in the municipality of Barbacena, in the State of Minas Gerais, in 1999. Arquivos Brasileiros De Cardiologia, 2003, 81, 381-386.	0.3	18
1713	Estimated Protein Intake and Blood Pressure in a Screened Cohort in Okinawa, Japan. Hypertension Research, 2003, 26, 289-294.	1.5	15
1714	New Insights into the Combined Burden of Type 2 Diabetes and Hypertension. Cardiology, 2003, 3, 25-33.	0.3	2
1715	Epidemiology and Stroke Risk Factors. , 2003, , 252-268.		0
1716	The prevalence of orthostatic hypotension and its risk factors among 40 years and above adult population in Indonesia. Medical Journal of Indonesia, 0, 13, 180.	0.2	0
1717	Prevalência dos fatores de risco para doença cardiovascular em funcionários do Centro de Pesquisas da Petrobras. Arquivos Brasileiros De Cardiologia, 2004, 82, 5-8, 1-4.	0.3	22
1718	Assessment of Drug Therapy Management and the Prevalence of Heart Failure in a Managed Care Population With Hypertension. Journal of Managed Care Pharmacy, 2004, 10, 513-520.	2.2	9
1719	Design and Rationale of the Japanese Coronary Artery Disease (JCAD) Study. International Heart Journal, 2004, 45, 895-911.	0.6	20
1720	Lowering blood pressure in 2003. Medical Journal of Australia, 2004, 180, 47-47.	0.8	5
1721	Relation of Pulsatility of Brachial Artery Pressure to Resistant Hypertension. Hypertension Research, 2004, 27, 641-646.	1.5	0
1722	Prevention of coronary heart disease in women. , 2004, , 209-224.		1
1723	Alternatives for Potentially Inappropriate Medications in the Elderly Population: Treatment Algorithms for Use in the Fleetwood Phase III Study. The Consultant Pharmacist, 2004, 19, 1011-1028.	0.4	10

#	Article	IF	CITATIONS
1724	Effects of a Low Dose of Indapamide, a Diuretic, Given Daily or Every-Other-Day on Blood Pressure and Metabolic Parameters. Hypertension Research, 2004, 27, 141-145.	1.5	19
1725	Hostility and Physiological Risk in the National Heart, Lung, and Blood Institute Family Heart Study. Archives of Internal Medicine, 2004, 164, 2442.	4.3	15
1726	Perfil de crise hipertensiva: prevalência e apresentação clÃnica. Arquivos Brasileiros De Cardiologia, 2004, 83, 125-130.	0.3	97
1727	Stress Profile in Essential Hypertension. Hypertension Research, 2004, 27, 619-624.	1.5	30
1728	Practical Efficacy of Telmisartan for Decreasing Morning Home Blood Pressure and Pulse Wave Velocity in Patients with Mild-to-Moderate Hypertension. Hypertension Research, 2004, 27, 545-550.	1.5	38
1729	Association between Angiotensin II Type 1 Receptor Gene Polymorphism and Essential Hypertension: the Ohasama Study. Hypertension Research, 2004, 27, 551-556.	1.5	49
1730	Trends in Prevalence, Awareness, Treatment and Control of Hypertension in the Middle-Aged Population of China, 1992-1998. Hypertension Research, 2004, 27, 703-709.	1.5	79
1731	Alcohol Consumption and Cardiovascular Disease Mortality in Hypertensive Men. Archives of Internal Medicine, 2004, 164, 623.	4.3	<b>7</b> 5
1732	The Shift in the "Paradigm" of the Pharmacology of Hypertension. Current Topics in Medicinal Chemistry, 2004, 4, 487-498.	1.0	4
1733	The Protective Effect of Habitual Tea Consumption on Hypertension. Archives of Internal Medicine, 2004, 164, 1534.	4.3	228
1734	Narrowing the Gap in Hypertension: Effectiveness of a Complex Antihypertensive Program in the Elderly. Disease Management: DM, 2004, 7, 235-244.	1.0	15
1735	Guidelines of the Cardiogeriatrics Department of the Brazilian Cardiology Society: Commentary by Editorial Board Members of The American Journal of Geriatric Cardiology. CARDIAC ARRHYTHMIAS. HEART FAILURE. CORONARY ARTERY DISEASE (CHRONIC STABLE ANGINA, ACUTE CORONARY SYNDROME,) Tj E	TQ <b>q.1</b> ; 1 0.1	78 <b>4</b> 314 rg8⊺
1736	American Journal of Geriatric Cardiology, 2004, 13, 200-200.  Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2004, 13, 49-51.	0.7	0
1737	Risk factors for hypertensive crisis: importance of out-patient blood pressure control. Family Practice, 2004, 21, 420-424.	0.8	52
1738	Guidelines for Antihypertensive Treatment: An Update after the ALLHAT Study. Journal of the American Society of Nephrology: JASN, 2004, 15, 51S-54.	3.0	19
1739	Thirty-year Trends in Cardiovascular Risk Factor Levels among US Adults with Diabetes: National Health and Nutrition Examination Surveys, 1971-2000. American Journal of Epidemiology, 2004, 160, 531-539.	1.6	118
1740	Review: simplifying dosing regimens appears to improve treatment adherence in patients with high blood pressure in ambulatory settings. Evidence-based Nursing, 2004, 7, 110-110.	0.1	2
1741	Relation of Vegetable, Fruit, and Meat Intake to 7-Year Blood Pressure Change in Middle-aged Men: The Chicago Western Electric Study. American Journal of Epidemiology, 2004, 159, 572-580.	1.6	156

#	Article	IF	CITATIONS
1742	A Collaborative Initiative to Improve the Care of Elderly Medicare Patients With Hypertension. American Journal of Medical Quality, 2004, 19, 103-111.	0.2	4
1743	Cardiovascular Risk Factor Control Among Veterans With Diabetes: The Ambulatory Care Quality Improvement Project. Diabetes Care, 2004, 27, B33-B38.	4.3	11
1744	Why hypertensive patients do not comply with the treatment: Results from a qualitative study. Family Practice, 2004, 21, 125-130.	0.8	116
1745	Acute and chronic effects of oestradiol on left ventricular diastolic function in hypertensive postmenopausal women with left ventricular diastolic dysfunction. British Heart Journal, 2004, 90, 777-781.	2.2	35
1746	Race, Rural Residence, and Control of Diabetes and Hypertension. Annals of Family Medicine, 2004, 2, 563-568.	0.9	112
1747	Chapter 2 Primary Prevention of Stroke by Modification of Selected Risk Factors. Blue Books of Practical Neurology, 2004, 29, 5-54.	0.1	0
1748	The Prevalence of Prehypertension and Hypertension Among US Adults According to the New Joint National Committee Guidelines. Archives of Internal Medicine, 2004, 164, 2126.	4.3	473
1749	Uric Acid Level as a Risk Factor for Cardiovascular and All-Cause Mortality in Middle-aged Men. Archives of Internal Medicine, 2004, 164, 1546.	4.3	557
1750	Sympathetic activity is reduced by nCPAP in hypertensive obstructive sleep apnoea patients. European Respiratory Journal, 2004, 23, 255-262.	3.1	81
1751	Clinical Usefulness of Ambulatory Blood Pressure Monitoring. Journal of the American Society of Nephrology: JASN, 2004, 15, 30S-33.	3.0	41
1752	Physician-Related Barriers to Hypertension Management. Medical Principles and Practice, 2004, 13, 282-285.	1.1	29
1753	The Complex World of Prescribing Behavior. JAMA - Journal of the American Medical Association, 2004, 291, 104.	3.8	24
1754	Quantifying Risk of Adverse Clinical Events With One Set of Vital Signs Among Primary Care Patients with Hypertension. Annals of Family Medicine, 2004, 2, 209-217.	0.9	20
1755	Treatment of the Patient With Diabetes Mellitus and Risk of Nephropathy. Archives of Internal Medicine, 2004, 164, 125.	4.3	19
1756	Continuous Recording of Blood Pressure in Cerebrovascular Disease: When Should It Be Done?. Cerebrovascular Diseases, 2004, 17, 34-42.	0.8	5
1757	Effective Stroke Prevention in Patients with Symptomatic Carotid Stenosis. Cerebrovascular Diseases, 2004, 17, 89-104.	0.8	15
1758	Atherosclerosis in Dialyzed Patients. Blood Purification, 2004, 22, 28-37.	0.9	25
1759	Medical Treatment of Retinopathy of Type-2 Diabetes. Ophthalmologica, 2004, 218, 291-296.	1.0	5

#	Article	IF	CITATIONS
1760	Statins for the prevention of cerebrovascular disease: the rationale for robust intervention. European Heart Journal Supplements, 2004, 6, C34-C42.	0.0	4
1761	Guidelines from the British Hypertension Society. BMJ: British Medical Journal, 2004, 328, 593-594.	2.4	24
1762	Chapter 10 Risk Factor Modification for Secondary Prevention. Blue Books of Practical Neurology, 2004, 29, 197-210.	0.1	0
1763	Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. European Heart Journal, 2004, 25, 523-530.	1.0	89
1764	Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. European Heart Journal, 2004, 25, 1509-1516.	1.0	152
1765	Measuring Adherence to Practice Guidelines for the Management of Hypertension. Hypertension, 2004, 44, 602-608.	1.3	102
1766	The Deep-Breath Test as a Diagnostic Maneuver for White-Coat Effect in Hypertensive Patients. Journal of the American Board of Family Medicine, 2004, 17, 184-189.	0.8	3
1767	Changing Prescribing Patterns and Increasing Prescription Expenditures in Medicaid. Annals of Family Medicine, 2004, 2, 488-493.	0.9	12
1768	Angiotensin II Receptor Blockers in Older Patients. The American Journal of Geriatric Cardiology, 2004, 13, 197-205.	0.7	7
1769	Traditional and Novel Risk Factors in Older Adults: Cardiovascular Risk Assessment Late in Life. The American Journal of Geriatric Cardiology, 2004, 13, 69-78.	0.7	27
1770	Preventing Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2004, 351, 1941-1951.	13.9	952
1771	Cardiovascular and Renal Risk Assessment as a Guide for Treatment in Primary Hypertension. Journal of the American Society of Nephrology: JASN, 2004, 15, 34S-36.	3.0	5
1772	Relationship between Blood Glucose Control, Pathogenesis and Progression of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2004, 15, 1S-5.	3.0	27
1773	Impact of Clinical Trial Results on National Trends in α-Blocker Prescribing, 1996-2002. JAMA - Journal of the American Medical Association, 2004, 291, 54.	3.8	84
1774	Prevalence and awareness of risk factors and behaviours of coronary heart disease in an urban population of Karachi, the largest city of Pakistan: a community survey. Journal of Public Health, 2004, 26, 245-249.	1.0	47
1775	RISK FACTORS FOR CORONARY ARTERY DISEASE (CAD) IN LEBANESE-ARMENIAN WOMEN. Health Care for Women International, 2004, 25, 933-949.	0.6	11
1776	SYSTEMIC LUPUS ERYTHEMATOSUS AND THE KIDNEY. , 2004, , 877-912.		6
1777	Efficacy of Extended-Release Niacin With Lovastatin for Hypercholesterolemia. Archives of Internal Medicine, 2004, 164, 1121.	4.3	58

#	Article	IF	CITATIONS
1778	Epidemiology of Stroke. , 2004, , 13-34.		76
1779	Does asymptomatic hyperuricaemia contribute to the development of renal and cardiovascular disease? An old controversy renewed. Nephrology, 2004, 9, 394-399.	0.7	59
1780	Prevalence of and risk factors for nocturia: Analysis of a health screening program. International Journal of Urology, 2004, 11, 282-287.	0.5	137
1781	Synergism of atenolol and amlodipine on lowering and stabilizing blood pressure in spontaneously hypertensive rats. Fundamental and Clinical Pharmacology, 2004, 18, 33-38.	1.0	20
1782	Development of a Parametric Simulation Model for Forecasting Goal-Oriented Treatment Outcomes. Value in Health, 2004, 7, 482-489.	0.1	0
1783	Prevalence of nutrition and exercise counseling for patients with hypertension. Journal of General Internal Medicine, 2004, 19, 917-924.	1.3	61
1785	Adherence to Oral Therapy for Type 2 Diabetes: Opportunities for Enhancing Glycemic Control. Journal of the American Academy of Nurse Practitioners, 2004, 16, 9-17.	1.4	26
1786	Comparison of Quality-of-Hypertension-Care Indicators for Groups Treated by Physician Versus Groups Treated by Physician-Nurse Team. Journal of the American Academy of Nurse Practitioners, 2004, 16, 18-23.	1.4	8
1787	Detection of cardiovascular risk factors by anthropometric measures in Tehranian adults: receiver operating characteristic (ROC) curve analysis. European Journal of Clinical Nutrition, 2004, 58, 1110-1118.	1.3	114
1788	Diagnostic value of strategy for the detection of white coat hypertension based on ambulatory and home blood pressure monitoring. Journal of Human Hypertension, 2004, 18, 85-89.	1.0	23
1789	Do variations in blood pressures of South Asian, African and Chinese descent children reflect those of the adult populations in the UK? A review of cross-sectional data. Journal of Human Hypertension, 2004, 18, 229-237.	1.0	38
1790	Improvement of blood pressure control in a hypertension clinic: a 10-year follow-up study. Journal of Human Hypertension, 2004, 18, 273-278.	1.0	20
1791	Prevalence, awareness, treatment, and control of hypertension in the Czech Republic. Results of two nationwide cross-sectional surveys in 1997/1998 and 2000/2001, Czech Post-MONICA Study. Journal of Human Hypertension, 2004, 18, 571-579.	1.0	45
1792	Creatinine clearance and signs of end-organ damage in primary hypertension. Journal of Human Hypertension, 2004, 18, 511-516.	1.0	19
1793	Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. Journal of Human Hypertension, 2004, 18, 545-551.	1.0	133
1794	Effectiveness of antihypertensive treatment in chronic renal failure: to what extent and with which drugs do patients treated by nephrologists achieve the recommended blood pressure?. Journal of Human Hypertension, 2004, 18, 649-654.	1.0	9
1795	Prevalence, awareness, treatment and control of hypertension in employees of factories of Northern Greece: the Naoussa study. Journal of Human Hypertension, 2004, 18, 623-629.	1.0	32
1796	Association of ACE gene haplotype with essential hypertension. Journal of Human Hypertension, 2004, 18, 913-914.	1.0	4

#	Article	IF	CITATIONS
1797	Hypertension prevalence and blood pressure trends in 88 653 subjects in Mumbai, India. Journal of Human Hypertension, 2004, 18, 907-910.	1.0	40
1798	The paradigm has shifted to systolic blood pressure. Journal of Human Hypertension, 2004, 18, S3-S7.	1.0	54
1799	Isolate diffuse thickening of glomerular capillary basement membrane: a renal lesion in prediabetes?. Modern Pathology, 2004, 17, 1506-1512.	2.9	50
1800	Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. American Journal of Transplantation, 2004, 4, 13-53.	2.6	320
1801	Lipids and lipoprotein(a) concentrations in Tunisian type 2 diabetic patients. Journal of Diabetes and Its Complications, 2004, 18, 258-263.	1.2	35
1803	Treatment of hypertension in the hispanic community: Cultural case studies. Clinical Cornerstone, 2004, 6, 71-75.	1.0	14
1804	Educating Patients With Diabetes About Cardiovascular Disease Risk. Progress in Cardiovascular Nursing, 2004, 19, 107-113.	0.5	2
1805	The Antihypertensive Efficacy and Safety of a Chronotherapeutic Formulation of Propranolol in Patients With Hypertension. Journal of Clinical Hypertension, 2004, 6, 231-241.	1.0	13
1806	Failure of Computerized Treatment Suggestions to Improve Health Outcomes of Outpatients with Uncomplicated Hypertension: Results of a Randomized Controlled Trial. Pharmacotherapy, 2004, 24, 324-337.	1.2	110
1807	Clinical Pharmacists Save Thousands of Lives: Big Decrease in Dose-Related Adverse Effects. Pharmacotherapy, 2004, 24, 422-425.	1.2	O
1808	Hypertension Management and Control in Primary Care: A Study of 20 Practices in 14 States. Pharmacotherapy, 2004, 24, 500-507.	1.2	46
1809	Development and Preliminary Testing of a Patient Decision Aid to Assist Pharmaceutical Care in the Prevention of Cardiovascular Disease. Pharmacotherapy, 2004, 24, 909-922.	1.2	41
1810	Hemodynamic Changes During Long Meditation. Applied Psychophysiology Biofeedback, 2004, 29, 213-221.	1.0	25
1811	Health Status Among Urban African American Women: Associations Among Well-Being, Perceived Stress, and Demographic Factors. Journal of Behavioral Medicine, 2004, 27, 63-76.	1.1	14
1812	Patients with uncontrolled hypertension or concomitant hypertension and benign prostatic hyperplasia. Clinical Cardiology, 2004, 27, 63-69.	0.7	5
1813	Evolving targets for risk reduction in diabetes. Clinical Cardiology, 2004, 27, 125-128.	0.7	1
1814	Characteristics of contemporary patients with hypertension and coronary artery disease. Clinical Cardiology, 2004, 27, 571-576.	0.7	16
1815	Pathophysiology and therapeutic targets for ischemic stroke. Clinical Cardiology, 2004, 27, 12-24.	0.7	10

#	Article	IF	CITATIONS
1816	Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. American Journal of Hypertension, 2004, 17, 809-816.	1.0	66
1818	Health Conditions Among Aging Narcotics Addicts: Medical Examination Results. Journal of Behavioral Medicine, 2004, 27, 607-622.	1.1	75
1819	Patterns of antihypertensive drug utilization in primary care. European Journal of Clinical Pharmacology, 2004, 60, 135-142.	0.8	73
1820	Treatment of hypertension and prevention of ischemic stroke. Current Cardiology Reports, 2004, 6, 124-129.	1.3	31
1821	Hypertension in black patients: Special issues and considerations. Current Cardiology Reports, 2004, 6, 416-420.	1.3	12
1822	Remission and regression of diabetic nephropathy. Current Hypertension Reports, 2004, 6, 377-382.	1.5	23
1823	Diastolic heart failure: The forgotten manifestation of hypertensive heart disease. Current Hypertension Reports, 2004, 6, 164-170.	1.5	8
1824	A novel approach to treatment of hypertension in diabetic patients at a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 ât rationale and design [ISRCTN55725285]. Current	1.5	6
1825	Lack of chart reminder effectiveness on family medicine resident JNC-VI and NCEP III guideline knowledge and attitudes. BMC Family Practice, 2004, 5, 14.	2.9	8
1826	Artériopathie diabétique des membres inférieurs. EMC - Endocrinologie, 2004, 1, 117-132.	0.0	3
1827	Coenzyme Q10 and Adverse Effects of Statins. Journal of Nutritional and Environmental Medicine, 2004, 14, 17-28.	0.1	4
1828	The REACT Study. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 61-63.	1.0	1
1829	Pharmacoeconomic Burden of Undertreating Hypertension. Pharmacoeconomics, 2004, 22, 907-928.	1.7	30
1830	Concentric left ventricular morphology in aerobically trained kayak canoeists. Journal of Sports Sciences, 2004, 22, 859-865.	1.0	11
1832	Continued importance of diuretics and $\hat{l}^2$ -adrenergic blockers in the management of hypertension. Medical Clinics of North America, 2004, 88, 167-187.	1.1	15
1834	Efectividad de una intervenci $ ilde{A}^3$ n de mejora de calidad en la reducci $ ilde{A}^3$ n del riesgo cardiovascular en pacientes hipertensos. Revista Espanola De Cardiologia, 2004, 57, 644-651.	0.6	7
1837	Lessons from curbing the coronary artery disease epidemic for confronting the impending epidemic of heart failure. Medical Clinics of North America, 2004, 88, 1129-1133.	1.1	12
1843	The prevention of heart failure in minority communities and discrepancies in health care delivery systems. Medical Clinics of North America, 2004, 88, 1347-1368.	1.1	18

#	Article	IF	Citations
1847	Target organ involvement in hypertension: a realistic promise of prevention and reversal. Medical Clinics of North America, 2004, 88, 209-221.	1.1	20
1849	Chronobiology of rupture and dissection of aortic aneurysms. Journal of Vascular Surgery, 2004, 40, 382-388.	0.6	91
1851	Use of Antihypertensive Drugs in Spain (1995-2001). Revista Espanola De Cardiologia (English Ed ), 2004, 57, 241-249.	0.4	7
1852	Effectiveness of a Quality Improvement Intervention in Reducing Cardiovascular Risk in Hypertensive Patients. Revista Espanola De Cardiologia (English Ed ), 2004, 57, 644-651.	0.4	3
1853	Serum Aldosterone and the Incidence of Hypertension in Nonhypertensive Persons. New England Journal of Medicine, 2004, 351, 33-41.	13.9	503
1854	Trends in pharmacogenomics of drugs acting on hypertension. Pharmacological Research, 2004, 49, 351-356.	3.1	17
1855	Relationship of ethnicity, gender, and ambulatory blood pressure to pain sensitivity: effects of individualized pain rating scales. Journal of Pain, 2004, 5, 183-191.	0.7	58
1856	Advanced Glycation Endproduct Crosslinking in the Cardiovascular System. Drugs, 2004, 64, 459-470.	4.9	120
1857	Fixed-Dose Combination Enalapril/Nitrendipine. Drugs, 2004, 64, 1135-1148.	4.9	18
1858	Efficacy and Safety of Valsartan 160mg/Hydrochlorothiazide 25mg Combination in Patients with Hypertension not Adequately Controlled by Valsartan 160mg/Hydrochlorothiazide 12.5mg. Clinical Drug Investigation, 2004, 24, 593-602.	1.1	5
1859	What is the Relationship Between Exercise and Metabolic Abnormalities?. Sports Medicine, 2004, 34, 371-418.	3.1	249
1860	National Performance Measures for Diabetes Mellitus Care. Disease Management and Health Outcomes, 2004, 12, 285-298.	0.3	4
1861	New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: An endocrinologist's view. Diabetes Care, 2004, 27, 805-812.	4.3	150
1862	Should the Insulin Resistance Syndrome be Treated in the Elderly?. Drugs and Aging, 2004, 21, 141-151.	1.3	14
1863	Do We Need Drug Therapy to Manage Mild Hypertension in the Elderly?. Drugs and Aging, 2004, 21, 1-6.	1.3	3
1865	Indicadores de calidad mÃnimos para la mejora de la gestión de la hipertensión arterial en Atención Primaria. Hipertension Y Riesgo Vascular, 2004, 21, 100-107.	0.3	1
1867	Efecto del tratamiento antihipertensivo con candesartán sobre la presión de pulso. Hipertension Y Riesgo Vascular, 2004, 21, 55-60.	0.3	1
1868	Antihypertensive Therapy and Incidence of Type 2 Diabetes: A systematic review. Diabetes Care, 2004, 27, 247-255.	4.3	185

#	ARTICLE	IF	CITATIONS
1869	Hypertension: a review for clinicians. Nursing Clinics of North America, 2004, 39, 793-814.	0.7	8
1870	Hypertensive Retinopathy. New England Journal of Medicine, 2004, 351, 2310-2317.	13.9	618
1871	Pacientes hipertensos mal controlados: variables relacionadas con el tiempo hasta modificar el tratamiento (estudio HIMOT: hipertensi $\tilde{A}^3$ n y modificaci $\tilde{A}^3$ n del tratamiento). Hipertension Y Riesgo Vascular, 2004, 21, 442-447.	0.3	0
1872	Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clinical Therapeutics, 2004, 26, 1701-1713.	1.1	88
1873	Frequency of cardiovascular events in patients treated with anti hypertensive agents: A cohort study based on claims data generated by primary care practice. Current Therapeutic Research, 2004, 65, 398-412.	0.5	0
1874	Variability in the presence of the metabolic syndrome in Type 2 diabetic patients attending a diabetes clinic. Diabetes Research and Clinical Practice, 2004, 65, 135-142.	1.1	18
1875	Hypertension-related dietary patterns of rural older adults. Preventive Medicine, 2004, 38, 812-818.	1.6	22
1876	Diet and physical activity counseling during ambulatory care visits in the United States. Preventive Medicine, 2004, 39, 815-822.	1.6	125
1877	Alexithymia predicts attenuated autonomic reactivity, but prolonged recovery to anger recall in young women. International Journal of Psychophysiology, 2004, 53, 183-195.	0.5	82
1878	Ischemic heart disease in women and the role of hormone therapy. International Journal of Cardiology, 2004, 96, 7-19.	0.8	17
1879	Isosteviol acts on potassium channels to relax isolated aortic strips of Wistar rat. Life Sciences, 2004, 74, 2379-2387.	2.0	49
1880	Estimated healthcare savings associated with adequate dairy food intake. American Journal of Hypertension, 2004, 17, 88-97.	1.0	87
1881	Time interval between pairs of arterial blood pressure measurementsâ€"Does it matter?. American Journal of Hypertension, 2004, 17, 194-196.	1.0	8
1882	Effect of different antihypertensive drug classes on central aortic pressure. American Journal of Hypertension, 2004, 17, 118-123.	1.0	291
1883	Glucose effectiveness is strongly related to left ventricular mass in subjects with stage I hypertension or high-normal blood pressure. American Journal of Hypertension, 2004, 17, 146-153.	1.0	11
1884	Relationship between central sympathetic activity and stages of human hypertension. American Journal of Hypertension, 2004, 17, 217-222.	1.0	170
1885	Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. American Journal of Hypertension, 2004, 17, 701-706.	1.0	129
1886	Incremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimens. American Journal of Hypertension, 2004, 17, 676-683.	1.0	19

#	Article	IF	CITATIONS
1887	Correlates of hypertension control in a primary care setting. American Journal of Hypertension, 2004, 17, 915-920.	1.0	46
1888	Nurse management for hypertension. A systems approach. American Journal of Hypertension, 2004, 17, 921-927.	1.0	94
1889	Prevalence of isolated systolic and isolated diastolic hypertension subtypes in China. American Journal of Hypertension, 2004, 17, 955-962.	1.0	41
1890	Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans. American Journal of Hypertension, 2004, 17, 734-742.	1.0	12
1891	Antihypertensive medication use in the department of veterans affairs National analysis of prescribing patterns from 2000 to 20021. American Journal of Hypertension, 2004, 17, 1095-1099.	1.0	19
1892	Advanced glycation end-product cross-link breakersA novel approach to cardiovascular pathologies related to the aging process. American Journal of Hypertension, 2004, 17, S23-S30.	1.0	180
1894	Antihypertensive Utility of Perindopril in a Large, General Practiceâ€Based Clinical Trial. Journal of Clinical Hypertension, 2004, 6, 10-17.	1.0	37
1895	A Statewide Primary Care Approach to Cardiovascular Risk Factor Control in Highâ€Risk Diabetic and Nondiabetic Patients With Hypertension. Journal of Clinical Hypertension, 2004, 6, 18-25.	1.0	21
1896	Pharmacoeconomics of Antihypertensive Drug Treatment: An Analysis of How Long Patients Remain on Various Antihypertensive Therapies. Journal of Clinical Hypertension, 2004, 6, 76-82.	1.0	63
1897	An Assessment of Racial Differences in Clinical Practices for Hypertension at Primary Care Sites for Medically Underserved Patients. Journal of Clinical Hypertension, 2004, 6, 26-33.	1.0	16
1898	Comprehensive Lifestyle Modification and Blood Pressure Control: A Review of the PREMIER Trial. Journal of Clinical Hypertension, 2004, 6, 383-390.	1.0	38
1899	Hypertension Treatment in the Ambulatory Setting: Comparison by Race and Gender in a National Survey. Journal of Clinical Hypertension, 2004, 6, 223-228.	1.0	7
1900	Effect of the Dietary Approaches to Stop Hypertension Diet and Reduced Sodium Intake on Blood Pressure Control. Journal of Clinical Hypertension, 2004, 6, 373-381.	1.0	64
1901	Managing Hypertension in Africanâ€American Patients. Journal of Clinical Hypertension, 2004, 6, 19-25.	1.0	8
1902	Random Thoughts on Guidelines: How Are They Determined? Are They Followed?. Journal of Clinical Hypertension, 2004, 6, 360-362.	1.0	1
1903	Different Effects of Losartan and Moxonidine on Endothelial Function During Sympathetic Activation in Essential Hypertension. Journal of Clinical Hypertension, 2004, 6, 682-689.	1.0	11
1904	Trends in Hypertensionâ€Related Death in the United States: 1980–1998. Journal of Clinical Hypertension, 2004, 6, 675-681.	1.0	9
1905	Why Is Selfâ€Monitoring Reimbursed for Blood Glucose but Not Blood Pressure?. Journal of Clinical Hypertension, 2004, 6, 526-531.	1.0	1

#	Article	IF	CITATIONS
1906	Combination Angiotensin Receptor Blocker/Hydrochlorothiazide as Initial Therapy in the Treatment of Patients With Severe Hypertension. Journal of Clinical Hypertension, 2004, 6, 614-620.	1.0	35
1907	Treatment of Hypertension in the Elderly. Journal of Clinical Hypertension, 2004, 6, 18-23.	1.0	0
1908	Exaggerated exercise blood pressure is related to impaired endothelial vasodilator function. American Journal of Hypertension, 2004, 17, 314-320.	1.0	160
1909	Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey. Diabetes and Metabolism, 2004, 30, 327-333.	1.4	11
1910	Postmarketing surveillance study of benazepril in chinese patients with hypertension: An open-label, experimental, epidemiologic study. Current Therapeutic Research, 2004, 65, 300-319.	0.5	4
1911	Efficacy and tolerability of a switch to fixed-dose combination therapy with amlodipine besylate/benazepril hydrochloride after monotherapy with amlodipine besylate: Data from the African-American subpopulation of a practice-based, open-label study (the LOGIC study)*1. Current Therapeutic Research, 2004, 65, 138-148.	0.5	0
1912	Blood pressure control and weight loss in overweight or obese patients with previously treated or untreated mild to moderate hypertension given valsartan: An open-label study comparing pretreatment and posttreatment values. Current Therapeutic Research, 2004, 65, 172-184.	0.5	3
1913	Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. Atherosclerosis, 2004, 177, 83-88.	0.4	55
1914	Patterns of insulin resistance in the general population of southeast Spain. Diabetes Research and Clinical Practice, 2004, 65, 247-256.	1.1	26
1915	The KARTAN study: A postmarketing assessment of Irbesartan in patients with hypertension. Clinical Therapeutics, 2004, 26, 232-244.	1.1	17
1916	Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?. Clinical Therapeutics, 2004, 26, A21-A27.	1.1	12
1917	Renoprotective Effect of Losartan in Comparison to Amlodipine in Patients with Chronic Kidney Disease and Hypertension-a Report of the Japanese Losartan Therapy Intended for the Global Renal Protection Hypertensive Patients (JLIGHT) Study. Hypertension Research, 2004, 27, 21-30.	1.5	69
1918	Reducing the Public Health Burden From Elevated Blood Pressure Levels in the United States by Lowering Intake of Dietary Sodium. American Journal of Public Health, 2004, 94, 19-22.	1.5	77
1919	Effects of amlodipine and lisinopril on intima–media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension, 2004, 22, 1309-1316.	0.3	58
1920	Regular Exercise as an Effective Approach in Antihypertensive Therapy. Medicine and Science in Sports and Exercise, 2004, 36, 4-8.	0.2	46
1921	Drug therapy for autonomic dysreflexia. Cmaj, 2004, 170, 1210-1210.	0.9	8
1922	C-reactive protein for the prediction of cardiovascular risk: Ready for prime-time?. Cmaj, 2004, 170, 1563-1565.	0.9	8
1923	Hypertension: A Clinical Pharmacist's Synopsis of JNC 7. American Journal of Pharmaceutical Education, 2004, 68, 71.	0.7	1

#	Article	IF	Citations
1924	Screening for High Blood Pressure: Recommendations and Rationale. American Journal of Nursing, 2004, 104, 82-87.	0.2	0
1925	Serum cholesterol levels, blood pressure response to stress and incidence of stable hypertension in young subjects with high normal blood pressure. Journal of Hypertension, 2004, 22, 265-272.	0.3	30
1926	If Suicide Is a Public Health Problem, What Are We Doing to Prevent It?. American Journal of Public Health, 2004, 94, 37-45.	1.5	238
1927	Update in Renal Transplantation. Archives of Internal Medicine, 2004, 164, 1373.	4.3	96
1928	Association Between Cardiovascular Outcomes and Antihypertensive Drug Treatment in Older Women. JAMA - Journal of the American Medical Association, 2004, 292, 2849.	3.8	99
1929	Strategies for Prevention and Management of Hypertension throughout Life. Journal of Epidemiology, 2004, 14, 112-117.	1.1	4
1930	Long-Term Follow-up in Japanese Public Office Workers of the Influence of Blood Pressure on ECG Changes. Circulation Journal, 2004, 68, 563-567.	0.7	2
1931	Epidemiology of Hypertension Based on Ambulatory Blood Pressure Monitoring and Self-Measurement of Blood Pressure at Home. Journal of Health Science, 2004, 50, 113-119.	0.9	4
1932	Insulin Resistance in Patients With Hypertrophic Cardiomyopthy. Circulation Journal, 2004, 68, 650-655.	0.7	18
1933	Accuracy of Offspring Reports of Parental Cardiovascular Disease History: The Framingham Offspring Study. Annals of Internal Medicine, 2004, 140, 434.	2.0	156
1934	Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction: A Class Effect?. Annals of Internal Medicine, 2004, 141, 102.	2.0	109
1935	Orlistat, Sibutramine, or Combination Therapy: Which Performs Better on Waist Circumference in Relation with Body Mass Index in Obese Patients?. Tohoku Journal of Experimental Medicine, 2004, 202, 173-180.	0.5	23
1936	Practical Aspect of Monitoring Hypertension Based on Self-measured Blood Pressure at Home. Internal Medicine, 2004, 43, 771-778.	0.3	35
1937	A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction. Archives of Internal Medicine, 2004, 164, 1490.	4.3	54
1938	Men's Health Initiative Risk Assessment Study: Effect of Community Pharmacy–Based Screening. Journal of the American Pharmacists Association: JAPhA, 2004, 44, 569-577.	0.7	13
1940	Aggressive Hypertension Management in Patients of Advancing and Advanced Age. Southern Medical Journal, 2005, 98, 805-808.	0.3	4
1941	Race/Ethnicity, Income, Major Risk Factors, and Cardiovascular Disease Mortality. American Journal of Public Health, 2005, 95, 1417-1423.	1.5	110
1942	Posting Guidelines: A Practical and Effective Way to Promote Appropriate Hypertension Treatment. Joint Commission Journal on Quality and Patient Safety, 2005, 31, 227-232.	0.4	6

#	Article	IF	CITATIONS
1943	Daily Life Activity and the Risk of Developing Hypertension in Middle-aged Japanese Men. Archives of Internal Medicine, 2005, 165, 214.	4.3	32
1944	Quantitative Study of Circadian Variations of Ambulatory Blood Pressure in Chinese Healthy, Hypertensive, and Diabetes Subjects. Clinical and Experimental Hypertension, 2005, 27, 187-194.	0.5	10
1946	Relation of Serum Total Cholesterol and Other Factors to Risk of Cerebral Infarction in Japanese Men With Hypercholesterolemia-The Kyushu Lipid Intervention Study Circulation Journal, 2005, 69, 1-6.	0.7	21
1947	Elevated Blood Pressure in Urban Emergency Department Patients. Academic Emergency Medicine, 2005, 12, 835-843.	0.8	39
1948	Metabolic Syndrome and Cardiac Disease in Japanese Men: Applicability of the Concept of Metabolic Syndrome Defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese Men-The Tanno and Sobetsu Study. Hypertension Research, 2005, 28, 203-208.	1.5	148
1949	Sympathetic Hypertensive Syndrome: A Possible Surgically Curable Type of Hypertension. Hypertension Research, 2005, 28, 409-414.	1.5	4
1950	Status of Home Blood Pressure Measured in Morning and Evening: Evaluation in Normotensives and Hypertensives in Japanese Urban Population. Hypertension Research, 2005, 28, 491-498.	1.5	35
1951	How Does Deep Breathing Affect Office Blood Pressure and Pulse Rate?. Hypertension Research, 2005, 28, 499-504.	1.5	39
1952	High Blood Pressure, Bone-Mineral Loss and Insulin Resistance in Women. Hypertension Research, 2005, 28, 565-570.	1.5	46
1953	Blood Pressure-Lowering Effects of Lifestyle Modification: Possible Involvement of Nitric Oxide Bioavailability. Hypertension Research, 2005, 28, 779-786.	1.5	38
1954	Decision making and effort in the self-regulation of hypertension: Testing two competing theories. British Journal of Health Psychology, 2005, 10, 505-530.	1.9	53
1955	Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril Study (INVEST). Clinical Cardiology, 2005, 28, 321-328.	0.7	8
1956	Medical management of peripheral arterial disease. Journal of Thrombosis and Haemostasis, 2005, 3, 1628-1637.	1.9	50
1957	Patterns of antihypertensive therapy among patients with diabetes. Journal of General Internal Medicine, 2005, 20, 842-846.	1.3	32
1958	Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME) Tj ETQq0 0 0	rgBT /Ove	rlock 10 Tf 5
1959	Hypertension knowledge, awareness, and attitudes in a hypertensive population. Journal of General Internal Medicine, 2005, 20, 219-225.	1.3	152
1960	Clinical implications of an accurate problem list on heart failure treatment. Journal of General Internal Medicine, 2005, 20, 143-147.	1.3	62
1961	Microalbuminuria as a predictor of myocardial infarction in a Mexican population: The Mexico City Diabetes Study. Kidney International, 2005, 68, S34-S39.	2.6	13

#	Article	IF	Citations
1962	QT dispersion in type 2 diabetic patients with altered diurnal blood pressure rhythm. Diabetes, Obesity and Metabolism, 2005, 7, 136-143.	2.2	6
1963	Incidence of insulin resistance in obese subjects in a rural Japanese population: The Tanno and Sobetsu study. Diabetes, Obesity and Metabolism, 2005, 7, 83-87.	2.2	34
1964	Association between alcohol consumption and serum dehydroepiandrosterone sulphate concentration in men with Type 2 diabetes: a link to decreased cardiovascular risk. Diabetic Medicine, 2005, 22, 1446-1450.	1.2	11
1965	Bradycardia and hypertension in anticipation of, and exacerbated by, peribulbar block: a prospective audit. Acta Anaesthesiologica Scandinavica, 2005, 49, 1207-1213.	0.7	2
1966	Relation of hypertension and glucose tolerance impairment in elderly people to the development of arteriosclerosis: Investigation using pulse wave velocity*. Geriatrics and Gerontology International, 2005, 5, 10-16.	0.7	1
1967	CARDIOVASCULAR AUTONOMIC REGULATION IN SUBJECTS WITH NORMAL BLOOD PRESSURE, HIGH-NORMAL BLOOD PRESSURE and RECENT-ONSET HYPERTENSION. Clinical and Experimental Pharmacology and Physiology, 2005, 32, 488-494.	0.9	40
1968	Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the Hypertension Clinic 1996-2004. British Journal of Clinical Pharmacology, 2005, 60, 90-97.	1.1	14
1969	Glutathione levels in patients with erectile dysfunction, with or without diabetes mellitus. Journal of Developmental and Physical Disabilities, 2005, 28, 156-162.	3.6	24
1970	Whole-grain consumption and the metabolic syndrome: a favorable association in Tehranian adults. European Journal of Clinical Nutrition, 2005, 59, 353-362.	1.3	228
1971	Effect of lifestyle modifications on blood pressure by race, sex, hypertension status, and age. Journal of Human Hypertension, 2005, 19, 21-31.	1.0	195
1972	Sodium reduction for hypertension prevention in overweight adults: further results from the Trials of Hypertension Prevention Phase II. Journal of Human Hypertension, 2005, 19, 33-45.	1.0	73
1973	Associations of short-term weight changes and weight cycling with incidence of essential hypertension in the EPIC-Potsdam Study. Journal of Human Hypertension, 2005, 19, 61-67.	1.0	36
1974	The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. Journal of Human Hypertension, 2005, 19, 211-217.	1.0	33
1975	Effects of weight status on the recommendations of and adherence to lifestyle modifications among hypertensive adults. Journal of Human Hypertension, 2005, 19, 365-371.	1.0	17
1976	High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. Journal of Human Hypertension, 2005, 19, 491-496.	1.0	39
1977	Left ventricular filling abnormalities and obesity-associated hypertension: relationship with overproduction of circulating transforming growth factor $\hat{l}^21$ . Journal of Human Hypertension, 2005, 19, 543-550.	1.0	21
1978	Knowledge of blood pressure levels and targets in patients with coronary artery disease in the USA. Journal of Human Hypertension, 2005, 19, 769-774.	1.0	19
1979	Hypertension prevention: from nutrients to (fortified) foods to dietary patterns. Focus on fatty acids. Journal of Human Hypertension, 2005, 19, S25-S33.	1.0	46

#	Article	IF	Citations
1980	Renin–angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics Journal, 2005, 5, 14-20.	0.9	44
1981	Alcohol-Induced Endothelial Changes Are Associated With Oxidative Stress and Are Rapidly Reversed After Withdrawal. Alcoholism: Clinical and Experimental Research, 2005, 29, 1889-1898.	1.4	41
1982	Abnormal pocket depth and gingival recession as distinct phenotypes. Periodontology 2000, 2005, 39, 22-29.	6.3	16
1983	Synergistic effects of atenolol and amlodipine for lowering and stabilizing blood pressure in 2K1C renovascular hypertensive rats1. Acta Pharmacologica Sinica, 2005, 26, 1303-1308.	2.8	14
1984	Prognostic Value of a Multiparametric Risk Score in Patients Undergoing Dipyridamole Stress Echocardiography. American Journal of Cardiology, 2005, 96, 529-532.	0.7	5
1985	Characterization of Systemic Hypertension in the San Francisco Chinese Community. American Journal of Cardiology, 2005, 96, 570-573.	0.7	15
1986	Hypertension, Overweight and Abdominal Adiposity in Women. An Analytical Perspective. Archives of Medical Research, 2005, 36, 404-411.	1.5	6
1989	Association of heart disease with diabetes and hypertension in patients with ESRD. American Journal of Kidney Diseases, 2005, 45, 316-323.	2.1	32
1990	Diet and blood pressure in South Africa: Intake of foods containing sodium, potassium, calcium, and magnesium in three ethnic groups. Nutrition, 2005, 21, 39-50.	1.1	99
1991	Quality of care for hypertension in the United States. BMC Cardiovascular Disorders, 2005, 5, 1.	0.7	72
1992	Determinants of racial/ethnic differences in blood pressure management among hypertensive patients. BMC Cardiovascular Disorders, 2005, 5, 16.	0.7	26
1993	Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial. European Journal of Clinical Pharmacology, 2005, 61, 87-96.	0.8	20
1994	Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. European Journal of Clinical Pharmacology, 2005, 61, 225-230.	0.8	24
1995	Long-term Follow-up after Adrenalectomy for Primary Aldosteronism. World Journal of Surgery, 2005, 29, 155-159.	0.8	94
1996	An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia, 2005, 48, 17-26.	2.9	192
1997	Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia, 2005, 48, 1300-1306.	2.9	188
1998	Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?. Diabetologia, 2005, 48, 1445-1453.	2.9	115
1999	Vascular risk factors in the Swiss population. Journal of Neurology, 2005, 252, 1210-1216.	1.8	13

#	Article	IF	CITATIONS
2000	Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other angiotensin-receptor blockers. Advances in Therapy, 2005, 22, 263-277.	1.3	8
2001	Effect of low-dose omega-3 fatty acids substitution on blood pressure, hyperinsulinemia and dyslipidemia in Indians with essential hypertension: A pilot study. Indian Journal of Clinical Biochemistry, 2005, 20, 4-9.	0.9	4
2002	Lipoprotein Lipase Gene is Linked and Associated with Hypertension in Taiwan Young-onset Hypertension Genetic Study. Journal of Biomedical Science, 2005, 12, 651-658.	2.6	18
2003	Treatment of leukoaraiosis. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 173-177.	0.4	10
2004	Clinical Trials Reports. Current Hypertension Reports, 2005, 7, 201-203.	1.5	0
2005	Hypertension in black patients: Special issues and considerations. Current Hypertension Reports, 2005, 7, 244-248.	1.5	24
2006	Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care. Current Hypertension Reports, 2005, 7, 439-449.	1.5	8
2007	Hypertension and head injury. Current Hypertension Reports, 2005, 7, 450-453.	1.5	15
2008	Does ALLHAT change the management of hypertension in chronic kidney disease?. Current Hypertension Reports, 2005, 7, 474-483.	1.5	5
2009	Physical Activity, Cardiorespiratory Fitness, and their Relationship to Cardiovascular Risk Factors in African Americans and Non-African Americans With Above-Optimal Blood Pressure. Journal of Community Health, 2005, 30, 107-124.	1.9	12
2010	Marital differences in blood pressure and the risk of hypertension among Polish men. European Journal of Epidemiology, 2005, 20, 421-427.	2.5	39
2011	Different antioxidants status, total antioxidant power and free radicals in essential hypertension. Molecular and Cellular Biochemistry, 2005, 277, 89-99.	1.4	80
2012	Secondary Prevention in Coronary Heart Disease: Goal Achievement and Drug Prescribing. International Journal of Clinical Pharmacy, 2005, 27, 472-474.	1.4	2
2013	The Blood Pressure "Uncertainty Range" – a pragmatic approach to overcome current diagnostic uncertainties (II). Current Controlled Trials in Cardiovascular Medicine, 2005, 6, 5.	1.5	19
2014	Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement – is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I). Current Controlled Trials in Cardiovascular Medicine, 2005, 6, 6.	1,5	29
2015	Management of Hypertensive Emergencies and Urgencies. , 2005, , 826-837.		1
2016	Relationship between Vision Impairment and Eye Disease to Vision-Specific Quality of Life and Function in Rural India: The Aravind Comprehensive Eye Survey., 2005, 46, 2308.		90
2017	Evaluation of Waist Circumference to Predict Cardiovascular Risk Factors in an Overweight Tehranian Population: Findings from Tehran Lipid and Glucose Study. International Journal for Vitamin and Nutrition Research, 2005, 75, 347-356.	0.6	12

#	Article	IF	CITATIONS
2018	Factor Analysis of Lifestyle-related Factors in 12,525 Urban Japanese Subjects. Journal of Atherosclerosis and Thrombosis, 2005, 12, 29-34.	0.9	9
2019	$\hat{l}^2$ 1 Adrenergic Receptor Polymorphisms Arg389Gly and Ser49Gly in the Amerindian and Mestizo Populations of Mexico. Human Biology, 2005, 77, 515-520.	0.4	9
2020	Adapting the Chronic Care Model to Treat Chronic Illness at a Free Medical Clinic. Journal of Health Care for the Poor and Underserved, 2005, 16, 286-296.	0.4	48
2021	Prevalence of and Risk Factors for Atrial Fibrillation in Korean Adults Older than 40 Years. Journal of Korean Medical Science, 2005, 20, 26.	1.1	94
2022	A community-based epidemiological study of elevated serum alanine aminotransferase levels in Kinmen, Taiwan. World Journal of Gastroenterology, 2005, 11, 1616.	1.4	24
2025	First-Line First? Trends in Thiazide Prescribing for Hypertensive Seniors. PLoS Medicine, 2005, 2, e80.	3.9	11
2026	Prehypertension and Cardiovascular Morbidity. Annals of Family Medicine, 2005, 3, 294-299.	0.9	194
2027	Quality of US Outpatient Care. Archives of Internal Medicine, 2005, 165, 1354.	4.3	56
2028	The Effect of Web-Based, Personalized, Osteoarthritis Quality Improvement Feedback on Patient Satisfaction With Osteoarthritis Care. American Journal of Medical Quality, 2005, 20, 127-137.	0.2	12
2029	Diabetic Retinopathy Is Associated With Mortality and Cardiovascular Disease Incidence: The EURODIAB Prospective Complications Study. Diabetes Care, 2005, 28, 1383-1389.	<b>4.</b> 3	157
2030	Secular Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US Adults. JAMA - Journal of the American Medical Association, 2005, 293, 1868.	3.8	821
2031	A Prospective Study of Hypertension and Risk of Uterine Leiomyomata. American Journal of Epidemiology, 2005, 161, 628-638.	1.6	89
2032	Hypertension in Adults Across the Age Spectrum. JAMA - Journal of the American Medical Association, 2005, 294, 466.	3.8	519
2033	The Reasons for Geographic and Racial Differences in Stroke Study: Objectives and Design. Neuroepidemiology, 2005, 25, 135-143.	1.1	948
2034	Sex Hormone-Binding Clobulin and Insulin-Like Growth Factor-Binding Protein-1 as Indicators of Metabolic Syndrome, Cardiovascular Risk, and Mortality in Elderly Men. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1550-1556.	1.8	133
2036	Effect of Casein Hydrolysate, Prepared with Protease Derived from Aspergillus oryzae, on Subjects with High-Normal Blood Pressure or Mild Hypertension. Journal of Medicinal Food, 2005, 8, 423-430.	0.8	71
2037	Computational Coronary Artery Bypass Grafting. , 0, , .		1
2038	Ischemic Cerebrovascular Disease: Differences between Ethnic South Asian and Ethnic Chinese Patients. Cerebrovascular Diseases, 2005, 20, 407-409.	0.8	17

#	Article	IF	CITATIONS
2039	Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. Archives of Internal Medicine, 2005, 165, 1401.	4.3	256
2040	Hypertension Prevalence, Awareness, Treatment, and Control in an Adult Type 1 Diabetes Population and a Comparable General Population. Diabetes Care, 2005, 28, 301-306.	4.3	125
2041	Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. , 2005, , 321-359.		8
2042	Relative importance of atherosclerotic risk factors for coronary heart disease in Taiwan. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 95-101.	3.1	10
2043	Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. Archives of Internal Medicine, 2005, 165, 2479.	4.3	244
2044	Study of Î <sup>2</sup> -Adrenoreceptor Antagonistic Activity of DPJ 904 in Rats. Pharmacology, 2005, 74, 1-5.	0.9	9
2045	Angiotensin Receptor Blockade and Arterial Compliance in Chronic Kidney Disease: A Pilot Study. American Journal of Nephrology, 2005, 25, 393-399.	1.4	17
2046	Influence of Repeated Measurement on One Occasion, on Successive Days, and on Workdays on Home Blood Pressure Values. Clinical and Experimental Hypertension, 2005, 27, 215-222.	0.5	26
2047	Prevalencia de factores de riesgo cardiovascular en las Islas Baleares (estudio CORSAIB). Revista Espanola De Cardiologia, 2005, 58, 1411-1419.	0.6	43
2048	$S\tilde{A}$ ndrome metab $\tilde{A}^3$ lico en j $\tilde{A}^3$ venes: Diagn $\tilde{A}^3$ stico y tratamiento. Revista Espanola De Cardiologia, 2005, 58, 3-13.	0.6	3
2050	Early decrease of the percent of HOMA É-cell function is independently related to family history of diabetes in healthy young nonobese individuals. Diabetes and Metabolism, 2005, 31, 382-386.	1.4	15
2051	Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). Diabetes and Metabolism, 2005, 31, 479-485.	1.4	29
2052	Circadian and circaseptan (about-weekly) aspects of immigrant Indians' blood pressure and heart rate in California, USA. Biomedicine and Pharmacotherapy, 2005, 59, S76-S85.	2.5	6
2053	Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis, 2005, 183, 147-155.	0.4	114
2054	Beta blocker effects on plasma homocysteine levels in patients with hypertension. Atherosclerosis, 2005, 181, 399-402.	0.4	16
2055	Oral Agents in Managing Diabetes Mellitus in Children and Adolescents. Pediatric Clinics of North America, 2005, 52, 1689-1703.	0.9	4
2056	EpidemiologÃa de la hipertensión arterial en España. Situación actual y perspectivas. Hipertension Y Riesgo Vascular, 2005, 22, 353-362.	0.3	46
2057	Italian Audit on Therapy of Hypertension in Chronic Kidney Disease: The TABLE-CKD Study. Seminars in Nephrology, 2005, 25, 425-430.	0.6	19

#	Article	IF	CITATIONS
2058	Therapeutic Controversies in Hypertension. Seminars in Nephrology, 2005, 25, 227-235.	0.6	7
2060	Place of Drug Therapy in the Treatment of Carotid Stenosis. CNS Drugs, 2005, 19, 597-622.	2.7	5
2061	Drug-induced diabetes mellitus. Expert Opinion on Drug Safety, 2005, 4, 1097-1109.	1.0	34
2062	Antihypertensive Utility of Perindopril in a Large, General Practiceâ€Based Clinical Trial. Journal of Clinical Hypertension, 2005, 7, 10-17.	1.0	1
2063	Prescribing Patterns of Diuretics in Multiâ€Drug Antihypertensive Regimens. Journal of Clinical Hypertension, 2005, 7, 81-89.	1.0	5
2064	Do We Really Need a New Definition of Hypertension?. Journal of Clinical Hypertension, 2005, 7, 702-704.	1.0	7
2065	Gender―and Ageâ€Related Differences in Treatment and Control of Cardiovascular Risk Factors Among Highâ€Risk Patients With Angina. Journal of Clinical Hypertension, 2005, 7, 386-394.	1.0	4
2066	Visit Frequency and Hypertension. Journal of Clinical Hypertension, 2005, 7, 327-332.	1.0	31
2067	Singleâ€Pill Therapy in the Treatment of Concomitant Hypertension and Dyslipidemia (The) Tj ETQq0 0 0 rgBT /C	verlock 10	) Tf 50 422 T
2068	Expanding the Definition and Classification of Hypertension. Journal of Clinical Hypertension, 2005, 7, 505-512.	1.0	164
2069	Changes in the Continuation of Antihypertensive Drug Use After ALLHAT. Journal of Clinical Hypertension, 2005, 7, 649-653.	1.0	5
2070	A Drug Dose Model for Predicting Clinical Outcomes in Hypertensive Coronary Disease Patients. Journal of Clinical Hypertension, 2005, 7, 654-663.	1.0	10
2071	The ASCOT Trial. Journal of Clinical Hypertension, 2005, 7, 748-750.	1.0	7
2072	A risk score predicted coronary heart disease and stroke in a Chinese cohort. Journal of Clinical Epidemiology, 2005, 58, 951-958.	2.4	74
2073	Modest Improvement in Risk Factor Control After Admission for a Stroke or Transient Ischemic Attack. Journal of Stroke and Cerebrovascular Diseases, 2005, 14, 174-178.	0.7	8
2074	Acute administration of $17\hat{l}^2$ -estradiol improves endothelium-dependent vasodilation in postmenopausal women. Maturitas, 2005, 50, 266-274.	1.0	38
2075	Modulation of blood pressure, lipid profiles and redox status in hypertensive patients taking different edible oils. Clinica Chimica Acta, 2005, 355, 97-104.	0.5	142
2076	Baseline characteristics of menopausal women with coronary heart disease in cardiovascular outcomes clinical trials of menopausal hormone therapy or raloxifene. Contemporary Clinical Trials, 2005, 26, 612-615.	0.8	3

#	ARTICLE	IF	CITATIONS
2077	Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension. Clinical Therapeutics, 2005, 27, 1658-1668.	1.1	2
2078	Role of transforming growth factor $\hat{l}^2 2$ in, and apossible transforming growth factor $\hat{l}^2 2$ gene polymorphism as a marker of, renal dysfunction in essential hypertension: A study in Turkish patients. Current Therapeutic Research, 2005, 66, 266-278.	0.5	1
2079	Effects of oral fixed-dose combinations of telmisartan plus ramipril and losartan plus ramipril in hypertension: A multicenter, prospective, randomized, double-blind, phase iii trial in adult indian patients. Current Therapeutic Research, 2005, 66, 630-642.	0.5	2
2080	Role of endothelial dysfunction in the development of cardiorenal syndrome in patients with type 1 diabetes mellitus. Diabetes Research and Clinical Practice, 2005, 68, S65-S72.	1.1	26
2081	Management of hypertension in low and middle income countries: Challenges and opportunities. Prevention and Control: the Official Journal of the World Heart Federation, 2005, 1, 275-284.	0.3	12
2082	Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. Thrombosis Research, 2005, 115, 359-366.	0.8	22
2083	Diabetes and Hypertension in Isolated Sixth Nerve PalsyA Population-Based Study. Ophthalmology, 2005, 112, 760-763.	2.5	60
2084	Systolic hypertension: An overview. American Heart Journal, 2005, 149, 769-775.	1.2	9
2085	Moderate-to-severe blood pressure elevation at ED entry. American Journal of Emergency Medicine, 2005, 23, 474-479.	0.7	36
2086	Metabolic syndrome and insulin resistance in the TROPHY sub-study: Contrasting views in patients with high-normal blood pressure. American Journal of Hypertension, 2005, 18, 3-12.	1.0	45
2087	Relationship among end-stage renal disease, hypertension, and sleep apnea in nondiabetic dialysis patients. American Journal of Hypertension, 2005, 18, 152-157.	1.0	44
2088	Low mineral intake is associated with high systolic blood pressure in the Third and Fourth National Health and Nutrition Examination SurveysCould we all be right?. American Journal of Hypertension, 2005, 18, 261-269.	1.0	38
2089	Relation of genetic predisposition and insulin resistance to left ventricular hypertrophy in hypertension. American Journal of Hypertension, 2005, 18, 457-463.	1.0	8
2090	Self-reported hypertension treatment beliefs and practices of primary care physicians in a managed care organization. American Journal of Hypertension, 2005, 18, 566-571.	1.0	22
2091	Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Report of experience in a health maintenance organization. American Journal of Hypertension, 2005, 18, 464-469.	1.0	29
2092	Nondipping Status Does Not Attenuate the Conjugated Estrogen-Induced Improvement in Aortic Stiffness in Postmenopausal Women with Untreated Hypertension. American Journal of Hypertension, 2005, 18, 607-611.	1.0	10
2093	Resistant Hypertension Revisited: A Comparison of Two University-Based Cohorts. American Journal of Hypertension, 2005, 18, 619-626.	1.0	210
2094	Is Population-Wide Diuretic Use Directly Associated With the Incidence of End-Stage Renal Disease in the United States?A Hypothesis. American Journal of Hypertension, 2005, 18, 744-749.	1.0	46

#	Article	IF	CITATIONS
2095	Predictors of Failure to Initiate Randomized Treatment in a Large Trial of Antihypertensive Drug Therapy in the Aged. American Journal of Hypertension, 2005, 18, 885-888.	1.0	1
2096	A Summary of the Effects of Antihypertensive Medications on Measured Blood Pressure. American Journal of Hypertension, 2005, 18, 935-942.	1.0	102
2097	Diuretic Use and ESRD, Precipitating Factor or Epiphenomenon. American Journal of Hypertension, 2005, 18, 739-740.	1.0	5
2098	Hypertension in HIV-Infected Patients: Prevalence and Related Factors. American Journal of Hypertension, 2005, 18, 1396-1401.	1.0	81
2099	The Role of $\hat{I}^2$ -Blockers as a Cornerstone of Cardiovascular Therapy. American Journal of Hypertension, 2005, 18, 165-168.	1.0	27
2100	From "Prehypertension―to Hypertension? Additional Evidence. Annals of Epidemiology, 2005, 15, 720-725.	0.9	70
2105	Hemodynamic Influences of Losartan on the Brain in Hypertensive Patients. Hypertension Research, 2005, 28, 43-49.	1.5	30
2106	Development and Progression of Atherosclerotic Disease in Relation to Insulin Resistance and Hyperinsulinemia. Hypertension Research, 2005, 28, 665-670.	1.5	28
2107	Trandolapril/Verapamil Sustained Release. Drugs, 2005, 65, 1893-1914.	4.9	11
2108	Prevalence of Cardiovascular Risk Factors in the Balearic Islands (CORSAIB Study). Revista Espanola De Cardiologia (English Ed ), 2005, 58, 1411-1419.	0.4	5
2109	Increased Ambulatory Pulse Pressure Is a Strong Risk Factor for Coronary Endothelial Vasomotor Dysfunction. Journal of the American College of Cardiology, 2005, 45, 1461-1466.	1.2	28
2110	Place du sport dans le traitement de l'hypertension artérielle. EMC - Cardiologie-Angeiologie, 2005, 2, 431-435.	0.9	3
2111	Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Current Medical Research and Opinion, 2005, 21, 37-46.	0.9	10
2112	How Does Renal Intervention Compare to Medical Management Alone?. Journal of Vascular and Interventional Radiology, 2005, 16, P100-P103.	0.2	0
2113	Hypertension in the Elderly. Drugs and Aging, 2005, 22, 297-314.	1.3	11
2114	Cardioselective beta-blockers for chronic obstructive pulmonary disease. The Cochrane Library, 2005, , CD003566.	1.5	212
2115	Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous?. Annals of Internal Medicine, 2006, 144, 884.	2.0	664
2116	A Review of Calcium Channel Antagonists in the Treatment of Pediatric Hypertension. Paediatric Drugs, 2006, 8, 357-373.	1.3	39

#	ARTICLE	IF	Citations
2117	Discrepant Antihypertensive Dose Recommendations. Clinical and Experimental Hypertension, 2006, 28, 171-180.	0.5	6
2120	Management of Global Risk Across the Continuum of Hypertensive Heart Disease. Journal of Clinical Hypertension, 2006, 8, 21-30.	1.0	2
2122	Na+, K+-ATPase: An Indispensable Ion Pumping-Signaling Mechanism Across Mammalian Cell Membranes. Seminars in Nephrology, 2006, 26, 386-392.	0.6	37
2123	High Prevalence of Classic Cardiovascular Risk Factors in a Population of University Students From South Central Chile. Revista Espanola De Cardiologia (English Ed ), 2006, 59, 1099-1105.	0.4	13
2124	Initiation of Acetylcholinesterase Inhibitors and Complications of Chronic Airways Disorders in Elderly Patients. Drug Safety, 2006, 29, 1077-1085.	1.4	12
2125	Indapamide Sustained Release. Drugs, 2006, 66, 257-271.	4.9	34
2126	Efficacy and Safety of Amlodipine. Clinical Drug Investigation, 2006, 26, 125-133.	1.1	11
2129	Traditional Cardiovascular Risk Factors in Relation to Left Ventricular Mass, Volume, and Systolic Function by Cardiac Magnetic Resonance Imaging. Journal of the American College of Cardiology, 2006, 48, 2285-2292.	1.2	262
2130	Impact of sex-specific body composition on cardiovascular risk factors: the Hong Kong Cardiovascular Risk Factor Study. Metabolism: Clinical and Experimental, 2006, 55, 563-569.	1.5	18
2131	Cardiovascular/non–insulin-dependent diabetes mellitus risk factors and intramyocellular lipid in healthy subjects: a sex comparison. Metabolism: Clinical and Experimental, 2006, 55, 128-134.	1.5	11
2132	Association of vascular risk factors with increasing glycemia even in normoglycemic subjects in an older Chinese population: the Guangzhou Biobank Cohort Study. Metabolism: Clinical and Experimental, 2006, 55, 1035-1041.	1.5	18
2133	Improvement of metabolic syndrome markers through altitude specific hiking vacations. Journal of Endocrinological Investigation, 2006, 29, 497-504.	1.8	45
2134	Determinants of normoglycemia and contribution to cardiovascular risk factors in a Chinese population: The Hong Kong Cardiovascular Risk Factor Study. Journal of Endocrinological Investigation, 2006, 29, 528-535.	1.8	6
2135	Risk Factors for Photodynamic Therapy of Predominantly Classic Choroidal Neovascularization in Age-related Macular Degeneration. American Journal of Ophthalmology, 2006, 142, 441-447.e2.	1.7	5
2136	Determinants of Sustained Uncontrolled Blood Pressure in a National Cohort of Persons With Diabetes. American Journal of Hypertension, 2006, 19, 161-169.	1.0	19
2137	Prevalence, Awareness, Treatment and Control of Hypertension in Hellas, GreeceThe Hypertension Study in General Practice in Hellas (HYPERTENSHELL) National Study. American Journal of Hypertension, 2006, 19, 53-60.	1.0	68
2138	Relation of C-Reactive Protein to Oxidative Stress and to Endothelial Activation in Essential Hypertension. American Journal of Hypertension, 2006, 19, 313-318.	1.0	77
2139	The Effect of Age on Hypertension Control and Management. American Journal of Hypertension, 2006, 19, 520-527.	1.0	47

#	Article	IF	CITATIONS
2140	Are Blood Pressure Predictors of Cardiovascular Disease Mortality Different for Prehypertensives Than for Hypertensives?. American Journal of Hypertension, 2006, 19, 454-461.	1.0	13
2141	Young Scholars Award Lecture: Intratubular Angiotensinogen in Hypertension and Kidney Diseases. American Journal of Hypertension, 2006, 19, 541-550.	1.0	93
2142	Association of Pulse Pressure With Cardiovascular Outcome Is Independent of Left Ventricular Hypertrophy and Systolic Dysfunction: The Strong Heart Study. American Journal of Hypertension, 2006, 19, 601-607.	1.0	37
2143	Association Between Levels of Blood Pressure and Measures of Subclinical DiseaseMulti-Ethnic Study of Atherosclerosis. American Journal of Hypertension, 2006, 19, 1110-1117.	1.0	34
2144	Effect of Body Weight Loss on Blood Pressure After 6 Years of Follow-Up in Stage 1 Hypertension. American Journal of Hypertension, 2006, 19, 1103-1109.	1.0	25
2145	24-Hour ambulatory blood pressure monitoring. American Heart Journal, 2006, 151, 962-968.	1.2	12
2146	Acute myocardial infarction: Clinical characteristics and plaque morphology between expansive remodeling and constrictive remodeling by intravascular ultrasound. American Heart Journal, 2006, 151, 332-337.	1.2	25
2147	Effects of particulate air pollution on systolic blood pressure: A population-based approach. Environmental Research, 2006, 101, 89-93.	3.7	72
2148	Soluble interleukin-2 receptor as a marker for progression of coronary artery calcification in type 1 diabetes. International Journal of Biochemistry and Cell Biology, 2006, 38, 996-1003.	1.2	49
2149	Metabolic characteristics and insulin resistance of impaired fasting glucose among the middle-aged and elderly Taiwanese. Diabetes Research and Clinical Practice, 2006, 71, 170-176.	1.1	28
2150	Conventional, Emerging, Heredity, Lifestyle, and Psychosocial Coronary Risk Factors: Relationships to Subclinical Atherosclerosis. Preventive Cardiology, 2006, 9, 25-32.	1.1	21
2151	More Confusing Messages From the Hypertension Treatment Trials. Journal of Clinical Hypertension, 2006, 8, 8-11.	1.0	1
2152	Dispelling the Myth of "Aggressive―Antihypertensive Therapy. Journal of Clinical Hypertension, 2006, 8, 4-11.	1.0	23
2153	Attempted Forced Titration of Blood Pressure to <130/85 mm Hg in Type 2 Diabetic Hypertensive Patients in Clinical Practice: The Diastolic Cost. Journal of Clinical Hypertension, 2006, 8, 29-34.	1.0	8
2154	Prevalence, Awareness, Treatment, and Control of Hypertension: United States National Health and Nutrition Examination Survey 2001–2002. Journal of Clinical Hypertension, 2006, 8, 93-98.	1.0	82
2155	Hypertensionâ€Related Morbidity and Mortality in African Americansâ€"Why We Need to Do Better. Journal of Clinical Hypertension, 2006, 8, 21-30.	1.0	51
2156	Clinical and Nonclinical Correlates of Adherence to Prescribing Guidelines for Hypertension in a Large Managed Care Organization. Journal of Clinical Hypertension, 2006, 8, 414-419.	1.0	3
2157	Atherosclerotic Renal Artery Stenosis and Renovascular Hypertension: Clinical Diagnosis and Indications for Revascularization. Journal of Clinical Hypertension, 2006, 8, 502-509.	1.0	15

#	Article	IF	CITATIONS
2158	Changing Patterns of Initial Drug Therapy for the Treatment of Hypertension in a Medicaid Population, 2001?2005. Journal of Clinical Hypertension, 2006, 8, 706-712.	1.0	5
2159	Efficacy and Safety of Coadministered Amlodipine and Atorvastatin in Patients With Hypertension and Dyslipidemia: Results of the AVALON Trial. Journal of Clinical Hypertension, 2006, 8, 571-583.	1.0	51
2160	Efficacy and Safety of Irbesartan/HCTZ Combination Therapy As Initial Treatment for Rapid Control of Severe Hypertension. Journal of Clinical Hypertension, 2006, 8, 850-859.	1.0	50
2161	Optimizing Hypertension Control in Patients With Multiple Cardiovascular Risk Factors. Journal of Clinical Hypertension, 2006, 8, 2-4.	1.0	1
2162	Are Racial Differences in Antihypertensive Responsiveness Reflected in Usage After Stroke?. Journal of Stroke and Cerebrovascular Diseases, 2006, 15, 260-265.	0.7	1
2163	Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women. Maturitas, 2006, 53, 306-314.	1.0	9
2164	Independent and inverse association of hip circumference with metabolic risk factors in Tehranian adult men. Preventive Medicine, 2006, 42, 354-357.	1.6	15
2165	Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 137-147.	1.1	39
2166	Incidence of erectile dysfunction in 800 hypertensive patients: A multicenter Egyptian national study. Urology, 2006, 67, 575-578.	0.5	48
2167	Management of chronic prostatitis/chronic pelvic pain syndrome: An evidence-based approach. Urology, 2006, 67, 881-888.	0.5	36
2168	Haematological, lipid profile and other biochemical parameters in normal and hypertensive subjects among the population of the eastern province of Saudi Arabia. East African Medical Journal, 2006, 83, 44-8.	0.0	6
2169	The Relationship Between Hypertensive Retinopathy and Angiotensin Converting Enzyme Gene Polymorphism. Cardiovascular & Hematological Disorders Drug Targets, 2006, 6, 57-61.	0.2	3
2170	Association of Body Mass Index, Body Fat and Hypertension among Postmenopausal Women. Journal of Human Ecology: International, Interdisciplinary Journal of Man-environment Relationship, 2006, 20, 171-175.	0.1	6
2171	Providers' Assessment of Barriers to Effective Management of Hypertension and Hyperlipidemia in Community Health Centers. Journal of Health Care for the Poor and Underserved, 2006, 17, 70-85.	0.4	27
2172	Blood Pressure Goal Attainment According to JNC 7 Guidelines and Utilization of Antihypertensive Drug Therapy in MCO Patients With Type 1 or Type 2 Diabetes. Journal of Managed Care Pharmacy, 2006, 12, 303-309.	2.2	33
2173	Perioperative management of hypertension. , 0, , 107-124.		0
2174	Diurnal Variations of Blood Pressure in Cats. Journal of Veterinary Medical Science, 2006, 68, 243-248.	0.3	24
2175	Therapy Modifications in Response to Poorly Controlled Hypertension, Dyslipidemia, and Diabetes Mellitus. Annals of Internal Medicine, 2006, 144, 475.	2.0	175

#	Article	IF	CITATIONS
2177	The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-term Follow-up of the Modification of Diet in Renal Disease Study. Yearbook of Cardiology, 2006, 2006, 74-76.	0.0	0
2178	Blood-Pressure Control for Renoprotection in Patients With Nondiabetic Chronic Renal Disease (REIN-2): Multicentre, Randomised Controlled Trial. Yearbook of Cardiology, 2006, 2006, 76-78.	0.0	0
2182	Pression artérielle. Régulation et épidémiologie. Mesures et valeurs normales. EMC - Cardiologie, 2006, 1, 1-15.	0.0	0
2183	Should sports activity be encouraged or contraindicated in hypertensive subjects?. Journal of Cardiovascular Medicine, 2006, 7, 288-295.	0.6	2
2184	Effects of Comprehensive Lifestyle Modification on Diet, Weight, Physical Fitness, and Blood Pressure Control: 18-Month Results of a Randomized Trial. Annals of Internal Medicine, 2006, 144, 485.	2.0	494
2185	Psychosocial Factors and Coronary Calcium in Adults without Clinical Cardiovascular Disease. Annals of Internal Medicine, 2006, 144, 822.	2.0	74
2186	Diabetes and dyslipidaemia. Diabetes, Obesity and Metabolism, 2006, 8, 355-364.	2.2	31
2187	Mortality in African-Americans with Type $1$ diabetes: The New Jersey 725. Diabetic Medicine, 2006, 23, 698-706.	1.2	39
2188	Prevention of Progression of Kidney Disease. Nephrology, 2006, 11, S2-S197.	0.7	29
2189	Antihypertensive therapy in diabetic nephropathy. Nephrology, 2006, 11, S73-S78.	0.7	0
2190	Preventive medicine beyond 65. Geriatrics and Gerontology International, 2006, 6, 73-81.	0.7	5
2191	Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Medicine, 2006, 7, 10-15.	1.0	133
2192	Indications for and utilization of ACE inhibitors in older individuals with diabetes. Journal of General Internal Medicine, 2006, 21, 315-319.	1.3	30
2193	Japanese Society of Hypertension. Hypertension Research, 2006, 29, S1-S105.	1.5	32
2194	Effects of different dietary protein intakes on body composition and vascular reactivity. European Journal of Clinical Nutrition, 2006, 60, 643-649.	1.3	24
2195	Influence of childhood socioeconomic circumstances, height, and obesity on pulse pressure and systolic and diastolic blood pressure in older people. Journal of Human Hypertension, 2006, 20, 73-82.	1.0	24
2196	Aim, design and methods of the â€reasons for not intensifying antihypertensive treatment' (RIAT): an international registry in essential hypertension. Journal of Human Hypertension, 2006, 20, 31-36.	1.0	6
2197	Evaluation of cerebral blood flow by single-photon emission computed tomography in young Asian Indians with hypertension. Journal of Human Hypertension, 2006, 20, 143-148.	1.0	5

#	Article	IF	CITATIONS
2198	The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. Journal of Human Hypertension, 2006, 20, 169-175.	1.0	36
2199	Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. Journal of Human Hypertension, 2006, 20, 255-262.	1.0	31
2200	Fatality of acute coronary events in relation to hypertension and low-grade inflammation: a population-based cohort study. Journal of Human Hypertension, 2006, 20, 581-586.	1.0	14
2201	Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting. Journal of Human Hypertension, 2006, 20, 894-897.	1.0	14
2202	Evaluation of 'partnership care model' in the control of hypertension. International Journal of Nursing Practice, 2006, 12, 153-159.	0.8	25
2203	Hypertensive left ventricular hypertrophy is associated with abnormal myocardial fatty acid metabolism and myocardial efficiency. Journal of Nuclear Cardiology, 2006, 13, 369-377.	1.4	50
2204	Normal and High-Normal Blood Pressures, but Not Body Mass Index, Are Risk Factors for the Subsequent Occurrence of Both Preeclampsia and Gestational Hypertension: A Retrospective Cohort Study. Hypertension Research, 2006, 29, 161-167.	1.5	52
2205	Using Regular Expressions to Abstract Blood Pressure and Treatment Intensification Information from the Text of Physician Notes. Journal of the American Medical Informatics Association: JAMIA, 2006, 13, 691-695.	2.2	78
2206	Influence of Nighttime Bathing on Evening Home Blood Pressure Measurements: How Long Should the Interval Be after Bathing?. Hypertension Research, 2006, 29, 129-133.	1.5	34
2207	Sex-Related Differences in the Relations of Insulin Resistance and Obesity to Left Ventricular Hypertrophy in Japanese Hypertensive Patients. Hypertension Research, 2006, 29, 499-504.	1.5	17
2208	Synthetic/Secreting and Apoptotic Phenotypes in Renal Biopsy Tissues from Hypertensive Nephrosclerosis Patients. Hypertension Research, 2006, 29, 573-580.	1.5	2
2209	Analysis of Yearly Variations in Drug Expenditure for One Patient Using Data Warehouse in a Hospital. Journal of Medical Systems, 2006, 31, 17-24.	2.2	5
2210	Failure to decrease blood pressure during sleep: non-dippers are among us. International Journal of Cardiovascular Imaging, 2006, 22, 167-169.	0.7	1
2211	Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15Âyears than in the normal population?. Clinical Rheumatology, 2006, 25, 24-29.	1.0	86
2212	Proposal for mapping renal failure in Japan and its application for strategy to arrest endstage renal disease. Clinical and Experimental Nephrology, 2006, 10, 8-12.	0.7	10
2213	Hypertension in black Americans as a special population: Why so special?. Current Cardiology Reports, 2006, 8, 405-410.	1.3	9
2214	Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the united states?. Current Hypertension Reports, 2006, 8, 219-225.	1.5	6
2215	$\hat{l}^21$ -adrenergic receptor gene polymorphisms in Mexican patients with idiopathic dilated cardiomyopathy. Experimental and Molecular Pathology, 2006, 80, 279-282.	0.9	8

#	ARTICLE	IF	CITATIONS
2216	Prevalence of Hypertension in Type 2 Diabetes Mellitus: Impact of the Tightening Definition of High Blood Pressure and Association With Confounding Risk Factors. Journal of the Cardiometabolic Syndrome, 2006, $1,95-101$ .	1.7	62
2217	Cardiovascular risk in operators under radiofrequency electromagnetic radiation. International Journal of Hygiene and Environmental Health, 2006, 209, 133-138.	2.1	28
2218	Do Captopril Renogram and Losartan Renogram Influence the Choice of Drug (Angiotensin Converting) Tj ETQq0 of Nephrology, 2006, 8, 61-67.	0 0 rgBT / 0.0	Overlock 10 0
2219	Hypertension and the Cardiometabolic Syndrome? Is It the Blood Pressure Lowering or the Blood Pressure Medication That Is Important?. Journal of the Cardiometabolic Syndrome, 2006, 1, 72-73.	1.7	0
2220	Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Social Science and Medicine, 2006, 63, 2890-2898.	1.8	28
2221	Investigation of altered heart rate variability, nonlinear properties of heart rate signals, and organ dysfunction longitudinally over time in intensive care unit patients. Journal of Critical Care, 2006, 21, 95-103.	1.0	48
2222	QT dispersion. Journal of Diabetes and Its Complications, 2006, 20, 88-97.	1.2	13
2223	Trends in the management of arterial hypertension in patients with type 1 and insulin-treated type 2 diabetes mellitus over a period of 10 years (1989/1990–1994/1995). Results of the JEVIN trial. Journal of Diabetes and Its Complications, 2006, 20, 273-279.	1.2	6
2224	Duloxetine for the treatment of major depressive disorder: A closer look at efficacy and safety data across the approved dose range. Journal of Psychiatric Research, 2006, 40, 337-348.	1.5	106
2225	Does personality predict blood pressure over a 10-year period?. Personality and Individual Differences, 2006, 40, 1313-1321.	1.6	10
2226	Systolic Hypertension in Older Persons: How Aggressive Should Treatment Be?. Progress in Cardiovascular Diseases, 2006, 48, 397-406.	1.6	5
2227	Risk of ischaemic heart disease and acute myocardial infarction in a Spanish population: observational prospective study in a primary-care setting. BMC Public Health, 2006, 6, 38.	1.2	45
2228	Coronary Artery Disease and Hypertension: Outcomes of a Pharmacist-Managed Blood Pressure Program. Pharmacotherapy, 2006, 26, 1333-1341.	1.2	23
2229	Predictive Implications of Recurrent Transient Ischemic Attacks in Large-Artery Atherosclerosis. Cerebrovascular Diseases, 2006, 22, 240-244.	0.8	6
2230	Polycystic ovary syndrome and metabolic syndrome. Expert Review of Obstetrics and Gynecology, 2006, 1, 183-194.	0.4	0
2231	Metabolic Syndrome Compared With Type 2 Diabetes Mellitus as a Risk Factor for Stroke. Archives of Internal Medicine, 2006, 166, 106.	4.3	144
2232	Birth weight and risk of type 2 diabetes, abdominal obesity and hypertension among Chinese adults. European Journal of Endocrinology, 2006, 155, 601-607.	1.9	108
2233	Endothelial function in HIV-infected patients with low or mild cardiovascular risk. Journal of Antimicrobial Chemotherapy, 2006, 58, 133-139.	1.3	45

#	Article	IF	CITATIONS
2234	Blood Pressure and Hematocrit in Diabetes and the Role of Endothelial Responses in the Variability of Blood Viscosity. Diabetes Care, 2006, 29, 1523-1528.	4.3	37
2235	Clinical Trials in Hypertension—Reply. JAMA - Journal of the American Medical Association, 2006, 296, 1463.	3.8	0
2236	Hyperinsulinemia in Healthy Children and Adolescents With a Positive Family History for Type 2 Diabetes. Pediatrics, 2006, 118, e1516-e1522.	1.0	27
2237	Metabolic Syndrome May Not Associate With Carotid Plaque in Subjects With Optimal, Normal, or High-Normal Blood Pressure. Hypertension, 2006, 48, 411-417.	1.3	16
2238	Effects of Demographic Characteristics, Health-Related Behaviors and Lifestyle Factors on the Prevalence of Hypertension for the Middle-Aged and Elderly in the Guangxi Hei Yi Zhuang and Han Populations. Kidney and Blood Pressure Research, 2006, 29, 312-320.	0.9	19
2239	Evolution of Clinical Practice Guidelines: Evidence Supporting Expanded Use of Medicines. Disease Management: DM, 2006, 9, 210-223.	1.0	18
2240	Amlodipine/atorvastatin single pill for the management of hypertensive patients with additional cardiovascular risk factors. Future Cardiology, 2006, 2, 145-159.	0.5	1
2241	Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients. The American Journal of Geriatric Cardiology, 2007, 16, 24-29.	0.7	11
2242	Influence of Hispanic Ethnicity on Blood Pressure Control and Cardiovascular Outcomes in Women with CAD and Hypertension: Findings from INVEST. Journal of Women's Health, 2007, 16, 632-640.	1.5	15
2243	Hypertension in the elderly: a compelling contraindication for $\hat{l}^2$ -blockers?. Journal of Human Hypertension, 2007, 21, 259-260.	1.0	8
2244	Independent Components of Chronic Kidney Disease as a Cardiovascular Risk State. Archives of Internal Medicine, 2007, $167$ , $1122$ .	4.3	197
2245	Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European Heart Journal, 2007, 29, 1327-1334.	1.0	276
2246	Improvement of Blood Pressure Control in Hypertensive Patients with Renal Diseases. Hypertension Research, 2007, 30, 295-300.	1.5	1
2247	Efonidipine Reduces Proteinuria and Plasma Aldosterone in Patients with Chronic Glomerulonephritis. Hypertension Research, 2007, 30, 621-626.	1.5	42
2248	Effects of Hypertension and Type 2 Diabetes Mellitus on the Risk of Total Cardiovascular Events in Japanese Patients with Hypercholesterolemia: Implications from the Japan Lipid Intervention Trial (J-LIT). Hypertension Research, 2007, 30, 119-123.	1.5	9
2249	Outpatient Hypertension Treatment, Treatment Intensification, and Control in Western Europe and the United States. Archives of Internal Medicine, 2007, 167, 141.	4.3	246
2250	The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003. Current Medical Research and Opinion, 2007, 23, 1423-1430.	0.9	20
2251	The Effect of Music on Hypertensive Patients. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2007, 2007, 4649-51.	0.5	21

#	Article	IF	CITATIONS
2252	Serum Cystatin C Predicts Progression of Subclinical Coronary Atherosclerosis in Individuals With Type 1 Diabetes. Diabetes, 2007, 56, 2774-2779.	0.3	69
2253	Lack of Effect of Guideline Changes on Hypertension Control for Patients With Diabetes in the U.S., 1995-2005. Diabetes Care, 2007, 30, 49-52.	4.3	10
2254	Association of diarrhoea in childhood with blood pressure and coronary heart disease in older age: analyses of two UK cohort studies. International Journal of Epidemiology, 2007, 36, 1349-1355.	0.9	9
2255	The genetic polymorphisms of $\hat{l}^2$ 3-adrenergic receptor (AR) Trp64Arg and $\hat{l}^2$ 2-AR Gln27Glu are associated with obesity in Chinese male hypertensive patients. Clinical Chemistry and Laboratory Medicine, 2007, 45, 493-8.	1.4	11
2256	Risk Factors of Intracranial Cerebral Atherosclerosis among Asymptomatics. Cerebrovascular Diseases, 2007, 24, 355-360.	0.8	114
2257	Relationship of Physician Volume With Process Measures and Outcomes in Diabetes. Diabetes Care, 2007, 30, 1442-1447.	4.3	23
2258	The New "Normal" Blood Pressure: What Are the Implications for Family Medicine?. Journal of the American Board of Family Medicine, 2007, 20, 45-51.	0.8	7
2259	Characteristics of Framingham Offspring Participants With Long-lived Parents. Archives of Internal Medicine, 2007, 167, 438.	4.3	55
2260	Interrelationship Between Insulin Resistance and Menopause on the Metabolic Syndrome and Its Individual Component Among Nondiabetic Women in the Kinmen Study. American Journal of the Medical Sciences, 2007, 333, 208-214.	0.4	16
2261	Differential Control of Systolic and Diastolic Blood Pressure: Factors Associated With Lack of Blood Pressure Control in Rural Community of Liaoning Province, China. Journal of Health Science, 2007, 53, 209-214.	0.9	4
2262	Elevated Plasma Levels of Oxidized Low-Density Lipoprotein Relate to the Presence of Angiographically Detected Complex and Thrombotic Coronary Artery Lesion Morphology in Patients With Unstable Angina. Circulation Journal, 2007, 71, 681-687.	0.7	34
2263	Using motivational interviewing as a supplement to obesity treatment: A stepped-care approach Health Psychology, 2007, 26, 369-374.	1.3	159
2264	Dietary energy density in the treatment of obesity: a year-long trial comparing 2 weight-loss diets. American Journal of Clinical Nutrition, 2007, 85, 1465-1477.	2.2	313
2265	KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenetics and Genomics, 2007, 17, 719-729.	0.7	65
2266	Cardiorespiratory Fitness, BMI, and Risk of Hypertension. Medicine and Science in Sports and Exercise, 2007, 39, 1687-1692.	0.2	67
2268	Blood Pressure Usually Considered Normal Is Associated with an Elevated Risk of Cardiovascular Disease. Yearbook of Cardiology, 2007, 2007, 38-40.	0.0	0
2269	Physical Activity in Young Adults and Incident Hypertension Over 15 Years of Follow-Up: The CARDIA Study. American Journal of Public Health, 2007, 97, 703-709.	1.5	109
2270	Obesity and Benign Prostatic Enlargement: A Large Observational Study in China. Urology, 2007, 69, 680-684.	0.5	40

#	Article	IF	Citations
2271	Les facteurs non hÃ@modynamiques deÂvariation deÂlaÂpression artÃ@rielle chezÂd'anciens sportifs demeurÃ@s actifs. Science and Sports, 2007, 22, 28-34.	0.2	0
2272	Physician Knowledge Levels and Barriers to Coronary Risk Prevention in Women. Women's Health Issues, 2007, 17, 93-100.	0.9	48
2273	Using ankle-brachial index to detect peripheral arterial disease: Prevalence and associated risk factors in a random population sample. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 41-49.	1.1	47
2274	Role of endogenous androgens on carotid atherosclerosis in non-obese postmenopausal women. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 705-711.	1.1	20
2275	Obstructive sleep apnea: An update on mechanisms and cardiovascular consequences. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 233-240.	1.1	95
2276	British Hypertension Society Recommends That ?-Blockers Are No Longer Indicated as Initial Treatment of Hypertension: Has the Pendulum Swung Too Far?. Journal of Clinical Hypertension, 2007, 9, 99-120.	1.0	6
2277	Comparison of Increasing Doses of Olmesartan Medoxomil, Losartan Potassium, and Valsartan in Patients With Essential Hypertension. Journal of Clinical Hypertension, 2007, 9, 187-195.	1.0	79
2278	Does Participatory Decision Making Improve Hypertension Self-Care Behaviors and Outcomes?. Journal of Clinical Hypertension, 2007, 9, 330-336.	1.0	10
2279	Hypertension After Renal Transplant. Journal of Clinical Hypertension, 2007, 9, 538-545.	1.0	16
2280	A Modern Perspective on ?-Blocker Use in Hypertension: Clinical Trials and Their Influence on Clinical Practice. Journal of Clinical Hypertension, 2007, 9, 10-18.	1.0	10
2281	Hypertension Management: Results of a New National Survey for the Hypertension Education Foundation: Harris Interactive. Journal of Clinical Hypertension, 2007, 9, 316-323.	1.0	80
2282	Understanding Uncontrolled Hypertension: Is It the Patient or the Provider?. Journal of Clinical Hypertension, 2007, 9, 937-943.	1.0	48
2283	Blood Pressureâ€"The Better Biomarker: Delay in Clinical Application. Journal of Clinical Hypertension, 2007, 9, 918-920.	1.0	3
2284	Hypertension Treatment Guidelines: Is It Time for an Update?. Journal of Clinical Hypertension, 2007, 9, 9-14.	1.0	9
2285	Laboratory Screening at Preventive Health Exams. American Journal of Preventive Medicine, 2007, 32, 59-62.	1.6	15
2286	Effectiveness of Community Health Workers in the Care of People with Hypertension. American Journal of Preventive Medicine, 2007, 32, 435-447.	1.6	237
2287	Inadequate Cytoplasmic Antioxidant Enzymes Response Contributes to the Oxidative Stress in Human Hypertension. American Journal of Hypertension, 2007, 20, 62-69.	1.0	43
2288	Underserved Urban African American Men: Hypertension Trial Outcomes and Mortality During 5 Years. American Journal of Hypertension, 2007, 20, 164-171.	1.0	45

#	Article	IF	CITATIONS
2289	Metabolic Syndrome and Incident Cardiovascular Morbidity and Mortality in a Mediterranean Hypertensive Population. American Journal of Hypertension, 2007, 20, 558-564.	1.0	43
2290	Cardiovascular Outcome in Relation to Progression to Hypertension in the Copenhagen MONICA Cohort. American Journal of Hypertension, 2007, 20, 483-491.	1.0	41
2291	Differential Effects of Ramipril on Ambulatory Blood Pressure in African Americans and Caucasians. American Journal of Hypertension, 2007, 20, 884-891.	1.0	10
2292	Risk of Progression to Hypertension in a Low-Income Mexican Population With Prehypertension and Normal Blood Pressure. American Journal of Hypertension, 2007, 20, 929-936.	1.0	24
2293	An RCT of the effect of motivational interviewing on medication adherence in hypertensive African Americans: Rationale and design. Contemporary Clinical Trials, 2007, 28, 169-181.	0.8	66
2294	Hypertensive patients with false-positive Thallium-201 scintigraphic results in the infero-posterior wall are in high risk for coronary artery disease development. International Journal of Cardiology, 2007, 117, 178-183.	0.8	2
2295	Racial difference in endothelial function: Role of the infective burden. Atherosclerosis, 2007, 191, 227-234.	0.4	13
2296	The importance of diastolic blood pressure in predicting cardiovascular risk. Journal of the American Society of Hypertension, 2007, $1,82-93$ .	2.3	48
2297	Understanding essential hypertension from the perspective of the cardiometabolic syndrome. Journal of the American Society of Hypertension, 2007, 1, 120-134.	2.3	9
2298	Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: A three-way crossover study. Clinical Therapeutics, 2007, 29, 413-418.	1.1	33
2299	Automedida de la presión arterial. Documento de Consenso Español 2007. Revista Espanola De Geriatria Y Gerontologia, 2007, 42, 115-128.	0.2	1
2300	Automedida de la presión arterial. Documento de Consenso Español 2007. Semergen, 2007, 33, 176-187.	0.2	0
2301	Treatment of hypertension in patients with nondiabetic chronic kidney disease. Canadian Journal of Cardiology, 2007, 23, 595-601.	0.8	9
2303	Functional Vascular Endothelial Growth Factor -634G>C SNP Is Associated With Proliferative Diabetic Retinopathy: A case-control study in a Brazilian population of European ancestry. Diabetes Care, 2007, 30, 275-279.	4.3	38
2305	Study on the Responses of Hypertensive Patients to Music. , 2007, , .		5
2306	A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial. Journal of Clinical Pharmacology, 2007, 47, 1555-1569.	1.0	53
2307	Supplementation of Conventional Therapy With the Novel Grain Salba ( <i>Salvia hispanica L</i> ) Improves Major and Emerging Cardiovascular Risk Factors in Type 2 Diabetes. Diabetes Care, 2007, 30, 2804-2810.	4.3	156
2308	Severe Hypertension in the Geriatric Patientâ€"Is it an Emergency or Not?. Clinics in Geriatric Medicine, 2007, 23, 363-370.	1.0	4

#	Article	IF	CITATIONS
2310	Automedida de la presi $\tilde{A}^3$ n arterial. Documento de Consenso Espa $\tilde{A}\pm$ ol 2007. Hipertension Y Riesgo Vascular, 2007, 24, 70-83.	0.3	7
2315	Quinapril for Treatment of Hypertension in Turkey. Clinical Drug Investigation, 2007, 27, 613-622.	1.1	0
2316	BP Goal Achievement in Patients withÂUncontrolled Hypertension. Clinical Drug Investigation, 2007, 27, 783-796.	1.1	6
2317	Blood Pressure Findings in Spanish Dyslipidemic Primary-Care Patients. LIPICAP–PA Study. Revista Espanola De Cardiologia (English Ed ), 2007, 60, 825-832.	0.4	2
2318	Perindopril: the evidence of its therapeutic impact in hypertension. Core Evidence, 2007, Volume 2, 0-0.	4.7	3
2319	Neural Control of Blood Pressure: Focusing on Capsaicin-Sensitive Sensory Nerves. Cardiovascular & Hematological Disorders Drug Targets, 2007, 7, 37-46.	0.2	29
2320	Blood Pressure in Westernized and Isolated Populations. , 2007, , 21-30.		2
2321	Treatment Guidelines: The United States JNC7., 2007, , 1173-1175.		0
2322	Hypertension among Polish males during the economic transition. Economics and Human Biology, 2007, 5, 61-73.	0.7	16
2323	Vascular events after liver transplantation: a long-term follow-up study. Transplant International, 2007, 21, 070917205208001-???.	0.8	38
2324	Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease. Nephrology, 2007, 12, 294-298.	0.7	9
2325	The effect of screening for cardioâ€renal risk factors on drug use in the general population. British Journal of Clinical Pharmacology, 2007, 64, 810-818.	1.1	5
2326	Influence of the Angiotensin II Type I Receptor Gene 1166A > C Polymorphism on BP and Aortic Pulse Wave Velocity Among Malays. Annals of Human Genetics, 2007, 71, 86-95.	0.3	14
2327	A polymorphism of the aldehyde dehydrogenase 2 gene is a risk factor for multiple lacunar infarcts in Japanese men: the Takahata Study. European Journal of Neurology, 2007, 14, 428-434.	1.7	35
2328	Doppler-Derived Indexes and B-Type Natriuretic Peptide in Prediction of Paroxysmal Atrial Fibrillation in Essential Hypertension: A Prospective Study. Echocardiography, 2007, 24, 911-922.	0.3	13
2329	Impaired Functional Status and Echocardiographic Abnormalities Signifying Global Dysfunction Enhance the Prognostic Significance of Previously Unrecognized Myocardial Infarction Detected by Electrocardiography. Annals of Noninvasive Electrocardiology, 2007, 12, 27-37.	0.5	7
2330	Are Guidelines Effectively Guiding Antihypertensive Therapy?. American Journal of Cardiology, 2007, 100, 143-144.	0.7	5
2331	Comparison of Clinical Characteristics and Arterial Remodeling by Intravascular Ultrasonic Imaging in Three Age Groups (≧5, 56 to 69 and ≥70 Years) of Japanese Patients With Acute Myocardial Infarction. American Journal of Cardiology, 2007, 100, 1713-1717.	0.7	6

#	ARTICLE	IF	CITATIONS
2332	Enhancing Dosage Flexibility in Combination Therapy. Journal of Clinical Hypertension, 2007, 9, 796-799.	1.0	4
2333	Treatment of Hypertension With Thiazides: Benefit or Damage?Effect of Low- and High-Dose Thiazide Diuretics on Arterial Elasticity and Metabolic Parameters in Hypertensive Patients With and Without Glucose Intolerance. Journal of the Cardiometabolic Syndrome, 2007, 2, 16-23.	1.7	7
2334	Renal and retinal microangiopathy after 15 years of follow-up study in a sample of Type 1 diabetes mellitus patients. Journal of Diabetes and Its Complications, 2007, 21, 93-100.	1.2	48
2335	ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification. Journal of Diabetes and Its Complications, 2007, 21, 273-279.	1.2	21
2336	Diabetic macular edema and its relationship to renal microangiopathy: a sample of Type I diabetes mellitus patients in a 15-year follow-up study. Journal of Diabetes and Its Complications, 2007, 21, 172-180.	1.2	33
2337	La diabetes mellitus entendida como una enfermedad cardiovascular de origen metabólico. Revista Espanola De Cardiologia Suplementos, 2007, 7, 12H-19H.	0.2	4
2338	Low levels of awareness of suboptimal health conditions in a high-risk working population: The "better health for better Hong Kong―health promotion campaign. International Journal of Behavioral Medicine, 2007, 14, 63-69.	0.8	15
2339	Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. European Journal of Clinical Pharmacology, 2007, 63, 1055-1061.	0.8	61
2340	Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. European Journal of Clinical Pharmacology, 2007, 63, 973-978.	0.8	26
2341	Antihypertensive drug utilization at health centres in a district of Istanbul. International Journal of Clinical Pharmacy, 2007, 29, 116-121.	1.4	13
2342	Cardiovascular risk under electromagnetic exposure in physiotherapy. The Environmentalist, 2007, 27, 539-543.	0.7	12
2343	JNC-7 guidelines: Are they still relevant?. Current Hypertension Reports, 2007, 9, 380-386.	1.5	8
2344	Race-based therapeutics. Current Cardiovascular Risk Reports, 2007, 1, 108-117.	0.8	0
2345	Can a Chronic Care Model Collaborative Reduce Heart Disease Risk in Patients with Diabetes?. Journal of General Internal Medicine, 2007, 22, 215-222.	1.3	89
2346	Hypertensive Patients' Race, Health Beliefs, Process of Care, and Medication Adherence. Journal of General Internal Medicine, 2007, 22, 768-774.	1.3	93
2347	Association Between Antihypertensive Medication Use and Non-cardiovascular Outcomes in Older Men. Journal of General Internal Medicine, 2007, 22, 1661-1667.	1.3	8
2348	Development of an illustrated medication schedule as a low-literacy patient education tool. Patient Education and Counseling, 2007, 66, 368-377.	1.0	174
2349	Retinal and renal complications in patients with a mutation of mitochondrial DNA at position 3,243 (maternally inherited diabetes and deafness). A case–control study. Diabetologia, 2008, 51, 1664-1670.	2.9	37

#	Article	IF	CITATIONS
2350	Posttransplant diabetes and hypertension: Pathophysiologic insights and therapeutic rationale. Current Diabetes Reports, 2008, 8, 221-227.	1.7	3
2351	Race-based therapeutics. Current Hypertension Reports, 2008, 10, 276-285.	1.5	18
2352	Pharmacologic considerations in the positioning of $\hat{l}^2$ -blockers in antihypertensive therapy. Current Hypertension Reports, 2008, 10, 330-335.	1.5	8
2353	Does earlier attainment of blood pressure goal translate into fewer cardiovascular events?. Current Hypertension Reports, 2008, 10, 398-404.	1.5	30
2354	Impact of Computerized Decision Support on Blood Pressure Management and Control: A Randomized Controlled Trial. Journal of General Internal Medicine, 2008, 23, 429-441.	1.3	77
2355	Hypertension Management in Minority Communities: A Clinician Survey. Journal of General Internal Medicine, 2008, 23, 81-86.	1.3	10
2356	The Accuracy of Clinician Perceptions of "Usual―Blood Pressure Control. Journal of General Internal Medicine, 2008, 23, 180-183.	1.3	30
2357	Why Don't Diabetes Patients Achieve Recommended Risk Factor Targets? Poor Adherence versus Lack of Treatment Intensification. Journal of General Internal Medicine, 2008, 23, 588-594.	1.3	214
2358	The Impact of Concordant and Discordant Conditions on the Quality of Care for Hyperlipidemia. Journal of General Internal Medicine, 2008, 23, 1208-1213.	1.3	39
2359	Prehypertension: Detection, evaluation, and management. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 273-282.	0.4	2
2360	Severe Impairment of Endothelial Function with the HIV-1 Protease Inhibitor Indinavir is not Mediated by Insulin Resistance in Healthy Subjects. Cardiovascular Toxicology, 2008, 8, 15-22.	1.1	26
2361	Combining data from primary and ancillary surveys to assess the association between neighborhoodâ€level characteristics and health outcomes: the Multiâ€Ethnic Study of Artherosclerosis. Statistics in Medicine, 2008, 27, 5745-5763.	0.8	5
2362	Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study. Journal of Infection, 2008, 57, 33-40.	1.7	49
2363	Hypertension in Vascular Surgery: Aortic Dissection and Carotid Revascularization. Annals of Emergency Medicine, 2008, 51, S28-S33.	0.3	7
2364	Carbohydrate templates for the synthesis of prototype renin inhibitors. Tetrahedron: Asymmetry, 2008, 19, 2123-2129.	1.8	3
2365	Cumulative Anticholinergic Exposure Is Associated with Poor Memory and Executive Function in Older Men. Journal of the American Geriatrics Society, 2008, 56, 2203-2210.	1.3	192
2366	Insulin resistance and lichen planus in patients with HCV-infectious liver diseases. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 580-585.	1.4	32
2367	Hypomagnesaemia and risk for metabolic glucose disorders: a 10â€year followâ€up study. European Journal of Clinical Investigation, 2008, 38, 389-396.	1.7	82

#	Article	IF	CITATIONS
2368	Literacy and blood pressure $\hat{a}\in$ " do healthcare systems influence this relationship? A cross-sectional study. BMC Health Services Research, 2008, 8, 219.	0.9	26
2369	Physician Adherence to Blood Pressure Guidelines and Its Effect on Seniors. Pharmacotherapy, 2008, 28, 843-851.	1.2	27
2370	Exercise Blood Pressure and the Risk of Incident Cardiovascular Disease (from the Framingham Heart) Tj ETQq0 0	OrgBT /O	verlock 10 Tf 101
2371	Health data quality improvement by comparing administrative medical data and billing data. International Journal of Medical Informatics, 2008, 77, 527-533.	1.6	9
2372	Patient and Social Environment Factors Associated With Self Blood Pressure Monitoring by Male Veterans With Hypertension. Journal of Clinical Hypertension, 2008, 10, 692-699.	1.0	7
2373	Blood Pressure Control by Drug Group in the Antihypertensive and Lipid‣owering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of Clinical Hypertension, 2008, 10, 751-760.	1.0	80
2374	National Utilization of Antihypertensive Medications From 2000 to 2006 in the Veterans Health Administration: Focus on Thiazide Diuretics. Journal of Clinical Hypertension, 2008, 10, 770-778.	1.0	10
2375	State of Hypertension Management in the United States: Confluence of Risk Factors and the Prevalence of Resistant Hypertension. Journal of Clinical Hypertension, 2008, 10, 130-139.	1.0	97
2376	Diagnostic Thresholds for Ambulatory Blood Pressure Moving Lower: A Review Based on a Meta-Analysis—Clinical Implications. Journal of Clinical Hypertension, 2008, 10, 377-381.	1.0	34
2377	$\hat{l}^2$ -Blockers in the Treatment of Hypertension: New Data, New Directions. Journal of Clinical Hypertension, 2008, 10, 234-238.	1.0	7
2378	Ability of Blood Pressure to Predict Left Ventricular Hypertrophy in Children with Primary Hypertension. Journal of Pediatrics, 2008, 152, 73-78.e1.	0.9	166
2379	Treatment of Acute Severe Hypertension. Drugs, 2008, 68, 283-297.	4.9	140
2380	Vascular Cognitive Impairment: Prodromal Stages of Ischemic Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2008, 25, 451-460.	0.7	18
2383	Eplerenona en la disfunción cardiorrenal y bloqueo del sistema renina-angiotensina-aldosterona. Dialisis Y Trasplante, 2008, 29, 21-28.	0.4	0
2384	Cardiovascular Disease: Overview and Trends. , 2008, , 511-538.		0
2385	Blood pressure control in the year following coronary events. International Journal of Cardiology, 2008, 130, 205-210.	0.8	3
2386	Central obesity: Association with left ventricular dysfunction and mortality in the community. American Heart Journal, 2008, 156, 975-981.	1.2	78
2387	Weight Loss During the Intensive Intervention Phase of the Weight-Loss Maintenance Trial. American Journal of Preventive Medicine, 2008, 35, 118-126.	1.6	274

#	ARTICLE	IF	CITATIONS
2388	High Blood Pressure and Cardiovascular Disease Mortality Risk Among U.S. Adults: The Third National Health and Nutrition Examination Survey Mortality Follow-up Study. Annals of Epidemiology, 2008, 18, 302-309.	0.9	138
2389	Increased levels of circulating progenitor cells after 1-week sojourn at moderate altitude (Austrian) Tj ETQq1	1 0.784314 rg	gBT dOverloc
2390	A possible association between aldosterone response to vasopressin and circadian change of aldosterone in the patients with aldosterone-producing adenoma. Peptides, 2008, 29, 2225-2231.	1.2	4
2391	Maternally inherited hypertension is associated with the mitochondrial tRNAlle A4295G mutation in a Chinese family. Biochemical and Biophysical Research Communications, 2008, 367, 906-911.	1.0	43
2392	The mitochondrial ND1 T3308C mutation in a Chinese family with the secondary hypertension. Biochemical and Biophysical Research Communications, 2008, 368, 18-22.	1.0	22
2393	Electronic Communications and Home Blood Pressure Monitoring (e-BP) study: Design, delivery, and evaluation framework. Contemporary Clinical Trials, 2008, 29, 376-395.	0.8	49
2394	The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: A 3-year, randomized, multicenter, double-blind, placebo-controlled study. Clinical Therapeutics, 2008, 30, 482-498.	1.1	35
2395	Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: A single-center, 4-year, open-label study. Clinical Therapeutics, 2008, 30, 1120-1134.	1.1	24
2396	Implications of increased weight and waist circumference on vascular risk in an older Chinese population: The Guangzhou Biobank Cohort Study. Atherosclerosis, 2008, 196, 682-688.	0.4	9
2397	Thirty-year survival for black and white hypertensive individuals in the Evans County Heart Study and the Hypertension Detection and Follow-up Program. Journal of the American Society of Hypertension, 2008, 2, 448-454.	2.3	23
2398	The ADVANCE trial. Lancet, The, 2008, 371, 25.	6.3	6
2399	Prevalence and Determinants of Hypertension in a Rural Community. Medical Journal Armed Forces India, 2008, 64, 21-25.	0.3	23
2400	Traitement de l'hypertension artérielle. , 2008, , 41-71.		0
2401	Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Annals of the Rheumatic Diseases, 2008, 67, 64-69.	0.5	277
2402	Standardizing blood pressure measurement - is it possible?. , 2008, , .		1
2403	The long-term effect of music on hypertensive patients. , 2008, , .		1
2404	Why Are We Still Measuring Blood Pressure by Ear?. , 2008, , .		2
2405	Aortic Root Diameter and Longitudinal Blood Pressure Tracking. Hypertension, 2008, 52, 473-477.	1.3	16

#	Article	IF	CITATIONS
2406	Prevalence of smoking and its relationship with carotid atherosclerosis in Alaskan Eskimos of the Norton Sound region: The GOCADAN Study. Nicotine and Tobacco Research, 2008, 10, 483-491.	1.4	13
2407	Serum magnesium and C-reactive protein levels. Archives of Disease in Childhood, 2008, 93, 676-680.	1.0	47
2408	Long-Term Stroke Prognosis in Relation to Medical Prevention and Lifestyle Factors. Cerebrovascular Diseases, 2008, 25, 526-532.	0.8	21
2409	Chronic Bronchitis and Acute Infections as New Risk Factors for Ischemic Stroke and the Lack of Protection Offered by the Influenza Vaccination. Cerebrovascular Diseases, 2008, 26, 339-347.	0.8	32
2410	Peripheral artery disease: therapeutic advances. Expert Review of Cardiovascular Therapy, 2008, 6, 539-553.	0.6	18
2411	Screening for Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 616-623.	2.2	89
2412	Dyslipidaemia as a predictor of hypertension in middle-aged men. European Heart Journal, 2008, 29, 2561-2568.	1.0	121
2413	Disparities between persons with and without disabilities in their participation rates in mass screening. European Journal of Public Health, 2008, 19, 85-90.	0.1	34
2414	Predicting Stroke Risk in Hypertensive Patients With Coronary Artery Disease. Stroke, 2008, 39, 343-348.	1.0	29
2415	Methodological Overview of an African American Couple-Based HIV/STD Prevention Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, S3-S14.	0.9	18
2416	Increased Blood Pressure Levels Relative to Subjective Feelings of Intensity of Exercise Determined with the Borg Scale in Male Patients with Hypertension. Clinical and Experimental Hypertension, 2008, 30, 191-201.	0.5	5
2417	Guidelines for the management of chronic kidney disease. Cmaj, 2008, 179, 1154-1162.	0.9	280
2418	Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ: British Medical Journal, 2008, 336, 1114-1117.	2.4	684
2419	Screening, Treatment, and Control of Hypertension in US Private Physician Offices, 2003–2004. Hypertension, 2008, 51, 1275-1281.	1.3	43
2420	Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?. Current Cardiology Reviews, 2008, 4, 22-33.	0.6	7
2421	The relationship between dietary protein intake and blood pressure: results from the PREMIER study. Journal of Human Hypertension, 2008, 22, 745-754.	1.0	75
2422	â€~Induction of inflammatory gene expression by THP-1 macrophages cultured in normocholesterolaemic hypertensive sera and modulatory effects of green tea polyphenols'. Journal of Human Hypertension, 2008, 22, 141-143.	1.0	19
2424	Adherence to the Mediterranean Diet Is Inversely Associated With Circulating Interleukin-6 Among Middle-Aged Men. Circulation, 2008, 117, 169-175.	1.6	122

#	Article	IF	CITATIONS
2425	Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology, 2008, 48, 250-253.	0.9	134
2426	Coronary Artery Calcification Compared With Carotid Intima-Media Thickness in the Prediction of Cardiovascular Disease Incidence <subtitle>The Multi-Ethnic Study of Atherosclerosis (MESA)</subtitle> . Archives of Internal Medicine, 2008, 168, 1333.	4.3	635
2427	Deteriorating Dietary Habits Among Adults With Hypertension. Archives of Internal Medicine, 2008, 168, 308.	4.3	316
2428	No Impairment of Endothelial Function or Insulin Sensitivity with 4 Weeks of the HIV Protease Inhibitors Atazanavir or Lopinavirâ€Ritonavir in Healthy Subjects without HIV Infection: A Placeboâ€Controlled Trial. Clinical Infectious Diseases, 2008, 47, 567-574.	2.9	62
2429	Thiazide-Type Diuretics and $\hat{l}^2$ -Adrenergic Blockers as First-Line Drug Treatments for Hypertension. Circulation, 2008, 117, 2691-2705.	1.6	46
2430	Cash Component of Conditional Cash Transfer Program Is Associated with Higher Body Mass Index and Blood Pressure in Adults. Journal of Nutrition, 2008, 138, 2250-2257.	1.3	93
2431	Design considerations and rationale of a multi-center trial to sustain weight loss: the weight loss maintenance trial. Clinical Trials, 2008, 5, 546-556.	0.7	46
2432	Renal Insufficiency and Mortality in Patients with Known or Suspected Coronary Artery Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 158-163.	3.0	66
2433	Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes. JAMA - Journal of the American Medical Association, 2008, 299, 1678.	3.8	217
2434	Blood Pressure Control and Pharmacotherapy Patterns in the United States Before and After the Release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) Guidelines. Journal of the American Board of Family Medicine, 2008, 21, 512-521.	0.8	40
2435	Cognitive function and blood pressure control in hypertensive patients over 60 years of age: COGNIPRES study. Current Medical Research and Opinion, 2008, 24, 3331-3340.	0.9	44
2436	Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension. Current Medical Research and Opinion, 2008, 24, 2863-2871.	0.9	6
2437	Evaluation of a workplace health program to reduce coronary risk factors. Clinical Governance, 2008, 13, 95-105.	0.4	11
2438	Weight-reducing drug therapy and hypertension. Therapy: Open Access in Clinical Medicine, 2008, 5, 779-785.	0.2	2
2439	What role do lay beliefs about hypertension etiology play in perceptions of medication effectiveness?. Health Psychology, 2008, 27, 320-326.	1.3	19
2440	Assessment of Aortic Atheromatous Plaque and Stiffness by 64-Slice Computed Tomography is Useful for Identifying Patients With Coronary Artery Disease. Circulation Journal, 2008, 72, 2021-2027.	0.7	14
2441	Interindividual variation in serum sodium and longitudinal blood pressure tracking in the Framingham Heart Study. Journal of Hypertension, 2008, 26, 2121-2125.	0.3	23
2442	Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. Yearbook of Medicine, 2008, 2008, 347-349.	0.1	0

#	Article	IF	CITATIONS
2443	Left ventricular mass and incident hypertension in individuals with initial optimal blood pressure: the Strong Heart Study. Journal of Hypertension, 2008, 26, 1868-1874.	0.3	25
2444	Blood pressure reduction due to hemoglobin glycosylation in type 2 diabetic patients. Vascular Health and Risk Management, 2008, Volume 4, 917-922.	1.0	7
2445	Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vascular Health and Risk Management, 2008, Volume 4, 1159-1166.	1.0	14
2446	<b>Significance of Pulsatility of Brachial Artery Pressure for Blood Pressure Control</b> . International Heart Journal, 2008, 49, 295-302.	0.5	0
2447	Adherence to International Guidelines in the Management of Hypertension in a Tertiary Hospital in Nigeria. Tropical Journal of Pharmaceutical Research, 2008, 7, .	0.2	15
2448	Hypertension Management in the District Hospitals in Dar es Salaam, Tanzania. East and Central African Journal of Pharmaceutical Sciences, 2008, 10, .	0.1	0
2449	Perioperative hypertension management. Vascular Health and Risk Management, 2008, Volume 4, 615-627.	1.0	148
2450	Rates and Related Factors of Progression to Hypertension among Prehypertensive Local Residents Aged 45 or Over in Chuncheon City: Hallym Aging Study from a Community-Based Cross-Sectional Study. Korean Circulation Journal, 2008, 38, 43.	0.7	6
2451	The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target. Vascular Health and Risk Management, 2008, Volume 4, 1315-1325.	1.0	30
2452	Cardiovascular Risk Factors and Its Management. TAJ Journal of Teachers Association, 2009, 20, 71-78.	0.1	0
2453	Prescribing Patterns and Cost of Antihypertensive Drugs in Private Hospitals in Dar es Salaam, Tanzania. East and Central African Journal of Pharmaceutical Sciences, 2009, 11, .	0.1	7
2454	Therapeutic Strategies for Diastolic Dysfunction: A Clinical Perspective. Journal of Cardiovascular Imaging, 2009, 17, 86.	0.8	19
2455	BDNF val66met polymorphism influences age differences in microstructure of the corpus callosum. Frontiers in Human Neuroscience, 2009, 3, 19.	1.0	37
2456	Predicting New Onset Diabetes Mellitus in Older Taiwanese: Metabolic Syndrome or Impaired Fasting Glucose?. Journal of Atherosclerosis and Thrombosis, 2009, 16, 627-632.	0.9	13
2457	Measurement of Blood Pressure using magnetic method of blood pulse acquisition., 2009,,.		6
2458	Obesity and Hypertension. Obesity Management, 2009, 5, 57-61.	0.2	4
2459	Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community. Circulation, 2009, 119, 1101-1107.	1.6	58
2460	What do studies of diet patterns tell us?. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 567-568.	8.2	2

#	Article	IF	CITATIONS
2461	Internationally recognized guidelines for 'sensible' alcohol consumption: is exceeding them actually detrimental to health and social circumstances? Evidence from a population-based cohort study. Journal of Public Health, 2009, 31, 360-365.	1.0	20
2462	Single Versus Combined Blood Pressure Components and Risk for Cardiovascular Disease. Circulation, 2009, 119, 243-250.	1.6	287
2463	Shifting the Disease Management Paradigm From Glucose: What are the pros?. Diabetes Care, 2009, 32, S349-S352.	4.3	6
2464	Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. European Heart Journal, 2009, 30, 1395-1401.	1.0	86
2465	Lipoprotein-Associated Phospholipase A <sub>2</sub> and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 2009, 40, 376-381.	1.0	79
2466	Racial Differences in Vascular Risk Factors and Outcomes of Patients With Intracranial Atherosclerotic Arterial Stenosis. Stroke, 2009, 40, 719-725.	1.0	51
2467	Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). Journal of Human Hypertension, 2009, 23, 196-210.	1.0	34
2468	Can Individuals Meet Multiple Physical Activity and Dietary Behavior Goals. American Journal of Health Behavior, 2009, 33, 277-86.	0.6	20
2469	Endothelium-specific overexpression of human IC53 downregulates endothelial nitric oxide synthase activity and elevates systolic blood pressure in mice. Cardiovascular Research, 2009, 84, 292-299.	1.8	7
2470	Quality Health Care and Health Communication: An Ethical and Societal Challenge. Journal of Health Communication, 2009, 14, 311-314.	1.2	1
2471	Initial combination therapy for rapid and effective control of moderate and severe hypertension. Journal of Human Hypertension, 2009, 23, 4-11.	1.0	14
2472	Failures in Mitochondrial tRNA <sup>Met</sup> and tRNA <sup>Gln</sup> Metabolism Caused by the Novel 4401A>G Mutation Are Involved in Essential Hypertension in a Han Chinese Family. Hypertension, 2009, 54, 329-337.	1.3	65
2473	Allostatic Load and Frailty in the Women's Health and Aging Studies. Biological Research for Nursing, 2009, 10, 248-256.	1.0	63
2474	Isolated Systolic Hypertension and Incident Heart Failure in Older Adults. Hypertension, 2009, 53, 458-465.	1.3	65
2475	Lifestyle Interventions Reduce Coronary Heart Disease Risk. Circulation, 2009, 119, 2026-2031.	1.6	216
2476	Genetic Effect on Blood Pressure Is Modulated by Age. Hypertension, 2009, 53, 35-41.	1.3	56
2477	Characteristics and Outcomes of Revascularized Patients With Hypertension. Hypertension, 2009, 53, 624-630.	1.3	8
2478	Blood Pressure Control Among Persons Without and With Chronic Kidney Disease. Hypertension, 2009, 54, 47-56.	1.3	121

#	Article	IF	Citations
2479	Aging white matter and cognition: Differential effects of regional variations in diffusion properties on memory, executive functions, and speed. Neuropsychologia, 2009, 47, 916-927.	0.7	398
2480	Obesity and its associations with hypertension and type 2 diabetes among Chinese adults age 40 years and over. Nutrition, 2009, 25, 1143-1149.	1.1	39
2481	Clinical Foundation for Efficient Treatment of Obstructive Sleep Apnea. Journal of Oral and Maxillofacial Surgery, 2009, 67, 2171-2182.	0.5	9
2482	Changes in the diabetic retinopathy epidemiology after 14 years in a population of Type 1 and 2 diabetic patients after the new diabetes mellitus diagnosis criteria and a more strict control of the patients. Journal of Diabetes and Its Complications, 2009, 23, 229-238.	1.2	40
2483	Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. Journal of Diabetes and Its Complications, 2009, 23, 349-359.	1.2	18
2484	JNC 8: Expectations, Challenges, and Wishes-A Primary Care Perspective. Journal of Clinical Hypertension, 2009, 11, 573-576.	1.0	2
2485	Pattern of normal age-related regional differences in white matter microstructure is modified by vascular risk. Brain Research, 2009, 1297, 41-56.	1.1	172
2486	Predictors of work ability in occupations with psychological stress. Zeitschrift Fur Gesundheitswissenschaften, 2009, 17, 9-18.	0.8	45
2487	Relationship between cardiovascular risk factors and high blood pressure by community pharmacists in Spain. International Journal of Clinical Pharmacy, 2009, 31, 406-412.	1.4	4
2488	Recommendations for global hypertension monitoring and prevention. Current Hypertension Reports, 2009, 11, 444-449.	1.5	24
2489	Hypertension Guideline Adherence Among Nursing Home Patients. Journal of General Internal Medicine, 2009, 24, 499-503.	1.3	14
2490	Time trends in the use of antiâ€hypertensive medications: results from the Multiâ€Ethnic Study of Atherosclerosis. Pharmacoepidemiology and Drug Safety, 2009, 18, 826-832.	0.9	5
2491	Hypertension Improvement Project (HIP): study protocol and implementation challenges. Trials, 2009, 10, 13.	0.7	40
2492	Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials, 2009, 10, 5.	0.7	672
2493	Reverse modulation of the HDL Anionic Peptide Factor and phospholipid transfer protein activity in coronary artery disease and type 2 diabetes mellitus. Clinical Biochemistry, 2009, 42, 845-851.	0.8	14
2494	Urbanization and the spread of diseases of affluence in China. Economics and Human Biology, 2009, 7, 200-216.	0.7	115
2495	Urinary incontinence in community-dwelling older Mexican American and European American women. Archives of Gerontology and Geriatrics, 2009, 48, 232-237.	1.4	8
2496	Systolic Blood Pressure and Subjective Wellâ€Being in Patients with Coronary Artery Disease. Clinical Cardiology, 2009, 32, 627-632.	0.7	15

#	Article	IF	CITATIONS
2497	Introduction: The European INVESTigators meeting. Clinical Cardiology, 2001, 24, A6-A6.	0.7	2
2498	Characteristics of patients with coronary artery disease and hypertension: A report from INVEST. Clinical Cardiology, 2001, 24, V-6-V-8.	0.7	0
2499	INVEST substudies: Design and patient characteristics. Clinical Cardiology, 2001, 24, V-9-V-11.	0.7	3
2500	How will INVEST and other hypertension trials change clinical practice?. Clinical Cardiology, 2009, 24, V-24-V-29.	0.7	5
2501	What is Next for the Dietary Reference Intakes for Bone Metabolism Related Nutrients Beyond Calcium: Phosphorus, Magnesium, Vitamin D, and Fluoride?. Critical Reviews in Food Science and Nutrition, 2009, 49, 136-144.	5.4	52
2502	Helplessness predicts the development of hypertension in older Mexican and European Americans. Journal of Psychosomatic Research, 2009, 67, 333-337.	1.2	14
2503	Association between epistaxis and hypertension: A one year follow-up after an index episode of nose bleeding in hypertensive patients. International Journal of Cardiology, 2009, 134, e107-e109.	0.8	36
2504	Metabolic Syndrome Is Associated with Intracranial Large Artery Disease among Ethnic Chinese Patients with Stroke. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 424-427.	0.7	18
2505	Therapeutic Interventions and Success in Risk Factor Control for Secondary Prevention of Stroke. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 460-465.	0.7	36
2506	The Effect of a Hypertension Self-Management Intervention on Diabetes and Cholesterol Control. American Journal of Medicine, 2009, 122, 639-646.	0.6	19
2507	Effect of Treatment and Adherence on Ethnic Differences in Blood Pressure Control Among Adults with Hypertension. Annals of Epidemiology, 2009, 19, 172-179.	0.9	26
2508	A Systematic Review of the Management of Autonomic Dysreflexia After Spinal Cord Injury. Archives of Physical Medicine and Rehabilitation, 2009, 90, 682-695.	0.5	330
2509	Salt taste sensitivity threshold and exercise-induced hypertension. Appetite, 2009, 52, 609-613.	1.8	21
2510	Components of metabolic syndrome and the incidence of type 2 diabetes in an elderly Taiwanese cohort. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2009, 3, 90-95.	1.8	4
2512	Ethnic South Asian ischaemic stroke patients have a higher prevalence of a family history of vascular disease compared to age, gender and diabetes-matched ethnic Chinese subjects. Journal of the Neurological Sciences, 2009, 285, 118-120.	0.3	7
2513	Combined hyperlipidemia in relation to race/ethnicity, obesity, and insulin resistance in the Multi-Ethnic Study of Atherosclerosis. Metabolism: Clinical and Experimental, 2009, 58, 212-219.	1.5	32
2514	Effectiveness and Tolerability of Fixed-Dose Combination Enalapril plus Nitrendipine in Hypertensive Patients. Clinical Drug Investigation, 2009, 29, 459-469.	1.1	5
2515	Effect of Slow- and Fast-Breathing Exercises on Autonomic Functions in Patients with Essential Hypertension. Journal of Alternative and Complementary Medicine, 2009, 15, 711-717.	2.1	105

#	Article	IF	CITATIONS
2517	Hypertension and Cognitive Function. Clinics in Geriatric Medicine, 2009, 25, 259-288.	1.0	55
2518	Swimming Exercise. Sports Medicine, 2009, 39, 377-387.	3.1	69
2519	Mitochondrial Transfer RNA <sup>Met</sup> 4435A> G Mutation Is Associated With Maternally Inherited Hypertension in a Chinese Pedigree. Hypertension, 2009, 53, 1083-1090.	1.3	82
2520	Blood Pressure-Lowering Effects of Angiotensin Receptor Antagonist Monotherapy and in Combination with Other Anti-Hypertensive Drugs in Primary Care Settings in Japan. Clinical and Experimental Hypertension, 2009, 31, 127-141.	0.5	5
2521	INVEST revisited: review of findings from the International Verapamil SR–Trandolapril Study. Expert Review of Cardiovascular Therapy, 2009, 7, 1329-1340.	0.6	36
2522	Influence of Guidelines on Physicians' Assessment of Blood Pressure Lowering Effects and Achievement Rate of Blood Pressure Target During Transitional Period of Guidelines. Clinical and Experimental Hypertension, 2009, 31, 116-126.	0.5	2
2523	Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis, 2009, 207, 597-602.	0.4	61
2524	Comparison of Information Content of Structured and Narrative Text Data Sources on the Example of Medication Intensification. Journal of the American Medical Informatics Association: JAMIA, 2009, 16, 362-370.	2.2	40
2526	Hypertension: Reflections on Risks and Prognostication. Medical Clinics of North America, 2009, 93, 541-558.	1.1	62
2527	Treatment Intensification and Risk Factor Control. Medical Care, 2009, 47, 395-402.	1.1	68
2528	Blood pressure, atherosclerosis, and albuminuria in 10 113 participants in the Atherosclerosis Risk In Communities study. Journal of Hypertension, 2009, 27, 397-409.	0.3	28
2529	Long-term Effects of Renin-Angiotensin System–Blocking Therapy and a Low Blood Pressure Goal on Progression of Hypertensive Chronic Kidney Disease in African Americans. Yearbook of Cardiology, 2009, 2009, 47-48.	0.0	1
2530	Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial. Yearbook of Cardiology, 2009, 2009, 51-53.	0.0	0
2531	Hormonal Therapy Use for Prostate Cancer and Mortality in Men With Coronary Artery Disease–Induced Congestive Heart Failure or Myocardial Infarction. JAMA - Journal of the American Medical Association, 2009, 302, 866.	3.8	256
2532	Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. Yearbook of Cardiology, 2009, 2009, 49-51.	0.0	0
2533	Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus. Yearbook of Cardiology, 2009, 2009, 111-113.	0.0	0
2535	Treatment blood pressure targets for hypertension. Yearbook of Cardiology, 2010, 2010, 37-39.	0.0	0
2536	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Yearbook of Cardiology, 2010, 2010, 67-68.	0.0	0

#	Article	IF	CITATIONS
2537	Alterations in capillary morphology are found in mild blood pressure elevation. Journal of Hypertension, 2010, 28, 2258-2266.	0.3	11
2538	Validation of the Stanford Brief Activity Survey: Examining Psychological Factors and Physical Activity Levels in Older Adults. Journal of Physical Activity and Health, 2010, 7, 87-94.	1.0	62
2541	Modulation of Gene Expression by Polyalthia longifolia in Postmenopausal Women with Coronary Artery Disease: An In Vitro Study. Journal of Cardiovascular Translational Research, 2010, 3, 570-579.	1.1	2
2542	Effects of the PREMIER Interventions on Health-Related Quality of Life. Annals of Behavioral Medicine, 2010, 40, 302-312.	1.7	22
2543	Increased occurrence of cardiovascular events and comorbidities in a general rheumatology cohort. Irish Journal of Medical Science, 2010, 179, 273-276.	0.8	2
2544	Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification. International Journal of Cardiovascular Imaging, 2010, 26, 459-468.	0.7	68
2545	Alcohol Drinking May Not Be a Major Risk Factor for Fatty Liver in Japanese Undergoing a Health Checkup. Digestive Diseases and Sciences, 2010, 55, 176-182.	1.1	31
2546	Heritability of Measures of Kidney Disease Among Zuni Indians: The Zuni Kidney Project. American Journal of Kidney Diseases, 2010, 56, 289-302.	2.1	35
2547	Overweight, obesity, and their associations with insulin resistance and $\hat{l}^2$ -cell function among Chinese: a cross-sectional study in China. Metabolism: Clinical and Experimental, 2010, 59, 1823-1832.	1.5	28
2548	A community-based study of hypertension and cardio-metabolic syndrome in semi-urban and rural communities in Nigeria. BMC Health Services Research, 2010, 10, 71.	0.9	116
2549	Construct validity of a continuous metabolic syndrome score in children. Diabetology and Metabolic Syndrome, 2010, 2, 8.	1.2	101
2550	Patterns of Antihypertensive Treatment in Patients with Acute Severe Hypertension from a Nonneurologic Cause: Studying the Treatment of Acute Hypertension (STAT) Registry. Pharmacotherapy, 2010, 30, 1087-1096.	1.2	14
2551	Estrogen Receptor Beta Genetic Variants and Combined Oral Contraceptive Use as Relates to the Risk of Hypertension in Chinese Women. Archives of Medical Research, 2010, 41, 599-605.	1.5	10
2552	Alternative Strategies for the Management of Chronic Stable Angina. Current Problems in Cardiology, 2010, 35, 384-446.	1.1	6
2553	Association of Capillary Density and Function Measures With Blood Pressure, Fasting Plasma Glucose, and Insulin Sensitivity. Journal of Clinical Hypertension, 2010, 12, 125-135.	1.0	18
2554	Predicted Coronary Heart Disease Risk Reduction and Dual Blood Pressure/Cholesterol Goal Attainment in Patients With Hypertension Treated in Realâ€World Clinical Practice. Journal of Clinical Hypertension, 2010, 12, 396-406.	1.0	3
2555	Effects of Continuous and Interval Training Programs in the Management of Hypertension: A Randomized Controlled Trial. Journal of Clinical Hypertension, 2010, 12, 841-849.	1.0	25
2556	Metabolic characteristics of breakfast-vegetarian (BV) elderly people in rural Taiwan. Archives of Gerontology and Geriatrics, 2010, 50, 20-23.	1.4	4

#	Article	IF	CITATIONS
2557	High density lipoprotein-anionic peptide factor effect on reverse cholesterol transport in type 2 diabetic patients with and without coronary artery disease. Clinical Biochemistry, 2010, 43, 1079-1084.	0.8	4
2558	Randomized trial of achieving healthy lifestyles in psychiatric rehabilitation: the ACHIEVE trial. BMC Psychiatry, 2010, 10, 108.	1.1	34
2559	Lower Frailty Incidence in Older Mexican Americans than in Older European Americans: The San Antonio Longitudinal Study of Aging. Journal of the American Geriatrics Society, 2010, 58, 2142-2148.	1.3	44
2560	The competence of primary care doctors in the investigation of patients with elevated blood pressure: results of a crossâ€sectional study using clinical vignettes. Journal of Evaluation in Clinical Practice, 2010, 16, 784-789.	0.9	4
2561	Effect of combined angiotensinâ€converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients. Nephrology, 2010, 15, 211-215.	0.7	7
2562	Cardioprotective and β-adrenoceptor antagonistic activity of a newly synthesized aryloxypropanolamine derivative PP-36. Journal of Experimental Pharmacology, 2010, 2, 37.	1.5	1
2563	Prehypertension Among Middle-Aged and Elderly People in Taiwan: A Five-Year Follow-Up. Journal of Atherosclerosis and Thrombosis, 2010, 17, 189-194.	0.9	17
2564	Hypertensive Retinopathy and Associated Target Organ Damage in Korean Hypertensive Patients. Journal of Korean Ophthalmological Society, 2010, 51, 1231.	0.0	2
2565	Advanced Glycation End Product-Mediated Matrix Metallo-proteinase-9 and Apoptosis via Renin-Angiotensin System in Type 2 Diabetes. Journal of Atherosclerosis and Thrombosis, 2010, 17, 578-589.	0.9	21
2566	The Heart Failure Epidemic. International Journal of Environmental Research and Public Health, 2010, 7, 1807-1830.	1.2	130
2567	Intra-Arterial Blood Pressure Response in Hypertensive Subjects during Low- and High-Intensity Resistance Exercise. Clinics, 2010, 65, 271-277.	0.6	76
2568	High-sensitivity C-reactive protein and liver enzymes in individuals with Metabolic Syndrome in Talca, Chile. Experimental and Therapeutic Medicine, 2010, 1, 175-179.	0.8	6
2569	Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control. Integrated Blood Pressure Control, 2010, 3, 133.	0.4	3
2570	US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008. JAMA - Journal of the American Medical Association, 2010, 303, 2043.	3.8	1,689
2571	Continuous positive airway pressure titration for obstructive sleep apnoea: automatic versus manual titration. Thorax, 2010, 65, 606-611.	2.7	38
2572	A Randomized Trial of Cholecalciferol versus Doxercalciferol for Lowering Parathyroid Hormone in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 299-306.	2.2	67
2573	Encounter Frequency and Blood Pressure in Hypertensive Patients With Diabetes Mellitus. Hypertension, 2010, 56, 68-74.	1.3	53
2574	Effects of the Dietary Approaches to Stop Hypertension Diet Alone and in Combination With Exercise and Caloric Restriction on Insulin Sensitivity and Lipids. Hypertension, 2010, 55, 1199-1205.	1.3	128

#	Article	IF	CITATIONS
2575	Effects of Adult Age and Blood Pressure on Executive Function and Speed of Processing. Experimental Aging Research, 2010, 36, 153-168.	0.6	58
2576	Clinical correlates of renal dysfunction in hypertensive patients without cardiovascular complications: the REDHY study. Journal of Human Hypertension, 2010, 24, 44-50.	1.0	16
2577	The epidemiology and management of severe hypertension. Journal of Human Hypertension, 2010, 24, 9-18.	1.0	12
2578	Blood pressure directly correlates with blood viscosity in diabetes type 1 children but not in normals. Clinical Hemorheology and Microcirculation, 2010, 44, 55-61.	0.9	27
2579	Microalbuminuria and its relations with serum lipid abnormalities in adult Nigerians with newly diagnosed hypertension. Annals of African Medicine, 2010, 9, 62.	0.2	3
2580	A comparative study of nebivolol and (S) atenolol on blood pressure and heart rate on essential hypertensive patients. Indian Journal of Pharmacology, 2010, 42, 401.	0.4	2
2581	Effects of Prehypertension on Arterial Stiffness and Wave Reflections. Clinical and Experimental Hypertension, 2010, 32, 84-89.	0.5	41
2582	Self blood pressure monitoring: a worthy substitute for ambulatory blood pressure?. Journal of Human Hypertension, 2010, 24, 801-806.	1.0	30
2583	Effects of the DASH Diet Alone and in Combination With Exercise and Weight Loss on Blood Pressure and Cardiovascular Biomarkers in Men and Women With High Blood Pressure. Archives of Internal Medicine, 2010, 170, 126.	4.3	459
2584	Trajectories of Neighborhood Poverty and Associations With Subclinical Atherosclerosis and Associated Risk Factors: The Multi-Ethnic Study of Atherosclerosis. American Journal of Epidemiology, 2010, 171, 1099-1108.	1.6	61
2585	Implementation of portable monitor based on mobile phone for music therapy on hypertension. , 2010, ,		1
2586	Evidence that prehypertension is a risk factor for Type 2 diabetes. Expert Review of Cardiovascular Therapy, 2010, 8, 335-337.	0.6	5
2587	Quality Improvement Guidelines for Angiography, Angioplasty, and Stent Placement for the Diagnosis and Treatment of Renal Artery Stenosis in Adults. Journal of Vascular and Interventional Radiology, 2010, 21, 421-430.	0.2	24
2589	A secondary prevention lipid clinic reaches low-density lipoprotein cholesterol goals more often than usual cardiology care with coronary heart disease. Journal of Clinical Lipidology, 2010, 4, 46-52.	0.6	6
2590	Economic analysis of the diabetes and hypertension screening collaboration between community pharmacies and a Thai government primary care unit. Primary Care Diabetes, 2010, 4, 155-164.	0.9	15
2591	Trajectories of brain aging in middle-aged and older adults: Regional and individual differences. Neurolmage, 2010, 51, 501-511.	2.1	504
2592	Amlodipine/Atorvastatin. Drugs, 2010, 70, 191-213.	4.9	28
2593	Is newer always better? Re-evaluating the benefits of newer pharmaceuticals. Journal of Health Economics, 2010, 29, 743-750.	1.3	8

#	Article	IF	CITATIONS
2594	Hypertension and Cognitive Function in the Elderly. Disease-a-Month, 2010, 56, 106-147.	0.4	35
2595	Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. Biochemical and Biophysical Research Communications, 2010, 403, 258-263.	1.0	27
2596	Cardiovascular disease prevalence and its relation to risk factors in Alaska Eskimos. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 350-358.	1.1	38
2597	The Effect of Nutrition on Blood Pressure. Annual Review of Nutrition, 2010, 30, 365-401.	4.3	<b>17</b> 3
2598	The Multicenter Uveitis Steroid Treatment Trial: Rationale, Design, and Baseline Characteristics. American Journal of Ophthalmology, 2010, 149, 550-561.e10.	1.7	179
2599	Serum Uric Acid Levels and the Risk of Type 2 Diabetes: A Prospective Study. American Journal of Medicine, 2010, 123, 957-961.	0.6	237
2600	El ejercicio fÃsico como terapia complementaria en el cÃ;ncer de próstata. Apunts Medicine De L'Esport, 2010, 45, 81-93.	0.5	6
2601	New cardiovascular risk factors and physical activity. Apunts Medicine De L'Esport, 2010, 45, 201-208.	0.5	4
2602	Leukocyte count is associated with incidence of coronary events, but not with stroke: A prospective cohort study. Atherosclerosis, 2010, 209, 545-550.	0.4	23
2603	Agency Social Workers Could Monitor Hypertension in the Community. Social Work in Health Care, 2010, 49, 424-443.	0.8	4
2604	Blood pressure lowering in patients with diabetesâ€"one level might not fit all. Nature Reviews Cardiology, 2011, 8, 42-49.	6.1	16
2605	Hypertension in the Pediatric Intensive Care Unit., 2011,, 1043-1057.		0
2606	A Genetic Variant of the Atrial Natriuretic Peptide Gene Is Associated With Cardiometabolic Protection in the General Community. Journal of the American College of Cardiology, 2011, 58, 629-636.	1.2	91
2607	Effectiveness of motivational interviewing and physical activity on prescription on leisure exercise time in subjects suffering from mild to moderate hypertension. BMC Research Notes, 2011, 4, 352.	0.6	19
2609	Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of people with type 1 diabetes. Diabetes Research and Clinical Practice, 2011, 94, 126-132.	1,1	40
2610	I. Stroke in General. Journal of Stroke and Cerebrovascular Diseases, 2011, 20, S7-S30.	0.7	22
2612	Treatment of hypertension in the emergency department. Journal of the American Society of Hypertension, 2011, 5, 366-377.	2.3	29
2613	Prevalence of Early Stages of Chronic Kidney Disease in Healthy Army Personnel. Medical Journal Armed Forces India, 2011, 67, 9-14.	0.3	10

#	Article	IF	CITATIONS
2614	Heart Failure as a Consequence of Hypertension. , 2011, , 435-444.		0
2615	Hypertensive emergency as a complication of brachial plexus block. BMJ Case Reports, 2011, 2011, bcr0120113754-bcr0120113754.	0.2	4
2617	Community-Based Participatory Research Approaches for Hypertension Control and Prevention in Churches. International Journal of Hypertension, 2011, 2011, 1-11.	0.5	10
2618	Knowledge of Hypertensive Patients With or Without HIV on Hypertension and Their Experience in Using Their Medicines in Dar es Salaam, Tanzania: The Role of the Pharmacist. Tropical Journal of Pharmaceutical Research, 2011, 10, .	0.2	2
2619	Post-resistance exercise hypotension in patients with intermittent claudication. Clinics, 2011, 66, 221-226.	0.6	19
2620	Prognosis after Stroke. , 2011, , 219-241.		5
2622	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. Yearbook of Cardiology, 2011, 2011, 67-69.	0.0	0
2623	Systematic Review: Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect Modifier. Annals of Internal Medicine, 2011, 154, 541.	2.0	292
2624	The effects of progressive exercise on cardiovascular function in elite athletes: Focus on oxidative stress. Acta Physiologica Hungarica, 2011, 98, 51-58.	0.9	13
2625	Body fat distribution and their associations with cardiovascular risk, insulin resistance and $\hat{l}^2$ -cell function: are there differences between men and women?. International Journal of Clinical Practice, 2011, 65, 592-601.	0.8	9
2626	Blood pressure reference intervals for healthy adult chimpanzees (Pan troglodytes). Journal of Medical Primatology, 2011, 40, 171-180.	0.3	20
2627	Association between attention-deficit/hyperactivity disorder symptoms and obesity and hypertension in early adulthood: a population-based study. International Journal of Obesity, 2011, 35, 852-862.	1.6	95
2628	Physical Exercise With Weight Reduction Lowers Blood Pressure and Improves Abnormal Left Ventricular Relaxation in Pharmacologically Treated Hypertensive Patients. Journal of Clinical Hypertension, 2011, 13, 23-29.	1.0	19
2629	Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience. Journal of Diabetes and Its Complications, 2011, 25, 362-367.	1.2	9
2630	Affective temperamental profiles are associated with white matter hyperintensity and suicidal risk in patients with mood disorders. Journal of Affective Disorders, 2011, 129, 47-55.	2.0	90
2631	Development of new concepts of non-adherence measurements among users of antihypertensives medicines. International Journal of Clinical Pharmacy, 2011, 33, 565-572.	1.0	14
2632	Antihypertensive medication adherence in cancer survivors and its affecting factors: results of a Korean population-based study. Supportive Care in Cancer, 2011, 19, 211-220.	1.0	39
2633	Dyslipidaemia Associated with Type 2 Diabetics with Micro and Macrovascular Complications among Ghanaians. Indian Journal of Clinical Biochemistry, 2011, 26, 261-268.	0.9	7

#	Article	IF	CITATIONS
2634	Haptoglobin Polymorphism and Association with Complications in Ghanaian Type 2 Diabetic Patients. Indian Journal of Clinical Biochemistry, 2011, 26, 366-372.	0.9	7
2635	Perioperative myocardial ischemia and isolated systolic hypertension in non-cardiac surgery. Canadian Journal of Anaesthesia, 2011, 58, 428-435.	0.7	7
2636	Delivering a lifestyle and weight loss intervention to individuals in real-world mental health settings: lessons and opportunities. Translational Behavioral Medicine, 2011, 1, 406-415.	1.2	20
2637	Optimal treatment for coronary artery disease in patients with diabetes: percutaneous coronary intervention, coronary artery bypass graft, and medications. General Thoracic and Cardiovascular Surgery, 2011, 59, 6-13.	0.4	1
2638	Resistant Hypertension: Concepts and Approach to Management. Current Hypertension Reports, 2011, 13, 347-355.	1.5	23
2639	Prevalence of visual impairment, cataract surgery and awareness of cataract and glaucoma in Bhaktapur district of Nepal: The Bhaktapur Glaucoma Study. BMC Ophthalmology, 2011, 11, 2.	0.6	60
2640	Associations of education with 30 year life course blood pressure trajectories: Framingham Offspring Study. BMC Public Health, 2011, 11, 139.	1,2	44
2641	Major inducing factors of hypertensive complications and the interventions required to reduce their prevalence: an epidemiological study of hypertension in a rural population in China. BMC Public Health, 2011, 11, 301.	1.2	25
2642	Implementing a hypertension management programme in a rural area: local approaches and experiences from Ba-Vi district, Vietnam. BMC Public Health, $2011, 11, 325$ .	1,2	23
2643	Project FIT: Rationale, design and baseline characteristics of a school- and community-based intervention to address physical activity and healthy eating among low-income elementary school children. BMC Public Health, $2011, 11, 607$ .	1.2	24
2644	A practice-based trial of blood pressure control in African Americans (TLC-Clinic): study protocol for a randomized controlled trial. Trials, 2011, 12, 265.	0.7	10
2645	Plasma tissue kallikrein level is negatively associated with incident and recurrent stroke: A multicenter case–control study in China. Annals of Neurology, 2011, 70, 265-273.	2.8	27
2646	Macrovascular angiopathy in children and adolescents with type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2011, 27, 436-460.	1.7	45
2647	Inability of waist-to-height ratio to predict new onset diabetes mellitus among older adults in Taiwan: A five-year observational cohort study. Archives of Gerontology and Geriatrics, 2011, 53, e1-e4.	1.4	9
2648	Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008. Circulation, 2011, 124, 1046-1058.	1.6	519
2649	Hypertensive emergencies. Current Opinion in Critical Care, 2011, 17, 569-580.	1.6	62
2650	Guidelines, Inertia, and Judgment. Hypertension, 2011, 58, 544-545.	1.3	3
2651	Antithrombotic medicines following intracerebral haemorrhage: where's the evidence?. Therapeutic Advances in Drug Safety, 2011, 2, 205-211.	1.0	5

#	Article	IF	Citations
2652	Better Glycemic Control Is Associated With Maintenance of Lower-Extremity Function Over Time in Mexican American and European American Older Adults With Diabetes. Diabetes Care, 2011, 34, 268-273.	4.3	41
2653	Home Blood Pressure Management and Improved Blood Pressure Control. Archives of Internal Medicine, 2011, 171, 1173.	4.3	201
2654	Progression of Left Ventricular Diastolic Dysfunction and Risk of Heart Failure. JAMA - Journal of the American Medical Association, 2011, 306, 856-63.	3.8	560
2655	Blood Pressure and Total Cholesterol Level Are Critical Risks Especially for Hemorrhagic Stroke in Akita, Japan. Cerebrovascular Diseases, 2011, 31, 100-106.	0.8	60
2656	Morbidity pattern amongst elderly patients presenting at a primary care clinic in Nigeria. African Journal of Primary Health Care and Family Medicine, 2011, 3, .	0.3	15
2657	Association between adiposity indices and cardiometabolic risk factors among adults living in Puerto Rico. Public Health Nutrition, 2011, 14, 1714-1723.	1.1	32
2658	Cardiovascular disease risk factors in relation to suicide mortality in Asia: prospective cohort study of over one million Korean men and women. European Heart Journal, 2011, 32, 2773-2780.	1.0	69
2659	The tRNAMet 4435A>G mutation in the mitochondrial haplogroup G2a1 is responsible for maternally inherited hypertension in a Chinese pedigree. European Journal of Human Genetics, 2011, 19, 1181-1186.	1.4	41
2660	Physical Inactivity and Mortality Risk. Cardiology Research and Practice, 2011, 2011, 1-10.	0.5	70
2661	Trends of blood pressure levels and management in VÃsterbotten County, Sweden, during 1990–2010. Global Health Action, 2012, 5, 18195.	0.7	37
2662	Detrimental effects of early rural life on blood pressure among urban male migrants in WrocÅ,aw, Poland. Anthropological Review, 2012, 75, 83-91.	0.2	1
2663	Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension. Patient Preference and Adherence, 2012, 6, 555.	0.8	7
2664	Prospective Study of Particulate Air Pollution Exposures, Subclinical Atherosclerosis, and Clinical Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air). American Journal of Epidemiology, 2012, 176, 825-837.	1.6	126
2666	Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus. Kidney International Supplements, 2012, 2, 363-369.	4.6	24
2667	Severe Hypoglycemia and Cardiovascular Disease Incidence in Type 1 Diabetes. Diabetes Care, 2012, 35, 1598-1604.	4.3	72
2668	Lifestyle Counseling in Routine Care and Long-Term Glucose, Blood Pressure, and Cholesterol Control in Patients With Diabetes. Diabetes Care, 2012, 35, 334-341.	4.3	48
2669	Etiology, Risk Factors and Sex Differences in Ischemic Stroke in the Ludwigshafen Stroke Study, a Population-Based Stroke Registry. Cerebrovascular Diseases, 2012, 33, 69-75.	0.8	99
2670	Prevalence, Awareness, Treatment and Control of Hypertension in Adults with Chronic Kidney Disease in Turkey: Results from the CREDIT Study. Kidney and Blood Pressure Research, 2012, 36, 36-46.	0.9	27

#	Article	IF	CITATIONS
2671	Cardiovascular Disease Risk Factor Patterns and Their Implications for Intervention Strategies in Vietnam. International Journal of Hypertension, 2012, 2012, 1-11.	0.5	30
2672	Current therapeutic agents and anesthetic considerations for diabetes mellitus. Korean Journal of Anesthesiology, 2012, 63, 195.	0.9	3
2673	Presence of baseline prehypertension and risk of incident stroke: A meta-analysis. Yearbook of Cardiology, 2012, 2012, 31-33.	0.0	0
2674	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Yearbook of Cardiology, 2012, 2012, 53-55.	0.0	O
2676	Survival analysis of pediatric dialysis patients in Taiwan. Nephrology, 2012, 17, 621-627.	0.7	17
2677	Posterior Circulation Ischemic Stroke—Clinical Characteristics, Risk Factors, and Subtypes in a North Indian Population. Neurohospitalist, The, 2012, 2, 46-50.	0.3	22
2678	Difference of antihypertensive prescribing between office- and hospital-based clinics in Taiwan. International Journal of Clinical Pharmacy, 2012, 34, 710-718.	1.0	0
2679	Determinants and Consequences of Adherence to the Dietary Approaches to Stop Hypertension Diet in African-American and White Adults with High Blood Pressure: Results from the ENCORE Trial. Journal of the Academy of Nutrition and Dietetics, 2012, 112, 1763-1773.	0.4	114
2680	Prognostic Value of Cardiac Troponin T After Myocardial Infarction: A Contemporary Community Experience. Mayo Clinic Proceedings, 2012, 87, 247-254.	1.4	28
2681	Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy. CardioRenal Medicine, 2012, 2, 256-267.	0.7	1
2682	Antidepressant Use and Cognitive Deficits in Older Men: Addressing Confounding by Indications with Different Methods. Annals of Epidemiology, 2012, 22, 9-16.	0.9	6
2684	First-attack pediatric hypertensive crisis presenting to the pediatric emergency department. BMC Pediatrics, 2012, 12, 200.	0.7	30
2685	Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study. Virology Journal, 2012, 9, 282.	1.4	9
2686	Antihypertensive Efficacy of the Losartan/Hydrochlorothiazide Combination and its Effect on Plasma B-Type Natriuretic Peptide in Hypertensive Patients Uncontrolled by Angiotensin II Type 1 Receptor Antagonist-Based Therapy. Clinical Drug Investigation, 2012, 32, 171-178.	1.1	2
2687	Presence of mutation m.14484T>C in a Chinese family with maternally inherited essential hypertension but no expression of LHON. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1535-1543.	1.8	21
2688	Evaluation of existing and candidate measures of obesity for detection of insulin resistance and cardiometabolic risk among Asian Indians: Development of two clinically useful models. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2012, 6, 181-186.	1.8	1
2689	Blood pressure reducing effects of (i>Phalaris canariensis (i>in normotensive and spontaneously hypertensive rats. Canadian Journal of Physiology and Pharmacology, 2012, 90, 201-208.	0.7	15
2690	Prognostic value of myocardial perfusion scintigraphy in elderly patients with hypertension: a 10-year follow-up analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1570-1580.	3.3	3

#	Article	IF	CITATIONS
2691	Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. BMC Medical Research Methodology, 2012, 12, 119.	1.4	19
2692	The Acute Effects of a Single Session of Expiratory Muscle Strength Training on Blood Pressure, Heart Rate, and Oxygen Saturation in Healthy Adults. Frontiers in Physiology, 2012, 3, 48.	1.3	10
2693	Ivabradine Prevents Heart Rate Acceleration in Patients with Chronic Obstructive Pulmonary Disease and Coronary Heart Disease after Salbutamol Inhalation. Pharmaceuticals, 2012, 5, 398-404.	1.7	7
2694	Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it "Ok―to Discontinue?. Current Cardiology Reviews, 2012, 8, 77-84.	0.6	60
2695	Association of Angiotensinogen (M235T) Gene Polymorphism with Blood Pressure Lowering Response to Angiotensin Converting Enzyme Inhibitor (Enalapril). Journal of Pharmacy and Pharmaceutical Sciences, 2012, 15, 399.	0.9	22
2696	The 12S rRNA A1555G mutation in the mitochondrial haplogroup D5a is responsible for maternally inherited hypertension and hearing loss in two Chinese pedigrees. European Journal of Human Genetics, 2012, 20, 607-612.	1.4	16
2697	Frailty Transitions in the San Antonio Longitudinal Study of Aging. Journal of the American Geriatrics Society, 2012, 60, 652-660.	1.3	159
2698	Uric Acid, Hypertension, and Chronic Kidney Disease Among Alaska Eskimos: The Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) Study. Journal of Clinical Hypertension, 2012, 14, 71-77.	1.0	23
2699	Severity and outcome of acute stroke in women: relation to adrenal sex steroid levels. Metabolism: Clinical and Experimental, 2012, 61, 84-91.	1.5	11
2700	Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats. Regulatory Toxicology and Pharmacology, 2012, 62, 7-15.	1.3	13
2701	Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case–control study from a single center. Rheumatology International, 2012, 32, 129-135.	1.5	22
2702	The Role of Religion in Relation to Blood Pressure Control Among a Southern California Thai Population with Hypertension. Journal of Religion and Health, 2012, 51, 187-197.	0.8	12
2703	Impaired Renal Function Further Increases Odds of 6-Year Coronary Artery Calcification Progression in Adults With Type 1 Diabetes. Diabetes Care, 2013, 36, 2607-2614.	4.3	41
2704	Intracerebral haemorrhage in a population-based stroke registry (LuSSt): incidence, aetiology, functional outcome and mortality. Journal of Neurology, 2013, 260, 2541-2550.	1.8	44
2705	Bringing prevention in geriatrics: Evidences from cardiovascular medicine supporting the new challenge. Experimental Gerontology, 2013, 48, 64-68.	1.2	25
2706	Ramipril and hydrochlorothiazide treatment of hypertensive urgency in the ED. American Journal of Emergency Medicine, 2013, 31, 1533-1534.	0.7	0
2707	Serum electrolyte levels in relation to macrovascular complications in Chinese patients with diabetes mellitus. Cardiovascular Diabetology, 2013, 12, 146.	2.7	32
2708	Quantifying the contributions of behavioral and biological risk factors to socioeconomic disparities in coronary heart disease incidence: the MORGEN study. European Journal of Epidemiology, 2013, 28, 807-814.	2.5	63

#	Article	IF	CITATIONS
2709	Association Between Pre-hypertension and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Prospective Studies. Current Hypertension Reports, 2013, 15, 703-716.	1.5	107
2710	Antihypertensive Medication Nonadherence in Black Men: Direct and Mediating Effects of Depressive Symptoms, Psychosocial Stressors, and Substance Use. Journal of Clinical Hypertension, 2013, 15, 201-209.	1.0	17
2711	Variations in blood pressure and lipid goal attainment in primary care. Current Medical Research and Opinion, 2013, 29, 1115-1125.	0.9	5
2712	U.S. and Canadian Hypertension Guidelines. , 2013, , 425-432.		0
2713	Blood pressure and TNF- $\hat{l}\pm$ act synergistically to increase leucocyte CD11b adhesion molecule expression in the BELFAST study: implications for better blood pressure control in ageing. Age, 2013, 35, 197-205.	3.0	7
2714	Alcohol is a Risk Factor not for Thalamic but for Putaminal Hemorrhage: The Akita Stroke Registry. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, 1064-1069.	0.7	5
2715	The Cooperative Lifestyle Intervention Program-II (CLIP-II): Design and methods. Contemporary Clinical Trials, 2013, 36, 382-393.	0.8	26
2716	Are there consequences of labeling patients with prehypertension? An experimental study of effects on blood pressure and quality of life. Journal of Psychosomatic Research, 2013, 74, 433-438.	1.2	14
2717	Risk of type 2 diabetes and cumulative excess weight exposure in the Framingham Offspring Study. Journal of Diabetes and Its Complications, 2013, 27, 214-218.	1.2	14
2718	Biophysical Basis of Glomerular Filtration. , 2013, , 693-719.		2
2719	Evaluating the impact of depression, anxiety & autonomic function on health related quality of life, vocational functioning and health care utilisation in acute coronary syndrome patients: the ADVENT study protocol. BMC Cardiovascular Disorders, 2013, 13, 103.	0.7	12
2720	Epidemiology of Heart Failure. Circulation Research, 2013, 113, 646-659.	2.0	1,352
2721	Hypertension Increases With Aging and Obesity in Chimpanzees ( <scp>P</scp> an troglodytes). Zoo Biology, 2013, 32, 79-87.	0.5	34
2723	Influence of explanatory and confounding variables on HRQoL after controlling for measurement bias and response shift in measurement. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 841-851.	0.7	7
2724	Metabolic syndrome in the rural population of Wardha, Central India: An exploratory factor analysis. Indian Journal of Community Medicine, 2013, 38, 33.	0.2	13
2725	Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study. Disease Markers, 2013, 35, 791-798.	0.6	45
2726	The association of brachial artery diameter with noncalcified coronary plaque burden in apparently healthy individuals. Coronary Artery Disease, 2013, 24, 657-662.	0.3	2
2727	Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenetics and Genomics, 2013, 23, 697-705.	0.7	12

#	Article	IF	CITATIONS
2728	Tâ€Helper Type 1 Bias in Healthy People Is Associated With Cytomegalovirus Serology and Atherosclerosis: The Multiâ€Ethnic Study of Atherosclerosis. Journal of the American Heart Association, 2013, 2, e000117.	1.6	56
2729	The Atrial Natriuretic Peptide Genetic Variant rs5068 Is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population. Diabetes Care, 2013, 36, 2850-2856.	4.3	51
2730	Effect of Meditation on Endothelial Function in Black Americans With Metabolic Syndrome. Psychosomatic Medicine, 2013, 75, 591-599.	1.3	12
2731	Doing the Right Thing for Health. Journal of Health Communication, 2013, 18, 895-897.	1.2	0
2732	Correlation between Left Ventricular Mass Index and Calcium Metabolism in Patients with Essential Hypertension. Balkan Medical Journal, 2013, 30, 85-89.	0.3	6
2733	Impact of Diabetes on Cardiovascular Disease: An Update. International Journal of Hypertension, 2013, 2013, 1-15.	0.5	321
2734	Blood Pressure and Cholesterol Control in Hypertensive Hypercholesterolemic Patients. Circulation, 2013, 128, 29-41.	1.6	123
2735	The <scp>H</scp> ispanic <scp>P</scp> aradox and Predictors of Mortality in an Aging <scp>B</scp> iethnic <scp>C</scp> ohort of <scp>M</scp> exican <scp>A</scp> mericans and <scp>E</scp> uropean <scp>A</scp> mericans: The <scp>S</scp> an <scp>A</scp> ntonio Longitudinal Study of Aging, Journal of the American Geriatrics Society, 2013, 61, 1522-1529.	1.3	24
2736	Different Definitions of Prevalent Hypertension Impact: The Clinical Epidemiology of Hypertension and Attainment of Healthy People Goals. Journal of Clinical Hypertension, 2013, 15, 154-161.	1.0	29
2737	Simple Integer Risk Score to Determine Prognosis of Patients With Hypertension and Chronic Stable Coronary Artery Disease. Journal of the American Heart Association, 2013, 2, e000205.	1.6	11
2738	Prevalence, awareness, treatment and control of hypertension in the Palestinian population. Journal of Human Hypertension, 2013, 27, 623-628.	1.0	31
2739	Pulse Pressure Is Useful for Determining the Choice of Antihypertensive Drugs in Postmenopausal Women. Pulse, 2013, 1, 152-160.	0.9	1
2740	Cardiovascular Risk Impact in the Oil Industry. , 2013, , .		0
2741	Changing Diagnostic and Treatment Criteria for Chronic Illness: A Critical Consideration of Their Impact on Low-Income Hispanic Patients. Human Organization, 2013, 72, 242-253.	0.2	3
2742	Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. Journal of Hypertension, 2013, 31, 698-704.	0.3	63
2743	Effect of interval training programme on pulse pressure in the management of hypertension: A randomized controlled trial. African Health Sciences, 2013, 13, 571-8.	0.3	12
2744	Reversed Dipper Blood-Pressure Pattern Is Closely Related to Severe Renal and Cardiovascular Damage in Patients with Chronic Kidney Disease. PLoS ONE, 2013, 8, e55419.	1.1	75
2745	Lycopene Supplement and Blood Pressure: An Updated Meta-Analysis of Intervention Trials. Nutrients, 2013, 5, 3696-3712.	1.7	46

#	Article	IF	CITATIONS
2746	The Mean Platelet Volume in Patients with Retinal Vein Occlusion. Journal of Ophthalmology, 2013, 2013, 1-4.	0.6	27
2747	Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. PLoS ONE, 2014, 9, e113048.	1.1	143
2748	Public health Economic aspects of hypertension treatment in Poland. Archives of Medical Science, 2014, 3, 607-617.	0.4	3
2749	Patient-related barriers to hypertension control in a Nigerian population. International Journal of General Medicine, 2014, 7, 345.	0.8	41
2750	Global Trends in Cardiovascular Diseaseâ~†., 2014, , .		0
2751	Largeâ€Scale Geneâ€Centric Analysis Identifies Polymorphisms for Resistant Hypertension. Journal of the American Heart Association, 2014, 3, e001398.	1.6	32
2752	Factors Influencing the Decline in Stroke Mortality. Stroke, 2014, 45, 315-353.	1.0	655
2753	Differences in Vascular Nitric Oxide and Endothelium-Derived Hyperpolarizing Factor Bioavailability in Blacks and Whites. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1320-1327.	1.1	50
2754	Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: A pharmacoeconomic comparison of antihypertensive efficacy of beta blockers. Indian Journal of Pharmacology, 2014, 46, 485.	0.4	4
2755	Effects of dietary sodium and the DASH diet on the occurrence of headaches: results from randomised multicentre DASH-Sodium clinical trial. BMJ Open, 2014, 4, e006671.	0.8	48
2756	Variations in Aging, Gender, Menopause, and Obesity and Their Effects on Hypertension in Taiwan. International Journal of Hypertension, 2014, 2014, 1-7.	0.5	27
2757	The diagnostic yield of neuroimaging in sixth nerve palsy - Sankara Nethralaya Abducens Palsy Study (SNAPS): Report 1. Indian Journal of Ophthalmology, 2014, 62, 1008.	0.5	25
2758	Visitâ€toâ€Visit Variability of Blood Pressure and Renal Function Decline in Patients With Diabetic Chronic Kidney Disease. Journal of Clinical Hypertension, 2014, 16, 362-366.	1.0	20
2759	Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women With Suspected Myocardial Ischemia: A Report From the NHLBIâ€5ponsored WISE Study. Journal of the American Heart Association, 2014, 3, e000660.	1.6	57
2760	Burden and predictors of hypertension in India: results of SEEK (Screening and Early Evaluation of) Tj ETQq0 0 0 r	gBT /Overl	ი <u>ი</u> გ 10 Tf 50
2761	Systematic analysis of the clinical and biochemical characteristics of maternally inherited hypertension in Chinese Han families associated with mitochondrial. BMC Medical Genomics, 2014, 7, 73.	0.7	7
2762	Sex Differences in Mental Stress–Induced Myocardial Ischemia in Young Survivors of an Acute Myocardial Infarction. Psychosomatic Medicine, 2014, 76, 171-180.	1.3	97
2763	Systolic Blood Pressure Goals to Reduce Cardiovascular Disease Among Older Adults. American Journal of the Medical Sciences, 2014, 348, 129-134.	0.4	11

#	Article	IF	CITATIONS
2764	Prevention of Cardiovascular Disease in Women. Seminars in Reproductive Medicine, 2014, 32, 447-453.	0.5	4
2765	The Growing Gap in Hypertension Control Between Insured and Uninsured Adults. Hypertension, 2014, 64, 997-1004.	1.3	55
2767	Difference by sex but not by race/ethnicity in the visceral adipose tissue-depressive symptoms association: The Multi-Ethnic Study of Atherosclerosis. Psychoneuroendocrinology, 2014, 47, 78-87.	1.3	17
2768	Clinical significance of home blood pressure and its possible practical application. Clinical and Experimental Nephrology, 2014, 18, 24-40.	0.7	11
2769	A 12-Week Weight Reduction Intervention for Overweight Individuals Taking Antipsychotic Medications. Community Mental Health Journal, 2014, 50, 974-980.	1.1	18
2770	The Prevalence of Diabetic Cardiomyopathy: A Population-Based Study in Olmsted County, Minnesota. Journal of Cardiac Failure, 2014, 20, 304-309.	0.7	116
2771	Closing the Gap in Hypertension Control Between Younger and Older Adults. Circulation, 2014, 129, 2052-2061.	1.6	34
2772	Psychosocial Risk Factors for Hypertension: an Update of the Literature. Current Hypertension Reports, 2014, 16, 483.	1.5	131
2773	Hypertension in the United States, 1999 to 2012. Circulation, 2014, 130, 1692-1699.	1.6	176
2774	2014 Hypertension Recommendations From the Eighth Joint National Committee Panel Members Raise Concerns for Elderly Black and Female Populations. Journal of the American College of Cardiology, 2014, 64, 394-402.	1.2	79
2775	2014 Eighth Joint National Committee Panel Recommendation for BloodÂPressureÂTargets Revisited. Journal of the American College of Cardiology, 2014, 64, 784-793.	1.2	67
2776	Antihypertensive effect of few-flower wild rice (Zizania latifolia Turcz.) in spontaneously hypertensive rats. Food Science and Biotechnology, 2014, 23, 439-444.	1.2	7
2777	The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice. Diabetology and Metabolic Syndrome, 2014, 6, 31.	1.2	28
2778	Physical Environment May Modify the Association Between Depressive Symptoms and Change in Waist Circumference: The Multi-Ethnic Study of Atherosclerosis. Psychosomatics, 2014, 55, 144-154.	2.5	11
2779	Atherogenic lipids and vascular complications in a selected diabetic population with normal urinary albumin/creatinine ratios. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 124-127.	1.8	3
2780	Diabetes and age-related demographic differences in risk factor control. Journal of the American Society of Hypertension, 2014, 8, 394-404.	2.3	11
2781	Cross-sectional Associations of Medication and Supplement Use With Retinal Vascular Diameter in the Beaver Dam Eye Study. JAMA Ophthalmology, 2014, 132, 23.	1.4	8
2782	Sasang constitution may act as a risk factor for prehypertension. BMC Complementary and Alternative Medicine, 2015, 15, 231.	3.7	6

#	Article	IF	CITATIONS
2783	Sex and race/ethnic disparities in the cross-sectional association between depressive symptoms and muscle mass: the Multi-ethnic Study of Atherosclerosis. BMC Psychiatry, 2015, 15, 221.	1.1	8
2784	Elevated blood pressure and headache disorders in China – associations, under-treatment and implications for public health. Journal of Headache and Pain, 2015, 16, 86.	2.5	7
2785	Use of Renally Inappropriate Medications in Older Veterans: A National Study. Journal of the American Geriatrics Society, 2015, 63, 2290-2297.	1.3	55
2786	Long-term Exposure to Air Pollution and Markers of Inflammation, Coagulation, and Endothelial Activation. Epidemiology, 2015, 26, 310-320.	1.2	198
2787	The results of treatment in renal artery stenosis due to Takayasu disease: comparison between surgery, angioplasty, and stenting. A monocentrique retrospective study. Giornale Di Chirurgia, 2015, 36, 161-7.	0.5	21
2788	Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC-7 Guidelines. American Journal of Pharmacology and Toxicology, 2015, 10, 27-31.	0.7	5
2789	Quality of Life on Arterial Hypertension: Validity of Known Groups of MINICHAL. Arquivos Brasileiros De Cardiologia, 2015, 104, 299-307.	0.3	7
2790	Risk Factors of Coronary Artery Disease in Secondary Prevention—Results from the AtheroGene—Study. PLoS ONE, 2015, 10, e0131434.	1.1	26
2791	Coronary Atherosclerotic Plaque Detected by Computed Tomographic Angiography in Subjects with Diabetes Compared to Those without Diabetes. PLoS ONE, 2015, 10, e0143187.	1.1	16
2792	Early Detection of Regional and Global Left Ventricular Myocardial Function Using Strain and Strain-rate Imaging in Patients with Metabolic Syndrome. Chinese Medical Journal, 2015, 128, 226-232.	0.9	9
2793	Hypertension Detection, Management, Control and Associated Factors Among Residents Accessing Community Health Services In Beijing. Scientific Reports, 2014, 4, 4845.	1.6	20
2794	Premature graying of hair: An independent risk marker for coronary artery disease in smokers - A retrospective case control study. Ethiopian Journal of Health Sciences, 2015, 25, 123.	0.2	9
2795	Coronary Artery Calcium Improves Risk Assessment in Adults With a Family History of Premature Coronary Heart Disease. Circulation: Cardiovascular Imaging, 2015, 8, e003186.	1.3	49
2796	Hypertension in African Americans Aged 60 to 79ÂYears: Statement From the International Society of Hypertension in Blacks. Journal of Clinical Hypertension, 2015, 17, 252-259.	1.0	12
2797	Change in the association of body mass index and systolic blood pressure in Germany – national cross-sectional surveys 1998 and 2008–2011. BMC Public Health, 2015, 15, 705.	1.2	14
2798	Chronic kidney disease as a risk factor for incident gout among men and women: retrospective cohort study using data from the Framingham Heart Study. BMJ Open, 2015, 5, e006843-e006843.	0.8	35
2799	2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension. Journal of the Chinese Medical Association, 2015, 78, 1-47.	0.6	183
2800	Antihypertensive Therapy and the J-curve: Fact or Fiction?. Current Hypertension Reports, 2015, 17, 6.	1.5	11

#	Article	IF	CITATIONS
2801	Factors Contributing to 50-ft Walking Speed and Observed Ethnic Differences in Older Community-Dwelling Mexican Americans and European Americans. Physical Therapy, 2015, 95, 871-883.	1.1	18
2802	Risk factors for acute myocardial infarction in Central India: A case-control study. Indian Journal of Community Medicine, 2015, 40, 19.	0.2	13
2803	Survival in Subcortical Vascular Dementia: Predictors and Comparison to Probable Alzheimer's Disease in a Tertiary Memory Clinic Population. Dementia and Geriatric Cognitive Disorders, 2015, 40, 210-221.	0.7	10
2804	Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: A systematic review and meta-analysis of randomized controlled trials. Atherosclerosis, 2015, 241, e190-e191.	0.4	4
2805	A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy. Indian Journal of Pharmacology, 2015, 47, 148.	0.4	9
2806	Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. Medical Principles and Practice, 2015, 24, 401-415.	1.1	1,060
2807	Incidence of early-onset dementia in Mar del Plata. NeurologÃa (English Edition), 2015, 30, 77-82.	0.2	0
2808	Understanding multifactorial influences on the continuum of maternal weight trajectories in pregnancy and early postpartum: study protocol, and participant baseline characteristics. BMC Pregnancy and Childbirth, 2015, 15, 71.	0.9	3
2809	Cardiovascular risk assessment: a global perspective. Nature Reviews Cardiology, 2015, 12, 301-311.	6.1	94
2810	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. American Journal of Hypertension, 2015, 28, 995-1009.	1.0	18
2811	Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population. Current Therapeutic Research, 2015, 77, 83-89.	0.5	5
2812	The unruptured intracranial aneurysm treatment score. Neurology, 2015, 85, 881-889.	1.5	301
2813	Tratamiento anticoagulante en pacientes con fibrilación auricular no valvular en un centro de salud. Grado de control del INR e incidencia de episodios cardioembólicos. Medicina General Y De Familia, 2015, 4, 37-42.	0.1	0
2814	Provider Perspectives on Essential Functions for Care Management in the Collaborative Treatment of Hypertension: The P.A.R.T.N.E.R. Framework. Journal of General Internal Medicine, 2015, 30, 454-461.	1.3	11
2815	Effects of established blood pressure loci on blood pressure values and hypertension risk in an Algerian population sample. Journal of Human Hypertension, 2015, 29, 296-302.	1.0	6
2816	Neighborhood-Level Racial/Ethnic Residential Segregation and Incident Cardiovascular Disease. Circulation, 2015, 131, 141-148.	1.6	216
2817	Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels. Indian Journal of Clinical Biochemistry, 2015, 30, 275-280.	0.9	12
2818	A Mitochondrial DNA A8701G Mutation Associated with Maternally Inherited Hypertension and Dilated Cardiomyopathy in a Chinese Pedigree of a Consanguineous Marriage. Chinese Medical Journal, 2016, 129, 259-266.	0.9	16

#	Article	IF	CITATIONS
2819	A Brief, Multifaceted, Generic Intervention to Improve Blood Pressure Control and Reduce Disparities Had Little Effect. Ethnicity and Disease, 2016, 26, 27.	1.0	8
2820	Prevalence of Metabolic Syndrome and its Related Risk Factors in the City of Oran, Algeria: the ISOR Study. Ethnicity and Disease, 2016, 26, 99.	1.0	20
2821	Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. Journal of the American Heart Association, $2016,5,.$	1.6	5
2822	Pulsatile Load Components, Resistive Load and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA). Journal of Cardiac Failure, 2016, 22, 988-995.	0.7	33
2823	A Hypertension-Associated tRNA <sup>Ala</sup> Mutation Alters tRNA Metabolism and Mitochondrial Function. Molecular and Cellular Biology, 2016, 36, 1920-1930.	1.1	48
2824	The Natural History of Patients With Isolated Metabolic Syndrome. Mayo Clinic Proceedings, 2016, 91, 623-633.	1.4	12
2825	Cardiovascular Disease and Related Disorders in the Elderly. , 2016, , 1-37.		0
2826	Association of Elevated Serum Lipoprotein(a), Inflammation, Oxidative Stress and Chronic Kidney Disease with Hypertension in Non-diabetes Hypertensive Patients. Indian Journal of Clinical Biochemistry, 2016, 31, 446-451.	0.9	4
2827	Relationship between body mass index changes and blood pressure changes from childhood to adulthood in a general Chinese population: a 26 year cohort follow-up study. Blood Pressure, 2016, 25, 319-326.	0.7	7
2828	Diuretics in primary hypertension – Reloaded. Indian Heart Journal, 2016, 68, 720-723.	0.2	17
2829	Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study. Rheumatology International, 2016, 36, 1691-1699.	1.5	8
2830	Fresh Start, a postpartum weight loss intervention for diverse low-income women: design and methods for a randomized clinical trial. BMC Public Health, 2016, 16, 953.	1.2	9
2831	Relationships between blood pressure and health and fitness-related variables in obese women. Journal of Physical Therapy Science, 2016, 28, 2933-2937.	0.2	6
2832	Relationship of Albuminuria and Renal Artery Stent Outcomes. Hypertension, 2016, 68, 1145-1152.	1.3	50
2833	Relationship between retinopathy and renal abnormalities in black hypertensive patients. Clinical Hypertension, 2016, 22, 19.	0.7	6
2834	Self-reported experiences of discrimination and inflammation among men and women: The multi-ethnic study of atherosclerosis Health Psychology, 2016, 35, 343-350.	1.3	81
2835	An Update on Nutrients and Blood Pressure. Journal of Atherosclerosis and Thrombosis, 2016, 23, 276-289.	0.9	63
2836	Sleep Disturbances and Depression in the Multi-Ethnic Study of Atherosclerosis. Sleep, 2016, 39, 915-925.	0.6	39

#	Article	IF	CITATIONS
2838	Booker T. Washington and the Secret of Hypertension in African Americans. American Journal of the Medical Sciences, 2016, 352, 416-419.	0.4	0
2839	Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. Journal of Women's Health, 2016, 25, 996-1003.	1.5	14
2840	Hypertension and stroke: an appraisal of the evidence and implications for clinical management. Expert Review of Cardiovascular Therapy, 2016, 14, 609-616.	0.6	13
2841	Comparison of stethoscope bell and diaphragm, and of stethoscope tube length, for clinical blood pressure measurement. Blood Pressure Monitoring, 2016, 21, 178-183.	0.4	14
2842	Hypertensive Crisis in Pregnancy. , 2016, , 271-276.		0
2843	Tumor Necrosis Factor-Î', Interleukin-6, C-Reactive Protein Levels and Insulin Resistance Associated with Type 2 Diabetes in Abdominal Obesity Women. Indian Journal of Clinical Biochemistry, 2016, 31, 68-74.	0.9	56
2844	The impacts of premorbid hypertension treatment on functional outcomes of ischemic stroke. Journal of the Neurological Sciences, 2016, 363, 1-4.	0.3	6
2845	Hypertension unawareness among Chinese patients with first-ever stroke. BMC Public Health, 2016, 16, 170.	1.2	11
2846	Metabolic syndrome and the risk of sudden cardiac death in middle-aged men. International Journal of Cardiology, 2016, 203, 792-797.	0.8	38
2847	Beta-blockers for hypertension. The Cochrane Library, 2017, 2017, CD002003.	1.5	205
2848	Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Nature Reviews Endocrinology, 2017, 13, 365-374.	4.3	29
2849	Lung function, percent emphysema, and QT duration: The Multi-Ethnic Study of Atherosclerosis (MESA) lung study. Respiratory Medicine, 2017, 123, 1-7.	1.3	12
2850	Racial discrimination associated with higher diastolic blood pressure in a sample of <scp>A</scp> merican <scp>I</scp> ndian adults. American Journal of Physical Anthropology, 2017, 163, 122-128.	2.1	23
2851	The role of occult hypertension in retinal vein occlusions and diabetic retinopathy. Canadian Journal of Ophthalmology, 2017, 52, 225-228.	0.4	6
2852	Using Predicted Cardiovascular DiseaseÂRisk in Conjunction WithÂBloodÂPressure toÂGuide Antihypertensive Medication Treatment. Journal of the American College of Cardiology, 2017, 69, 2446-2456.	1.2	58
2853	Declining blood pressure and intensification of blood pressure management among people over 80 years. Journal of Hypertension, 2017, 35, 1276-1282.	0.3	10
2854	Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg. Circulation, 2017, 136, 798-812.	1.6	60
2855	Engagement in Pleasant Leisure Activities and Blood Pressure: A 5-Year Longitudinal Study in Alzheimer Caregivers. Psychosomatic Medicine, 2017, 79, 735-741.	1.3	19

#	Article	IF	CITATIONS
2856	Choline and its metabolites are differently associated with cardiometabolic risk factors, history of cardiovascular disease, and MRI-documented cerebrovascular disease in older adults,. American Journal of Clinical Nutrition, 2017, 105, 1283-1290.	2.2	48
2857	Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China. Clinical Rheumatology, 2017, 36, 1023-1029.	1.0	18
2858	The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension. Annals of Internal Medicine, 2017, 167, 630.	2.0	127
2859	Hypertension: An Evidence Informed, Case Based Approach. Physician Assistant Clinics, 2017, 2, 557-570.	0.1	0
2860	Impact of Clinical Factors on the Achievement of Target Blood Pressure in Hypertensive Patients from Ivanovo Region of Russia: Data of 2015. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 425-435.	1.0	5
2861	Temporal trends in Prevalence, Awareness, Treatment, and Control of Hypertension from 2000 to 2010 in Chengdu, China. Scientific Reports, 2017, 7, 8964.	1.6	7
2862	A hypertension-associated mitochondrial DNA mutation alters the tertiary interaction and function of tRNALeu(UUR). Journal of Biological Chemistry, 2017, 292, 13934-13946.	1.6	29
2863	Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respiratory Research, 2017, 18, 124.	1.4	30
2864	Association Between <i>APOL1</i> Genotypes and Risk of Cardiovascular Disease in MESA (Multi thnic) Tj ET	-Qq0,0 0 r	gBT /Overlock
2865	Cardiovascular Risk Factors in White Collar Workers Under Shift Work. Acta Medica Bulgarica, 2017, 44, 5-9.	0.0	3
2867	Efficacy of Various Antihypertensive Drugs in the Treatment of Hypertension in the Patients of End-Stage Renal Disease Leading to Haemodialysis- A Retrospective Study. Journal of Nephrology & Therapeutics, 2017, 07, .	0.1	0
2869	The Mitochondrial tRNA <sup>Ala</sup> T5655C Mutation May Modulate the Phenotypic Expression of tRNA <sup>Met</sup> and tRNA <sup>Gln</sup> A4401G Mutation in a Han Chinese Family With Essential Hypertension. International Heart Journal, 2017, 58, 95-99.	0.5	8
2870	Global Trends in Cardiovascular Disease. , 2017, , 301-329.		7
2871	Ambient Coarse Particulate Matter and the Right Ventricle: The Multi-Ethnic Study of Atherosclerosis. Environmental Health Perspectives, 2017, 125, 077019.	2.8	6
2872	Utilization Study of Antihypertensives in a South Indian Tertiary Care Teaching Hospital and Adherence to Standard Treatment Guidelines. Journal of Basic and Clinical Pharmacy, 2017, 8, 33.	9.3	13
2873	Implications of Recent Clinical Trials and Hypertension Guidelines on Stroke and Future Cerebrovascular Research. Stroke, 2018, 49, 772-779.	1.0	30
2874	Elevations in neutrophils with obstructive sleep apnea: The Multi-Ethnic Study of Atherosclerosis (MESA). International Journal of Cardiology, 2018, 257, 318-323.	0.8	24
2875	Importance of the lipidâ€related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multiâ€Ethnic Study of Atherosclerosis. Pharmacoepidemiology and Drug Safety, 2018, 27, 365-372.	0.9	7

#	Article	IF	CITATIONS
2876	Evaluation of non-HDL cholesterol as a predictor of non-fatal cardiovascular events in a prospective population cohort. Cl $\tilde{A}$ nica E Investigaci $\tilde{A}$ 3n En Arteriosclerosis (English Edition), 2018, 30, 64-71.	0.1	5
2877	Hypertension Across a Woman'sÂLifeÂCycle. Journal of the American College of Cardiology, 2018, 71, 1797-1813.	1.2	159
2878	Exercise Testing in Hypertension and Hypertension in Athletes. , 2018, , 741-753.		0
2879	ValoraciÃ <sup>3</sup> n del colesterol no HDL como predictor de episodios cardiovasculares no mortales en una cohorte prospectiva de origen poblacional. ClÃnica E InvestigaciÃ <sup>3</sup> n En Arteriosclerosis, 2018, 30, 64-71.	0.4	8
2880	Relationship between systolic blood pressure and all-cause mortality: a prospective study in a cohort of Chinese adults. BMC Public Health, 2018, 18, 107.	1.2	10
2881	Basic vs More Complex Definitions of Family History in the Prediction of Coronary Heart Disease: The Multi-Ethnic Study of Atherosclerosis. Mayo Clinic Proceedings, 2018, 93, 1213-1223.	1.4	33
2882	Incidencia de enfermedad cerebrovascular en adultos: estudio epidemiol $ ilde{A}^3$ gico prospectivo basado en poblaci $ ilde{A}^3$ n cautiva en Argentina. Neurologia Argentina, 2018, 10, 8-15.	0.1	0
2883	Pharmacological heart rate lowering in patients with a preserved ejection fractionâ€"review of a failing concept. Heart Failure Reviews, 2018, 23, 499-506.	1.7	17
2884	Mitochondrial tRNAThr 15909A>G mutation associated with hypertension in a Chinese Han pedigree. Biochemical and Biophysical Research Communications, 2018, 495, 574-581.	1.0	11
2885	Propofol Versus Thiopental for Rapid-Sequence Induction in Isolated Systolic Hypertensive Patients: A Factorial Randomized Double-Blind Clinical Trial. Turkish Journal of Anaesthesiology and Reanimation, 2018, 46, 367-372.	0.9	1
2886	Cross-sectional study of the association between day-to-day home blood pressure variability and visceral fat area measured using the dual impedance method. PLoS ONE, 2018, 13, e0206945.	1.1	2
2887	Low self-reported sports activity before stroke predicts poor one-year-functional outcome after first-ever ischemic stroke in a population-based stroke register. BMC Neurology, 2018, 18, 181.	0.8	9
2888	Association of Blood Pressure Classification in Korean Young Adults According to the 2017 American College of Cardiology/American Heart Association Guidelines With Subsequent Cardiovascular Disease Events. JAMA - Journal of the American Medical Association, 2018, 320, 1783.	3.8	170
2889	Control of Cardiovascular Disease in the 20th Century: Meeting the Challenge of Chronic Degenerative Disease. Perspectives in Biology and Medicine, 2018, 61, 550-559.	0.3	8
2890	Mechanisms of isolevuglandin-protein adduct formation in inflammation and hypertension. Prostaglandins and Other Lipid Mediators, 2018, 139, 48-53.	1.0	15
2891	Association between Obstructive Sleep Apnea and Cardiovascular Risk Factors: Variation by Age, Sex, and Race. The Multi-Ethnic Study of Atherosclerosis. Annals of the American Thoracic Society, 2018, 15, 970-977.	1.5	59
2892	Complexity Changes in Brain Activity in Healthy Ageing: A Permutation Lempel-Ziv Complexity Study of Magnetoencephalograms. Entropy, 2018, 20, 506.	1.1	12
2893	Prevalence and determinants of hypertension among adult population in Nepal: Data from Nepal Demographic and Health Survey 2016. PLoS ONE, 2018, 13, e0198028.	1,1	58

#	Article	IF	CITATIONS
2894	Prevalence of severe hypertension in a Sub-Saharan African community. International Journal of Cardiology: Hypertension, 2019, 2, 100016.	2.2	5
2895	Angiotensin Receptor Blockers and Subclinical Interstitial Lung Disease: The MESA Study. Annals of the American Thoracic Society, 2019, 16, 1451-1453.	1.5	8
2896	New American and European Hypertension Guidelines, Reconciling the Differences. Cardiology and Therapy, 2019, 8, 157-166.	1.1	17
2897	Role of Nutrition and Exercise Programs in Reducing Blood Pressure: A Systematic Review. Journal of Clinical Medicine, 2019, 8, 1393.	1.0	18
2898	Hypertension Awareness, Treatment, and Control in US Adults: Trends in the Hypertension Control Cascade by Population Subgroup (National Health and Nutrition Examination Survey, 1999–2016). American Journal of Epidemiology, 2019, 188, 2165-2174.	1.6	48
2899	Tapered vs. Uniform Tube-Load Modeling of Blood Pressure Wave Propagation in Human Aorta. Frontiers in Physiology, 2019, 10, 974.	1.3	6
2900	Impact of Department of Veterans Affairs Cooperative Studies Program clinical trials on practice guidelines for high blood pressure management. Contemporary Clinical Trials Communications, 2019, 13, 100313.	0.5	3
2901	A unified mapping framework of multifaceted pharmacodynamic responses to hypertension interventions. Drug Discovery Today, 2019, 24, 883-889.	3.2	2
2902	Poor management of hypertension is an important precipitating factor for the development of acute aortic dissection. Journal of Clinical Hypertension, 2019, 21, 804-812.	1.0	19
2903	Is Prevalence of Atherosclerotic Risk Factors Increasing Among Young Adults? It Depends on How You Ask. Journal of the American Heart Association, 2019, 8, e010883.	1.6	9
2904	Evolution of Blood Pressure Clinical Practice Guidelines: A Personal Perspective. Canadian Journal of Cardiology, 2019, 35, 570-581.	0.8	13
2905	Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 89-96.	1.1	91
2906	Blood Pressure Goals in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 161-169.	2.2	42
2907	Potential Cardiovascular Disease Events Prevented with Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. Circulation, 2019, 139, 24-36.	1.6	42
2908	Association of High Levels of Spot Urine Protein with High Blood Pressure, Mean Arterial Pressure and Pulse Pressure with the Development of Diabetic Chronic Kidney Dysfunction or Failure among Diabetic Patients. Statistical Regression Modeling to Predict Diabetic Proteinuria. Current Diabetes Reviews, 2019, 15, 486-496.	0.6	6
2909	Diabetes Mellitus Is an Independent Predictor for the Development of Heart Failure. Mayo Clinic Proceedings, 2020, 95, 124-133.	1.4	26
2910	Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure. ESC Heart Failure, 2020, 7, 124-130.	1.4	5
2911	Mild primary aldosteronism (PA) followed by overt PA are possibly the most common forms of low renin hypertension: a single-center retrospective study. Journal of Human Hypertension, 2020, 34, 633-640.	1.0	4

#	Article	IF	CITATIONS
2912	Mitochondrial tRNASer(UCN) 7471delC may be a novel mutation associated with maternally transmitted hypertension. Irish Journal of Medical Science, 2020, 189, 489-496.	0.8	7
2913	Intensive BP Control and eGFR Declines: Are These Events Due to Hemodynamic Effects and Are Changes Reversible?. Current Cardiology Reports, 2020, 22, 117.	1.3	3
2914	Association of <i>APOL1</i> Genotypes With Measures of Microvascular and Endothelial Function, and Blood Pressure in MESA. Journal of the American Heart Association, 2020, 9, e017039.	1.6	7
2915	Association between Serum Mg2+ Concentrations and Cardiovascular Organ Damage in a Cohort of Adult Subjects. Nutrients, 2020, 12, 1264.	1.7	3
2916	Trends in ambulatory blood pressure monitoring use for confirmation or monitoring of hypertension and resistant hypertension among the commercially insured in the U.S., 2008–2017. International Journal of Cardiology: Hypertension, 2020, 6, 100033.	2.2	9
2917	Identifying hotspots of cardiometabolic outcomes based on a Bayesian approach: The example of Chile. PLoS ONE, 2020, 15, e0235009.	1.1	6
2918	The Association between Hypertension and Race/Ethnicity among Breast Cancer Survivors. Journal of Racial and Ethnic Health Disparities, 2020, 7, 1172-1177.	1.8	9
2919	Chronic Diseases Multimorbidity among Adult People Living with HIV at Hawassa University Comprehensive Specialized Hospital, Southern Ethiopia. International Journal of Chronic Diseases, 2020, 2020, 1-9.	1.9	9
2920	Reimbursement of ambulatory blood pressure monitoring in the US commercial insurance marketplace. Journal of Clinical Hypertension, 2020, 22, 6-15.	1.0	10
2921	Effects of chronic consumption of specific fruit (berries, citrus and cherries) on CVD risk factors: a systematic review and meta-analysis of randomised controlled trials. European Journal of Nutrition, 2021, 60, 615-639.	1.8	42
2922	Temporal trends in prevalence of cardiovascular disease (CVD) and CVD risk factors among U.S. older workers: NHIS 2004–2018. Annals of Epidemiology, 2021, 55, 78-82.	0.9	10
2923	The Association of Neighborhood Medical Facilities with Aging in Place and Risk of Incident Myocardial Infarction. Journal of Aging and Health, 2021, 33, 227-236.	0.9	1
2925	Spatially Weighted Coronary Artery Calcium Score and Coronary Heart Disease Events in the Multi-Ethnic Study of Atherosclerosis. Circulation: Cardiovascular Imaging, 2021, 14, e011981.	1.3	16
2926	Office Blood Pressure Range and Cardiovascular Events in Patients With Hypertension: A Nationwide Cohort Study in South Korea. Journal of the American Heart Association, 2021, 10, e017890.	1.6	7
2927	Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease. JAMA Network Open, 2021, 4, e218418.	2.8	19
2928	Doctors' views and strategies to improve patients' adherence to medication. Hormones, 2021, 20, 603-611.	0.9	7
2929	Progression of Preclinical Heart Failure: A Description of Stage A and B Heart Failure in a Community Population. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007216.	0.9	7
2930	Potassium Metabolism and Management in Patients with CKD. Nutrients, 2021, 13, 1751.	1.7	36

#	Article	IF	Citations
2931	THE APPLICATION OF COMBINED PREPARATIONS WITH CONSTANT DOSES OF ANTIHYPERTENSIVE DRUGS AS THE INITIAL TACTICS OF TREATMENT AT HIGH BLOOD PRESSURE LEVEL: PROVEN FACTS AND EXPERT€™S OPINION. Eurasian Heart Journal, 2021, , 92-102.	0.2	0
2932	High plasma renin activity associates with obesity-related diabetes and arterial hypertension, and predicts persistent hypertension after bariatric surgery. Cardiovascular Diabetology, 2021, 20, 118.	2.7	8
2933	Prevalence of ApoB100 rs693 gene polymorphism in metabolic syndrome among female students at King Abdulaziz University. Saudi Journal of Biological Sciences, 2021, 28, 3249-3253.	1.8	4
2934	Relationship between Clinic and Ambulatory Blood Pressure Measurements in Children. Journal of Data Science, 2004, 2, 383-397.	0.5	1
2935	Medication Adherence and the Role of Pictograms in Medication Counselling of Chronic Patients: a Review. Frontiers in Pharmacology, 2021, 12, 582200.	1.6	12
2936	Differentiation between Stroke Subtypes and the Causes of Monthly Variations: The Akita Stroke Registry. Internal Medicine, 2021, 60, 2933-2938.	0.3	1
2937	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. Diabetes/Metabolism Research and Reviews, 2022, 38, e3494.	1.7	74
2938	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 31-42.	1.4	14
2939	Mutational Analysis of Mitochondrial tRNA Genes in 200 Patients with Type 2 Diabetes Mellitus. International Journal of General Medicine, 2021, Volume 14, 5719-5735.	0.8	3
2940	Using Restricted Cubic Splines to Study the Trajectory of Systolic Blood Pressure in the Prognosis of Acute Myocardial Infarction. Frontiers in Cardiovascular Medicine, 2021, 8, 740580.	1.1	2
2941	Sleep apnea, coronary artery calcium density, and cardiovascular events: results from the Multi-Ethnic Study of Atherosclerosis. Journal of Clinical Sleep Medicine, 2021, 17, 2075-2083.	1.4	5
2942	Psychosocial stressors at work and inflammatory biomarkers: PROspective Quebec Study on Work and Health. Psychoneuroendocrinology, 2021, 133, 105400.	1.3	6
2943	Effects of Caloric Restriction Diet on Arterial Hypertension and Endothelial Dysfunction. Nutrients, 2021, 13, 274.	1.7	35
2944	The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and Obstructive Sleep Apnea: Let Their Silence Not Be Matched by the Silence of the Ordinary Physician. Archives of Internal Medicine, 1998, 158, 1272-1273.	4.3	7
2945	The Long-term Prognostic Significance of Repeated Blood Pressure Measurements in the Elderly. Archives of Internal Medicine, 1999, 159, 1205.	4.3	49
2946	Goal Blood Pressure in Treating Hypertension. Archives of Internal Medicine, 2002, 162, 105-106.	4.3	4
2947	Better Hypertension Control? Not Without Broad Interventions by Strong Public Health Institutions. Archives of Internal Medicine, 2002, 162, 1530-1531.	4.3	1
2948	Barriers to Blood Pressure Control. Archives of Internal Medicine, 2002, 162, 2245-2245.	4.3	3

#	Article	IF	Citations
2949	Undertreatment of Hypertension: A Dozen Reasons. Archives of Internal Medicine, 2002, 162, 2246-2248.	4.3	18
2950	Ethnic, Racial, and Sex-Specific Factors Are Important in Cardiovascular Pharmacotherapeutics. Archives of Internal Medicine, 2002, 162, 2494-2495.	4.3	1
2951	Blood Pressure in Early Life and Cardiovascular Disease Mortality. Archives of Internal Medicine, 2002, 162, 610-611.	4.3	29
2952	Antihypertensive Therapy: Recommendations and Realities. JAMA - Journal of the American Medical Association, 1998, 279, 746-747.	3.8	1
2953	beta-Blockers as First-Line Agents for Hypertension in the Elderly. JAMA - Journal of the American Medical Association, 1999, 281, 131-133.	3.8	5
2955	Neuropsychological Consequences of Cardiovascular Disease. Critical Issues in Neuropsychology, 2001, , 51-83.	0.4	14
2956	Acupuncture Therapy for Hypertension and Hypotension. , 2010, , 289-325.		4
2957	Characteristics of Pulse Pressure Parameters in Acute Intracerebral Hemorrhage Patients. Acta Neurochirurgica Supplementum, 2011, 111, 349-352.	0.5	1
2958	Outcome following Stroke. , 2004, , 35-57.		7
2959	Carotid Occlusive Disease. , 2011, , 3615-3620.		1
2961	Genes, environment, and race: Quantitative genetic approaches American Psychologist, 2005, 60, 104-114.	3.8	21
2962	Expressive writing and blood pressure , 0, , 17-30.		18
2964	The epidemiology of hypertension and its associated risk factors in the city of Debrecen, Hungary. Public Health, 2002, 116, 138-44.	1.4	19
2965	Ambulatory blood pressure in heart failure. European Journal of Clinical Investigation, 2001, 31, 18-25.	1.7	6
2966	Pharmacology and pharmacotherapy of cardiovascular drugs in patients with chronic renal disease. Seminars in Nephrology, 2001, 21, 66-78.	0.6	6
2967	In memory of a legendary athlete: Measured success in diabetic nephropathy. Seminars in Nephrology, 2001, 21, 124-132.	0.6	2
2968	Influence of Repeated Measurement on One Occasion, on Successive Days, and on Workdays on Home Blood Pressure Values. Clinical and Experimental Hypertension, 2005, 27, 215-222.	0.5	8
2970	Established major coronary risk factors: historical overview., 2005, , 18-31.		12

#	Article	IF	CITATIONS
2971	Current status: six established major risk factors – and low risk. , 2005, , 32-70.		26
2972	Blood pressure and the burden of coronary heart disease. , 2005, , 152-173.		3
2973	Life course influences on coronary heart disease. , 2005, , 568-590.		5
2974	Epidemiology: the foundation of public health. , 2015, , 403-410.		4
2975	Inhibitors of the renin angiotensin system: implications for the anaesthesiologist. Current Opinion in Anaesthesiology, 1998, 11, 321-326.	0.9	6
2976	A review of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Current Opinion in Cardiology, 1999, 14, 161.	0.8	24
2977	Treatment of stable angina. Current Opinion in Cardiology, 1999, 14, 349-358.	0.8	38
2978	Bicycle exercise blood pressure can be useful in a clinical practice. Journal of Hypertension, 1999, 17, 147-148.	0.3	5
2979	Isolated systolic hypertension: Cardiovascular risk and treatment benefits. Journal of Hypertension, 2001, 19, 2279-2281.	0.3	8
2980	Should high-normal blood pressure be treated?. Journal of Hypertension, 2002, 20, 1028-1030.	0.3	2
2981	Hypertensive Patients and Diabetes: A High-Risk Population. Journal of Cardiovascular Pharmacology, 1998, 32, S1-S8.	0.8	5
2982	Twenty-Four Hour Antihypertensive Efficacy of Indapamide, 1.5-Mg Sustained Release: Results of Two Randomized Double-Blind Controlled Studies. Journal of Cardiovascular Pharmacology, 1998, 32, 673-678.	0.8	27
2983	Clinical Experience with Spirapril in Human Hypertension. Journal of Cardiovascular Pharmacology, 1999, 34, S25-S30.	0.8	2
2984	A Look at Hypertension in Young African-American Men. Nurse Practitioner, 2003, 28, 59-60.	0.2	3
2985	Clinical and economic benefits of angiotensin-converting enzyme inhibitors in diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 1999, 8, 243-249.	1.0	1
2986	Angiotensin converting enzyme inhibitors: first line therapy in patients with diabetic hypertension?. Current Opinion in Nephrology and Hypertension, 1999, 8, 333-334.	1.0	4
2987	Aldosterone Receptor Blockade: A Therapy Resurrected. Heart Disease (Hagerstown, Md ), 2003, 5, 85-88.	1.3	4
2988	The 'ABPM effect' gradually decreases but does not disappear in successive sessions of ambulatory monitoring. Journal of Hypertension, 2003, 21, 2265-73.	0.3	14

#	Article	IF	Citations
2989	Ambulatory Blood Pressure Monitoring. Southern Medical Journal, 2003, 96, 563-568.	0.3	19
2990	Treatment of Chronic Hypertension for the Prevention of Stroke. Southern Medical Journal, 2003, 96, 359-362.	0.3	9
2991	Urine Dipstick as a Screening Test for Serum Creatinine Elevation in Emergency Department Patients with Severe Hypertension. Academic Emergency Medicine, 2002, 9, 27-34.	0.8	13
2992	The Effect of Hypertension on Uncontrolled Hemorrhage in a Rodent Model. Academic Emergency Medicine, 2002, 9, 767-774.	0.8	5
2994	Do drug company promotions influence physician behavior?. Western Journal of Medicine, 2001, 174, 232-233.	0.3	23
2995	Hypertensive therapy: attacking the renin-angiotensin system. Western Journal of Medicine, 2001, 175, 119-124.	0.3	1
2996	ACE inhibitors and insulin sensitivity. Postgraduate Medical Journal, 1999, 75, 445-445.	0.9	1
2997	Using Angiotensin Converting Enzyme Inhibitors in African-American Hypertensives: A New Approach to Treating Hypertension and Preventing Target-Organ Damage. , 0, .		18
2998	Hypertriglyceridemia: A Review of Clinical Relevance and Treatment Options: Focus on Cerivastatin. , 0,		8
2999	Patient adherence to antihypertensive medications in upper Egypt: a cross-sectional study. Egyptian Heart Journal, 2020, 72, 29.	0.4	13
3000	Effect of $\hat{i}^2$ -blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis. Journal of Geriatric Cardiology, 2019, 16, 291-297.	0.2	5
3001	Goals of Treatment., 2002,, 13-20.		1
3002	Hyperlipidemia and Diabetes Mellitus., 2002,,.		1
3004	Characteristics of Cardiovascular Morphology and Function in the High-Normal Subset of Hypertension Defined by JNC-VI Recommendations Hypertension Research, 1999, 22, 291-295.	1.5	21
3005	Urinary Excretions of Albumin and Type IV Collagen in Normotensive and Hypertensive Subjects Hypertension Research, 2000, 23, 459-466.	1.5	12
3006	Roles of Renal Dopamine and Kallikrein-Kinin Systems in Antihypertensive Mechanisms of Exercise in Rats Hypertension Research, 2000, 23, 511-519.	1.5	6
3007	Profiles of Patients Who Control the Doses of Their Antihypertensive Drugs by Self-Monitoring of Home Blood Pressure Hypertension Research, 2001, 24, 203-207.	1.5	7
3008	Trends in Pharmacologic Management of Hypertension in Japan One Year after the Publication of the JSH 2000 Guidelines. Hypertension Research, 2002, 25, 175-178.	1.5	25

#	Article	IF	CITATIONS
3009	Vascular Remodeling of the Carotid Artery in Patients with Untreated Essential Hypertension Increases with Age Hypertension Research, 2002, 25, 373-379.	1.5	28
3010	Brain Natriuretic Peptide as a Risk Marker for Incident Hypertensive Cardiovascular Events Hypertension Research, 2002, 25, 669-676.	1.5	44
3011	The Status of Hypertension Management in Japan in 2000 Hypertension Research, 2002, 25, 717-725.	1.5	36
3012	Hypertension Attenuates the Efficacy of Hypoglycemic Therapy for Preserving Coronary Flow Reserve in Patients with Type 2 Diabetes Hypertension Research, 2002, 25, 893-900.	1.5	12
3013	Guidelines for Treatment of Hypertension in the Elderly. 2002 Revised Version Hypertension Research, 2003, 26, 1-36.	1.5	41
3014	Effects of Hormone Replacement Therapy on Office and Ambulatory Blood Pressure in Japanese Hypertensive Postmenopausal Women. Hypertension Research, 2003, 26, 369-376.	1.5	15
3015	T+31C Polymorphism (M235T) of the Angiotensinogen Gene and Home Blood Pressure in the Japanese General Population: The Ohasama Study Hypertension Research, 2003, 26, 47-52.	1.5	14
3016	Different Coronary Blood Flow Increase in Left Ventricular Hypertrophy Due to Hypertension Compared to Hypertrophic Cardiomyopathy at Elevated Heart Rate. Hypertension Research, 2003, 26, 789-793.	1.5	6
3017	Insulin Resistance and Hypertension: Seven-Year Follow-Up Study in Middle-Aged Japanese Men (the KEIO) Tj ETQ	0q9 <u>.</u> 9 0 rgE	BT 10verlock
3018	Blunted Reduction of Pulse Pressure during Nighttime Is Associated with Left Ventricular Hypertrophy in Elderly Hypertensive Patients. Hypertension Research, 2004, 27, 573-579.	1.5	14
3019	Association of Genetic Polymorphisms of Sodium-Calcium Exchanger 1 Gene, NCX1, with Hypertension in a Japanese General Population. Hypertension Research, 2004, 27, 697-702.	1.5	17
3020	Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertension Research, 2006, 29, S1-S106.	1.5	198
3021	Cognitive Deficits Are Associated with Frontal and Temporal Lobe White Matter Lesions in Middle-Aged Adults Living in the Community. PLoS ONE, 2010, 5, e13567.	1.1	52
3022	Prevalence of Major Chronic Conditions among Older Chinese Adults: The Study on Global AGEing and Adult Health (SAGE) Wave 1. PLoS ONE, 2013, 8, e74176.	1.1	88
3023	Total and Abdominal Adiposity and Hypertension in Indigenous Women in Midwest Brazil. PLoS ONE, 2016, 11, e0155528.	1.1	11
3024	Socioeconomic Status and Poor Health Outcome at 10 Years of Follow-Up in the Multi-Ethnic Study of Atherosclerosis. PLoS ONE, 2016, 11, e0165651.	1.1	26
3025	A Comparison of the Cardiovascular Risks of Rural, Suburban, and Urban Women. Online Journal of Rural Nursing and Health Care: the Official Journal of the Rural Nurse Organization, 2001, 2, 6-23.	0.4	1
3026	Significance of Mean Blood Pressure for Blood Pressure Control. International Heart Journal, 2005, 46, 691-699.	0.5	7

#	ARTICLE	IF	CITATIONS
3027	Portective Action of Angiotensin Converting Enzyme Inhibitors on Cardiac Hypertrophy in the Aortic-Banded Rat International Heart Journal, 1999, 40, 645-654.	0.6	4
3028	Difference in the Occurrence of Cardiovascular Events According to Class of Antihypertensive Agent, Based on a Follow-Up Study of Japanese Hypertension Patients International Heart Journal, 2001, 42, 585-595.	0.6	3
3029	Elevated White Blood Cell Count as a Risk Factor of Coronary Artery Disease International Heart Journal, 2003, 44, 201-211.	0.6	29
3030	<b>Cardiovascular Disease Risk Factors in Post-Menopausal Women in West Anatolia</b> . International Heart Journal, 2004, 45, 119-131.	0.6	8
3031	Is the Beneficial Effect of Preinfarction Angina Related to an Immune Response?. International Heart Journal, 2004, 45, 205-215.	0.6	4
3032	Development of a Health Risk Index Associated with Degree of Overweight in School Children. The Showa University Journal of Medical Sciences, 2001, 13, 235-241.	0.1	1
3033	The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics, 2004, 114, 555-576.	1.0	4,715
3034	Evidence-based medicine. A lesson for electrocardiography?. Arquivos Brasileiros De Cardiologia, 2003, 81, 102-10.	0.3	3
3036	Revisão dos critérios de Sokolow-Lyon-Rappaport e cornell para hipertrofia do ventrÃculo esquerdo. Arquivos Brasileiros De Cardiologia, 2008, 90, 46-53.	0.3	18
3037	Hipertensão arterial entre trabalhadores de petróleo expostos a ruÃdo. Cadernos De Saude Publica, 2001, 17, 1481-1488.	0.4	6
3038	Are hypertensive elderly patients treated differently?. Clinical Interventions in Aging, 2006, 1, 289-294.	1.3	5
3039	Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Therapeutics and Clinical Risk Management, 2007, 3, 181-196.	0.9	9
3040	Barriers to and strategies for effective blood pressure control. Vascular Health and Risk Management, 2005, 1, 9-14.	1.0	15
3041	Treatment of high blood pressure and gain in event-free life expectancy. Vascular Health and Risk Management, 2005, 1, 163-169.	1.0	25
3042	Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vascular Health and Risk Management, 2006, 2, 491-498.	1.0	10
3043	Genetic Signatures in the Treatment of Stroke. Current Pharmaceutical Design, 2014, 21, 343-354.	0.9	5
3044	The Impact of Treatment Adherence for Patients With Diabetes and Hypertension on Cardiovascular Disease Risk: Protocol for a Retrospective Cohort Study, 2008-2018. JMIR Research Protocols, 2019, 8, e13571.	0.5	2
3045	Prediction of Incident Hypertension Within the Next Year: Prospective Study Using Statewide Electronic Health Records and Machine Learning. Journal of Medical Internet Research, 2018, 20, e22.	2.1	151

#	ARTICLE	IF	Citations
3046	Fosinopril and amlodipine in the treatment of isolated systolic hypertension. Medicinski Pregled, 2004, 57, 45-53.	0.1	4
3047	Effect of nutritional intervention on the prevalence of metabolic syndrome and heart disease risk factors in urban Tehran [Tehran Lipid and Glucose Study]. Eastern Mediterranean Health Journal, 2011, 17, 501-508.	0.3	2
3048	The treatment of patients with advanced renal involvement., 2003,, 189-197.		1
3049	Determinants of Blood Pressure among Youth in Ajman, UAE. Journal of College of Medical Sciences-Nepal, 2010, 1, 17-21.	0.2	4
3051	Time Trends in Cardiometabolic Risk Factors in Adults. Deutsches Ärzteblatt International, 2016, 113, 712-719.	0.6	40
3052	Hypertension in Germany. Deutsches Ärzteblatt International, 2016, 113, 809-815.	0.6	36
3053	Dietary Sodium and Blood Pressure in Older Adults. Californian Journal of Health Promotion, 2006, 4, 25-46.	0.3	4
3054	Repeated analysis of estimated insulin resistance using the HOMAIR index in nondiabetic patients on peritoneal dialysis and its relationship with cardiovascular disease and mortality. Nefrologia, 2013, 33, 85-92.	0.2	8
3055	Sex-specific associations of nutrition with hypertension and systolic blood pressure in Alaska Natives findings from the GOCADAN study. International Journal of Circumpolar Health, 2011, 70, 254-265.	0.5	8
3056	Dietary Intake Ratios of Calcium-to-Phosphorus and Sodium-to-Potassium Are Associated with Serum Lipid Levels in Healthy Korean Adults. Preventive Nutrition and Food Science, 2012, 17, 93-100.	0.7	19
3057	Incidence of and Risk Factors for Bundle Branch Block in Adults older than 40 years. Korean Journal of Internal Medicine, 2004, 19, 171-178.	0.7	27
3058	To Investigate the Relation of Hypertension and Anthropometric Measurement among Elderly in Malaysia. Journal of Applied Sciences, 2008, 8, 3963-3968.	0.1	15
3059	The Association of Hypertension with Major Risks Factors among University Putra Malaysia Retirees. Journal of Medical Sciences (Faisalabad, Pakistan), 2008, 8, 254-261.	0.0	8
3060	Blood Pressure Monitoring: Older Adults' Perceptions. Journal of Gerontological Nursing, 2004, 30, 44-52.	0.3	4
3061	Association between adherence to the Mediterranean diet and oxidative stress. American Journal of Clinical Nutrition, 2008, 88, 1364-70.	2.2	175
3062	The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure Cleveland Clinic Journal of Medicine, 2003, 70, 263-269.	0.6	4
3063	Using C-reactive protein to assess cardiovascular disease risk Cleveland Clinic Journal of Medicine, 2003, 70, 634-640.	0.6	43
3064	Treat high blood pressure sooner: tougher, simpler JNC 7 guidelines Cleveland Clinic Journal of Medicine, 2003, 70, 721-728.	0.6	5

#	Article	IF	CITATIONS
3065	A different approach to resistant hypertension Cleveland Clinic Journal of Medicine, 2007, 74, 449-456.	0.6	8
3066	Can patients with COPD or asthma take a beta-blocker. Cleveland Clinic Journal of Medicine, 2010, 77, 498-499.	0.6	5
3067	Blood Pressure Control in Outpatients With Hypertension After the Publication of the JSH2000 Guidelines. Japanese Journal of Clinical Pharmacology and Therapeutics, 2003, 34, 283-288.	0.1	3
3068	Secondary Prevention of Coronary Artery Disease in Elderly Persons: A Treatise on a Report by the American Heart Association. American Journal of Critical Care, 2006, 15, 514-518.	0.8	1
3069	Association between Primary Care Quality and Health Behaviors in Patients with Essential Hypertension Who Visit a Family Physician as a Usual Source of Care. Korean Journal of Family Medicine, 2011, 32, 104.	0.4	9
3070	Sonographic assessment of the carotid intima-media thickness on B-mode ultrasonography in a Nigerian population. Nigerian Medical Journal, 2015, 56, 357.	0.6	8
3071	Clinical efficacy of Coleus forskohlii (Willd.) Briq. (Makandi) in hypertension of geriatric population. AYU: an International Quarterly Journal of Research in Ayurveda, 2011, 32, 59.	0.3	18
3072	Development of Arabic version of Berlin questionnaire to identify obstructive sleep apnea at risk patients. Annals of Thoracic Medicine, 2011, 6, 212.	0.7	61
3073	Morbidity pattern and its sociodemographic determinants among elderly population of Raichur district, Karnataka, India. Journal of Family Medicine and Primary Care, 2017, 6, 340.	0.3	12
3074	Knowledge and Attitudes. , 2008, , 127-140.		18
3075	The Pulse Pressure Amplitude as a Marker of Myocardial Infarction Risk. Journal of Clinical & Experimental Cardiology, 2013, 04, .	0.0	2
3076	Metabolic Syndrome (Ms) among Adults in Urban Slums – A Cross Sectional Study in Hyderabad, Andhra Pradesh, India. , 2012, 02, .		1
3077	Rapid Stability-indicating RRLC Method for Simultaneous Estimation of Irbesartan and its Related Impurities. Indian Journal of Pharmaceutical Sciences, 2016, 78, .	1.0	3
3078	Cardiovascular Risk Factors for Incident Hypertension in the Prehypertensive Population. Epidemiology and Health, 2010, 32, e2010003.	0.8	21
3079	Cardiac benefits of renal artery stenting. EuroIntervention, 2010, 6, 485-491.	1.4	8
3080	Knowledge, Attitude and Self-Care Practice towards Control of Hypertension among Hypertensive Patients on Follow-up at St. Paul's Hospital, Addis Ababa. Ethiopian Journal of Health Sciences, 2019, 29, 421-430.	0.2	18
3081	Evaluation of thiazide diuretic use as preferred therapy in uncomplicated essential hypertension patients. Pharmacy Practice, 2007, 5, 130-4.	0.8	3
3082	Global left ventricular performance in non-diabetic non-hypertensive metabolic syndrome adults. World Journal of Cardiology, 2011, 3, 48.	0.5	3

#	ARTICLE	IF	CITATIONS
3083	Prehypertension: Underlying pathology and therapeutic options. World Journal of Cardiology, 2014, 6, 728.	0.5	16
3084	Renal sympathetic nervous system and the effects of denervation on renal arteries. World Journal of Cardiology, 2014, 6, 814.	0.5	21
3085	Autonomic dysreflexia: An important cardiovascular complication in spinal cord injury patients. Cardiology Journal, 2012, 19, 215-219.	0.5	32
3086	Association between Insomnia and Hypertension in Japanese Male Workers Health Evaluation and Promotion, 2003, 30, 457-461.	0.0	1
3087	Obesity and Hypertension: What Should We Do?. Annals of Internal Medicine, 2001, 134, 72.	2.0	4
3088	Sound Clinical Advice for Hypertensive Patients. Annals of Internal Medicine, 2001, 135, 1084.	2.0	1
3089	Arm Position and Blood Pressure Measurement. Annals of Internal Medicine, 2004, 140, 74.	2.0	10
3090	Association Between Posttraumatic Stress Disorder and Epigenetic Age Acceleration in a Sample of Twins. Psychosomatic Medicine, 2022, 84, 151-158.	1.3	9
3091	Is any association between alternate healthy eating index (AHEI) with lipid profile and liver enzymes? A cross-sectional Study. Journal of Diabetes and Metabolic Disorders, 2021, 20, 1537-1544.	0.8	1
3092	Randomized controlled trial of stress reduction with meditation and health education in black men and women with high normal and normal blood pressure. American Journal of Preventive Cardiology, 2021, 8, 100279.	1.3	5
3093	Cerebrovascular Disease in Women. , 2000, , 797-810.		1
3094	Does "white coat hypertension" increase the risk for any adverse outcome from hypertension?. Western Journal of Medicine, 2000, 172, 47-48.	0.3	O
3095	WHO/ISHé«~血圧管ç†1999å¹′ã®ã,¬ã,¤f‰ãƒ©ã,¤ƒ³ã«ã∰,ã√. Journal of Nippon Medical School, 2000, 67, 22	0 <b>22</b> 1.	0
3096	Relationship between silent brain infarction, periventricular hyperintensity and blood pressure Nosotchu, 2000, 22, 585-589.	0.0	O
3098	Development of the New Assessment Tools for Lifestyles: Japanese Health Practice Index (JHPI) Japanese Journal of MHTS, 2001, 28, 302-310.	0.0	5
3099	A Case of Renovascular Hypertension Due to Bilateral Renal Artery Microaneurysm Who Succeeded in Baby Delivery Hypertension Research, 2001, 24, 83-85.	1.5	1
3100	Vegetarian Diets and Dietary Guidelines for Chronic Disease Prevention. Modern Nutrition, 2001, , 371-409.	0.1	0
3101	Other Factors in Self-Reported Hypertension Treatment Practices Among Primary Care Physicians. Archives of Internal Medicine, 2001, 161, 1458-1458.	4.3	O

#	Article	IF	CITATIONS
3102	Secondary prevention of coronary heart disease. BMJ: British Medical Journal, 2002, 324, 611-611.	2.4	O
3104	Antenatal Surveillance in Preeclampsia and Chronic Hypertension. , 2002, , 235-262.		0
3105	Cardiology, Clinical Pharmacy Practice in. , 2002, , 119-126.		1
3106	Cardiology, Clinical Pharmacy Practice in. , 2002, , 119-126.		O
3107	Clinical value of diastolic dysfunciton in hypertension. Journal of Hypertension, 2002, 20, 2309-2310.	0.3	0
3109	Hypertension as An Important Public Health Challenge. , 2003, , .		0
3110	Weight Reduction., 2003,,.		0
3111	Policies for Prevention and Treatment of Hypertension. , 2003, , .		0
3112	Biofeedback and Relaxation. , 2003, , .		0
3113	Update in General Internal Medicine. Annals of Internal Medicine, 2003, 139, 285.	2.0	4
3114	Hypertensive Encephalopathy. , 2004, , 641-647.		0
3115	Strengthening the standards for preventing heart disease and stroke: the recent AHA guidelines Cleveland Clinic Journal of Medicine, 2004, 71, 426-432.	0.6	0
3116	Dietary Approaches to Hypertension Management: The DASH Studies., 2005,, 453-463.		0
3117	Anesthesia and Hypertension. , 2005, , 813-825.		0
3118	Initial Evaluation and Follow-Up Assessment. , 2005, , 295-304.		0
3119	Prognostic and Diagnostic Value of Ambulatory Blood Pressure Monitoring. , 2005, , 305-317.		2
3120	The VALUE Trial. , 2005, , 366-375.		1
3122	Quality Improvement for Endovascular Procedures. , 2005, , 1-27.		0

#	Article	IF	Citations
3123	Dyslipidemia Induced by Atenolol in Common Rabbits Oryctolagus cuniculus. International Journal of Pharmacology, 2006, 2, 553-556.	0.1	0
3124	Arterial Hypertension. Fundamental and Clinical Cardiology, 2006, , 19-62.	0.0	0
3125	A Historical Look at Hypertension: Celebrating 100 Years with the Southern Medical Association. Southern Medical Journal, 2006, 99, 1412-1413.	0.3	2
3126	Cardiovascular Hypertension., 2007,, 195-214.		0
3127	Prevalence, Awareness, Treatment, and Control of Hypertension: United States National Health and Nutrition Examination Survey 2001–2002. Yearbook of Cardiology, 2007, 2007, 13-15.	0.0	0
3128	Peripheral Vascular Surgery., 2007,, 394-398.		0
3129	U.S. and Canadian Guidelines for Hypertension. , 2007, , 551-570.		0
3130	Hypertension Disease Management Services. , 2007, , 527-534.		1
3131	Postoperative Hypertension (HTN)., 2007,, 588-589.		0
3132	Cardiovascular Disease and Lifestyle Modification. , 2007, , 540-554.		0
3133	Antihypertensive Medication Use Among US Adults With Hypertension. Yearbook of Cardiology, 2007, 2007, 20-22.	0.0	0
3134	Goal-Oriented Hypertension Management in Diabetic and Nondiabetic Patients., 2007,, 205-222.		0
3135	Is Metabolic Syndrome a Risk Factor for Carotid Atherosclerosis in Normotensive and Prehypertensive Individuals?. Journal of Atherosclerosis and Thrombosis, 2007, 14, 72-77.	0.9	2
3136	Health sector challenges and responses beyond the Alma-Ata Declaration: a Caribbean perspective. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2007, 21, 155-163.	0.6	2
3137	Public health and epidemiology. , 2007, , 173-182.		1
3138	What is adequate hypertension control? Having your dinner and dessert too Cleveland Clinic Journal of Medicine, 2007, 74, 748-754.	0.6	1
3140	Relationship between Low Evaluation by Recipients under 40 years old of Health Interviews by Occupational Health Nurses and Deterioration in Health Checkup Results over One year. Keio Journal of Medicine, 2008, 57, 90-98.	0.5	2
3141	Hipertensión (HTA) postoperatoria. , 2008, , 588-589.		O

#	Article	IF	Citations
3142	5.é«~é½¢è€ã®è¬¬ç‰©ç™,法ã®å•é;Œç,¹ ―循環噓é~域笾æ,£. Japanese Journal of Clinical Pha	arm <b>a.d</b> olog	y a <b>o</b> d Therape
3145	Long-term survival and prognostic implications of Chinese type 2 diabetic patients with coronary artery disease after coronary artery bypass grafting. Health, 2009, 01, 139-145.	0.1	0
3147	Drug Compliance Amongst Hypertensives in a Nigerian Community. TAF Preventive Medicine Bulletin, 2011, 10, 145.	0.1	0
3150	A Three Year Cohort Prospective Type 2 Diabetes Control Study in Basrah. Journal of Diabetes & Metabolism, 2011, 02, .	0.2	8
3152	Anthropometric parameter-based assessment for cardiovascular disease predisposition among young Indians. World Journal of Cardiology, 2012, 4, 221.	0.5	1
3153	Prehypertension: Definitions, Clinical Significance and Therapeutic Approachesâ€"To Treat or not to Treat?., 2012,, 3-12.		1
3154	Provocative dietary factors in geriatric hypertension: A surveillance study. AYU: an International Quarterly Journal of Research in Ayurveda, 2012, 33, 530.	0.3	0
3155	Periodontal Treatment of Medically Compromised Patients. , 2012, , 396-411.		2
3156	Lifestyle, Nutrition, and Hypertensive Disorders during Pregnancy., 2012,, 207-236.		1
3157	Study on the levels of oxidant and anti-oxidant enzymes in hypertensive patients. International Journal of Medical Science and Public Health, 2014, 3, 1074.	0.2	0
3158	Evidence-Based Medicine and ACE Inhibition. Journal of Cardiovascular Pharmacology, 1998, 32, S24-S35.	0.8	16
3160	é«~è;€åœ§ã®æ²»ç™,ãëä°å¾Œ(循簰噰ç−¾æ,£ã®æ²»ç™,ãëä°å¾Œ)(<特é>†>循簰噰å¦ã®é€²æ©).Jo	ourmoant of JO	CS <b>6</b> ardiologis
3161	The Invisible Woman. Archives of Internal Medicine, 1999, 159, 99-a-100.	4.3	0
3162	Human Aging at the Millennium. , 1999, , 11-18.		0
3163	The Effects of Carvedilol, a Vasodilating ^ ^beta;-adrenoceptor Blocker, on the Quality of Life in Hypertensive Patients. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 1999, 4, 133-148.	0.0	2
3164	Minerals and hypertension: facts and fiction. Current Opinion in Nephrology and Hypertension, 1999, 8, 225-229.	1.0	0
3165	Should beta-Blockers Be Used to Treat Hypertension in Elderly Patients?. JAMA - Journal of the American Medical Association, 1999, 281, 1988-1989.	3.8	1
3166	Diabetes and hypertension: an update. Current Opinion in Endocrinology, Diabetes and Obesity, 1999, 6, 245.	0.6	O

#	Article	IF	CITATIONS
3168	Dairy Foods and Hypertension. , 1999, , .		0
3169	Lactose Intolerance., 1999, , .		O
3170	Reliability of Self-Measured Blood Pressure for Research Purposes. Archives of Internal Medicine, 1999, 159, 2365-2366.	4.3	0
3171	Anthropometric Measureme nts, Dietary Intake and Lipid Profile of Hypertensive Young Adults (25-35) Tj ETQq1 1 Food Science, 2014, 2, 122-130.	0.784314 0.3	ł rgBT /Over O
3172	Neurovegetative status and 24 hours´ arterial pressure profile of hypertensive patients. Journal of New Medical Technologies, 2014, 8, 1-6.	0.0	0
3173	Association of N-Terminal Pro–Brain Natriuretic Peptide, Matrix –Metalloprotinase-9, and 8-Oxo-2 Deoxy Guanosine with the Incidence of Essential Hypertension. American Journal of Internal Medicine, 2015, 3, 67.	0.1	O
3174	Improving Medicine Adherence among Elderly Hypertensive Patients by Using a One-dose Package Medication Support System. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0 rg	BЂ <b>/O</b> verlo	c <b>k</b> 10 Tf 50
3175	Diagnostic Value of Noninvasive Cardiac Function Measurement for Hypertensive Disorders in Pregnancy. Open Journal of Obstetrics and Gynecology, 2015, 05, 181-184.	0.1	O
3176	Occurrence of metabolic syndrome with relation to job profile among mine employees. Journal of Obesity and Metabolic Research, 2016, 3, 32.	0.1	0
3177	Development of Blood Pressure Norms and Definition of Hypertension in Children., 2016, , 1-13.		O
3178	Comparative Efficiency of Enalapril and Perindopril in Terms of the Effect on Central Blood Pressure and Elastic Properties of Arteries in Patients with Mild to Moderate Hypertension. Hypertension, 2016,	0.2	1
3179	Management of arterial hypertension in Cotonou city, Benin: general practitioners' knowledge, attitudes and practice. Cardiovascular Journal of Africa, 2016, 27, e1-e6.	0.2	4
3180	Exercise Testing in Hypertension and Hypertension in Athletes. , 2017, , 1-13.		0
3181	Controlling Systolic Blood Pressure below 140 mm Hg in Most Hypertensive Patients matches Systolic Blood Pressure Intervention Trial Intensive Treatment: Practical Implications for Patient Care. Hypertension Journal, 2017, 3, 12-19.	0.1	O
3182	Isolated Systolic Hypertension. , 2018, , 251-261.		0
3183	Development of Blood Pressure Norms and Definition of Hypertension in Children., 2018,, 263-275.		O
3184	The Effect of Hypertension Health Management (HHM) Using IT for the Elderly: A Case Study in an Underdeveloped Area of China. Lecture Notes in Computer Science, 2018, , 177-185.	1.0	0
3185	Role of home Blood Pressure Monitoring in overcoming Therapeutic Inertia and improving Hypertension Control in Mexico. Annals of Clinical Hypertension, 0, , 017-023.	0.7	1

#	Article	IF	CITATIONS
3186	The study of prevalence and determinants of white-coat hypertension in medical personnel: A prospective study. Heart India, 2019, 7, 131.	0.2	0
3187	Malignant Hypertensive Retinopathy Revealing Bilateral Renal Atrophy in Adolescent at Chu-Campus of LomA©. International Journal of Ophthalmology & Visual Science, 2019, 4, 42.	0.0	0
3188	Pattern and appropriateness of antihypertensive prescriptions among hospitalized hypertensives in Nigeria. Nigerian Journal of Cardiology, 2019, 16, 18.	0.2	2
3189	Organización Temprana del SÃ-mismo desde una mirada de Complejidad Neuroafectiva. Revista De Psicoterapia, 2019, 30, 43-60.	0.0	1
3190	Blood Pressure Variability in Pregnancy: an Opportunity to Develop Improved Prognostic and Risk Assessment Tools. Current Hypertension Reports, 2020, 22, 10.	1.5	3
3191	The complex care of a torture survivor in the United States. Torture: Quarterly Journal on Rehabilitation of Torture Victims and Prevention of Torture, 2020, 30, 23-39.	0.1	0
3192	The Association among Blood Pressure, Blood Pressure Medications, and Glaucoma in a Nationwide Electronic Health Records Database. Ophthalmology, 2022, 129, 276-284.	2.5	13
3193	Factors Affecting Hypertension in the Adult Population of the Marmara Region, Turkey: A Descriptive Field Study. International Journal of Hypertension, 2020, 2020, 1-7.	0.5	1
3194	Therapeutic exercise for hypertension: An update for exercise prescribers. Nigerian Journal of Cardiology, 2020, 17, 11.	0.2	0
3196	Krankheiten des Kreislaufsystems. , 2008, , 375-399.		0
3197	Hypertensive Urgencies and Emergencies. , 2007, , 61-75.		0
3198	Glomerulonephritiden., 2005,, 529-553.		0
3199	Ischemic Heart Disease in the Older Hypertensive Patient. , 2005, , 229-254.		0
3200	Assessment of the Role of ACE Inhibitors in the Elderly. , 2005, , 321-348.		0
3201	Hypertension Therapy., 2005,, 615-637.		0
3203	The diversity of diagnoses of preeclampsia. Hypertension in Pregnancy, 2001, 20, 57-67.	0.5	10
3204	Cardiac risk factors and myocardial perfusion reserve in women with microvascular coronary dysfunction. Cardiovascular Diagnosis and Therapy, 2013, 3, 146-52.	0.7	13
3205	Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ: British Medical Journal, 1998, 317, 703-13.	2.4	1,610

#	Article	IF	CITATIONS
3206	When should hypertension be treated? The different perspectives of Canadian family physicians and patients. Cmaj, 2000, 163, 403-8.	0.9	29
3207	The management of hypertension in Canada: a review of current guidelines, their shortcomings and implications for the future. Cmaj, 2001, 164, 517-22.	0.9	18
3208	Slowing the progression of chronic renal insufficiency. Cmaj, 2002, 166, 906-7.	0.9	1
3209	Left ventricular diastolic function and circadian variation of blood pressure in essential hypertension. Texas Heart Institute Journal, 2005, 32, 28-34.	0.1	11
3210	Secondary prevention of coronary heart disease. Ill defined inclusion criteria resulted in missed trials. BMJ, The, 2002, 324, 611.	3.0	0
3211	A cost evaluation of the Georgia Stroke and Heart Attack Prevention Program. Preventing Chronic Disease, 2006, 3, A12.	1.7	11
3212	Offline testing of the ATHENA Hypertension decision support system knowledge base to improve the accuracy of recommendations. AMIA Annual Symposium proceedings, 2006, , 539-43.	0.2	10
3213	Executive summary of the African-American Initiative. MedGenMed: Medscape General Medicine, 2007, 9, 28.	0.2	3
3215	Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: effectiveness in combination with diuretics or beta-blockers for treating hypertension. Vascular Health and Risk Management, 2007, 3, 579-85.	1.0	8
3216	Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy. Vascular Health and Risk Management, 2007, 3, 1029-37.	1.0	19
3217	Oportunidades program participation and body mass index, blood pressure, and self-reported health in Mexican adults. Preventing Chronic Disease, 2008, 5, A81.	1.7	17
3218	Strategies for establishing policy, environmental, and systems-level interventions for managing high blood pressure and high cholesterol in health care settings: a qualitative case study. Preventing Chronic Disease, 2008, 5, A83.	1.7	5
3222	Hypertension and hyperlipidemia management in patients treated at community health centers. Journal of Clinical Outcomes Management, 2008, 15, 125-131.	1.7	9
3223	Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. International Journal of COPD, 2007, 2, 535-40.	0.9	29
3224	Association of three polymorphisms in the gene coding for endothelin-1 with essential hypertension, overweight and smoking. Experimental and Clinical Cardiology, 2002, 7, 201-4.	1.3	2
3225	Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure. Experimental and Clinical Cardiology, 2003, 8, 173-83.	1.3	62
3226	Abnormal cardiac structure and function in the metabolic syndrome: a population-based study. Mayo Clinic Proceedings, 2008, 83, 1350-7.	1.4	22
3228	Arterial baroreceptors in the management of systemic hypertension. Medical Science Monitor, 2010, 16, RA1-8.	0.5	45

#	Article	IF	CITATIONS
3229	Perindopril: the evidence of its therapeutic impact in hypertension. Core Evidence, 2007, 2, 63-79.	4.7	2
3230	Factors in relation with self-regulation of hypertension, based on the model of goal directed behavior in Yazd city. Journal of Medicine and Life, 2011, 4, 30-5.	0.4	7
3231	Management of renal artery stenosis - an update. Libyan Journal of Medicine, 2008, 3, 91-100.	0.8	0
3234	Are we satisfied with the follow-up of hypertensive and chronic kidney disease patients in outpatient clinics?. Hippokratia, 2011, 15, 44-9.	0.3	1
3235	Race/ethnic and sex differentials in pulse pressure among us adults. Ethnicity and Disease, 2005, 15, 601-6.	1.0	7
3236	A Prelimenary Result of the Cardiovascular Risk factors Intervention Study (Pikom Study): Diabetes Mellitus, Hypertension and their Associated Factors. The Malaysian Journal of Medical Sciences, 2005, 12, 20-5.	0.3	1
3237	Influence of blood pressure and blood pressure change on the risk of congestive heart failure in the elderly. Swiss Medical Weekly, 2010, 140, 202-8.	0.8	10
3238	Hypertension research program at ochsner: a program in translational research. Ochsner Journal, 2002, 4, 204-10.	0.5	1
3239	Frequency of risk factors for coronary heart disease among diabetic patients in Al-rabwah phc center in riyadh. Journal of Family and Community Medicine, 2004, 11, 53-8.	0.5	1
3240	Hypertension in diabetics registered in primary health care centers in makkah district, saudi arabia. Journal of Family and Community Medicine, 2000, 7, 23-8.	0.5	3
3241	The potential role of clinical pharmacy services in patients with cardiovascular diseases. Journal of Tehran University Heart Center, 2012, 7, 41-6.	0.2	3
3242	Increasing serum troponin I and early prognosis in patients with chest pain or angina equivalent symptoms in the emergency department. Iranian Journal of Public Health, 2012, 41, 63-9.	0.3	4
3243	Dairy consumption and stroke risk. International Journal of Preventive Medicine, 2013, 4, S294-9.	0.2	4
3244	Evaluating the effects of a low volume stairclimbing programme on measures of health-related fitness in sedentary office workers. Journal of Sports Science and Medicine, 2007, 6, 448-54.	0.7	38
3245	Hypertension management: an update. American Health and Drug Benefits, 2010, 3, 47-56.	0.5	45
3248	An evaluation of a clinical pharmacy-directed intervention on blood pressure control. Pharmacy Practice, 2006, 4, 110-6.	0.8	4
3249	Prehypertension: What is the Current Status?. Malaysian Family Physician, 2008, 3, 72-6.	0.2	4
3252	Race and Sex Differences in Correlates of Systolic Blood Pressure in Community-Dwelling Older Adults. Journal of Health Disparities Research and Practice, 2014, 7, 32-50.	1.1	1

#	Article	IF	CITATIONS
3253	Close association of arterial plaques with left ventricular hypertrophy and ejection fraction in hemodialysis patients. Journal of Nephropharmacology, 2014, 3, 9-12.	0.2	1
3254	A randomized controlled trial of co-payment elimination: the CHORD trial. American Journal of Managed Care, 2015, 21, e455-64.	0.8	7
3255	Hypertension and Coronary Heart Disease. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2003, 14, 67-73.	0.7	1
3256	Late onset of type 2 diabetes is associated with mitochondrial tRNA <sup>Trp</sup> A5514G and tRNA <sup>Ser(AGY)</sup> C12237T mutations. Journal of Clinical Laboratory Analysis, 2022, 36, e24102.	0.9	5
3257	ANTIHYPERTENSIVE PHARMACOTHERAPY IN HYPERTENSIVE PATIENTS AT A TERTIARY CARE TEACHING HOSPITAL AND MEDICAL COLLEGE IN INDIA. Asian Journal of Pharmaceutical and Clinical Research, 0, , 30-36.	0.3	0
3258	Cardiological Society of India. AsiaIntervention, 2021, 7, 76-78.	0.1	2
3259	The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics, 2004, 114, 555-576.	1.0	1,416
3260	OUT-PATIENT METHODS OF REGISTRATION OF BLOOD PRESSURE IN CLINICAL PRACTICE. Eurasian Heart Journal, 2015, , 38-44.	0.2	O
3261	Towards detecting morning surge from sleep self-evaluations. , 2020, , .		0
3262	Association of Pericardial Fat with Cardiac Structure, Function, and Mechanics: The Multi-Ethnic Study of Atherosclerosis. Journal of the American Society of Echocardiography, 2022, 35, 579-587.e5.	1.2	2
3263	Immunomodulatory Potential of Diuretics. Biology, 2021, 10, 1315.	1.3	4
3264	A chronotherapeutic approach to effective blood pressure management. Journal of Clinical Hypertension, 2002, 4, 15-9.	1.0	2
3265	Blood pressure interactions with the DASH dietary pattern, sodium, and potassium: The International Study of Macro-/Micronutrients and Blood Pressure (INTERMAP). American Journal of Clinical Nutrition, 2022, 116, 216-229.	2.2	13
3266	Relationship of indoor solid fuel use for cooking with blood pressure and hypertension among the elderly in China. Environmental Science and Pollution Research, 2022, 29, 53444-53455.	2.7	6
3267	Association between 24-h movement guidelines and cardiometabolic health in Chilean adults. Scientific Reports, 2022, 12, 5805.	1.6	6
3268	Starting Hypertension Treatment: Setting Targets. , 0, , 201-208.		O
3269	Chronic Critical Limb Ischemia: Diagnosis and Treatment. , 0, , 93-118.		0
3270	Risk Factors and the Prevention of Heart Disease. , 0, , 185-205.		O

#	Article	IF	CITATIONS
3271	Management of Renal Artery Stenosis - An Update. Libyan Journal of Medicine, 2008, 3, 91-100.	0.8	0
3273	Defining hypertension: never as simple as it seems. Journal of Hypertension, 2003, 21, 473-4.	0.3	1
3274	Pharmacogenomics of hypertension. Current Opinion in Nephrology and Hypertension, 2003, 12, 61-70.	1.0	11
3276	Serum Aldosterone and Urine Electrolytes Dynamics in Response to DASH Diet Intervention – an Inpatient Mechanistic Study. Journal of Clinical and Translational Science, 0, , 1-28.	0.3	1
3280	Stress-induced Anger and Hypertension: An Evaluation of the Effects of Homeopathic Treatment. , 0, , .		0
3282	Isolated Diastolic Hypertension and Risk of Cardiovascular Disease: Controversies in Hypertension - Pro Side of the Argument. Hypertension, 2022, 79, 1563-1570.	1.3	9
3283	Incidence of Preclinical Heart Failure in a Community Population. Journal of the American Heart Association, $0, \dots$	1.6	3
3284	The Prevalence of Uncontrolled Hypertension among Patients Taking Antihypertensive Medications and the Associated Risk Factors in North Palestine: A Cross-Sectional Study. Advances in Medicine, 2022, 2022, 1-7.	0.3	4
3285	Pulmonary Blood Volume Among Older Adults in the Community: The MESA Lung Study. Circulation: Cardiovascular Imaging, 2022, 15, .	1.3	4
3286	A comparative evaluation of fixed dose and separately administered combinations of lisinopril and hydrochlorothiazide in treatment-naÃve adult hypertensive patients in a rural Nigerian community. International Journal of Cardiology Cardiovascular Risk and Prevention, 2022, 14, 200144.	0.4	1
3287	The ambulatory blood pressure monitoring among obese and nonobese diabetes mellitus patients. Annals of African Medicine, 2022, 21, 255.	0.2	1
3288	Kidney Disease after Heart and Lung Transplantation. Methodist DeBakey Cardiovascular Journal, 2022, 18, 34-40.	0.5	1
3289	The Correlation Between Estimated Glucose Disposal Rate and Coagulation Indexes in Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 15, 2643-2652.	1.1	1
3290	Who should be screened for primary aldosteronism? A comprehensive review of current evidence. Journal of Clinical Hypertension, 2022, 24, 1194-1203.	1.0	6
3291	Role of α1â€blockers in the current management of hypertension. Journal of Clinical Hypertension, 2022, 24, 1180-1186.	1.0	9
3292	Even high normal blood pressure affects live birth rate in women undergoing fresh embryo transfer. Human Reproduction, 2022, 37, 2578-2588.	0.4	1
3293	Role of ambulatory blood pressure monitoring in hypertensive patients having controlled office blood pressure. Indian Heart Journal, 2022, 74, 474-477.	0.2	1
3294	Influence of blood pressure and blood pressure change on the risk of congestive heart failure in the elderly. Swiss Medical Weekly, 0, , .	0.8	3

#	Article	IF	Citations
3295	Management of arterial hypertension: practical aspects in young athletes. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2022, 67, 130-134.	0.1	0
3296	Psychosocial Determinants of Recommended Lifestyle Behaviors among Hypertensive Patients: An Integrative Literature Review. Western Journal of Nursing Research, 0, , 019394592211441.	0.6	0
3297	Sex and gender in hypertension guidelines. Journal of Human Hypertension, 2023, 37, 654-661.	1.0	7
3298	Exercise Testing in Hypertension and Hypertension in Athletes. , 2023, , 827-842.		0
3299	Development of Blood Pressure Norms and Definition of Hypertension in Children. , 2023, , 297-309.		0
3301	Changing trends of the disease burden of non-rheumatic valvular heart disease in China from 1990 to 2019 and its predictions: Findings from global burden of disease study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
3302	Egg Intake Is Associated with Lower Risks of Impaired Fasting Glucose and High Blood Pressure in Framingham Offspring Study Adults. Nutrients, 2023, 15, 507.	1.7	1
3303	The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review. , 2023, 2, 122-164.		1
3305	Work-Related Psychosocial Factors and Global Cognitive Function: Are Telomere Length and Low-Grade Inflammation Potential Mediators of This Association?. International Journal of Environmental Research and Public Health, 2023, 20, 4929.	1.2	0
3309	Arterielle Hypertonie – Begutachtung. Springer Reference Medizin, 2023, , 1-8.	0.0	0